Document:

EX-10.9

 Exhibit 10.9 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE
HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 COLLABORATION, OPTION AND LICENSE AGREEMENT 

by and between 
 NURIX
THERAPEUTICS, INC. 
 and 

GILEAD SCIENCES, INC. 

dated as of June 10, 2019 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	ARTICLE 1 DEFINITIONS	  	 	6	 
		
	ARTICLE 2 RESEARCH	  	 	28	 
	 2.1
	 	Research Programs	  	 	28	 
	 2.2
	 	Collaboration Targets	  	 	29	 
	 2.3
	 	Reserved Targets	  	 	31	 
	 2.4
	 	Selection Campaigns	  	 	32	 
	 2.5
	 	Research Activities	  	 	33	 
	 2.6
	 	Gilead Provided Property	  	 	33	 
	 2.7
	 	Information Sharing; Records Retention	  	 	34	 
	 2.8
	 	Audits	  	 	36	 
	 2.9
	 	Exclusivity	  	 	36	 
		
	ARTICLE 3 LICENSE OPTION	  	 	37	 
	 3.1
	 	General	  	 	37	 
	 3.2
	 	License Option	  	 	37	 
	 3.3
	 	Antitrust Filings	  	 	38	 
	 3.4
	 	Treatment of Compounds Incorporating Gilead Target Binders	  	 	39	 
		
	ARTICLE 4 DEVELOPMENT	  	 	39	 
	 4.1
	 	Responsibility	  	 	39	 
	 4.2
	 	Development Diligence	  	 	39	 
	 4.3
	 	Development Updates	  	 	39	 
		
	ARTICLE 5 REGULATORY	  	 	40	 
	 5.1
	 	Regulatory Matters	  	 	40	 
	 5.2
	 	Regulatory Materials	  	 	40	 
	 5.3
	 	Right of Reference; Access to Data	  	 	41	 
		
	ARTICLE 6 COMMERCIALIZATION	  	 	41	 
		
	ARTICLE 7 MANUFACTURING; PHARMACOVIGILANCE	  	 	41	 
		
	ARTICLE 8 NURIX OPTIONS	  	 	42	 
	 8.1
	 	Profit-Share Options	  	 	42	 
	 8.2
	 	Co-Detail Option	  	 	43	 
		
	ARTICLE 9 GOVERNANCE	  	 	43	 
	 9.1
	 	Alliance Manager	  	 	43	 
	 9.2
	 	Working Group	  	 	43	 
	 9.3
	 	Joint Steering Committee	  	 	44	 
	 9.4
	 	Joint Research Committee	  	 	45	 
	 9.6
	 	Scope of Committee Authority	  	 	47	 
	 9.7
	 	Day-to-Day Responsibilities	  	 	47	 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	 	 	  	Page	 
	ARTICLE 10 ASSISTANCE; TRANSITION; UPSTREAM LICENSE AGREEMENTS	  	 	48	 
	 10.1
	 	Assistance	  	 	48	 
	 10.2
	 	Know-How Transfer	  	 	48	 
	 10.3
	 	Licensed Products Inventory Transfer	  	 	48	 
	 10.4
	 	Assignment of Agreements	  	 	48	 
	 10.5
	 	Upstream License Agreements	  	 	49	 
		
	ARTICLE 11 FINANCIAL TERMS	  	 	49	 
	 11.1
	 	Upfront Payment	  	 	49	 
	 11.2
	 	Research Term Extension Fee	  	 	49	 
	 11.3
	 	[*] Reservation Fee Per Target	  	 	50	 
	 11.4
	 	Selection Campaign Fee	  	 	50	 
	 11.5
	 	Option Fee	  	 	50	 
	 11.6
	 	Milestones	  	 	50	 
	 11.7
	 	Sales Milestones	  	 	53	 
	 11.8
	 	Royalties	  	 	54	 
	 11.9
	 	Milestone Payment and Royalty Offset for Third Party Payments	  	 	56	 
	 11.10
	 	Additional Payment Terms	  	 	56	 
	 11.11
	 	Records; Audit Rights	  	 	57	 
	 11.12
	 	Upstream License Agreements and Nurix-Third Party Agreements	  	 	58	 
		
	ARTICLE 12 LICENSE; INTELLECTUAL PROPERTY	  	 	58	 
	 12.1
	 	License Grants	  	 	58	 
	 12.2
	 	Subcontracting	  	 	58	 
	 12.3
	 	Sublicensing	  	 	58	 
	 12.4
	 	No Implied Licenses	  	 	59	 
	 12.5
	 	Ownership	  	 	59	 
	 12.6
	 	Prosecution and Maintenance	  	 	60	 
	 12.7
	 	Enforcement	  	 	61	 
	 12.8
	 	Defense	  	 	63	 
	 12.9
	 	Recovery	  	 	63	 
	 12.10
	 	Trademarks	  	 	63	 
	 12.11
	 	Patent Extensions	  	 	64	 
		
	ARTICLE 13 CONFIDENTIALITY	  	 	64	 
	 13.1
	 	Nondisclosure	  	 	64	 
	 13.2
	 	Exceptions	  	 	64	 
	 13.3
	 	Authorized Disclosure	  	 	65	 
	 13.4
	 	Terms of this Agreement	  	 	66	 
	 13.5
	 	Securities Filings; Disclosure under Applicable Law	  	 	66	 
	 13.6
	 	Publicity	  	 	67	 
	 13.7
	 	Publications	  	 	67	 
	 13.8
	 	Use of Names	  	 	68	 
	 13.9
	 	Clinical Trials Registry	  	 	68	 

  
 3 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	 	 	  	Page	 
	ARTICLE 14 REPRESENTATIONS AND WARRANTIES; COVENANTS	  	 	68	 
	 14.1
	 	Representations and Warranties of Each Party	  	 	68	 
	 14.2
	 	Representations and Warranties of Nurix	  	 	69	 
	 14.3
	 	Representations and Warranties of Gilead	  	 	72	 
	 14.4
	 	Covenants	  	 	72	 
	 14.5
	 	Disclaimer	  	 	73	 
		
	ARTICLE 15 INDEMNIFICATION; INSURANCE	  	 	74	 
	 15.1
	 	Indemnification	  	 	74	 
	 15.2
	 	Procedure	  	 	75	 
	 15.3
	 	Insurance	  	 	76	 
	 15.4
	 	Limitation of Liability	  	 	76	 
		
	ARTICLE 16 TERM AND TERMINATION	  	 	77	 
	 16.1
	 	Term; Expiration	  	 	77	 
	 16.2
	 	Termination for Material Breach	  	 	77	 
	 16.3
	 	Termination at Will	  	 	78	 
	 16.4
	 	Termination for Bankruptcy	  	 	78	 
	 16.5
	 	Effects of Termination	  	 	79	 
	 16.6
	 	Certain Additional Remedies of Gilead in Lieu of Termination	  	 	80	 
	 16.7
	 	Surviving Provisions	  	 	80	 
		
	ARTICLE 17 MISCELLANEOUS	  	 	81	 
	 17.1
	 	Severability	  	 	81	 
	 17.2
	 	Notices	  	 	81	 
	 17.3
	 	Force Majeure	  	 	82	 
	 17.4
	 	Assignment; Change of Control	  	 	82	 
	 17.5
	 	Waivers and Modifications	  	 	83	 
	 17.6
	 	Choice of Law; Dispute Resolution; Jurisdiction	  	 	83	 
	 17.7
	 	Relationship of the Parties	  	 	85	 
	 17.8
	 	Fees and Expenses	  	 	85	 
	 17.9
	 	Third Party Beneficiaries	  	 	85	 
	 17.10
	 	Entire Agreement	  	 	85	 
	 17.11
	 	Counterparts	  	 	85	 
	 17.12
	 	Equitable Relief; Cumulative Remedies	  	 	86	 
	 17.13
	 	Interpretation	  	 	86	 
	 17.14
	 	Further Assurances	  	 	87	 
	 17.15
	 	Extension to Affiliates	  	 	87	 

  

					
	SCHEDULES	  	
			
	Schedule 1.79:	 	Final Data Package	  	
	Schedule 1.108:	 	Interim Data Package	  	
	Schedule 1.118:	 	Knowledge	  	
	Schedule 1.147:	 	Nurix Patents	  	
	Schedule 1.236:	 	Existing Upstream License Agreements	  	
	Schedule 2.2.1:	 	Initial Collaboration Targets	  	

  
 4 

 TABLE OF CONTENTS 

(continued) 
  

			
	 Schedule 2.2.2:
	  	 Exclusive Third Party Targets and Nurix Internal Targets

	 Schedule 2.3.1
	  	 Initial Reserved Targets

	 Schedule 10.2:
	  	 Technology Transfer Documentation

	 Schedule 11.6:
	  	 Criteria for Pre-Clinical Milestone
Events

	 Schedule 14.2:
	  	 Exceptions to Representations and Warranties of Nurix

		
	EXHIBITS	  	
		
	 Exhibit A:
	  	 Form of Research Plan

	 Exhibit A.1:
	  	 Initial Research Plans

	 Exhibit B:
	  	 Profit-Share Exhibit

	 Exhibit C:
	  	 Form of Press Release

  
 5 

 COLLABORATION, OPTION AND LICENSE AGREEMENT 

This COLLABORATION, OPTION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of June 10, 2019
(the “Effective Date”) by and between Nurix Therapeutics, Inc., a Delaware corporation (“Nurix”) and Gilead Sciences, Inc., a Delaware corporation (“Gilead”). Nurix and Gilead are each referred to
herein by name or as a “Party” or, collectively, as the “Parties.” 
 RECITALS 

WHEREAS, Nurix is a biotechnology company developing therapies that control ubiquitin E3 ligases, the key enzymes responsible for
protein breakdown in human cells, which have applications in the treatment of various diseases. 
 WHEREAS, Gilead is a
pharmaceutical company with expertise in the development and commercialization of pharmaceutical products. 
 WHEREAS, Gilead is
interested in accessing Nurix’s DNA-encoded libraries and working with Nurix to identify Target Binders (as defined below) that are Directed To Targets (as defined below) of interest, with the goal of
identifying and developing drug candidates to treat oncological diseases. 
 WHEREAS, Nurix will screen its DELs (as defined below)
against Targets of interest, identify Target Binders that are Directed To such Targets and conduct other research activities with respect to Degrader Compounds and Degrader Products (each as defined below), subject to the terms and conditions set
forth herein. 
 WHEREAS, Gilead will have an option to take an exclusive license to up to five (5) Research Programs (as
defined below) and, following the exercise by Gilead of such option, perform further development, manufacturing and commercialization of such drug products, subject to the terms and conditions set forth herein. 

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements set forth below, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 Unless
specifically set forth to the contrary herein, the following terms will have the respective meanings set forth below. 

1.1    “Accounting Standard” means U.S. generally accepted accounting principles, consistently applied.

 1.2    “Acquired Person” is defined in Section 1.24 (Change of Control). 

 

 1.3    “Acquiring Person” means,
collectively, the Person or group of Persons referenced in the definition of Change of Control (and such Person’s Affiliates), that are not (a) the Acquired Person in the definition of Change of Control, or (b) such Acquired
Person’s Affiliates, in each case as determined immediately prior to the closing of such Change of Control. 

1.4    “Action” means any claim, action, suit, arbitration, inquiry, audit, proceeding or investigation
by or before, or otherwise involving, any Governmental Authority. 
 1.5    “Additional Active” is
defined in Section 1.34 (Combination Product). 
 1.6    “Advancement Criteria” means, with
respect to any Research Program, the criteria set forth in the Research Plan for such Research Program, which criteria are intended to provide guidance to the JRC for advancing a Target Binder, Degrader Compound or Degrader Product (as applicable)
to the next Research Phase of such Research Program. 
 1.7    “Affiliate” means any Person which,
directly or indirectly through one (1) or more intermediaries, controls, is controlled by or is under common control with a Party. For purposes of this Section 1.7 (Affiliate) only, the term “control” (including, with correlative
meanings, the terms “controlled by” and “under common control with”) as used with respect to a Person means: (a) direct or indirect ownership of fifty percent (50%) or more of the voting securities or other voting interest
of any Person (including attribution from related parties); or (b) the possession, directly or indirectly, of the power to direct, or cause the direction of, the management and policies of such Person, whether through ownership of voting
securities, by contract, as a general partner, as a manager or otherwise. 
 1.8    “Agreement” is
defined in the preamble set forth above. 
 1.9    “Agreement Payment” means any payment made by a
Payor to a Payee under this Agreement. 
 1.10    “Alliance Manager” is defined in Section 9.1
(Alliance Manager). 
 1.11    “Annual Net Sales” means, on a Licensed
Product-by-Licensed Product basis, [*], calculated in accordance with the Accounting Standard. 

1.12    “[*] Reservation Fee Per Target” is defined in Section 11.3 ([*] Reservation Fee Per
Target). 
 1.13    “Antitrust Filing” is defined in Section 3.2.1 (License Option Exercise). 

1.14    “Antitrust Law” means any Applicable Law that is designed to prohibit, restrict or regulate
actions having the purpose or effect of monopolization, lessening of competition or restraint of trade, including the HSR Act. 

1.15    “Applicable Law” means all applicable laws, statutes, rules, regulations, treaties (including tax
treaties), orders, judgments or ordinances having the effect of law of any national, multinational, federal, state, provincial, county, city or other political subdivision, including, to the extent applicable, GCP, GLP and GMP, as well as all
applicable data protection and privacy laws, 

  
 7 

 
rules and regulations, including, to the extent applicable, the United States Department of Health and Human Services privacy rules under the Health Insurance Portability and Accountability Act
and the Health Information Technology for Economic and Clinical Health Act and the EU Data Protection Directive (Council Directive 95/46/EC) and applicable laws implementing the EU Data Protection Directive and the General Data Protection Regulation
(2016/679). 
 1.16    “Audited Party” is defined in Section 11.11.2 (Audit Rights). 

1.17    “Auditing Party” is defined in Section 11.11.2 (Audit Rights). 

1.18    “Auditor” is defined in Section 11.11.2 (Audit Rights). 

1.19    “Background IP” is defined in Section 12.5 (Ownership). 

1.20    “Business Day” means any day other than: (a) a Saturday or Sunday or any day on which
commercial banks in San Francisco, California, are authorized or required by Applicable Law to remain closed; or (b) December 26 through December 31. 

1.21    “Calendar Quarter” means each of the three (3) month periods ending March 31,
June 30, September 30 and December 31; provided that the first Calendar Quarter of the Term extends from the Effective Date to the end of the then-current Calendar Quarter, and the last Calendar Quarter extends from the first day of such
Calendar Quarter until the effective date of the termination or expiration of this Agreement. 

1.22    “Calendar Year” means each period beginning on January 1 and ending on December 31; provided
that the first Calendar Year of the Term extends from the Effective Date to December 31 of the then-current Calendar Year, and the last Calendar Year extends from January 1 of such Calendar Year until the effective date of the termination
or expiration of this Agreement. 
 1.23    “CAPA” is defined in Section 2.8 (Audits). 

1.24    “Change of Control” means, with respect to a Person (an “Acquired Person”), from
and after the Effective Date, a transaction involving such Acquired Person in which: (a) any Person or group of Persons becomes the beneficial owner (directly or indirectly) of more than fifty percent (50%) of the voting shares of such Acquired
Person, (b) such Acquired Person consolidates with or merges into or with another Person pursuant to a transaction in which more than fifty percent (50%) of the voting shares of the acquiring or resulting entity outstanding immediately after
such consolidation or merger is not held by the holders of the outstanding voting shares of such Acquired Person immediately preceding such consolidation or merger, or (c) that Acquired Person sells or transfers to another Person all or
substantially all of its assets (such transaction described in sub-clause (c), a “Sale Transaction”). Notwithstanding the foregoing, the following shall not constitute a Change of Control:
(i) a sale of capital stock to underwriters in an underwritten public offering of a Party’s capital stock solely for the purpose of financing, (ii) the acquisition of securities of the Acquired Person by any Person or group of Persons
that acquires the Acquired Person’s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Acquired Person through the issuance of equity securities, or (iii) a transaction
solely to change the domicile of a Party. 

  
 8 

 1.25    “Clinical Milestone Event” is defined in
Section 11.6.2 (Clinical and Development Milestones). 
 1.26    “Clinical Milestone Payment” is
defined in Section 11.6.2 (Clinical and Development Milestones). 
 1.27    “Clinical Trial” means
any human clinical trial of a pharmaceutical or biological product. 

1.28    “Co-Detail Option” is defined in Section 8.2 (Co-Detail Option). 
 1.29    “Code” is defined in
Section 16.4.2 (Section 365(n) Rights). 
 1.30    “Collaboration Target” means (a) any
Initial Collaboration Target that has not been replaced by a Replacement Collaboration Target or (b) any Replacement Collaboration Target. For clarity, a Target will be a Collaboration Target for so long as it (or a protein that is a non-synonymous mutation of, or splice variation on, the protein in such Collaboration Target) remains the subject of an active Research Program as set forth herein (including Section 2.2.1 (Initial and
Replacement Targets)). 
 1.31    “Collaboration Target Replacement Notice” is defined in
Section 2.2.1(b) (Initial and Replacement Targets). 
 1.32    “Collaboration Target Replacement
Period” is defined in Section 2.2.1(b) (Initial and Replacement Targets). 

1.33    “Collaboration Term” means such period beginning on the Effective Date and ending on the
expiration of the last-to-expire Research Term. 

1.34    “Combination Product” means: (a) a Licensed Product that contains one (1) of the
compounds or products described in Section 1.125(a)-(d) (Licensed Product) and one (1) or more active pharmaceutical or biological ingredients for which no royalty would be due hereunder if such ingredients were sold separately (each, an
“Additional Active”); or (b) a Licensed Product that consists of one (1) of the compounds or products described in Section 1.125(a)-(d) (Licensed Product) and is co-packaged or
combined with one (1) or more Additional Actives for which no royalty would be due hereunder if such item(s) were sold separately, and such compounds or product described in Section 1.125(a)-(d) (Licensed Product) and Additional Active(s)
are sold for a single price. 
 1.35    “Combined Degrader Compound IP” is defined in Section 12.5
(Ownership). 
 1.36    “Commercialization” means any and all activities directed to the
commercialization of a product, including marketing; Detailing; promotion; market research; distributing; order processing; handling returns and recalls; booking sales; customer service; administering and commercially selling such product;
importing, exporting and transporting such product for commercial sale; and seeking Pricing Approval of a product (if applicable), whether before or after Regulatory Approval has been obtained, as well all regulatory compliance with respect to the
foregoing. For clarity, “Commercialization” does not include: (a) Manufacturing or (b) any Clinical Trials and other trials commenced after Regulatory Approval. When used as a verb, “Commercialize” means
to engage in Commercialization. 

  
 9 

 1.37    “Commercially Reasonable Efforts” means, with
respect to a particular activity, Degrader Product and Party, [*]. 
 1.38    “Committee” is defined in
Section 9.3.1 (JSC Membership). 
 1.39    “Competing Product” means, at any given time, any
product that is Directed To a Restricted Target at such time. For clarity, a product that contains a Competing Product and one (1) or more active pharmaceutical or biological ingredients or is co-packaged
or combined with one (1) or more active pharmaceutical or biological ingredients will constitute a Competing Product. 

1.40    “Compulsory License” means, with respect to a Licensed Product in a country or territory, rights
(including a license) granted to a Third Party by a governmental agency within such country or territory to sell or offer for sale such Licensed Product in such country or territory under any Patents or
Know-How owned or controlled by either Party or its Affiliates, without direct or indirect authorization from such Party or its Affiliates. 

1.41    “Compulsory Licensee” means a Third Party granted a Compulsory License. 

1.42    “Confidential Information” means, with respect to a Party, all confidential and proprietary
information Controlled by such Party, including chemical or biological materials, chemical structures, Commercialization plans, correspondence, customer lists, data, Development plans, formulae, improvements, Inventions, Know-How, processes, regulatory filings, reports, strategies, techniques or other information, in each case, that are disclosed or made available by or on behalf of such Party to the other Party pursuant to this
Agreement, regardless of whether any of the foregoing are marked “confidential” or “proprietary” or communicated to the other Party by or on behalf of the disclosing Party in oral, written, visual, graphic or electronic form.

 1.43    “Control,” “Controls” or “Controlled” means, subject to
Section 10.5 (Upstream License Agreements) and Section 17.4.2 (Change of Control), with respect to any material, Patent, Know-How, other intellectual property right or Confidential Information, the
ability of a Party or its Affiliates, as applicable (whether through ownership or license (other than a license granted in this Agreement)) to grant to the other Party the licenses or sublicenses as provided herein, to otherwise disclose such Know-How, intellectual property right or Confidential Information to the other Party, or to grant access to such material to the extent not in violation of the terms of any then-existing agreement with any Third
Party at the time such Party or its Affiliates, as applicable, would be required hereunder to grant the other Party such license or sublicenses as provided herein or to otherwise disclose such Know-How,
intellectual property right or Confidential Information to the other Party. 
 1.44    “Cover” means,
with reference to a Valid Claim and a product, that the Development, Manufacture, Commercialization, making, using, offering to sell, selling, importing or exporting of such product would infringe such Valid Claim in the country in which such
activity occurs without a license thereto (or ownership thereof). 

  
 10 

 1.45    “Cure Period” is defined in Section 16.2.1
(Material Breach). 
 1.46    “Damages” means all losses, costs, claims, damages, judgments,
liabilities and expenses (including reasonable attorneys’ fees and other reasonable out-of-pocket costs in connection therewith). 

1.47    “Deadlocked Matter” is defined in Section 9.5 (Committee Decisions). 

1.48    “Default” means: (a) any material breach, violation or default; (b) the existence of
circumstances or the occurrence of an event that with the passage of time or the giving of notice or both would constitute a material breach, violation or default or (c) the existence of circumstances or the occurrence of an event that, with or
without the passage of time or the giving of notice or both, would give rise to a right of termination, renegotiation, acceleration or material change of terms. 

1.49    “Degrader Compound” means, with respect to a Collaboration Target, (a) any compound that
(i) is conceived of or reduced to practice prior to the expiration of the applicable Research Term or Target Exclusivity Period, whichever is later, (ii) consists of a Selected Target Binder, Linker and Ligase Binder and (iii) is
Directed To and leads to degradation of such Collaboration Target, or (b) any Selected Target Binder (other than a Gilead Target Binder) that (x) the JRC elects to Develop as a Degrader Compound in and of itself (without a Linker or Ligase
Binder) and (y) is Directed To and is either an inhibitor or leads to the degradation of such Collaboration Target. 

1.50    “Degrader Compound Selection Milestone” is defined in
sub-section (b) in the table in Section 11.6.1 (Pre-Clinical Milestones). 

1.51    “Degrader Product” means any product that constitutes, incorporates, comprises or contains a
Degrader Compound, whether or not as the sole active ingredient, and in all forms, presentations and formulations including manner of delivery and dosage. 

1.52    “Degrader Product Patent” means, subject to Section 12.6.1(b) (Before Exercise of License
Option), any Nurix Patent that: (a) includes at least one (1) claim that Covers the composition of matter for an entire Degrader Compound of a Licensed Product; or (b) if such Nurix Patent does not include a claim that Covers the
composition of matter for an entire Degrader Compound of a Licensed Product, solely claims an entire Licensed Product (or Degrader Compound incorporated therein), including formulations thereof, methods of use for such Licensed Product or Degrader
Compound, or methods of manufacture for such Licensed Product or Degrader Compound. For clarity, any Nurix Patent that claims a portion of a Degrader Compound, such as a Ligase Binder on its own or a combination of a Ligase Binder and a Linker, is
not a Degrader Product Patent even if such Ligase Binder or Linker are components of a Degrader Compound that is a Licensed Product, provided that such Nurix Patent does not also claim the composition of the entire Degrader Compound of a Licensed
Product. 
 1.53    “DEL” means the DNA-encoded libraries and
related technology Controlled by Nurix, as may be modified from time to time during the Term. 

  
 11 

 1.54    “Development” means clinical drug development
activities and other development activities with respect to a product, including Clinical Trials (and other trials commenced after Regulatory Approval), test method development and stability testing; toxicology; formulation; process development;
qualification; validation; quality assurance and quality control; statistical analysis and report writing; the preparation and submission of INDs and MAAs; regulatory affairs with respect to the foregoing and all other activities necessary or useful
or otherwise requested or required by a Regulatory Authority or as a condition or in support of obtaining or maintaining a Regulatory Approval. For clarity, “Development” does not include Research or Manufacturing. When used as a verb,
“Develop” means to engage in Development. 
 1.55    “Development Candidate” means any
Degrader Product selected and approved by the JRC to be advanced to Development. 
 1.56    “Development
Milestone Event” is defined in Section 11.6.2 (Clinical and Development Milestones). 

1.57    “Development Milestone Payment” is defined in Section 11.6.2 (Clinical and Development
Milestones). 
 1.58    “Directed To” means, with regard to a particular Target, that the compound,
molecule or product at issue binds directly to such Target. When required grammatically, the defined term “Directed To” may be separated and will have the same meaning set forth above; e.g., when discussing Targets To which a compound,
molecule or product is Directed. 
 1.59    “Disclosing Party” is defined in Section 13.1
(Nondisclosure). 
 1.60    “Disclosure Letter” is defined in Section 14.2 (Representations and
Warranties of Nurix). 
 1.61    “Dispute” is defined in Section 17.6.2 (Dispute Escalation). 

1.62    “DOJ” is defined in Section 3.3.1 (Antitrust Filings: Filings) 

1.63    “Dollars” or “$” means the legal tender of the United States. 

1.64    “Effective Date” is defined in the preamble to this Agreement. 

1.65    “Electronic Delivery” is defined in Section 17.11 (Counterparts). 

1.66    “EMA” is defined in Section 1.179 (Regulatory Authority). 

1.67    “Encumbered Licensed Product” means any Licensed Product with respect to which Gilead or one of
its Affiliates [*]. 
 1.68    “Enforcing Party” is defined in Section 12.7.2(c) (Right to
Enforce). 
 1.69    “EU” means all countries that are officially recognized as member states of the
European Union at any particular time; except that, for purposes of this Agreement, the EU will be deemed to include France, Germany, Italy, Spain and the United Kingdom, irrespective of whether any such country leaves the European Union. 

  
 12 

 1.70    “EU Regulatory Approval” means Regulatory
Approval (excluding Pricing Approvals) of a Licensed Product by EMA or the relevant Regulatory Authority in one (1) Major European Market. 

1.71    “Excluded Target” means any Target that is (a) an Exclusive Third Party Target, (b) a
Nurix Internal Target, or (c) a Reverted Target. 
 1.72    “Exclusive Third Party Target” is
defined in Section 2.2.1(c) (Initial and Replacement Targets). 
 1.73    “Executive Officer”
means: (a) with respect to Nurix, the Chief Executive Officer of Nurix or his/her designee or successor with appropriate decision-making authority; and (b) with respect to Gilead, the Head of Research of Gilead or his/her designee or
successor with appropriate decision-making authority. 
 1.74    “Existing Regulatory Materials” is
defined in Section 5.2.1 (Existing Regulatory Materials). 
 1.75    “Existing Upstream License
Agreement” is defined in Section 1.236 (Upstream License Agreement). 
 1.76    “Extended Research
Term” is defined in Section 2.1.2 (Research Term). 
 1.77    “FDA” is defined in
Section 1.179 (Regulatory Authority). 
 1.78    “Field” means any and all uses or purposes,
including the treatment, prophylaxis, palliation, diagnosis or prevention of any human or animal disease, disorder or condition. 

1.79    “Final Data Package” means, with respect to any Development Candidate, an information package
relating to the Collaboration Target of such Development Candidate and the Development Candidate, Degrader Products, Degrader Compounds and Selected Target Binders in each case Directed To such Collaboration Target, containing such items set forth
in Schedule 1.79 (Final Data Package). 
 1.80    “First Commercial Sale” means, on a Licensed Product-by-Licensed Product and country-by-country basis, the first sale of such Licensed
Product in such country for use or consumption by the general public (following receipt of all Regulatory Approvals that are required in order to sell such Licensed Product in such country) and for which any of Gilead or its Affiliates or
Sublicensees has invoiced sales of Licensed Products in the Territory; provided, however, that the following will not constitute a First Commercial Sale: (a) any sale to an Affiliate or Sublicensee, unless such Affiliate or Sublicensee is the
last Person in the distribution chain of the Licensed Product; (b) any use of such Licensed Product in Clinical Trials or non-clinical development activities with respect to such Licensed Product by or on
behalf of a Party; or (c) any disposal or transfer of such Licensed Product for a bona fide charitable purpose, compassionate use or samples. 

  
 13 

 1.81    “FTC” is defined in Section 3.3.1
(Filings). 
 1.82    “GCP” means the applicable then-current ethical and scientific quality standards
for designing, conducting, recording and reporting Clinical Trials as are required by applicable Regulatory Authorities or Applicable Law in the relevant jurisdiction, including, in the United States, Good Clinical Practices established through FDA
guidances, and, outside the United States, Guidelines for Good Clinical Practice – ICH Harmonized Tripartite Guideline (ICH E6). 

1.83    “Generic Competition” means, with respect to a Licensed Product in a country in the Territory,
the sale of [*] or more Generic Product(s) for an approved Indication of such Licensed Product in such country in a given Calendar Quarter. 

1.84    “Generic Product” means, with respect to a given Licensed Product in a particular country in the
Territory, a pharmaceutical product that (a) is approved for use in such country pursuant to a Regulatory Approval process governing approval of a generic or interchangeable product of such Licensed Product based on the then-current standards
for Regulatory Approval in such country, whether or not such Regulatory Approval was based upon clinical data generated by the Parties pursuant to this Agreement or was obtained using an abbreviated, expedited or other process, and (b) is sold
in the same country as such Licensed Product by any Third Party that is not a Sublicensee (other than a Sublicensee that has been granted a sublicense to any Nurix IP by Gilead solely in connection with any settlement) and did not purchase such
pharmaceutical product in a chain of distribution that included any of Gilead, its Affiliates or its or their Sublicensees. 

1.85    “Gilead” is defined in the preamble to this Agreement. 

1.86    “Gilead Documentation” is defined in Section 2.6.1 (Provision of Gilead Materials). 

1.87    “Gilead Indemnitee” is defined in Section 15.1.2 (Indemnification by Nurix). 

1.88    “Gilead Materials” means any Gilead Target Binder or other materials, in each case developed
outside of this Agreement and Controlled by Gilead or its Affiliates provided by Gilead in accordance with Section 2.6.1 (Provision of Gilead Materials) for use in a Research Program. 

1.89    “Gilead Provided Property” means, on a Collaboration Target-by-Collaboration Target basis, the Gilead Materials and the Gilead Documentation related to such Collaboration Target provided by Gilead to Nurix in accordance with Section 2.6.1 (Provision of
Gilead Materials). 
 1.90    “Gilead Target Binder” is defined in Section 1.221 (Target Binder).

 1.91    “GLP” means the applicable then-current good laboratory practice standards as are required
by applicable Regulatory Authorities or Applicable Law in the relevant jurisdiction, including, in the United States, those promulgated or endorsed by the FDA in U.S. 21 C.F.R. Part 58, or the equivalent thereof as promulgated or endorsed by
the applicable Regulatory Authorities outside of the United States. 

  
 14 

 1.92    “GMP” means all applicable then-current good
manufacturing practice standards relating for fine chemicals, intermediates, bulk products or finished pharmaceutical or biological products, as are required by applicable Regulatory Authorities or Applicable Law in the relevant jurisdiction,
including, as applicable: (a) all applicable requirements detailed in the FDA’s current Good Manufacturing Practices regulations, U.S. 21 C.F.R. Parts 210 and 211; (b) all applicable requirements detailed in the EMA’s “The Rules
Governing Medicinal Products in the European Community, Volume IV, Good Manufacturing Practice for Medicinal Products” and (c) all Applicable Law promulgated by any Governmental Authority having jurisdiction over the Manufacture of the
applicable compound or pharmaceutical or biological product, as applicable. 
 1.93    “Governmental
Authority” means any: (a) federal, state, local, municipal, foreign, or other government; (b) governmental or quasi-governmental authority of any nature (including any agency, board, body, branch, bureau, commission, council,
department, entity, governmental division, instrumentality, office, officer, official, organization, representative, subdivision, unit, and any court or other tribunal); (c) multinational governmental organization or body; or (d) entity or body
exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature (including any arbiter). 

1.94    “HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (15 U.S.C. §
18a). 
 1.95    “IND” means an investigational new drug application (including any amendment or
supplement thereto) submitted to the FDA pursuant to U.S. 21 C.F.R. Part 312, including any amendments thereto. References herein to IND will include, to the extent applicable, any comparable filing(s) outside the U.S. for the investigation of any
product in any other country or group of countries (such as a Clinical Trial Application in the EU). 

1.96    “IND Acceptance” means, with respect to an IND, the earlier of: (a) receipt by a Party, its
Affiliate or a Sublicensee of written confirmation from a Regulatory Authority or other applicable Person that Clinical Trials may proceed under such IND or (b) expiration of the applicable waiting period under Applicable Law after which
Clinical Trials may proceed under such IND. 
 1.97    “Indemnification Claim Notice” is defined in
Section 15.2.1 (Notice). 
 1.98    “Indemnitee” is defined in Section 15.2.1 (Notice). 

1.99    “Indemnitor” is defined in Section 15.2.1 (Notice). 

1.100    “Indication” means an entirely separate and distinct disease or medical condition in humans
which a pharmaceutical or biological product: (a) that is in Clinical Trials is intended to treat in such Clinical Trials; or (b) has received a separate and distinct Regulatory Approval with an approved label claim to treat such disease
or condition, as applicable. For clarity: (i) moving from one line of therapy to another within an Indication (e.g., moving from second-line therapy to first-line therapy) will not be considered to be a new Indication; (ii) a single
Indication would include the primary disease and all variants or sub-divisions or sub-classifications within such primary disease, and regardless of prophylactic or
therapeutic use, pediatric or adult use and 

  
 15 

 
irrespective of different formulation(s), dosage forms, dosage strengths or delivery system(s) used; (iii) initiating a Clinical Trial or obtaining Regulatory Approval for use of a
pharmaceutical or biological product in combination with another pharmaceutical or biological product, where a Clinical Trial had been initiated or Regulatory Approval obtained for such first pharmaceutical or biological product for use as
monotherapy or in combination with a different pharmaceutical or biological product, will not be considered to be a new Indication; and (iv) initiating a Clinical Trial or obtaining Regulatory Approval for use of a pharmaceutical or biological
product in a specific patient population where a Clinical Trial had been initiated or Regulatory Approval obtained for such pharmaceutical or biological product without reference to a specific patient population or for a different patient
population, will not be considered a new Indication. 
 1.101    “Information Request Notice” is
defined in Section 2.7.4 (Additional Information). 
 1.102    “Infringement” is defined in
Section 12.7.1 (Notification). 
 1.103    “Initial Collaboration Target” is defined in
Section 2.2.1(a) (Initial and Replacement Targets). 
 1.104    “Initial Outside Date” is defined
in Section 3.3.3 (Outside Date). 
 1.105    “Initial Research Term” is defined in
Section 2.1.2 (Research Term). 
 1.106    “Initial Reserved Target” is defined in
Section 2.3.1 (Reserved Target). 
 1.107    “Initiation” means (a) with respect to a Phase 1
Clinical Trial (or the Phase 1 Clinical Trial portion of a combined Phase 1 Clinical Trial/Phase 2 Clinical Trial), the administration of the first dose of a Licensed Product to the third patient (or volunteer, as relevant) participating in such
Clinical Trial or (b) with respect to any Clinical Trial other than as set forth in sub-clause (a), the administration of the first dose of a Licensed Product or placebo to the first patient (or
volunteer, as relevant) participating in such Clinical Trial. 
 1.108    “Interim Data Package” means,
with respect to any Collaboration Target or Tabled Target (as applicable), an information package relating to the Degrader Products, Degrader Compounds and Target Binders that meet the criteria for achievement of the Target Binder Selection
Milestone, in each case Directed To such Collaboration Target or Tabled Target, containing such items set forth in Schedule 1.108 (Interim Data Package), to the extent in existence and in the Control of Nurix or its Affiliates at the time that such
information package is delivered to Gilead in accordance with Section 2.7.2 (Interim Data Package), and including such other information that the JRC may agree upon depending on the stage of Development of such Degrader Compounds Directed To
the applicable Collaboration Target or Tabled Target. 
 1.109    “Invention” means any process,
method, composition of matter, article of manufacture, discovery or finding that is conceived or reduced to practice. 

1.110    “JAMS” is defined in Section 17.6.3 (Baseball Arbitration). 

1.111    “Joint IP” is defined in Section 12.5 (Ownership). 

  
 16 

 1.112    “Joint Patent” is defined in
Section 12.6.1(a) (Before Exercise of License Option). 
 1.113    “JRC” is defined in
Section 9.4.1 (Joint Research Committee). 
 1.114    “JRC Chair” is defined Section 9.4.2
(Joint Research Committee). 
 1.115    “JSC” is defined in Section 9.3.1 (JSC Membership). 

1.116    “JSC Chair” is defined in Section 9.3.1 (JSC Membership). 

1.117    “Know-How” means algorithms, data, information,
Inventions, knowledge, methods (including methods of use or administration or dosing), practices, results, software, techniques, technology and trade secrets, including analytical and quality control data, analytical methods (including applicable
reference standards), assays, batch records, chemical structures and formulations, compositions of matter, formulae, manufacturing data, pharmacological, toxicological and clinical test data and results, processes, reports, research data, research
tools, sequences, standard operating procedures and techniques, in each case, whether patentable or not, and, in each case, tangible manifestations thereof. 

1.118    “Knowledge” means, with respect to a Party, the actual knowledge of those persons listed for
such Party on Schedule 1.118 (Knowledge) after due inquiry. 
 1.119    “License Option” is
defined in Section 3.1 (General). 
 1.120    “License Option Effective Date” is defined in
Section 3.3.2 (Effectiveness). 
 1.121    “License Option Exercise” is defined in
Section 3.2.1 (License Option Exercise). 
 1.122    “License Option Exercise Date” is
defined in Section 3.3.1 (Filings). 
 1.123    “License Option Exercise Notice” is defined
in Section 3.2.1 (License Option Exercise). 
 1.124    “License Option Period” means: 

1.124.1 with respect to any Collaboration Target, the period of time commencing on (a) in the case of an Initial Collaboration Target,
the Effective Date or (b) in the case of a Replacement Collaboration Target, such date that such Target becomes a Collaboration Target, and ending (i) in the event that a Final Data Package is delivered to Gilead with respect to such
Collaboration Target, [*] following receipt of such Final Data Package for such Collaboration Target or (ii) in the event that a Final Data Package is not delivered to Gilead with respect to such Collaboration Target, [*] following expiration
of the applicable Research Term for such Collaboration Target; and 
 1.124.2 with respect to any Tabled Target, the period of time
commencing on such date that such Target becomes a Tabled Target and ending [*] following the end of the Initial Research Term; 

  
 17 

 provided, however, that in each case (Section 1.124.1 and Section 1.124.2 (License Option Period)),
such period may be extended by an additional sixty (60) days in accordance with Section 3.2.3 (License Option Period Extension) and such other period of time described in Section 2.7.4 (Additional Information). For clarity, if any
License Option Period under Section 1.124.1 (License Option Period) expires, but upon expiration of such License Option Period, a Target is subject to the License Option Period under Section 1.124.2 (License Option Period), then the
License Option Period under Section 1.124.2 (License Option Period) will apply upon such expiration. 

1.125    “Licensed Product” means (a) any Optioned Product, (b) any Degrader Compound Directed
To the same Target as such Optioned Product, which Degrader Compound was identified, synthesized and Researched by or on behalf of Nurix or its Affiliates prior to the expiration of the applicable Research Term or Target Exclusivity Period,
whichever is longer and has achieved the Degrader Compound Selection Milestone (or was otherwise selected by the JSC as a Selected Degrader Compound), (c) any Degrader Compound Directed To the same Target as such Optioned Product and which Degrader
Compound was identified, synthesized and Researched by or behalf of Nurix or its Affiliates prior to the expiration of the applicable Research Term or Target Exclusivity Period, whichever is longer and is disclosed in any Patent Controlled by Nurix
or any of its Affiliates as of the Effective Date or thereafter during the Term that claims any Invention developed, conceived or reduced to practice in the course of performing Research activities prior to the expiration of the applicable Research
Term or Target Exclusivity Period, whichever is longer, or (d) any other product that constitutes, incorporates, comprises or contains the entirety of such compound described in sub-clause (b) or (c)
(whether or not as the sole active ingredient, and in all forms, presentations and formulations including manner of delivery and dosage). 

1.126    “Licensed Product Mark” is defined in Section 12.10 (Trademarks). 

1.127    “Licensed Product Transition Agreement” is defined in Section 16.5.1(c) (Termination by
Gilead at Will or by Nurix for Material Breach or Bankruptcy). 
 1.128    “Ligase Binder” means any
small molecule compound that (a) binds with an E3 ligase and [*]. 
 1.129    “Linker” means any
small molecule compound that is covalently bound to a Target Binder and a Ligase Binder. 

1.130    “MAA” [*]. 

1.131    “Major European Market” [*]. 

1.132    “Major Market Country” [*]. 

1.133    “Manufacture” means all activities related to the manufacturing of a product or any component or
ingredient thereof, including the production, manufacture, having manufactured, processing, filling, finishing, packaging, labeling, shipping and holding of product or any intermediate thereof, including process development, process qualification
and validation, scale-up, commercial manufacture and analytic development, product characterization, stability testing, quality assurance and quality control. 

  
 18 

 1.134    “Material Breach” means a breach of this
Agreement that is material to the rights and obligations of the Parties and the transactions contemplated by this Agreement, taken as a whole. 

1.135    “Milestone Event” means any Pre-Clinical Milestone
Event, Clinical Milestone Event or Development Milestone Event. 
 1.136    “Milestone Payment” means
any Pre-Clinical Milestone Payment, Clinical Milestone Payment or Development Milestone Payment. 

1.137    “NDA” means, with respect to a pharmaceutical product, a New Drug Application submitted to the
FDA in accordance with the United States Federal Food, Drug and Cosmetic Act (21 U.S.C. §§ 301 et seq.), as amended, and the rules and regulations promulgated thereunder, or any analogous application or submission with any Regulatory
Authority outside of the United States. 
 1.138    “Net Sales” [*] 

1.139    “Non-Enforcing Party” is defined in
Section 12.7.2(c) (Right of Enforcement). 

1.140    “Non-Prosecuting Party” is defined in
Section 12.6.3 (Cooperation). 
 1.141    “Nurix” is defined in the preamble to this Agreement.

 1.142    “Nurix Claim Scope Discussion” is defined in Section 12.6.1(b) (Before Exercise of
License Option). 
 1.143    “Nurix Indemnitee” is defined in Section 15.1.1 (Indemnification by
Gilead). 
 1.144    “Nurix Internal Target” means a Target (other than a Collaboration Target, Tabled
Target or Reserved Target) that is subject to a bona fide internal Nurix research program and is not conducted for a Third Party, where Nurix is conducting active drug discovery activities (including activities related to compound structure
discovery, drug discovery screening, compound chemistry, structure-activity relationships and manufacturing) with respect to a compound, molecule or product that is Directed To such Target, provided that such compound, molecule or product [*]. 

1.145    “Nurix IP” means the Nurix Patents and the Nurix
Know-How, but excluding any Joint IP. 
 1.146    “Nurix Know-How” means, subject to Section 17.4.2 (Change of Control), any and all Know-How Controlled by Nurix or any of its Affiliates as of the Effective Date or
thereafter during the Term which is necessary or reasonably useful for the Development, Manufacture or Commercialization of the Licensed Products in the Field in the Territory. 

1.147    “Nurix Patent” means, subject to Section 17.4.2 (Change of Control), any Patent Controlled
by Nurix or any of its Affiliates as of the Effective Date or thereafter during the Term which is necessary or reasonably useful for the Development, Manufacture or Commercialization of a Licensed Product in the Field in the Territory. Without
limiting the foregoing, Schedule 1.147 (Nurix Patents) sets forth a complete and accurate list of Nurix Patents (if any) as of the Effective Date. 

  
 19 

 1.148    “Nurix Proposed Claim Scope” is defined in
Section 12.6.1(b) (Before Exercise of License Option). 
 1.149    “Nurix-Third Party Agreement”
means any contract or agreement, other than any Upstream License Agreement, between Nurix (or any of its Affiliates, as applicable) and any Third Party that is related to the Research, Development or Manufacture of any Licensed Product. 

1.150    “Option Fee” is defined in Section 11.5 (Option Fee). 

1.151     “Optioned Product” means, with respect to any Research Program, any Degrader Product that
Gilead identifies in a License Option Exercise Notice for such Research Program. 
 1.152    “Outside
Date” is defined in Section 3.3.3 (Outside Date). 
 1.153    “Parenteral In Vivo Activity
Milestone” is defined in sub-section (c) in the table in Section 11.6.1 (Pre-Clinical Milestones). 

1.154    “Party” is defined in the preamble to this Agreement. 

1.155    “Patent” means: (a) any patent or patent application in any country or supranational
jurisdiction worldwide; (b) any substitution, divisional, continuation, continuation-in-part, reissue, renewal, registration, confirmation or the like of any such
patent or patent application or (c) any extension or restoration by existing or future extension or restoration mechanism, including revalidation, reissue, re-examination or extension, including any
supplementary protection certificate of any of the foregoing. 
 1.156    “Payee” means a Party
receiving a payment under this Agreement. 
 1.157    “Payor” means a Party owing or making a payment
under this Agreement. 
 1.158    “Person” means any individual, partnership, joint venture, limited
liability company, corporation, firm, trust, association, unincorporated organization, Governmental Authority or any other entity not specifically listed herein. 

1.159    “Phase 1 Clinical Trial” means a Clinical Trial which provides for the first
introduction into humans of a product, conducted in normal volunteers or patients to get information on product safety, tolerability, immunogenicity, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. §
312.21(a) (or the foreign equivalent thereof). 
 1.160    “Phase 2 Clinical Trial” means a single
randomized, placebo or active controlled Clinical Trial, the principal purposes of which are the evaluation of the efficacy of such product for a particular Indication in the target patient population and a determination of the common side-effects
and risks associated with the product in the dosage range to be prescribed and to obtain 

  
 20 

 
sufficient information about the efficacy for such pharmaceutical or biological product in the disease or condition being studied to permit the design and dose of such product in a Pivotal Trial,
and otherwise consistent with 21 C.F.R. §312.21(b) or its foreign equivalents. “Phase 2 Clinical Trial” will exclude in all cases any combined Phase 1 Clinical Trial/Phase 2 Clinical Trial. 

1.161    “Phase 3 Clinical Trial” means a controlled Clinical Trial of the efficacy and safety of a
product, which is prospectively designed to demonstrate statistically whether such product is effective and safe for use in a particular Indication in a manner sufficient to file for an MAA, and otherwise consistent with the requirements of US 21
C.F.R. § 312.21(c) or its foreign equivalents. 
 1.162    “Pivotal Trial” means a single
randomized, controlled (e.g., compared against SOC (standard of care), e.g., against a checkpoint inhibitor alone) Clinical Trial of a Licensed Product that: (a) (i) would satisfy the requirements of 21 C.F.R. 312.21(c) or
corresponding foreign regulations or (ii) is intended to provide sufficient efficacy data to support the filing of a MAA for such Licensed Product without the need for additional Clinical Trials; and (b) which, at the time of Initiation of
such Clinical Trial, is expected to be the basis for EU Regulatory Approval or Regulatory Approval by the FDA of such Licensed Product based on discussions with the relevant Regulatory Authority. 

1.163    “PK/PD Milestone” is defined in sub-section (d) in
the table in Section 11.6.1 (Pre-Clinical Milestones). 

1.164    “Pre-Clinical Milestone Event” is defined in
Section 11.6.1 (Pre-Clinical Milestones). 
 1.165    “Pre-Clinical Milestone Payment” is defined in Section 11.6.1 (Pre-Clinical Milestones). 

1.166    “Pricing Approval” means any approval, agreement, determination or decision establishing prices
that can be charged to consumers for a pharmaceutical or biological product or that will be reimbursed by Governmental Authorities for a pharmaceutical or biological product, in each case, in a country where Governmental Authorities approve or
determine pricing for pharmaceutical or biological products for reimbursement or otherwise. 
 1.167    “Prior
CDA” means that certain Amended and Restated Mutual Confidential Disclosure Agreement, dated October 31, 2018, by and between Nurix, Inc. and Gilead. 

1.168    “Profit-Share Data Package” is defined in Section 8.1.2 (Exercise of Profit-Share Options).

 1.169    “Profit-Share Option” is defined in Section 8.1.2 (Exercise of Profit-Share Options).

 1.170    “Profit-Share Option Exercise Notice” is defined in Section 8.1.2 (Profit-Share
Options). 

  
 21 

 1.171    “Profit-Share Product” means a Licensed
Product where the Parties have entered into a Profit-Share Agreement in accordance with Exhibit B (Profit-Share Exhibit) governing such Licensed Product, but only for so long as the applicable Profit-Share Term (as defined in Exhibit B (Profit-Share
Exhibit)) for such Licensed Product remains in effect. 
 1.172    “Progressed Collaboration Target”
means any Collaboration Target with respect to which the Parenteral In Vivo Activity Milestone has been achieved. 

1.173    “Prosecuting Party” is defined in Section 12.6.3 (Cooperation). 

1.174    “Prosecution and Maintenance” or “Prosecute and Maintain” means, with regard to
a Patent, the preparation, filing, prosecution and maintenance of such Patent, as well as re-examinations, reissues and appeals with respect to such Patent, together with the initiation or defense of
interferences, oppositions, inter partes review, derivations, re-examinations, post-grant proceedings and other similar proceedings (or other defense proceedings with respect to such Patent, but excluding the
defense of challenges to such Patent as a counterclaim in an infringement proceeding) with respect to the particular Patent, and any appeals therefrom, and actions to obtain patent term extensions and supplementary protection certificates with
respect to such Patent and the like. For clarification, “Prosecution and Maintenance” or “Prosecute and Maintain” will not include any other enforcement actions taken with respect to a Patent. 

1.175    “Publication” is defined in Section 13.7 (Publications) 

1.176    “Publishing Party” is defined in Section 13.7 (Publications). 

1.177    “Receiving Party” is defined in Section 13.1 (Nondisclosure). 

1.178    “Regulatory Approval” means all approvals, licenses and authorizations of the applicable
Regulatory Authority necessary for the marketing and sale of a pharmaceutical or biological product for a particular Indication in a country or region (including separate Pricing Approvals, as necessary), and including the approvals by the
applicable Regulatory Authority of any expansion or modification of the label for such Indication. 

1.179    “Regulatory Authority” means any national or supranational Governmental Authority, including the
U.S. Food and Drug Administration (and any successor entity thereto) (the “FDA”) in the U.S., the European Medicines Agency (and any successor entity thereto) (the “EMA”) in the EU or any health regulatory authority
in any country or region that is a counterpart to the foregoing agencies, in each case, that holds responsibility for development and commercialization of, and the granting of Regulatory Approval for, a pharmaceutical or biological product in such
country or region. 
 1.180    “Regulatory Exclusivity” means, with respect to a Licensed Product, any
exclusive rights or protection which are recognized, afforded or granted by any Regulatory Authority in any country or region with respect to the Licensed Product other than through Patents. 

1.181    “Regulatory Materials” means the regulatory registrations, applications, authorizations and
approvals (including approvals of MAAs, supplements and amendments, pre- and post-approvals, Pricing Approvals and labeling approvals), Regulatory Approvals and other

  
 22 

 
submissions made to or with any Regulatory Authority, including drug master files, for Research, Development (including the conduct of Clinical Trials), Manufacture or Commercialization of a
pharmaceutical or biological product in a regulatory jurisdiction, together with all related correspondence to or from any Regulatory Authority and all documents referenced in the complete regulatory chronology for each NDA, MAA, IND and foreign
equivalents of any of the foregoing. 
 1.182    “Rejection Event” is defined in
Section 16.4.1 (Reject Events). 
 1.183    “Replacement Collaboration Target” means any Target
selected to replace a Collaboration Target in accordance with and as set forth in Section 2.2.1 (Initial and Replacement Targets). 

1.184    “Replacement Collaboration Target Objection Period” is defined in Section 2.2.1(c) (Initial
and Replacement Targets). 
 1.185    “Replacement Right” is defined in Section 2.2.1(b) (Initial
and Replacement Targets). 
 1.186    “Research” means any
pre-clinical research activities (including Target validation, drug discovery, identification or synthesis) with respect to a Collaboration Target, Tabled Target, Target Binder, Degrader Compound or Degrader
Product. When used as a verb, “Research” means to engage in Research. 
 1.187    “Research
Extension” is defined in Section 2.1.2 (Research Term). 
 1.188    “Research Extension
Fee” is defined in Section 11.2 (Research Term Extension Fee). 
 1.189    “Research
Phase” means, with respect to any Research Program, the following series of related Research activities, each of which is identified as a distinct Research phase under the applicable Research Plan and is further described in such Research
Plan: [*]. 
 1.190    “Research Plan” means, on a Target-by-Target basis, the plan governing the Research activities under a Research Program, as such plan may be created and amended from time to time in accordance with this Agreement. Each Research Plan
will be substantially consistent with the form attached hereto as Exhibit A. 
 1.191    “Research
Program” means, on a Collaboration Target-by-Collaboration Target basis, all Research activities undertaken under the Research Plan for such Collaboration
Target, to identify compounds that are Target Binders, Degrader Compounds and Degrader Products, in each case that are Directed To such Collaboration Target. 

1.192    “Research Results” means any Research data, material, results or other information related to or
otherwise arising under or out of a Research Program, including (a) Selection Campaign Results, (b) such information provided to the JRC under Section 2.7.1 (Information Sharing) and Section 9.2 (Working Group), and (c) the
contents of any Interim Data Package or Final Data Package. 

  
 23 

 1.193    “Research Term” is defined in
Section 2.1.2 (Research Term). 
 1.194    “Reserved Target” is defined in Section 2.3.1
(Reserved Targets) 
 1.195    “Reserved Target Objection Period” is defined in Section 2.3.1
(Reserved Targets). 
 1.196    “Reserved Target Period” means, with respect to any Target, the period
of time with respect to which Gilead has paid an [*] Reservation Fee Per Target to keep such Target as a Reserved Target in accordance with Section 11.3 ([*] Reservation Fee Per Target). 

1.197    “Restricted Target” means (a) at any given time during the applicable License Option
Period, any Target that is a Collaboration Target at such time, (b) at any given time during the applicable License Option Period, any Target that is a Tabled Target at such time, (c) at any given time during the Reserved Target Period,
any Target that is a Reserved Target at such time or (d) for a period of [*] following the applicable License Option Effective Date, any Collaboration Target with respect to which Gilead exercised such License Option. 

1.198    “Reverted Target” is defined in Section 3.2.2 (License Option Exercise). 

1.199    “Reviewing Party” is defined in Section 13.7 (Publications). 

1.200    “ROW” means all of the countries in the Territory other than the United States. 

1.201    “Royalty Term” means, on a Licensed Product-by-Licensed Product and country-by-country basis, the period of time commencing on the First Commercial Sale of any
Licensed Product in such country and expiring upon the latest of: (a) the date on which there is no Valid Claim of an issued Patent within the Nurix Patents or Joint Patents which Covers such Licensed Product in such country; (b) the
expiration of any Regulatory Exclusivity with respect to such Licensed Product in the relevant country; or (c) the tenth (10th) anniversary of the date of First Commercial Sale of such Licensed Product in such country. 

1.202    “Royalty Territory” means: (a) the Territory, with respect to Royalty-Bearing Products; and
(b) the ROW, with respect to Profit-Share Products. 
 1.203    “Royalty-Bearing Product” means
any Licensed Product other than a Profit-Share Product. 
 1.204    “Sale Transaction” is defined in
Section 1.24 (Change of Control). 
 1.205    “Sales Milestone Event” is defined in
Section 11.7.1 (Sales Milestones). 
 1.206    “Sales Milestone Payment” is defined in
Section 11.7.1 (Sales Milestones). 
 1.207    “Securities Regulator” is defined in
Section 13.3.1(a) (Disclosure). 
 1.208    “Segregate” means, with respect to a Competing
Product, to segregate the Research, Development, Manufacture and Commercialization activities relating to such 

  
 24 

 
Competing Product from the Research, Development, Manufacture or Commercialization activities with respect to the Licensed Products or any products Directed To a Restricted Target under this
Agreement, including ensuring that: (a) no personnel involved in performing the Research, Development, Manufacture or Commercialization, as applicable, of such Competing Product have access to non-public
plans or non-public information relating to the Research, Development, Manufacture or Commercialization of Licensed Products or products Directed To any Restricted Target or any other relevant Confidential
Information of the applicable Party; and (b) no personnel involved in performing the Research, Development, Manufacture or Commercialization of Licensed Products or products Directed To any Restricted Target have access to non-public plans or information relating to the Research, Development, Manufacture or Commercialization of such Competing Product; provided that, in either case ((a) or (b)), senior management personnel may review
and evaluate plans and information regarding the Research, Development, Manufacture or Commercialization of such Competing Product solely in connection with monitoring the progress of products, including portfolio decision-making among product
opportunities. 
 1.209    “Selected Degrader Compound” means, with respect to a particular
Collaboration Target, a Degrader Compound Directed To such Collaboration Target approved by the JRC (or otherwise in accordance with Section 9.5 (Committee Decisions)) to be a “Selected Degrader Compound.” 

1.210    “Selected Target Binder” means, with respect to a particular Collaboration Target, a Target
Binder Directed To such Collaboration Target approved by the JRC (or otherwise in accordance with Section 9.5 (Committee Decisions)) to be a “Selected Target Binder.” 

1.211    “Selection Campaign” means, for a particular Collaboration Target, the selection experiments,
including DEL screens, conducted by Nurix against such Collaboration Target to identify Target Binder Hits Directed To such Collaboration Target described in the Research Plan for such Collaboration Target. 

1.212    “Selection Campaign Fee” is defined in Section 11.4 (Selection Campaign Fee). 

1.213    “Selection Campaign Results” means, for each Selection Campaign for a Collaboration Target, a
written summary of the Target Binders and the relevant experimental data (including enrichment data and any structure-activity relationship(s) with respect to the applicable Target Binders) from each Selection Campaign for such Collaboration Target.
For clarity, the Selection Campaign Results includes any list of Target Binder Hits for the respective Selection Campaign. 

1.214    “Settlement Sublicensee” means a Third Party that is granted a license or sublicense under a
settlement agreement between such Third Party and a Party, any of its Affiliates, or any of its or their respective licensees or sublicensees, which agreement was entered into in connection with any settlement or similar agreement. 

1.215    “Short-Form Dispute” is defined in Section 17.6.3 (Baseball Arbitration). 

1.216    “Sole IP” is defined in Section 12.5 (Ownership). 

  
 25 

 1.217    “Subcommittee” is defined in
Section 9.3.1 (JSC Membership). 
 1.218    “Sublicensee” means, with respect to Gilead, a Third
Party to whom Gilead has granted a sublicense or license in accordance with Section 12.3 (Sublicensing), either directly or indirectly, under the Nurix IP, in each case licensed to Gilead by Nurix pursuant to this Agreement, to Develop,
Manufacture or Commercialize a Licensed Product in the Field in the Territory, but excluding: (a) any Third Party acting as a distributor and (b) Nurix and any of its Affiliates. 

1.219    “Tabled Target” is defined in Section 2.2.1(b) (Initial and Replacement Targets). 

1.220    “Target” means (a) a specific protein that is (i) identified by a GenBank protein
accession number or by its amino acid sequence and (ii) coded by a genetic locus or (b) any non-synonymous mutation or splice variation of such protein described in
sub-clause (a) of this Section 1.220 (Target). 

1.221    “Target Binder” means, with respect to a Collaboration Target, any compound that is:
(a) discovered or derived from a DEL screen for such Collaboration Target (without any corresponding deoxyribonucleic acid tag), (b) based upon a molecule that has been publicly disclosed, or (c) provided by Gilead as Gilead Materials for
use in such Research Program and is Directed To the Collaboration Target of such Research Program (sub-clause (c), a “Gilead Target Binder”). 

1.222    “Target Binder Hit” means, with respect to a particular Collaboration Target, any Target Binder
Controlled by Nurix Directed To such Collaboration Target that is identified by the Working Group. 

1.223    “Target Binder Selection Milestone” is defined in
sub-section (a) in the table in Section 11.6.1 (Pre-Clinical Milestones). 

1.224    “Target Exclusivity Period” means: 

1.224.1     with respect to any Collaboration Target, the period commencing on (a) the Effective Date (with respect
to any Initial Collaboration Target) or (b) such day that a Target becomes a Collaboration Target in accordance with Section 2.2.1 (Initial and Replacement Targets) (with respect to any Replacement Collaboration Target) and ending on (i)
[*] of the applicable License Option Effective Date (if a License Option is exercised on any Degrader Product Directed To such Collaboration Target in accordance with Section 3.2 (License Option)) or (ii) the earlier of (x) the last
day of the applicable License Option Period or (y) such day that such Collaboration Target becomes a Tabled Target (in the case of sub-clause (ii), if no License Option is exercised on any Degrader
Product Directed To such Collaboration Target in accordance with Section 3.2 (License Option)); 
 1.224.2     with
respect to any Tabled Target, the period commencing on such day that a Collaboration Target becomes a Tabled Target and ending on the earlier of (a) the last day of the applicable License Option Period or (b) such day that such Target
becomes a Collaboration Target; and 

  
 26 

 1.224.3     with respect to any Reserved Target, the period commencing
on such day that a Target becomes a Reserved Target and ending on the earlier of (a) the last day of the applicable Reserved Target Period or (b) such day that such Target becomes a Collaboration Target or ceases to be a Reserved Target.

 For clarity, if any Target Exclusivity Period under Section 1.224.1 (Target Exclusivity Period), Section 1.224.2 (Target Exclusivity Period) or
Section 1.224.3 (Target Exclusivity Period), as may be applicable, ends, but upon the expiration of such Target Exclusivity Period a Target is subject to another Target Exclusivity Period under this Section 1.224 (Target Exclusivity
Period), such other Target Exclusivity Period will apply upon such expiration. 
 1.225    “Taxes” is
defined in Section 11.10.3 (Generally). 
 1.226    “Term” is defined in Section 16.1.1
(Term). 
 1.227    “Terminated Licensed Product” means: (a) in the case of the termination of
this Agreement with respect to a Licensed Product pursuant to Section 16.2 (Termination for Material Breach) or Section 16.3 (Termination at Will), the Licensed Product subject to such termination; (b) in the case of the termination
of this Agreement with respect to a country pursuant to Section 16.2 (Termination for Material Breach) or Section 16.3 (Termination at Will), all Licensed Products with respect to such country; and (c) in the case of termination of
this Agreement in its entirety pursuant to Section 16.2 (Termination for Material Breach) or Section 16.4 (Termination for Bankruptcy), all Licensed Products in all countries in the Territory. 

1.228    “Territory” means worldwide. 

1.229    “Third Party” means any Person other than Nurix or Gilead that is not an Affiliate of Nurix or
of Gilead. 
 1.230    “Third Party Claim” means any and all suits, claims, actions, proceedings or
demands brought by a Third Party. 
 1.231    “Third Party Infringement” is defined in
Section 12.8.1 (Notification). 
 1.232    “Third Party Target Restriction” is defined in
Section 2.2.1(c) (Initial and Replacement Targets). 

1.233    “Top-Line Data” is defined in Section 8.1.2
(Exercise of Profit-Share Options). 
 1.234    “Transferred Inventory” is defined in Section 10.3
(Licensed Products Inventory Transfer). 
 1.235    “United States” or “U.S.” means
the United States of America and all of its territories and possessions. 
 1.236    “Upstream License
Agreement” means any contract or agreement with a Third Party pursuant to which Nurix in-licenses or otherwise acquires Control of Patents, Know-How or other
intellectual property rights that constitute Nurix IP for purposes of this Agreement, including 

  
 27 

 
such Upstream License Agreements set forth on Schedule 1.236 (each, an “Existing Upstream License Agreement”) and any agreements which become Upstream License Agreements pursuant
to Section 10.5 (Upstream License Agreements). 
 1.237    “Valid Claim” means a claim of a Patent
that: (a) has issued and (b) has not expired, lapsed, been cancelled or abandoned, or been dedicated to the public, disclaimed or held unenforceable, invalid, revoked or cancelled by a court or administrative agency of competent
jurisdiction in an order or decision from which no appeal has been or can be taken, including through opposition, reexamination, reissue, disclaimer, inter partes review, post grant procedures or similar proceedings. 

1.238    “VAT” means value added tax. 

1.239    “Wire Instructions” is defined in Section 11.1 (Upfront Payment). 

1.240    “Working Group” is defined in Section 9.2 (Working Group). 

ARTICLE 2 
 RESEARCH

 2.1    Research Programs. 

2.1.1    Research Programs. Subject to the terms and conditions herein, during each applicable Research Term, on a
Collaboration Target-by-Collaboration Target basis, Nurix will conduct the Research activities in the applicable Research Plan (other than those activities expressly
allocated to Gilead thereunder) and will use Commercially Reasonable Efforts to identify a Target Binder, Degrader Compound or Degrader Product (as applicable), in each case (a) that is Directed To such Collaboration Target and (b) that
meets the applicable Advancement Criteria for each Research Phase. Each Research Program will be subject to the oversight of the JRC and the JSC. As between the Parties and subject to Section 11.4 (Selection Campaign Fee), each Party will bear
its own costs and expenses incurred by or on behalf of it or its respective Affiliates in the performance of such Party’s respective Research activities under this Agreement. 

2.1.2    Research Term. The Research activities hereunder will commence, on a Research Program-by-Research Program basis, on: (a) with respect to each Research Program for an Initial Collaboration Target, the Effective Date; and (b) with respect to
each Research Program for a Replacement Collaboration Target, such date that a Target replaces the Collaboration Target of such Research Program in accordance with Section 2.2.1 (Initial and Replacement Targets), and, unless terminated earlier,
will conclude on the [*] of the Effective Date (such period, the “Initial Research Term”). Gilead will have the right to extend, on a Collaboration
Target-by-Collaboration Target basis, each Initial Research Term with respect to any Research Program for such Collaboration Target then active at the end of such
Initial Research Term, for an additional [*] period (each, an “Extended Research Term” and, together with the Initial Research Term, subject to extension in accordance with this Section 2.1.2 (Research Term) and
Section 11.2 (Research Term Extension Fee), a “Research Term”) by providing written notice to Nurix at least [*] prior to the expiration of such Initial Research Term and paying the applicable fee set forth in Section 11.2
(Research Term Extension Fee) (each such extension, a “Research Extension”). In the event that the Collaboration Target of any Research Program has become a Tabled Target and 

  
 28 

 
is not active at the end of the Initial Research Term, the Parties may, upon mutual written agreement, agree to extend such period of time in accordance with and subject to the terms and
conditions of this Section 2.1.2 (Research Term), including payment of the applicable fee set forth in Section 11.2 (Research Term Extension Fee). 

2.1.3    Initial and Replacement Research Plans. The initial Research Plan for each of the Initial Collaboration
Targets is attached hereto as a sequentially numbered part of Exhibit A.1 (e.g., Exhibit A.1-(i), Exhibit A.1-(ii)). Within [*] following receipt by Nurix’s
Alliance Manager of a Collaboration Target Replacement Notice and subject to Section 2.2.1(c) (Initial and Replacement Targets), the JRC will discuss, prepare and approve a Research Plan for the respective Replacement Collaboration Targets.
Each Research Plan will be substantially consistent with the form of Research Plan attached hereto as Exhibit A and will include: (a) an identification of the Collaboration Target, (b) the specific activities for each Research Phase to be
performed by a Party with respect to such Collaboration Target, (c) an estimated timeline for the conduct of specific Research activities under the applicable Research Program, (d) the deliverables under such Research Program, (e) a
description of any Gilead Provided Property that will be provided for such Research Program, (f) the Advancement Criteria for each Research Phase under such Research Program, (g) the terms of supply of Degrader Products and Degrader
Compounds by Nurix to Gilead and any activities that may be performed by Gilead with respect to such Degrader Products and Degrader Compounds (including to validate the results included in any Interim Data Package or Final Data Package) and
(h) any other terms applicable to such Research Program. In addition, each Research Plan will provide, unless otherwise agreed by the JRC, that Gilead will control and perform (i) all pilot toxicology studies for any non-oncology Selected Degrader Compound that is Directed To a Progressed Collaboration Target under the applicable Research Program and (ii) in vivo efficacy studies for any
non-oncology Selected Degrader Compound nominated for such activities by the JRC under the applicable Research Program, in each case ((i) and (ii)) at Gilead’s cost and as further described in the
applicable Research Plan. From time to time (at least on an annual basis), the JRC will discuss, prepare and approve amendments, as appropriate, to each then-current Research Plan. Each amended Research Plan will become effective and supersede the
previous Research Plan as of the date of approval by the JRC. In addition, no later than [*] following receipt of a notice for a Research Extension with respect to any Research Program, the JRC will discuss, prepare and approve an amended Research
Plan for the Collaboration Target subject to such Research Extension. 
 2.2    Collaboration Targets. 

2.2.1    Initial and Replacement Targets. 

(a)     The five (5) Targets listed in Schedule 2.2.1 (Initial Collaboration Targets) are each
Collaboration Targets on the Effective Date (each, an “Initial Collaboration Target”). 

(b)    With respect to each Collaboration Target, and subject to this Section 2.2.1 (Initial and
Replacement Targets), Gilead will have the right beginning on the Effective Date and ending on the [*] of the Effective Date (the “Collaboration Target Replacement Period”) upon written notice to Nurix’s Alliance Manager (each,
a “Collaboration Target Replacement Notice”) to select a Target (other than a Target 

  
 29 

 
deemed to be an Excluded Target at such time) to replace such Collaboration Target (“Replacement Right”) (such replaced Collaboration Target thereafter, a “Tabled
Target”), provided, however, that (i) there will be in no event more than five (5) Collaboration Targets in total under this Agreement at any time during the Research Term, (ii) at any given time during the Research Term,
there will be no more than five (5) Research Programs with Collaboration Targets then ongoing, (iii) Gilead may not exercise its Replacement Right to replace any Progressed Collaboration Target or any Collaboration Target for which Gilead
has exercised its License Option, (iv) Gilead shall have the right to exercise its Replacement Right for the [*] under this Section 2.2.1(b) (Initial and Replacement Targets) without paying the Selection Campaign Fee, (v) for each of
the [*] that Gilead exercises its Replacement Right under this Section 2.2.1(b) (Initial and Replacement Targets), Gilead shall pay the Selection Campaign Fee in accordance with Section 11.4 (Selection Campaign Fee), and (vi) Gilead
shall only have the right to exercise its Replacement Right a maximum of [*], after which Gilead shall no longer have the right to exercise its Replacement Right. Additionally, with prior mutual written agreement of both Parties, the Parties may
(x) replace any Collaboration Target after the Collaboration Target Replacement Period, (y) perform more than [*] in total or (z) replace any Progressed Collaboration Target. 

(c)     In the event that Gilead wishes to replace a Collaboration Target, Gilead will provide a
Collaboration Target Replacement Notice to Nurix’s Alliance Manager identifying (i) the Collaboration Target to be replaced and (ii) the Target to replace such Collaboration Target. Nurix will provide written notice to Gilead’s
Alliance Manager no later than [*] following the receipt by Nurix’s Alliance Manager of the applicable Collaboration Target Replacement Notice (each, a “Replacement Collaboration Target Objection Period”) as to whether
(x) Nurix or one of its Affiliates has entered into a written agreement with a Third Party to undertake DEL screening or other Research activities with respect to such replacement Target exclusively in collaboration with or on behalf of such
Third Party, which agreement is then in effect (each such restriction, a “Third Party Target Restriction,” and each such proposed replacement Target, an “Exclusive Third Party Target” for so long as such Target is
subject to such a Third Party Target Restriction) or (y) such Target is a Nurix Internal Target (provided that Nurix provides Gilead at such time with documentation reasonably evidencing that such Target is a Nurix Internal Target). If Nurix
notifies Gilead’s Alliance Manager that such proposed replacement Target is an Exclusive Third Party Target or Nurix Internal Target within the applicable Replacement Collaboration Target Objection Period and timely provides Gilead with any
required written evidence described in this Section 2.2.1(c) (Initial and Replacement Targets) (as applicable), then such replacement Target will be deemed to be included in Schedule 2.2.2 (Exclusive Third Party Targets and Nurix Internal
Targets) and will not become a Collaboration Target hereunder. If Nurix notifies Gilead’s Alliance Manager that such Target is neither an Exclusive Third Party Target nor a Nurix Internal Target, or if Nurix fails to provide any notice
regarding whether such Target is an Exclusive Third Party Target or Nurix Internal Target within the Replacement Collaboration Target Objection Period, then Gilead’s Alliance Manager will so notify the JRC and the JRC will discuss, prepare and
approve a Research Plan for such replacement Target in accordance with Section 2.1.3 (Research Plans). Upon the JRC’s approval of a Research Plan for such replacement Target in accordance with Section 2.1.3 (Research

  
 30 

 
Plans), each such replacement Target will be deemed to be a Collaboration Target hereunder, and the replaced Collaboration Target will no longer be deemed to be a Collaboration Target hereunder
and shall thereafter be a Tabled Target. 
 (d)    Nurix may propose to Gilead Targets to replace
Collaboration Targets, but, subject to this Section 2.2.1 (Initial and Replacement Targets), Gilead will have sole discretion as to whether to replace any Collaboration Target with any Target proposed by Nurix. 

(e)     Subject to this Section 2.2.1 (Initial and Replacement Targets), Gilead will have the right to
exercise its Replacement Right by replacing a Collaboration Target with a Tabled Target at any time during the Collaboration Target Replacement Period. Each such reselected Tabled Target will be deemed to be a new Replacement Collaboration Target
for purposes of calculating the number of Collaboration Target replacements under this Section 2.2.1 (Initial and Replacement Targets) subject to the maximum number of replacements described therein. For clarity, with mutual written agreement
of both Parties, the Parties may reselect a Tabled Target to replace a Collaboration Target after the Collaboration Target Replacement Period. 

(f)     With respect to any Excluded Target set forth in Schedule 2.2.2 (Exclusive Third Party Targets and
Nurix Internal Targets) or any Target that becomes an Excluded Target under Section 2.2.1(c) (Initial and Replacement Targets) due to such Target being either an Exclusive Third Party Target or Nurix Internal Target, Nurix will promptly inform
Gilead’s Alliance Manager of [*] or (ii) such Target ceasing to be a Nurix Internal Target. Upon such Alliance Manager’s receipt of such notice, such Target will no longer be deemed to be an Exclusive Third Party Target or Nurix
Internal Target (as applicable) hereunder, and Gilead will be free to nominate such Target again to be a Collaboration Target in accordance with Section 2.2.1(c) (Initial and Replacement Targets), provided such Target is not otherwise an
Excluded Target at such time of nomination. 
 2.2.2    Excluded Targets. Schedule 2.2.2 (Exclusive Third Party
Targets and Nurix Internal Targets) sets forth a complete and accurate list of all Exclusive Third Party Targets and Nurix Internal Targets as of the Effective Date. 

2.2.3    Tabled Targets. Subject to Section 2.9.1 (Exclusivity Period), Nurix shall have the right, but not
the obligation, to perform Research on any Collaboration Target that becomes a Tabled Target. For clarity, all such Research by Nurix on a Tabled Target shall be deemed as being performed outside of a Research Program. 

2.3    Reserved Targets. 

2.3.1    Reserved Targets. Subject to the terms and conditions of this Section 2.3.1 (Reserved Targets) and
Section 11.3 ([*] Reservation Fee Per Target), at any given time during the Collaboration Term, Gilead may designate up to three (3) Targets in total (other than any Target that is deemed to be a Collaboration Target, Tabled Target or
Excluded Target at such time) that will be subject to the exclusivity obligations set forth in Section 2.9 (Exclusivity) (each, a 

  
 31 

 
“Reserved Target”). The three (3) Reserved Targets as of the Effective Date (each, an “Initial Reserved Target”) are set forth in Schedule 2.3.1
(Initial Reserved Targets). In the event that Gilead wishes to replace a Reserved Target that (a) has become a Collaboration Target in accordance with the process set forth in Section 2.2.1 (Initial and Replacement Targets) or (b) is
no longer a Reserved Target because the applicable [*] period described in Section 11.3 has expired with respect to such Reserved Target, Gilead will provide a notice to Nurix’s Alliance Manager identifying the Target to replace such
former Reserved Target, provided that there will be no more than three (3) Reserved Targets at any given time; provided, further, that if, for any reason, a Target is not held as a Reserved Target for the entire [*] period described in
Section 11.3, then Gilead may elect to designate a replacement Reserved Target to fill such spot for the remainder of such [*] period without payment of an additional [*] Reservation Fee Per Target. Nurix will provide written notice to
Gilead’s Alliance Manager no later than [*] following the receipt by Nurix’s Alliance Manager of such notice (each, a “Reserved Target Objection Period”) as to whether such Target is an Exclusive Third Party Target or
Nurix Internal Target. If Nurix notifies Gilead’s Alliance Manager that such Target is an Exclusive Third Party Target or Nurix Internal Target within the applicable Reserved Target Objection Period, then such replacement Target will be deemed
to be included in Schedule 2.2.2 (Exclusive Third Party Targets and Nurix Internal Targets) and will not become a Reserved Target hereunder. If Nurix notifies Gilead’s Alliance Manager that such Target is neither an Exclusive Third Party Target
nor Nurix Internal Target, or if Nurix fails to provide any notice regarding whether such Target is an Exclusive Third Party Target or Nurix Internal Target within the applicable Reserved Target Objection Period, then upon such notice or expiration
of the applicable Reserved Target Objection Period (as applicable) such replacement Target will immediately become a Reserved Target. If, prior to the expiration of any [*] period described in this Section 2.3.1 (Reserved Targets), Gilead
elects to keep a Target as a Reserved Target for the immediately subsequent [*], Gilead may keep such Target as a Reserved Target for such subsequent period without Nurix objecting to such extension as set forth above, so long as Gilead timely pays
the [*] Reservation Fee Per Target for such subsequent period. For clarity, except as expressly set forth in this Section 2.3.1, Gilead’s right to reserve any Reserved Target is subject to Gilead’s payment of the [*] Reservation Fee
Per Target for such Reserved Target as set forth in Section 11.3 ([*] Reservation Fee Per Target). 

2.3.2    Expiration of Third Party Target Restriction. With respect to any Target that becomes an Excluded Target
under Section 2.3.1 (Reserved Targets) due to such Target being an Exclusive Third Party Target or Nurix Internal Target, Nurix will promptly inform Gilead’s Alliance Manager of any Target ceasing to be an Exclusive Third Party Target or
Nurix Internal Target (as applicable). Upon such Alliance Manager’s receipt of such notice, such Target will no longer be deemed to be an Excluded Target hereunder, and Gilead will be free to nominate such Target again to be a Reserved Target
in accordance with Section 2.3.1 (Reserved Targets). 
 2.4    Selection Campaigns. Nurix will conduct a
Selection Campaign on each Collaboration Target in accordance with the applicable Research Plan. For clarity, Nurix may perform Selection Campaigns in parallel for more than one Collaboration Target at any given time while Research activities are
ongoing hereunder. If Nurix has performed Selection Campaigns on [*] Collaboration Targets, Gilead will pay the fee set forth in Section 11.4 (Selection Campaign Fee) for each Selection Campaign performed on any additional Target in excess of
[*]. 

  
 32 

 2.5    Research Activities. Nurix will use Commercially
Reasonable Efforts to identify Target Binders, Degrader Compounds and Degrader Products (as applicable) in each case Directed To the respective Collaboration Target that meet the applicable Advancement Criteria. Nurix will disclose all results from
each Research Phase for such Collaboration Target to the Working Group, and the Working Group shall share such Research Results with the JRC. The JRC will (a) review such results, (b) determine whether any Target Binder, Degrader Compound
or Degrader Product (as applicable) meets the applicable Advancement Criteria, for purposes of guiding the JRC’s decision of whether to advance such Target Binder, Degrader Compound or Degrader Product (as applicable) to the next Research
Phase, (c) decide whether any Target Binder or Degrader Compound will be a Selected Target Binder or Selected Degrader Compound, respectively, and (d) decide whether such Target Binder, Degrader Compound or Degrader Product (as applicable)
will be the subject of further Research activities. If the JRC elects to advance any such Target Binder, Degrader Compound or Degrader Product (as applicable) to the next Research Phase, Nurix may elect to continue conducting Research regarding the
suitability and feasibility of other Target Binders to function as part of Degrader Compounds for such Research Program for the remainder of the applicable Research Term. In addition, the JRC will identify any Degrader Product that meets all
applicable Advancement Criteria, and will decide whether to advance any Degrader Product to Development. 

2.6    Gilead Provided Property. 

2.6.1    Provision of Gilead Materials. Gilead will provide Nurix with (a) the Gilead Materials (including any
Gilead Target Binder) set forth in the applicable Research Plan and (b) any other data or written materials and information that relate to such Gilead Materials set forth in the applicable Research Plan (“Gilead
Documentation”). Nurix will have a period of thirty (30) days after Nurix’s receipt thereof, or such longer period of time as may be determined by the JRC, during which Nurix may validate the Gilead Materials and Gilead
Documentation provided by Gilead for a Collaboration Target, in each case, for the purpose of quality control, which may include ensuring the suitability of the Gilead Materials and Gilead Documentation provided by Gilead to be used as part of a
Research Program. Nurix may develop or generate any materials or assays that are necessary to perform any Research activities set forth under a Research Plan for a Collaboration Target if the Parties agree in writing that the Gilead Provided
Property with respect to a Collaboration Target are not available or are insufficient for use in the performance of such Research activities. 

2.6.2    Property of Gilead. All Gilead Provided Property will remain at all times the property of Gilead. No
Gilead Provided Property, or any derivatives, analogs, modifications or components thereof, may be transferred, delivered or disclosed (subject to exceptions to Confidential Information as set forth in Section 13.2 (Exceptions)) to any Third
Party without the prior written approval of Gilead. Nurix and its Affiliates may only use the Gilead Provided Property related to a particular Collaboration Target for the applicable Research Program and for no other purpose. Nurix will not, and
Nurix will cause its Affiliates to not, distribute or release the Gilead Provided Property to any Person other than Nurix’s or Nurix Affiliate’s laboratory personnel under the direct supervision of Nurix or a Nurix Affiliate. Gilead will
have no obligation to provide to Nurix additional Gilead Provided Property related to any Collaboration Target beyond those described in the applicable Research Plan for such Collaboration Target. Nurix will not use, and will ensure that its
Affiliates (as applicable) do not use, the Gilead Provided Property 

  
 33 

 
in connection with any Research or other activities that are subject to consulting or licensing obligations to any Third Party. Nurix will use, and will ensure that its Affiliates (as applicable)
use, the Gilead Provided Property in compliance with all Applicable Law. 
 2.6.3    No Warranties. NURIX
UNDERSTANDS THAT ALL GILEAD PROVIDED PROPERTY ARE SUPPLIED ON AN “AS IS” AND “WHERE IS” BASIS. NURIX ACKNOWLEDGES THAT GILEAD MATERIALS ARE EXPERIMENTAL IN NATURE AND MAY HAVE UNKNOWN HAZARDOUS CHARACTERISTICS, THAT NURIX IS
AWARE OF THE RISKS OF WORKING WITH EXPERIMENTAL MATERIAL AND THAT NURIX WILL STRICTLY ADHERE TO PROPER LABORATORY PROCEDURES FOR HANDLING MATERIAL WITH UNKNOWN HAZARDS AND ANY OTHER INSTRUCTIONS PROVIDED BY GILEAD WITH RESPECT TO SUCH GILEAD
MATERIALS. THE GILEAD MATERIALS WILL NOT BE USED IN HUMANS BY OR ON BEHALF OF NURIX OR ITS AFFILIATES. 

2.7    Information Sharing; Records Retention 

2.7.1    Information Sharing. During the applicable Research Term at each meeting of the JRC or as otherwise agreed
by the Parties, the Working Group will provide the JRC with written reports or presentations regarding the respective Selection Campaign Results (including Target Binder Hits) and each Party’s activities (as applicable) with respect to the
Research of respective Degrader Compounds and Degrader Products. In addition, during the Initial Research Term, Nurix will keep the Working Group reasonably informed of any Research activities conducted by Nurix or its Affiliates outside of this
Agreement on any Tabled Target (including by promptly notifying the Working Group of the discovery by Nurix or one (1) of its Affiliates of any Target Binder Directed To such Tabled Target). Each report or presentation under this
Section 2.7.1 (Information Sharing) will cover such activities since the previous JRC meeting, including a summary of results, information and data with respect to such Target Binders, Degrader Compounds and Degrader Products. Upon request by
the JRC or by the other Party, a Party will provide the JRC with such other information and such additional access to records with respect to Target Binders, Degrader Compounds and Degrader Products as the JRC or such other Party may reasonably
request for the conduct or evaluation of the respective Research Programs, including the underlying information used to create such summaries, such as data listings, data sets and programs used for the analyses collected by a Party in the course of
conducting its activities with respect to the respective Target Binders, Degrader Compounds and Degrader Products. 

2.7.2    Interim Data Package. With respect to each Collaboration Target and Tabled Target, [*] prior to the
expiration of the Initial Research Term, Nurix will provide Gilead with an Interim Data Package for each such Collaboration Target or Tabled Target. With respect to each Collaboration Target, [*] prior to the expiration of the applicable Extended
Research Term, Nurix will provide Gilead with an Interim Data Package for each such Collaboration Target. Notwithstanding the foregoing, with respect to any Collaboration Target, Nurix shall have no obligation to deliver an Interim Data Package for
such Collaboration Target if Nurix previously provided a Final Data Package for such Collaboration Target in accordance with Section 2.7.3 (Final Data Package). For clarity, one (1) Interim Data Package will cover one
(1) Collaboration Target or Tabled Target (as applicable). 

  
 34 

 2.7.3    Final Data Package. With respect to each Collaboration
Target, within [*] following the day that the JRC approves of a Development Candidate Directed To such Collaboration Target, Nurix will provide Gilead with the Final Data Package for such Collaboration Target. 

2.7.4    Additional Information. At any time during the License Option Period for a Collaboration Target or Tabled
Target following Gilead’s receipt of an Interim Data Package or Final Data Package for such Target, Gilead may provide Nurix with written notice requesting additional information with respect to such Target and the Degrader Products and
Degrader Compounds in each case Directed To such Target, or a discussion with Nurix representative(s) who have the relevant knowledge and information regarding such Target, Degrader Products and Degrader Compounds (each, an “Information
Request Notice”). Nurix will provide such information or hold such discussion as promptly as practicable, provided that (a) Nurix will provide any information reasonably accessible to or Controlled by Nurix and hold any such discussion
regarding such information described in this sub-clause (a) no later than [*] following receipt of such Information Request Notice and (b) to the extent that such information is consistent with the
Research Plan but not reasonably accessible to or Controlled by Nurix, or such discussion regards such information described in this sub-clause (b), Nurix will use commercially reasonable efforts to perform
any additional Research activities and obtain such information or hold such discussion, no later than [*] following receipt of such Information Request Notice. To the extent that Gilead reasonably and in good faith determines that Nurix has not
materially complied with the previous sentence of this Section 2.7.4 (Additional Information), Gilead will notify Nurix thereof and the applicable License Option Period will be extended by a period corresponding to the number of days between
(i) the expiration of such [*] or [*] period (as applicable) following Nurix’s receipt of such Information Request Notice and (ii) the date such requested information is provided to Gilead or such discussion is held between Nurix and
Gilead, provided, however, that: (x) Gilead submitted such Information Request Notice at least [*] prior to the expiration of the applicable License Option Period with respect to the information and discussions described in sub-clause (a) above and Gilead submitted such Information Request Notice at least [*] prior to the expiration of the applicable License Option Period with respect to the information and discussions described
in sub-clause (b) above; and (y) in no event will such extension period exceed [*]. Notwithstanding anything to the contrary in this Agreement, Nurix’s obligations under this Section 2.7.4
(Additional Information) with respect to any Target shall expire upon the expiration of the applicable License Option Period for such Target. 

2.7.5    Research Review. No later than [*] months prior to the expiration of the Initial Research Term, the
Parties shall conduct a review of the status of all Research activities with respect to Collaboration Targets and Tabled Targets (including data related to achievement of, or progression towards achievement of,
Pre-Clinical Milestone Events). 
 2.7.6    Records Retention. On a
Research Program-by-Research Program basis, each Party will retain, and cause its Affiliates and its and their permitted subcontractors to retain, all records, accounts,
notes, reports, data and laboratory notebooks with respect to the Research activities performed under such Research Program until the third (3rd) anniversary of the expiration of the Research Term for such Research Program or such longer period as
may be required by Applicable Law. 

  
 35 

 2.8    Audits. With respect to any facility or site at which
Nurix conducts any Research activities hereunder, Gilead will have the right, at its own expense, upon reasonable written notice to Nurix, and during normal business hours, to inspect such site and facility of Nurix and to accompany Nurix to inspect
any subcontractor site, in each case, no more than once per Calendar Year and also for cause, to verify Nurix’s compliance with Applicable Law in carrying out its obligations under this Agreement, including those relating to GMP, GLP and GCP.
In the event that any such facility or site is found to be non-compliant with GMP, GLP or GCP during such an audit, and such non-compliance relates to or impacts any
Research activities hereunder, Nurix will submit to Gilead proposed corrective and preventative actions (“CAPA”) within thirty (30) days after Gilead provides notice of such
non-compliance to Nurix. Gilead will have the right to review and comment on such CAPA, which comments Nurix will consider in good faith. Nurix will implement such CAPA promptly after review and comment by
Gilead. If any Governmental Authority conducts or gives notice of its intent to conduct any audit or inspection at any offices or facilities (including Research facilities) of Nurix or its Affiliates or any applicable permitted subcontractor where
such audit or inspection relates to any Degrader Product or Licensed Product, then Nurix will promptly notify Gilead and, to the extent such audit or inspection relates to a Degrader Product or Licensed Product and to the extent practicable and not
prohibited by Applicable Law, secure for Gilead the right to participate in any such audit or inspection. 

2.9    Exclusivity. 

2.9.1    Exclusivity Period. On a Restricted
Target-by-Restricted Target basis, during the applicable Target Exclusivity Period, Nurix will not conduct, and will cause its Affiliates to not conduct, in
collaboration with or on behalf of any Third Party any Research, Development, Manufacture or Commercialization activities with respect to any Restricted Target (including conducting any DEL screening on any Restricted Target, or directly or
indirectly Researching, Developing, Manufacturing or Commercializing any Competing Product of any product Directed To such Restricted Target, in each case in collaboration with or on behalf of any Third Party), other than such Research activities
expressly contemplated herein. In addition, and without limiting the foregoing, on a Collaboration Target-by-Collaboration Target basis, during the applicable Target
Exclusivity Period, Nurix will not conduct, and will cause its Affiliates to not conduct, on behalf of itself or themselves any Research, Development, Manufacture or Commercialization activities with respect to any Collaboration Target (including
conducting any DEL screening on any Collaboration Target, or directly or indirectly Researching, Developing, Manufacturing or Commercializing any Competing Product of any product Directed To such Collaboration Target in each case on behalf of itself
or themselves), other than such Research activities expressly contemplated herein. 
 2.9.2    Make Unavailable from
DEL Library. With respect to any Collaboration Target, immediately following the delivery of the Selection Campaign Results for such Collaboration Target to the JRC and identification of Target Binder Hits Directed To such Collaboration Target,
Nurix will promptly mark and identify all [*] from its DELs by electronic means so as to prevent such [*] Nurix may unmark and restore [*]. 

2.9.3    Exceptions for Change of Control. Notwithstanding anything in Section 2.9.1 (Exclusivity Period) to
the contrary, if Nurix undergoes a Change of Control and, on the date of the closing of such Change of Control, the Acquiring Person is Researching, 

  
 36 

 
Developing, Manufacturing or Commercializing a Competing Product for use in the Field (based on the applicable Regulatory Approval), then Nurix will not be in breach of Section 2.9.1
(Exclusivity Period) as a result of such Change of Control or the continuation of such activities by such Acquiring Person thereafter; provided that such Acquiring Person: (a) provides written notice to the Party which is not subject to such
Change of Control no later than sixty (60) days following the closing of such Change of Control which identifies such Competing Product and (b) Segregates such Competing Product. 

2.9.4    Research Results. All Research Results will be deemed the Confidential Information of both Parties;
provided, however, that (a) upon the expiration of a Target Exclusivity Period for any Collaboration Target or Tabled Target for which no License Option is exercised on a Degrader Product Directed To such Target, all Research Results related to
such Target will be deemed the Confidential Information of Nurix (and not Gilead), provided that Gilead and its Affiliates [*] and (b) all Research Results related to any Collaboration Target or Tabled Target for which Gilead has exercised a
License Option on a Degrader Product Directed To such Target will be deemed the Confidential Information of Gilead (and not Nurix) upon the exercise of such License Option. 

ARTICLE 3 
 LICENSE
OPTION 
 3.1    General. Subject to the terms of this Agreement, including this Section 3.1 (General)
and Section 3.2 (License Option), Nurix hereby grants to Gilead an exclusive option, on a Collaboration Target-by-Collaboration Target and Tabled Target-by-Tabled Target basis, during the applicable License Option Period for such Target, to obtain the exclusive license described in Section 12.1.2 (License to
Gilead), under the Nurix IP and Nurix’s interest in the Joint IP, to Develop, Manufacture and Commercialize Licensed Products Directed To such Target in the Field in the Territory (each, a “License Option”) on the terms
and conditions set forth in this Agreement; provided, however, that Gilead may exercise no more than five (5) License Options hereunder. For clarity, any such exercise will be determined by Gilead in its sole discretion. 

3.2    License Option. 

3.2.1    License Option Exercise. Gilead may exercise each License Option (each, a “License Option
Exercise”) at any time during the applicable License Option Period by providing written notice thereof (each, a “License Option Exercise Notice”) to Nurix, which notice will (a) identify the Degrader
Product(s) subject to such License Option Exercise, and (b) include Gilead’s determination as to whether any filings, notices, applications or other submissions under Antitrust Law are necessary or advisable in connection with such License
Option Exercise (each such filing, notice, application or other submission, an “Antitrust Filing”). In the event that Gilead does not provide a License Option Exercise Notice to Nurix with respect to a Collaboration Target within
the applicable License Option Period, then (a) if the Initial Research Term has not yet expired at such time, such Target shall become a Tabled Target upon the expiration of the applicable License Option Period (and Gilead may exercise a
License Option again with respect to such Tabled Target in accordance with the terms and conditions contained herein), and (b) if the Initial Research Term has expired at such time, Nurix’s exclusivity obligations under Section 2.9
(Exclusivity) and the license grant under Section 12.1.2 (License to Gilead) will terminate in each case with respect to such Collaboration Target. 

  
 37 

 3.2.2    Tabled Targets. For clarity, and subject to
Section 3.1 (General) and this Section 3.2 (License Option) (including with respect to the limit on the number of License Option Exercises by Gilead as described therein), Gilead shall have the right to exercise its License Option with
respect to Degrader Products and Degrader Compounds in each case Directed To Tabled Targets as if such Tabled Target were a Collaboration Target, in which case such Tabled Target will be deemed a Collaboration Target for all purposes under this
Agreement. If Gilead does not exercise its License Option with respect to such Tabled Target prior to the expiration of the applicable License Option Period for such Tabled Target, then such Tabled Target shall be deemed a “Reverted
Target.” 
 3.2.3    License Option Period Extension. Upon written notice by Gilead to Nurix prior to
the expiration of the applicable License Option Period (which notice may be delivered by Gilead to Nurix in Gilead’s sole discretion and for any reason), Gilead may extend such License Option Period for an additional [*] days. 

3.3    Antitrust Filings. 

3.3.1    Filings. As soon as reasonably practicable following the date on which Gilead provides a License Option
Exercise Notice to Nurix in accordance with Section 3.2.1 (License Option Exercise) (the “License Option Exercise Date”) and in any event within ten (10) Business Days following the applicable License Option
Exercise Date, each of Nurix and Gilead will prepare and submit any Antitrust Filings, including any such required filings under the HSR Act and the rules promulgated thereunder, with respect to the relevant License Option Exercise. In connection
with any such Antitrust Filings, the Parties will furnish promptly to the United States Federal Trade Commission (the “FTC”), the Antitrust Division of the United States Department of Justice (the “DOJ”) and any
other applicable Governmental Authority any additional information requested within their authority under the HSR Act or other Antitrust Law, use reasonable efforts to obtain antitrust clearance for the transactions contemplated hereunder as soon as
practicable with respect to the applicable License Option Exercise and otherwise cooperate with each other in the governmental antitrust clearance process. Gilead will bear all fees in connection with any filings under this Section 3.3
(Antitrust Filings), and each Party will bear its respective attorneys’ fees and other expenses in connection therewith. 

3.3.2    Effectiveness. Following a License Option Exercise, Gilead’s rights and obligations hereunder in
connection with such License Option Exercise (including any licenses to be granted in connection therewith) will not become effective unless and until: (a) (i) the applicable waiting period provided by the HSR Act, if any, will have expired or
been terminated and all other required antitrust clearances under Antitrust Law have been obtained (solely to the extent applicable to any Antitrust Filings) or (ii) where Gilead determines that no Antitrust Filings are required under Antitrust
Law and (b) Nurix shall have delivered to Gilead a written document, signed by a duly authorized officer of Nurix, certifying that each of the representations and warranties set forth in Section 14.2 (Representations and Warranties of
Nurix) have not materially changed since the last Disclosure Letter was provided to Gilead (provided that Nurix shall provide such Disclosure Letter to Gilead within ten (10) days following the occurrence of
sub-clause (i) or 

  
 38 

 
(ii), as applicable) (the occurrence of (a) and (b)), with respect to such License Option Exercise, the “License Option Effective Date.” In addition, Nurix shall
provide a Disclosure Letter to Gilead at such time as it provides an Interim Data Package or Final Data Package to Nurix for purposes of Section 14.2 (Representations and Warranties of Nurix). 

3.3.3    Outside Date. If (a) Gilead identifies any Antitrust Filings in a License Option Exercise Notice in
accordance with Section 3.2.1 (License Option Exercise) and (b) the applicable License Option Effective Date does not occur on or before [*] after the applicable License Option Exercise Date (each, an “Initial Outside
Date”), then Gilead may, in its sole discretion, provide written notice to Nurix on or prior to the applicable Initial Outside Date to extend such Initial Outside Date by [*] (an Initial Outside Date, as it may be extended, if applicable,
an “Outside Date”). 
 3.4    Treatment of Compounds Incorporating Gilead Target Binders.
In the event that no License Option is exercised by the last day of the applicable License Option Period with respect to a Collaboration Target or Tabled Target for which Gilead has provided a Gilead Target Binder to Nurix for the performance of
Research activities with respect to such Target, and such Gilead Target Binder has been incorporated into a Degrader Product or Degrader Compound in each case Directed To such Target and such Degrader Product or Degrader Compound has achieved [*],
the Parties will negotiate with one another in good faith to reach a written agreement pursuant to which Gilead would grant Nurix a license under any and all Gilead Sole IP or Gilead Background IP in each case that is reasonably necessary for the
Manufacture, use or sale of such Degrader Product or Degrader Compound. 
 ARTICLE 4 

DEVELOPMENT 
 From and after the applicable
License Option Effective Date: 
 4.1    Responsibility. Subject to the terms and conditions of this Agreement,
Gilead will have the sole right to Develop (and will solely control, at its discretion, the Development of), itself or with or through its Affiliates, Sublicensees or other Third Parties, the respective Licensed Products in the Field in the
Territory. Subject to Section 8.1.2 (Exercise of Profit-Share Options), all such Development will be at Gilead’s sole cost and expense. 

4.2    Development Diligence. Subject to the terms and conditions of this Agreement, with respect to any
Collaboration Target for which Gilead has exercised a License Option, Gilead itself or with or through its Affiliates or Sublicensees or other Third Parties will use Commercially Reasonable Efforts to Develop, for purposes of seeking Regulatory
Approval of, at least one (1) Licensed Product in the United States and at least one (1) Licensed Product in a Major European Market. 

4.3    Development Updates. With respect to any Licensed Product, until the date on which Gilead has submitted an
MAA to the applicable Regulatory Authority for at least one (1) Licensed Product Directed To such Collaboration Target in the United States, Gilead will submit to Nurix, one (1) time per Calendar Year, a written report summarizing
Gilead’s material Development activities with respect to the Licensed Products Directed To such Collaboration Target pursuant to this Agreement since Gilead’s delivery of the prior report. 

  
 39 

 ARTICLE 5 

REGULATORY 
 From and after the applicable
License Option Effective Date: 
 5.1    Regulatory Matters. 

5.1.1    Responsibility. Subject to the terms and conditions of this Agreement, Gilead will have the sole right (and
will solely control, at its discretion), itself or with or through its Affiliates, Sublicensees or other Third Parties, to: (a) prepare and submit to applicable Regulatory Authorities all Regulatory Materials, including NDAs and INDs, for the
respective Licensed Products and (b) obtain and maintain all Regulatory Approvals for the respective Licensed Products. 

5.1.2    Communications with Regulatory Authorities. For clarity and without limiting Section 5.1.1
(Responsibility), Gilead will have the exclusive right to correspond or communicate with Regulatory Authorities regarding the respective Licensed Products. Unless required by Applicable Law, Nurix, its Affiliates and its permitted subcontractors
will not correspond or communicate with Regulatory Authorities regarding any respective Licensed Product without first obtaining Gilead’s prior written consent. If Nurix, its Affiliates or its permitted subcontractors receive any correspondence
or other communication from a Regulatory Authority regarding a Licensed Product, Nurix will provide Gilead with access to or copies of all such material written or electronic correspondence promptly after its receipt. 

5.1.3    Nurix Support. Nurix will support Gilead as may be reasonably requested by Gilead from time to time in
connection with Gilead’s preparation, submission to Regulatory Authorities and maintenance of Regulatory Materials for respective Licensed Products, including, upon Gilead’s reasonable request, attending meetings with Regulatory
Authorities regarding any respective Licensed Product. Nurix will bear all costs of the first [*] of such support per Collaboration Target under this Agreement; thereafter, Gilead will reimburse Nurix for the costs of its support at the rate of [*].

 5.2    Regulatory Materials. 

5.2.1    Existing Regulatory Materials. Except to the extent notified otherwise in writing by Gilead, on a Licensed Product-by-Licensed Product basis, Nurix will assign and transfer (and hereby does assign and transfer as of the applicable License Option Effective Date), or cause to be
assigned and transferred to the extent not owned by Nurix, to Gilead (or its designee), no later than ten (10) days after the applicable License Option Effective Date any and all Regulatory Materials for the applicable Licensed Products
Controlled by or on behalf of Nurix, its Affiliates or contractors as of or prior to the applicable License Option Effective Date (the “Existing Regulatory Materials”), including by providing true, accurate and complete hard and
electronic copies thereof to Gilead. From and after such assignment and transfer, Gilead (or its designee) will have the sole right, in its sole discretion, to file, maintain and hold title to all such Existing Regulatory Materials. 

  
 40 

 5.2.2    New Regulatory Materials. All Regulatory Materials
generated or arising from or in connection with activities under this Agreement with respect to Licensed Products after the License Option Effective Date for such Licensed Product will be owned by and held in the name of Gilead or its designee, and,
except for Existing Regulatory Materials (which are addressed in Section 5.2.1 (Existing Regulatory Materials)), any such Regulatory Materials issued in the name of Nurix, its Affiliates or contractors will, promptly following the applicable
License Option Effective Date, be assigned by Nurix to Gilead or its designee to the extent permitted by Applicable Law or, in the event assignment is not permitted under Applicable Law, held in trust for, or for the sole benefit of, Gilead or its
designee. 
 5.3    Right of Reference; Access to Data. In the event of failure to transfer and assign any
Regulatory Materials to Gilead or its designee, as required by Section 5.2.1 (Existing Regulatory Materials) or Section 5.2.2 (New Regulatory Materials), Gilead and its designees will have, and Nurix (on behalf of itself and its
Affiliates) hereby grants to Gilead and its designees, access (as described in Section 5.2.1 (Existing Regulatory Materials) or Section 5.2.2 (New Regulatory Materials)) and a right of reference (without any further action required on the
part of Nurix, its Affiliates or contractors, whose authorization to file this consent with any Regulatory Authority is hereby granted) to all Existing Regulatory Materials and Regulatory Materials described in Section 5.2.2 (New Regulatory
Materials) and all data contained or referenced therein for Gilead and its designees to exercise its rights and perform its obligations under this Agreement with respect to the applicable Licensed Products. In all cases, Gilead and its designees
will have access to all data contained or referenced in all such Regulatory Materials Section 5.2.1 (Existing Regulatory Materials) or Section 5.2.2 (New Regulatory Materials), and Nurix will ensure that Gilead and its designees are
afforded such access by fulfilling its obligations thereunder. 
 ARTICLE 6 

COMMERCIALIZATION 
 From and after the
applicable License Option Effective Date, and subject to the terms and conditions of this Agreement including Section 8.2 (Co-Detail Option), Gilead will have the sole right to Commercialize (and will
solely control, at its discretion, the Commercialization of), itself or with or through its Affiliates, Sublicensees or other Third Parties, the applicable Licensed Products in the Field in the Territory. Gilead will use Commercially Reasonable
Efforts to Commercialize at least one (1) Licensed Product in each Major Market Country in which Gilead achieves Regulatory Approval for a Licensed Product. Subject to Section 8.1.2 (Exercise of Profit-Share Options) and Section 8.2 (Co-Detail Option), all such Commercialization will be at Gilead’s sole cost and expense. 

ARTICLE 7 

MANUFACTURING; PHARMACOVIGILANCE 
 From and
after the applicable License Option Effective Date, and subject to the terms and conditions of this Agreement, Gilead will have the sole right to Manufacture (and will solely control, at its discretion, the Manufacture of), itself or with or through
its Affiliates, Sublicensees or other Third Parties, the respective Licensed Products in the Field in the Territory. Subject to Section 8.1.2 (Exercise of Profit-Share Options), all such Manufacturing will be at Gilead’s sole cost and
expense. 

  
 41 

 ARTICLE 8 

NURIX OPTIONS 

8.1    Profit-Share Options. 

8.1.1    Encumbered Licensed Products. Upon the replacement of any Collaboration Target in accordance with
Section 2.2.1 (Initial and Collaboration Targets), Gilead will notify Nurix in writing if a product that is Directed To such Collaboration Target would be an Encumbered Licensed Product if Gilead were to exercise its License Option with respect
to such Collaboration Target, and will provide Nurix with such documentation reasonably evidencing that such product would be an Encumbered Licensed Product if Gilead were to exercise its License Option with respect to such Collaboration Target. The
Parties acknowledge and agree that (a) no Encumbered Licensed Product will be subject to a Profit-Share Option and (b) at no point, if Gilead were to exercise its License Option with respect to all Collaboration Targets, may there be
Encumbered Licensed Products to more than two (2) Collaboration Targets. 
 8.1.2    Exercise of Profit-Share
Options. Within [*] after Gilead’s filing of a complete clinical study report to the FDA for the applicable Phase 1 Clinical Trial (or the applicable Phase 1 Clinical Trial portion of a combined Phase 1 Clinical Trial/Phase 2 Clinical
Trial) for a Licensed Product other than (a) a Combination Product or (b) an Encumbered Licensed Product, Gilead will deliver to Nurix a top-line data package from such Phase 1 Clinical Trial (or
such Phase 1 Clinical Trial portion of a combined Phase 1 Clinical Trial/Phase 2 Clinical Trial) (such package, a “Profit-Share Data Package”). Beginning on Gilead’s delivery of a Profit-Share Data Package and ending [*] after
delivery of such Profit-Share Data Package, Nurix will have the option, exercisable by written notice provided to Gilead (such option, a “Profit-Share Option,” and such notice, a “Profit-Share Option Exercise
Notice”), to negotiate the terms of an agreement with respect to such Licensed Product that are the subject of such Profit-Share Data Package as further described in Exhibit B (Profit-Share Exhibit). In the event that the Parties are unable
to reach agreement on and execute such agreement within the applicable Profit-Share Negotiation Period as defined in and described in Exhibit B (Profit-Share Exhibit), then either Party may submit such matter to baseball arbitration for resolution
in accordance with Section 17.6.3 (Baseball Arbitration). Nurix may only exercise a Profit-Share Option once per Licensed Product on up to two (2) Licensed Products, provided, however, that Gilead will have the right to veto the exercise
of one (1) (and only one (1)) Profit-Share Option by providing written notice to Nurix of such veto within [*] of Gilead’s receipt of the applicable Profit-Share Option Notice. In the event that Gilead vetoes Nurix’s exercise of a
Profit-Share Option for any Licensed Product, Nurix will be deemed as not having exercised its Profit-Share Option with respect to such Licensed Product, and Nurix will be allowed to exercise another Profit-Share Option on another Licensed Product
(for example, if Gilead vetoed Nurix’s exercise of a Profit-Share Option for the first Licensed Product for which Nurix sought to exercise a Profit-Share Option, Nurix will be allowed to exercise its Profit-Share Option on another two
(2) Licensed Products). Once Nurix exercises the Profit-Share Option on two (2) Licensed Products (without any veto thereof by Gilead), Nurix’s right to exercise the Profit-Share Options under this Agreement will irrevocably
terminate. Each Profit-Share Data Package shall include: (a) a top-line data summary, including with respect to primary and secondary endpoints, and a summary of safety data, in each case from the Phase 1
Clinical Trial (or the Phase 1 Clinical Trial portion of a combined Phase 1 Clinical Trial/Phase 2 Clinical Trial) (“Top-Line Data”), (b) all data generated with respect to any IND-enabling toxicity 

  
 42 

 
study for such Licensed Product and (c) all material correspondence to and from any Regulatory Authority regarding such Licensed Product. For clarity, the information contained in each
Profit-Share Data Package will be deemed the Confidential Information of Gilead. 
 8.2    Co-Detail Option. If Nurix exercises a Profit-Share Option under Section 8.1.2 (Exercise of Profit-Share Options), it will have the option (a “Co-Detail
Option”), exercisable by providing written notice to Gilead in the applicable Profit-Share Option Exercise Notice, to negotiate the terms of certain Detailing-related activities with respect to the applicable Profit-Share Product as set
forth in Exhibit B (Profit-Share Exhibit). In the event that the Parties are unable to reach agreement on and execute an agreement containing such terms, within the applicable Profit-Share Negotiation Period as defined in and described in Exhibit B
(Profit-Share Exhibit) either Party may submit such matter to baseball arbitration for resolution in accordance with Section 17.6.3 (Baseball Arbitration). If Nurix does not exercise the Co-Detail Option
in accordance with this Section 8.2 (Co-Detail Option) with respect to such Profit-Share Product, then such option will be deemed to be irrevocably waived with respect to such Profit-Share Product.
Notwithstanding the foregoing in this Section 8.2 (Co-Detail Option), with respect to any Collaboration Target, Nurix’s right to exercise any Co-Detail Option
hereunder will terminate upon (a) the closing of a Change of Control of Nurix or (b) Nurix or one of its Affiliates initiating a program to Research, Develop or Commercialize any product Directed To such Collaboration Target, whether
internally or together with a Third Party. 
 ARTICLE 9 

GOVERNANCE 

9.1    Alliance Manager. Within thirty (30) days following the Effective Date, each Party will appoint an
individual to act as the alliance manager for such Party (each, an “Alliance Manager”). Each Alliance Manager will thereafter be permitted to attend meetings of the JSC and any Subcommittee as a nonvoting observer. The Alliance
Managers will be the primary point of contact for the Parties regarding the activities contemplated by this Agreement and will help facilitate all such activities hereunder. At any given time, the Alliance Managers will be responsible for keeping a
then-current list of with respect to each Research Program (a) Selected Target Binders, Selected Degrader Compounds and all Degrader Compounds and Degrader Products that are being Researched under such Research Program, (b) Pre-Clinical Milestone Events that have been achieved and (c) Collaboration Targets, Excluded Targets, Reserved Targets and Tabled Targets under such Research Program. The Alliance Managers will also
keep the JSC reasonably informed of any changes to the items identified in the immediately previous sentence. 

9.2    Working Group. Within thirty (30) days after the Effective Date, the Parties shall establish a working
group (the “Working Group”) consisting of such number of employee representatives of a Party as such Party determines in its sole discretion, provided that such Party shall provide written notice from time to time to the other Party
of the names of its representatives to the Working Group. The Working Group shall review and coordinate the responsibilities of the Parties under the Research Plan(s), oversee the implementation of Research Plans and review and provide the Research
Results to the JRC. The Working Group shall meet as mutually agreed by the Parties. 

  
 43 

 9.3    Joint Steering Committee. 

9.3.1    JSC Membership. Promptly, and in any event within thirty (30) days following the Effective Date, the
Parties will establish a joint steering committee (the “JSC”) to oversee and coordinate the activities of the Parties under this Agreement with respect to the Research Programs. The JSC will be comprised of three (3) employee
representatives of Gilead and three (3) employee representatives of Nurix (or such other equal number of representatives as the Parties may agree), and the Alliance Managers will also attend JSC meetings in a
non-voting capacity. Subject to the foregoing, each Party will appoint its respective representatives to the JSC from time to time, and may change its representatives, in its sole discretion, effective upon
notice to the other Party designating such change. One (1) of the members of the JSC appointed by Gilead will be designated the JSC chairperson (the “JSC Chair”). The JSC Chair will be responsible for calling meetings of the
JSC, circulating agenda and performing administrative tasks required to assure efficient operation of the JSC. The JSC may from time to time establish one (1) or more subcommittees (each, a “Subcommittee”), to perform certain
duties and exercise certain powers of the JSC as expressly set forth in this Agreement as delegated by the JSC to such Subcommittee (the JSC and any Subcommittee, including the JRC, are each referred to herein as a “Committee”). The
JSC, each Subcommittee and the Working Group will be promptly disbanded following the end of the last-to-expire Research Term. 

9.3.2    JSC Meetings. The JSC will meet once every year or as otherwise mutually agreed by the Parties. The
location for meetings will alternate between Nurix and Gilead facilities (or such other location as is determined by the JSC). Alternatively, the JSC may meet by means of teleconference, videoconference or other similar means. As appropriate,
additional employees or consultants of each Party may from time to time attend the JSC meetings as nonvoting observers; provided that any such consultant will agree in writing to comply with the confidentiality obligations substantially similar to
those under this Agreement; and provided further that no Third Party personnel may attend unless otherwise agreed by both Parties. Each Party will bear its own expenses related to the attendance of the JSC meetings by its representatives. Each Party
may also call for special meetings to resolve particular matters requested by such Party upon ten (10) Business Days’ prior written notice to the other Party. The JSC Chair or his/her designee will keep minutes of each JSC meeting that
record in writing all decisions made, action items assigned or completed and other appropriate matters. The JSC Chair or his/her designee will send meeting minutes to all members of the JSC promptly after a meeting for review. Each member will have
five (5) Business Days from receipt in which to comment on and to approve or provide comments to the minutes (such approval not to be unreasonably withheld, conditioned or delayed). If a member, within such time period, does not notify the JSC
Chair that he/she does not approve of the minutes, the minutes will be deemed to have been approved by such member. Each Party’s JSC members may designate another staff member of such Party, which could be the Alliance Manager, who will
coordinate the administrative work surrounding JSC, including sending the notice of holding JSC meetings, creating the draft of minutes or distributing the minutes. 

9.3.3    JSC Functions. The JSC’s responsibilities are as follows: 

(a)     Overseeing the performance of the Research Programs hereunder; 

  
 44 

 (b)    Resolving matters presented to it by any
Subcommittee that are within the scope of responsibilities delegated to such Subcommittee by the JSC or otherwise pursuant to this Agreement; and 

(c)     Fulfilling such other responsibilities as may be allocated to the JSC under this Agreement or by
mutual written agreement of the Parties. 
 9.4    Joint Research Committee. 

9.4.1    JRC Membership. Promptly, and in any event within thirty (30) days following the Effective Date, the
Parties will establish a joint research committee (the “JRC”) to oversee and coordinate the activities of the Parties under this Agreement with respect to the Research Programs. The JRC will be comprised of three (3) employee
representatives of Gilead and three (3) employee representatives of Nurix (or such other equal number of representatives as the JRC may determine), and the Alliance Managers will also attend JRC meetings in a
non-voting capacity. Subject to the foregoing, each Party will appoint its respective representatives to the JRC from time to time, and may change its representatives, in its sole discretion, effective upon
notice to the other Party designating such change. Representatives from each Party will have appropriate technical credentials, experience and knowledge pertaining to and ongoing familiarity with the Research activities hereunder. 

9.4.2    JRC Chair. One (1) of the members of the JRC appointed by Nurix will be designated solely by Nurix
the JRC chairperson (the “JRC Chair”). The JRC Chair will be responsible for calling meetings of the JRC, circulating agenda and performing administrative tasks required to assure efficient operation of the JRC. The JRC Chair or
his/her designee will send meeting minutes to all members of the JRC promptly after a meeting for review. Each member will have five (5) Business Days from receipt in which to comment on and to approve or provide comments to the minutes (such
approval not to be unreasonably withheld, conditioned or delayed). If a member, within such time period, does not notify the JRC Chair that he/she does not approve of the minutes, the minutes will be deemed to have been approved by such member. 

9.4.3    JRC Meetings. The JRC will meet by mutual written agreement of the Parties no less frequently than once
every three (3) months. The location for meetings will alternate between Nurix and Gilead facilities (or such other location as is determined by the JRC). Alternatively, the JRC may meet by means of teleconference, videoconference or other
similar means. Each Party may also call for special meetings to discuss particular matters requested by such Party upon ten (10) Business Days’ prior written notice to the other Party. 

9.4.4    Other Members; Expenses. As appropriate, additional employees or consultants of each Party may from time
to time attend the JRC meetings as nonvoting observers; provided that any such consultant will agree in writing to comply with the confidentiality obligations substantially similar to those under this Agreement; and provided further that no Third
Party personnel may attend unless otherwise agreed by both Parties. Each Party will bear its own expenses related to the attendance of the JRC meetings by its representatives. 

  
 45 

 9.4.5    JRC Functions. The purpose of the JRC will be to oversee
and coordinate the conduct of the Research Programs. The JRC’s specific responsibilities are as follows: 

(a)     Overseeing and coordinating the activities of each Party (including those of any of its Affiliates
and Third Parties acting under its authority) under each Research Program, including the conduct of Selection Campaigns and the performance of Research activities as set forth in the applicable Research Plan; 

(b)    Preparing and approving Research Plans and amendments to Research Plans; 

(c)     Deciding whether to designate any Target Binder Hit as a Selected Target Binder; 

(d)    Deciding whether to designate any Degrader Compound as a Selected Degrader Compound; 

(e)     Identifying any Target Binder, Degrader Compound or Degrader Product that meets the applicable
Advancement Criteria for a Research Phase and deciding whether to advance such Target Binder, Degrader Compound or Degrader Product (as applicable) to the next Research Phase; 

(f)     Identifying any Degrader Product that meets all applicable Advancement Criteria and deciding
whether to advance such Degrader Product to Development; 
 (g)    Determining whether any Pre-Clinical Milestone Event has been achieved; 
 (h)    Receiving and
reviewing Research Results provided by the Working Group to the JRC; 
 (i)     Reviewing progress
reports from the Working Group with respect to Selection Campaigns and performance of Research activities under any Research Plan, and requesting such additional information as set forth in Section 2.7.4 (Additional Information); 

(j)     Providing to the JSC such information necessary or reasonably useful for the JSC to carry out its
responsibilities; and 
 (k)    Fulfilling such other responsibilities as may be allocated to the JRC
under this Agreement or by mutual written agreement of the Parties. 
 9.5    Committee Decisions. The JRC will
endeavor to make decisions by consensus, with each of Gilead’s and Nurix’s representatives having, collectively, one (1) vote. If, despite using reasonable efforts, the JRC does not reach consensus on any matter within its
decision-making authority (each, a “Deadlocked Matter”) within a period of fourteen (14) days (or such other period as the Parties may agree in writing) after it has met and attempted to reach such

  
 46 

 
consensus, then either Party may, by written notice to the other Party, refer the Deadlocked Matter to the JSC. If, despite using reasonable efforts, the JSC does not reach consensus on any
Deadlocked Matter within a period of thirty (30) days (or such other period as the Parties may agree in writing) after it has met and attempted to reach such consensus, then either Party may, by written notice to the other Party, refer the
Deadlocked Matter to the Executive Officers; provided, however, that, if such Executive Officers do not reach agreement on such Deadlocked Matter within thirty (30) days after such Deadlocked Matter is referred to the Executive Officers, then
on a Research Program-by-Research Program basis, (a) Nurix will have the right to make the final decision with respect to such Deadlocked Matter to the extent
involving the implementation of any Research activity that is set forth in a Research Plan and (b) Gilead will have the right to make the final decision with respect to such Deadlocked Matter to the extent involving (i) the occurrence of a
Pre-Clinical Milestone Event, (ii) the content of any Research Plan, including any amendment thereto or (iii) the decision of whether to advance any Target Binder, Degrader Compound or Degrader
Product, irrespective of whether or not the applicable Advancement Criteria have been met. 
 9.6    Scope of
Committee Authority. For clarity and notwithstanding the creation of the JSC, JRC or any Subcommittee, each Party will retain the rights, powers and discretion granted to it hereunder, and none of the JSC, JRC or any Subcommittee will be
delegated or vested with such rights, powers or discretion unless such delegation or vesting is expressly provided herein, or the Parties expressly so agree in writing. None of the JSC, JRC, any Subcommittee or a Party via exercise of its final
decision-making authority will have the power to (a) resolve any Dispute regarding the existence or amount of any payment owed under this Agreement or (b) amend, waive or modify any term of this Agreement, and no decision of the JSC, JRC
or any Subcommittee will be in contravention of any terms and conditions of this Agreement. It is understood and agreed that issues to be formally decided by the JSC are limited to those specific issues that are expressly provided in
Section 9.3.3 (JSC Functions) of this Agreement and the Disputes which relate to subjects other than those set forth in Section 9.3.3 (JSC Functions) will be handled according to Section 17.6 (Choice of Law; Dispute Resolution;
Jurisdiction). It is further understood and agreed that issues to be formally decided by the JRC are limited to those specific issues that are expressly provided in Section 9.4.5 (JRC Functions) of this Agreement. Once a Committee is disbanded,
such Committee will have no further obligations under this Agreement and, thereafter, each Party will designate a contact person for the exchange of information under this Agreement or such exchange of information will be made through the Alliance
Managers. In the event a Committee is disbanded, any decisions that are designated under this Agreement as being subject to the review or approval of such Committee will be made by the Parties directly, subject to the other terms and conditions of
this Agreement. 
 9.7    Day-to-Day
Responsibilities. Each Party will be responsible for day-to-day implementation and operations of the activities for which it has or is otherwise assigned
responsibility under this Agreement; provided that such implementation is not inconsistent with the express terms of this Agreement or the decisions of the JSC or the JRC within the scope of its authority specified herein. 

  
 47 

 ARTICLE 10 

ASSISTANCE; TRANSITION; UPSTREAM LICENSE AGREEMENTS 

From and after the applicable License Option Effective Date and, with respect solely to the Degrader Products identified in the applicable License Option
Exercise Notice (which, for clarity, become Licensed Products upon the License Option Effective Date): 

10.1    Assistance. At no cost to Gilead, Nurix will, and will cause its Affiliates to, reasonably cooperate with
Gilead and its designees and provide reasonable assistance to Gilead and its designees to transition to Gilead and its designees the Development, Manufacture and Commercialization such Licensed Products after License Option exercise, as and to the
extent reasonably requested by Gilead, including by: (a) providing Gilead and its designees reasonable assistance with respect to Development, regulatory and Manufacturing transition matters related to such Licensed Products; and
(b) providing Gilead and its designees with reasonable access by teleconference or in-person (as requested by Gilead) to Nurix personnel (and personnel of its Affiliates and Third Party contractors)
involved in Development, regulatory or Manufacturing matters related to such Licensed Products to assist with the transition and answer questions related to such Licensed Products. 

10.2    Know-How Transfer. Without limiting the provisions of
Section 10.1 (Assistance), as soon as reasonably practicable following the applicable License Option Effective Date (but in no event later than thirty (30) days after the applicable License Option Effective Date), and thereafter during the
Term as may be reasonably requested by Gilead from time to time, Nurix will during such initial period disclose to Gilead and its designees in English, including by providing hard and electronic copies thereof: (a) all data, information, regulatory
filings, assets, DNA, protein sequences, constructs, synthesis routes and cell lines, and materials included therein and any other physical embodiments thereof, in each case relating to such Licensed Products or such Research Program and
(b) copies of the documents set forth on Schedule 10.2 (Technology Transfer Documentation), as applicable. Nurix will bear all costs of the first [*] of such assistance per Collaboration Target under this Agreement; thereafter, Gilead will
reimburse Nurix for the costs of its assistance at the rate of [*]. 
 10.3    Licensed Products Inventory
Transfer. Without limiting the provisions of Section 10.1 (Assistance), upon Gilead’s written request and at no cost to Gilead, Nurix will promptly following the applicable License Option Effective Date assign and transfer to Gilead or
its designee and deliver to Gilead or its designee, at a location to be specified by Gilead, any or all (as and to the extent requested by Gilead) inventory of such Licensed Products held at such time by or on behalf of Nurix or its Affiliates
(including any such inventory held at any contract manufacturer or any other location) (the “Transferred Inventory”), along with all applicable Manufacturing, GMP and shelf-life information. All Transferred Inventory will be
manufactured, packaged, labeled, tested, stored and handled in accordance with Applicable Law and applicable specifications, if any. In addition, all Transferred Inventory will be delivered free and clear of any encumbrances (including liens,
charges, securities, mortgages or otherwise) to Gilead. 
 10.4    Assignment of Agreements. Nurix will, or will
cause its Affiliates to, as applicable, to the extent legally permissible (provided that to the extent consent is required from the relevant counterparty, Nurix will, or will cause its Affiliates to, as applicable, use reasonable efforts to

  
 48 

 
obtain such consent): (a) assign to Gilead or its designee any or all (as designated by Gilead) Nurix-Third Party Agreements pertaining solely to such Licensed Products; or (b) assist Gilead
or one of its Affiliates in entering into new agreements directly with the counterparties to any or all Nurix-Third Party Agreements to cover the subject matter of such Nurix-Third Party Agreements as it relates to Licensed Products, as applicable,
in each case ((a) and (b)), to the extent requested by Gilead in writing. If any such Nurix-Third Party Agreement is assigned to Gilead, Nurix will be solely responsible for, and will indemnify and hold harmless Gilead and all other Gilead
Indemnitees from and against any costs and other Damages arising from, or relating to, any such Nurix-Third Party Agreement as a result of, or in connection with, events or occurrences prior to the date of such assignment (including any payments
that accrued prior to the date of such assignment but which do not become payable until after the date of such assignment). 

10.5    Upstream License Agreements. Other than with respect to Change of Control transactions (as further
described in Section 17.4.2 (Change of Control)), in the event that Nurix enters into a contract or agreement with a Third Party pursuant to which Nurix in-licenses or otherwise acquires any Patents, Know-How or other intellectual property rights that, but for this Section 10.5 (Upstream License Agreement), would be Controlled by Nurix and constitute Nurix IP for purposes of this Agreement, then Nurix will
promptly provide Gilead with notice and a copy of the applicable license or other contract or agreement with such Third Party. Within sixty (60) days following receipt of such notice, Gilead will decide, in its sole discretion, whether or not
to accept such Patents, Know-How or other intellectual property as Nurix IP licensed under this Agreement and provide Nurix written notice of such decision. In the event of acceptance, such Patents, Know-How or other intellectual property will constitute Nurix IP licensed to Gilead under this Agreement for as long as Gilead complies with the terms of this Section 10.5 (Upstream License Agreement) with
respect to payment, such agreement will thereafter be included within the definition of Upstream License Agreements and Gilead will be responsible for reimbursing Nurix for any payments arising thereunder solely as a result of Gilead’s
activities under this Agreement following Gilead’s receipt of an invoice therefor. In the event that Gilead does not accept such Third Party agreement as an Upstream License Agreement (including by failing to respond within such sixty
(60) day period), then Gilead and its Affiliates will have no obligations with respect to such Third Party agreement, such agreement shall not be an Upstream License Agreement, and such Patents, Know-How
or other intellectual property rights licensed to Nurix under such Agreement shall not be Controlled by Nurix and shall not be Nurix IP. 

ARTICLE 11 
 FINANCIAL
TERMS 
 11.1    Upfront Payment. No later than [*] days after the Effective Date, Gilead will pay to Nurix a
one (1) time payment of forty-five million dollars ($45,000,000) in immediately available funds by wire transfer, in accordance with wire instructions to be provided in writing by Nurix to Gilead no later than ten (10) days following the
Effective Date (“Wire Instructions”). 
 11.2    Research Term Extension Fee. Subject to the
terms and conditions herein (including Section 14.4.2(e) (Additional Nurix Covenants)), Gilead will make a one (1) time payment to Nurix of [*] in immediately available funds by wire transfer, in accordance with the Wire Instructions, for
each Collaboration Target extended in accordance with Section 2.1.2 (Research Term) (each, a “Research Extension Fee”). Nurix will invoice Gilead for a Research 

  
 49 

 
Extension Fee following such time that the Parties agree on an updated Research Plan for the applicable Research Extension. For clarity, if the Parties fail to reach agreement on a Research Plan
for an Extended Research Term prior to expiration of the Initial Research Term, (a) the Initial Research Term for such Collaboration Target will expire, unless (prior to the expiration of the Initial Research Term) Gilead requests additional
time for such negotiation period and Nurix agrees to such additional time, which additional time agreement will not be unreasonably withheld, conditioned or delayed and (b) no Research Extension Fee will be due, unless the Parties reach
agreement on a Research Plan for the Extended Research Term during the extended negotiation period described in sub-clause (a). 

11.3    [*] Reservation Fee Per Target. Subject to the terms and conditions herein (including
Section 14.4.2(e) (Additional Nurix Covenants)), during the Collaboration Term, Gilead may elect to pay to Nurix [*] in immediately available funds by wire transfer in accordance with the Wire Instructions, to hold one (1) Target as a
Reserved Target for [*] (each, an “[*] Reservation Fee Per Target”). Gilead will pay each [*] Reservation Fee Per Target in accordance with this Section 11.3 ([*] Reservation Fee Per Target) following Gilead’s receipt of
an invoice therefor from Nurix. 
 11.4    Selection Campaign Fee. Subject to the terms and conditions herein
(including Section 14.4.2(e) (Additional Nurix Covenants)), if Nurix performs Selection Campaigns on [*] Collaboration Targets, then, upon initiation of any Selection Campaigns on additional Collaboration Targets, Gilead will pay a one
(1) time payment to Nurix of [*] per such Collaboration Target in immediately available funds by wire transfer in accordance with the Wire Instructions, for each additional Collaboration Target in excess of [*] that undergoes a Selection
Campaign (each, a “Selection Campaign Fee”). Nurix will invoice Gilead for any Selection Campaign Fee following Nurix’s initiation of such Selection Campaign. For clarity, Gilead will only pay one (1) Selection Campaign
Fee for each Collaboration Target in excess of [*] as set forth in this Section 11.4 (Selection Campaign Fee). 

11.5    Option Fee. On a Collaboration
Target-by-Collaboration Target basis, and subject to the terms and conditions herein (including Section 14.4.2(e) (Additional Nurix Covenants)), in the event that
Gilead exercises a License Option with respect to a Collaboration Target, Gilead will pay to Nurix a one (1) time payment of [*] in immediately available funds by wire transfer, in accordance with the Wire Instructions, no later than [*] days
following the applicable License Option Effective Date (each, an “Option Fee”). Nurix will invoice Gilead for an Option Fee following the applicable License Option Effective Date. 

11.6    Milestones. 

11.6.1    Pre-Clinical Milestones. Subject to the terms and conditions
herein (including this Section 11.6.1 (Pre-Clinical Milestones), Section 11.9 (Milestone Payment and Royalty Offset for Third Party Payments), Section 11.10 (Additional Payment Terms),
Section 14.4.2(e) (Additional Nurix Covenants) and Section 16.6 (Certain Additional Remedies of Gilead in Lieu of Termination)), and on a Collaboration
Target-by-Collaboration Target basis, Gilead will pay the applicable amount set forth in the table below in this Section 11.6.1
(Pre-Clinical Milestones) associated with each milestone event described below (each event, a “Pre-Clinical Milestone Event” and each payment, a
“Pre-Clinical Milestone Payment”) with respect 

  
 50 

 
to the first (and only the first) Target Binder or Degrader Compound (as the case may be) to achieve such Pre-Clinical Milestone Event under this Agreement
for such Collaboration Target as determined by the JRC as may be adjusted in accordance herewith: 
  

			
	 Pre-Clinical Milestone
Event
	  	Pre-Clinical Milestone
Payment
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]

 Each Milestone Payment will be payable a maximum of one (1) time per Collaboration Target as set forth in
the table above, regardless of the number of Target Binders or Degrader Compounds, as applicable, that achieve the applicable Milestone Event for such Collaboration Target, and no Milestone Payment will be due hereunder for subsequent or repeated
achievement of any such Milestone Event for a Collaboration Target. For the avoidance of doubt, the maximum amount payable by Gilead pursuant to this Section 11.6.1 (Pre-Clinical Milestones) for any
Collaboration Target is [*], assuming that each Milestone Event in this Section 11.6.1 (Pre-Clinical Milestones) were achieved with respect to such Collaboration Target. In the event that Nurix achieved
any Pre-Clinical Milestone Event with respect to any Target Binder or Degrader Compound in each case Directed To a Tabled Target prior to such Tabled Target becoming a Collaboration Target again under this
Agreement, such Pre-Clinical Milestone Event will be deemed as having occurred as of such date that such Tabled Target became a Collaboration Target, and Gilead will pay the respective Pre-Clinical Milestone Payment in accordance with Section 11.6.1 (Pre-Clinical Milestones). With respect to each Collaboration Target, upon the applicable License Option
Effective Date, Gilead will not pay any Pre-Clinical Milestone Payment on any Pre-Clinical Milestone Event for such Collaboration Target that is achieved following such
License Option Effective Date. 
 [*] 

11.6.2    Clinical and Development Milestones. Subject to the terms and conditions herein (including this
Section 11.6.2 (Clinical and Development Milestones), Section 11.9 (Milestone Payment and Royalty Offset for Third Party Payments), Section 11.10 (Additional Payment Terms), Section 14.4.2(e) (Additional Nurix Covenants),
Section 16.6 (Certain Additional Remedies of Gilead in Lieu of Termination) and Exhibit B (Profit-Share Exhibit)), Gilead will pay the applicable amount set forth in the table below in this Section 11.6.2 (Clinical and Development
Milestones) associated with each milestone event described below (each event described in (a)-(d) in the table below, a “Clinical Milestone Event” and each respective payment, a “Clinical Milestone Payment,” and
each event described in (e)-(f) in the table below, a “Development Milestone Event,” and each respective payment, a “Development Milestone Payment”) with respect to the first (and only the first) Royalty-Bearing
Product or Profit-Share Product, as applicable, to achieve such Clinical Milestone Event or Development Milestone Event 

  
 51 

 
(as applicable) under this Agreement for a Collaboration Target, as may be adjusted in accordance herewith: 
  

					
	 Clinical Milestone Event
	  	Clinical Milestone
Payment for Royalty-
Bearing Product	 	Clinical Milestone
Payment for Profit-
Share Product
	 [*]
	  	[*]	 	[*]
	 [*]
	  	[*]	 	[*]
	 [*]
	  	[*]	 	[*]
	 [*]
	  	[*]	 	[*]
			
	 Development Milestone Event
	  	Development
Milestone Payment
for Royalty-Bearing
Product	 	Development
Milestone Payment
for Profit-Share
Product
	 [*]
	  	[*]	 	[*]
	 [*]
	  	[*]	 	[*]

 Each Clinical Milestone Payment and Development Milestone Payment will be payable a maximum of one
(1) time per Collaboration Target as set forth in the table above, regardless of the number of Royalty-Bearing Products or Profit-Share Products, as applicable, which achieve the applicable Clinical Milestone Event or Development Milestone
Event for such Collaboration Target, and no Clinical Milestone Payment or Development Milestone Payment will be due hereunder for subsequent or repeated achievement of any such same Clinical Milestone Event or Development Milestone Event (as the
case may be) for a Collaboration Target, including where a Clinical Milestone Event or Development Milestone Event (as applicable) is first achieved by a Royalty-Bearing Product and is subsequently achieved by a Profit-Share Product (and vice versa)
for any Collaboration Target. 
 [*] 

For the avoidance of doubt, (a) the maximum amount payable by Gilead pursuant to this Section 11.6.2 (Clinical and Development
Milestones) for any Collaboration Target would be [*] if each Clinical Milestone Event and Development Milestone Event in this Section 11.6.2 (Clinical and Development Milestones) were exclusively achieved by a Royalty-Bearing Product with
respect to such Collaboration Target and (b) the maximum amount payable by Gilead pursuant to this Section 11.6.2 (Clinical and Development Milestones) for any Collaboration Target would be [*] if each Clinical Milestone Event and
Development Milestone Event in this Section 11.6.2 (Clinical and Development Milestones) were exclusively achieved by a Profit-Share Product with respect to such Collaboration Target. 

  
 52 

 11.6.3    Invoice and Payment of Milestone Payments. 

(a)     In the event that Gilead, its Affiliates or its Sublicensees under this Agreement achieves a
Milestone Event, it will notify Nurix thereof within thirty (30) days of such achievement. Following Nurix’s receipt of notice from Gilead that Gilead has achieved a Milestone Event, Nurix will invoice Gilead for the applicable Milestone
Payment, and Gilead will pay such Milestone Payment within thirty (30) days after receipt of such invoice. 

(b)    In the event that Nurix or its Affiliates achieves a Milestone Event, it will notify Gilead thereof
within thirty (30) days of such achievement and invoice Gilead for the applicable Milestone Payment, and Gilead, subject to any good faith dispute as to whether such Milestone Event has been achieved, will pay such Milestone Payment within
thirty (30) days after receipt of such invoice. 
 11.7    Sales Milestones. 

11.7.1    Sales Milestones. Subject to the terms and conditions herein (including this Section 11.7 (Sales
Milestones), Section 11.9 (Milestone Payment and Royalty Offset for Third Party Payments), Section 11.11 (Records; Audit Rights), Section 14.4.2(e) (Additional Nurix Covenants), Section 16.6 (Certain Additional Remedies of Gilead
in Lieu of Termination) and Exhibit B (Profit-Share Exhibit)), Gilead will notify Nurix within sixty (60) days after the end of the Calendar Quarter during which a given milestone event described below in this Section 11.7.1 (Sales
Milestones) (each, a “Sales Milestone Event”) was first achieved by Gilead under this Agreement, and Gilead will thereafter pay the applicable amounts set forth below associated with the applicable Sales Milestone Event in
accordance with Section 11.7.2 (Invoice and Payment of Sales Milestone Payments) (each, a “Sales Milestone Payment”), as may be adjusted in accordance herewith: 

 

					
	 Sales Milestone Event
	  	Sales Milestone
Payment for Royalty-
Bearing Product	 	Sales Milestone
Payment for Profit-
Share Product
	 (a) Annual Net Sales in the Royalty Territory in a Calendar Year exceed [*]
	  	[*]	 	[*]
	 (b) Annual Net Sales in the Royalty Territory in a Calendar Year exceed [*]
	  	[*]	 	[*]
	 (c) Annual Net Sales in the Royalty Territory in a Calendar Year exceed [*]
	  	[*]	 	[*]

 Each Sales Milestone Event will be payable a maximum of one (1) time as set forth in the table above,
regardless of the number of times the applicable Sales Milestone Event was achieved, and no Sales Milestone Payment will be due hereunder for subsequent or repeated achievement of any such same Sales Milestone Event, including where a Sales
Milestone Event is first achieved 

  
 53 

 
by a Royalty-Bearing Product and is subsequently achieved by a Profit-Share Product (and vice versa). Further, Net Sales for a given Licensed Product in a given country for which the Royalty Term
has expired will not be included in the Annual Net Sales for purposes of the Sales Milestone Events or Sales Milestone Payments. 
 For the
avoidance of doubt, (a) the maximum amount payable by Gilead pursuant to this Section 11.7.1 (Sales Milestones) would be [*] if each Sales Milestone Event in this Section 11.7.1 (Sales Milestones) were exclusively achieved by a
Royalty-Bearing Product and (b) the maximum amount payable by Gilead pursuant to this Section 11.7.1 (Sales Milestones) would be [*] if each Sales Milestone Event in this Section 11.7.1 (Sales Milestones) were exclusively achieved by
a Profit-Share Product. 
 11.7.2    Invoice and Payment of Sales Milestone Payments. Gilead will notify Nurix if
the aggregate Annual Net Sales of any applicable Licensed Product first achieved a Sales Milestone Event during a Calendar Quarter in the royalty report for such Calendar Quarter as described in Section 11.8.4 (Royalty Payments and Reporting),
and Gilead will pay to Nurix such Sales Milestone Payment concurrent with the delivery of such report. 

11.8    Royalties. 

11.8.1    Royalty Rates. Subject to the terms and conditions herein (including this Section 11.8 (Royalties),
Section 11.9 (Milestone Payment and Royalty Offset for Third Party Payments), Section 11.11 (Records; Audit Rights), Section 14.4.2(e) (Additional Nurix Covenants) and Section 16.6 (Certain Additional Remedies of Gilead in Lieu
of Termination)), Gilead will pay Nurix royalties on Annual Net Sales in the Royalty Territory, on a Licensed Product-by-Licensed Product basis, during the applicable
Royalty Term, equal to the following portions of Annual Net Sales of the applicable Licensed Product multiplied by the applicable royalty rate set forth below for such portion of Annual Net Sales in the Royalty Territory during the applicable
Royalty Term for each such Licensed Product, as may be adjusted in accordance herewith. For clarity, the royalties (and royalty tiers) will be calculated separately on a Licensed
Product-by-Licensed Product basis. 
  

			
	 Annual Net Sales in the Royalty Territory for a given

Licensed Product in a given Calendar Year
	  	Royalty Rate
	 i. Portion of Annual Net Sales in the Royalty Territory of a given Licensed Product in a given
Calendar Year up to and including [*]
	  	[*]
	 ii. Portion of Annual Net Sales in the Royalty Territory of a given Licensed Product in a given
Calendar Year above [*] up to and including [*]
	  	[*]
	 iii. Portion of Annual Net Sales in the Royalty Territory of a given Licensed Product in a given
Calendar Year above [*]
	  	[*]

  
 54 

 The applicable royalty rate set forth in the table above will apply only to that portion of
the Annual Net Sales in the Royalty Territory of a given Licensed Product during a given Calendar Year that falls within the indicated range. For clarity: (i) if no royalty is payable on a given unit of Licensed Product (e.g., following the
Royalty Term for such Licensed Product in a given country), then the Net Sales in the Royalty Territory of such unit of Licensed Product will not be included for purposes of determining the royalties or royalty tiers; (ii) Net Sales in the
Royalty Territory of a given Licensed Product will not be combined with Net Sales in the Royalty Territory of any other Licensed Product for purposes of determining the foregoing royalties or royalty tiers; and (iii) only one (1) royalty
will be payable by Gilead to Nurix for each sale of a Licensed Product. 
 11.8.2    Royalty Term. Gilead’s
royalty obligations to Nurix under Section 11.8.1 (Royalty Rates) will apply, on a Licensed Product-by-Licensed Product and country-by-country basis, only during the applicable Royalty Term for such Licensed Product in such country. Following the expiration of the applicable Royalty Term for a given Licensed Product in a given
country: (a) no further royalties will be payable with respect to sales of such Licensed Product in such country; and (b) the license granted to Gilead under this Agreement with respect to such Licensed Product in such country will become
fully paid-up, perpetual, irrevocable and royalty-free in accordance with Section 16.1.1 (Term). 

11.8.3    Royalty Reductions. 

(a)     On a Licensed
Product-by-Licensed Product and country-by-country basis, if such Licensed Product is no
longer Covered by a Valid Claim within any Nurix Patent or Joint Patent in such country, then the royalties payable with respect to such Licensed Product pursuant to Section 11.8.1 (Royalty Rates) in such country will be reduced by [*] during
such period. 
 (b)    On a Licensed
Product-by-Licensed Product and country-by-country basis, if any Generic Competition
occurs in such country in a Calendar Quarter with respect to such Licensed Product, then, thereafter, the royalties payable with respect to Annual Net Sales of such Licensed Product pursuant to Section 11.8.1 (Royalty Rates) in such country
will be reduced to [*] of the royalties otherwise payable pursuant to Section 11.8.1 (Royalty Rates), as may be adjusted by Section 11.8.3(a) (Royalty Reductions). 

(c)     [*]. 

11.8.4    Royalty Payments and Reporting. Gilead will calculate all amounts payable to Nurix pursuant to this
Section 11.8 (Royalties) at the end of each Calendar Quarter. Gilead will pay to Nurix the royalty amounts due, less any applicable withholding tax that is required by Applicable Law in accordance with Section 11.10.3 (Taxes; Withholding),
with respect to a given Calendar Quarter within sixty (60) days after the end of such Calendar Quarter. Each payment of royalties due to Nurix will be accompanied by a royalty report stating the amount of gross sales and Net Sales of each
Licensed Product in each country of the Territory during the applicable Calendar Quarter and a detailed calculation of the amount of royalty payment due on such Net Sales for such Calendar Quarter (including all Net Sales reductions). 

  
 55 

 11.9    Milestone Payment and Royalty Offset for Third Party
Payments. 
 11.9.1     Royalty Reduction for Third Party Payments. If Gilead, any of its Affiliates or any of
its Sublicensees obtains a right or license under any Patent, Know-How or other intellectual property right of a Third Party after the Effective Date that is necessary or reasonably useful for the Development,
Manufacturing or Commercialization of the Licensed Products by or on behalf of Gilead, its Affiliates or its Sublicensees that results in a payment to such Third Party as a result of and to the extent that the exercise of such right or license by
Gilead, its Affiliates or its Sublicensees, as applicable, then Gilead may deduct from the Milestone Payments, Sales Milestone Payments or royalty payments that would otherwise have been due in a particular Calendar Quarter an amount equal to [*] of
the amount of any such payments (including payments for obtaining such right or license, royalties, milestones, amounts paid in settlement and any other amounts) paid or accrued by Gilead or any of its Affiliates or Sublicensees to such Third Party
for such right or license or the exercise thereof during such Calendar Quarter. 
 11.9.2    [*] 

11.10    Additional Payment Terms. 

11.10.1     Currency. All payments hereunder will be made in Dollars by wire transfer to a bank account designated
in writing by the Payee. Conversion of sales recorded in local currencies to Dollars will be performed in a manner consistent with the Accounting Standard and the Payor’s normal practices used to prepare its audited financial statements. 

11.10.2     Other Amounts Payable. With respect to any amounts owed under this Agreement by a Party to the other
Party for which no other invoicing and payment procedure is specified in this Agreement, the Party owing such payment obligation will provide to the other Party an invoice, together with reasonable supporting documentation, for such amounts owed and
such other Party will pay any undisputed amounts within sixty (60) days after receipt of the invoice, and will pay any disputed amounts owed by such other Party within forty-five (45) days of final resolution of the Dispute. 

11.10.3     Taxes; Withholding. 

(a)     Generally. Each Party will be liable for all taxes legally assessable against it arising
from any payment received under this Agreement, including income, applicable sales or use, goods and services, value added and consumption or other similar fees or taxes (“Taxes”). 

(b)    Tax Withholding. If Applicable Law requires the withholding of Taxes, the Payor will subtract
the amount thereof from the Agreement Payments and remit such withheld amount to the relevant Governmental Authority in a timely manner. For the avoidance of doubt, the Payor’s remittance of such withheld Taxes, together with payment to the
Payee of the remaining Agreement Payments, will constitute the Payor’s full satisfaction of Agreement Payments under this Agreement. The Payor will promptly (as available) submit to the Payee appropriate proof of payment of the withheld Taxes
as well as the official receipts within a reasonable period of time. The Parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate such withholding of Taxes under Applicable Law, including under the benefit of any
present or future treaty against double taxation. 

  
 56 

 11.11    Records; Audit Rights. 

11.11.1     Records. Each Party will keep, and will cause its Affiliates and as applicable Sublicensees, to keep
complete, true and accurate books and records in accordance with its Accounting Standard in relation to this Agreement and Net Sales, royalties, Milestone Payments, Sales Milestone Payments and any other payments required hereunder, as applicable.
Each Party will keep such books and records for at least three (3) years following the Calendar Year to which they pertain or for such longer period of time as required under any Applicable Law. 

11.11.2     Audit Rights. Subject to the other terms of this Section 11.11.2 (Audit Rights), during the Term,
at the request of a Party (the “Auditing Party”), which will not be made more frequently than one (1) time per Calendar Year, upon at least [*] days’ prior written notice from the Auditing Party, and at the expense of the
Auditing Party, the other Party (the “Audited Party”) will permit an independent, nationally-recognized certified public accountant selected by the Auditing Party and reasonably acceptable to the Audited Party (the
“Auditor”) to inspect, during regular business hours, the relevant records required to be maintained by the Audited Party under Section 11.11.1 (Records); provided that such audit right will not apply to records beyond three
(3) years from the end of the Calendar Year to which they pertain and that records for a particular period may only be audited once. Prior to its inspection, the Auditor will enter into a confidentiality agreement with both Parties having
obligations of confidentiality and non-use no less restrictive than those set forth in Article 13 (Confidentiality) and limiting the disclosure and use of such information by such accountant to authorized
representatives of the Parties and the purposes germane to Section 11.11.1 (Records). The Auditor will report to the Auditing Party only whether the particular amount being audited was accurate and, if not, the amount of any discrepancy and a
reasonable summary of the reason for such discrepancy, and the Auditor will not report any other information to the Auditing Party. The Auditing Party will treat the results of the Auditor’s review of the Audited Party’s records as
Confidential Information of the Audited Party subject to the terms of Article 13 (Confidentiality). In the event such audit leads to the discovery of a discrepancy to the Auditing Party’s detriment, the Audited Party will, within forty-five
(45) days after receipt of such report from the Auditor, pay any undisputed amount of the discrepancy. The Auditing Party will pay the full cost of the audit unless the underpayment of amounts due to the Auditing Party is greater than [*] of
the amount due for the entire period being examined and such underpayment also exceeds [*], in which case the Audited Party will pay the reasonable cost charged by the Auditor for such review. Any undisputed overpayments by the Audited Party
revealed by an examination will be paid by the Auditing Party within forty-five (45) days of the Auditing Party’s receipt of the applicable report. Gilead will use Commercially Reasonable Efforts to include substantially similar rights as
set forth in this Section 11.11.2 (Audit Rights) in any sublicense agreement with its Sublicensee; provided, however, that such sublicense agreement may provide that such audit be conducted by Gilead, its Affiliate or an independent auditor
designated by Gilead instead of by an independent auditor designated by Nurix. 
 11.11.3     Records Final. Upon
the expiration of three (3) years following the end of a given Calendar Year, subject and without prejudice to the determination of any review commenced prior to such third anniversary pursuant to Section 11.11.2 (Audit Rights), the
calculation of any amounts payable by a Party to the other Party with respect to such Calendar Year will not be subject to the audit provisions of this Section 11.11 (Records; Audit Rights). 

  
 57 

 11.12    Upstream License Agreements and Nurix-Third Party
Agreements. Notwithstanding anything to the contrary under this Agreement, but subject to Section 10.5 (Upstream License Agreements), Nurix will be solely responsible for all costs and payments of any kind (including all upfront fees,
annual payments, milestone payments and royalty payments) arising under any agreements between Nurix (or any of its Affiliates) and any Third Party, including under any Upstream License Agreements, unless and until such agreements have been accepted
by Gilead pursuant to Section 10.5 (Upstream License Agreements), and any Nurix-Third Party Agreements, as applicable. 
 ARTICLE 12

 LICENSE; INTELLECTUAL PROPERTY 

12.1    License Grants. 

12.1.1    Research Licenses. Subject to the terms and conditions of this Agreement, and on a Research Program-by-Research Program basis, each Party hereby grants to the other Party a non-exclusive, worldwide, transferrable (pursuant to
Section 17.4 (Assignment)) and sublicensable (solely to the other Party’s permitted subcontractors in accordance with Section 12.2 (Subcontracting) and Section 12.3 (Sublicensing)) license, under the Background IP Controlled by
such Party and such Party’s interest in the Joint IP, solely to the extent necessary for the other Party to perform the Research activities assigned to such other Party under the applicable Research Plan for the applicable Research Term and in
accordance with such Research Plan. 
 12.1.2    License to Gilead for Licensed Products. Subject to the
terms and conditions of this Agreement (including Article 3 (License Option)), Nurix hereby grants to Gilead an exclusive (even as to Nurix, except as set forth in Exhibit B (Profit-Share Exhibit)), transferrable (pursuant to Section 17.4
(Assignment)) and sublicensable (through multiple tiers in accordance with Section 12.3 (Sublicensing)) license, under the Nurix IP and Nurix’s interest in the Joint IP, to Develop, Manufacture and Commercialize Licensed Products in the
Field in the Territory. Gilead will not exercise its rights under the foregoing license with respect to any Degrader Product until the applicable License Option Effective Date for such Degrader Product. Nurix will provide an updated copy of Schedule
1.147 (Nurix Patents) to Gilead’s Alliance Manager as necessary from time to time to reflect the then-current Nurix Patents. 

12.2    Subcontracting. Each Party may subcontract the performance of tasks and other obligations hereunder to its
Affiliates or Third Parties (provided that prior to Nurix subcontracting such performance to Third Parties, it will obtain the prior written consent of Gilead, not to be unreasonably withheld, conditioned or delayed), which subcontract may include a
sublicense of rights necessary for the performance of the subcontract as reasonably required, provided that any such Third Party will not be deemed to be a Sublicensee as a result of such sublicense. 

12.3    Sublicensing. If a Party is permitted to grant a sublicense under the rights licensed to such Party under
Section 12.1 (License Grants), then the following terms shall apply to each sublicense: (a) any such permitted sublicense shall be consistent with and subject to the terms and 

  
 58 

 
conditions of this Agreement; and (b) such Party will continue to be responsible for full performance of its obligations under this Agreement and will be responsible for all actions of such
sublicensed Affiliate or Third Party, as applicable, as if such Affiliate or Third Party, as applicable, were such Party hereunder. 

12.4    No Implied Licenses. Each Party retains all rights under Patents,
Know-How or other intellectual property rights Controlled by such Party which are not expressly granted to the other Party pursuant to this Agreement. Except as otherwise expressly provided in this Agreement,
under no circumstances will a Party or any of its Affiliates, as a result of this Agreement, obtain any ownership interest, license or other right in or to any Patents, Know-How or other intellectual property
rights of the other Party, including tangible or intangible items owned, controlled or developed by the other Party, or provided by the other Party to the receiving Party at any time, in each case, pursuant to this Agreement. For clarity, Nurix
shall have the right to exercise or license the Nurix IP in any manner with respect to any compound or molecule that is not (a) a Licensed Product or (b) Degrader Compound incorporated into a Licensed Product, in each case ((a) and (b))
subject to the exclusivity provisions provided in Section 2.9 (Exclusivity). 
 12.5    Ownership. As
between the Parties, each Party will retain ownership of all Patents, Know-How and other intellectual property rights that are Controlled by such Party prior to the Effective Date or are otherwise developed by
such Party outside of this Agreement (with respect to such Party, its “Background IP”). As between the Parties, all Inventions made or created solely by a Party’s or any of its Affiliates’ employees, independent
contractors or consultants, in the course of conducting activities under this Agreement, together with all intellectual property rights therein, will be owned by such Party (“Sole IP”). All Inventions made or created jointly by each
Party’s (or any of its Affiliates’) employees, independent contractors or consultants, in the course of conducting activities under this Agreement, together with all Patents therein, will be jointly owned by the Parties (“Joint
IP”). For clarity, any Patent or Know-How covering any Degrader Compound identified, synthesized or Researched under a Research Program, where the Target Binder contained in such Degrader Compound is
covered by any Patent or Know-How Controlled by Gilead or its Affiliates and was contributed by Gilead or its Affiliates, and the Linker contained in such Degrader Compound is Controlled and was contributed by
Nurix or one of its Affiliates, will be deemed Joint IP (“Combined Degrader Compound IP”). Subject to the terms and conditions of this Agreement (including this Article 12), Joint IP will be owned jointly by Gilead and Nurix on the
basis of an equal, undivided interest without a duty to account to the other Party and will be deemed to be Controlled by each Party, and each Party will have the right to use such Joint IP, or license such Joint IP to its Affiliates or any Third
Party, or sell or otherwise transfer its interest in such Joint IP to its Affiliates or a Third Party, in each case without the consent of the other Party. Notwithstanding the immediately preceding sentence, but subject to the remaining terms of
this Agreement (including the remaining terms of this Article 12), each Party will only have the right to use Combined Degrader Compound IP, or license such Combined Degrader Compound IP to its Affiliates or any Third Party, or sell or otherwise
transfer its interest in such Combined Degrader Compound IP to its Affiliates or a Third Party, in each case, without the consent of the other Party, if and so long as such use, sale, license or transfer is limited to Research activities. If a Party
wishes to use any Combined Degrader Compound IP in any Development or Commercialization activities on behalf of itself, its Affiliates or any Third Party, such Party shall provide written notice to the other Party, and the Parties will negotiate
with one another in good faith for one hundred and eighty (180) days to agree upon the royalties to be paid to the other Party 

  
 59 

 
for use of such Combined Degrader Compound IP in such Development or Commercialization activities. In the event that the Parties are unable to reach agreement on such royalties within the one
hundred and eighty (180) day period as described above, then either Party may submit such matter to baseball arbitration for resolution in accordance with Section 17.6.3 (Baseball Arbitration). All determinations of inventorship under this
Agreement will be made in accordance with U.S. patent law. 
 12.6    Prosecution and Maintenance. 

12.6.1    Before Exercise of License Option. 

(a)     Prior to the exercise of the applicable License Option with respect to a Degrader Product, Nurix
will be responsible for the Prosecution and Maintenance of any (a) Degrader Product Patents and (b) Patents included in the Joint IP (each such Patent described in sub-clause (b), a “Joint
Patent”), using outside counsel reasonably acceptable to Gilead. The Degrader Product Patents will be Prosecuted and Maintained in Nurix’s name and at Nurix’s expense, and the Joint Patents will be Prosecuted and Maintained in
both Parties’ names and the costs thereof will be equally borne by the Parties. Nurix will notify Gilead of any decision not to file applications for, cease the Prosecution and Maintenance of or not continue to pay the expenses for the
Prosecution and Maintenance of any such Patents described in this Section 12.6.1 (Before Exercise of License Option). Nurix will provide such notice at least thirty (30) days prior to any filing or payment due date, or any other due date
that requires action, in connection with such Patent. In such event, Nurix will permit Gilead, at its sole discretion and expense, to file or to continue Prosecution and Maintenance of such Patent. 

(b)    Upon the request of either Party prior to the exercise of the applicable License Option with respect
to a Degrader Product or Degrader Compound, the Parties will in good faith discuss the claim scope of potential Degrader Product Patents for such Degrader Product or Degrader Compound, provided that if Nurix believes in good faith there is
sufficient basis to file one (1) or more Degrader Product Patents during such time period, then Nurix shall have the right to initiate a meeting pursuant to which Nurix shall propose to Gilead in writing a claim scope for the applicable
Degrader Product Patent(s). Thereafter, Nurix and Gilead shall discuss in good faith the claim scope of such Degrader Product Patent(s) (the “Nurix Claim Scope Discussion,” and the proposed claim scope for such Degrader Product
Patent(s), the “Nurix Proposed Claim Scope”), and Nurix shall reasonably consider Gilead’s comments with respect thereto. If, after a Nurix Claim Scope Discussion where Nurix continues to believe in good faith that there
is a sufficient basis to file a patent application (after taking into account all reasonable comments provided by Gilead), Nurix shall have the right to file such Degrader Product Patent with such Nurix Proposed Claim Scope in accordance with
Section 12.6.1(a) (Before Exercise of License Option) and subject to Section 12.6.3 (Cooperation). 

12.6.2    After Exercise of License Option. 

(a)     Following the exercise of the applicable License Option with respect to a Degrader Product, Gilead
will be responsible for the Prosecution and Maintenance of 

  
 60 

 
the Degrader Product Patents and Joint Patents, in each case necessary or reasonably useful for the Development, Manufacture or Commercialization of the respective Licensed Product. The Degrader
Product Patents will be Prosecuted and Maintained in Nurix’s name and at Gilead’s expense, and the Joint Patents will be Prosecuted and Maintained in both Parties’ names and the costs thereof will be equally borne by the Parties.
Gilead will notify Nurix of any decision not to file applications for, cease the Prosecution and Maintenance of or not continue to pay the expenses for the Prosecution and Maintenance of any such Patents described in this Section 12.6.2(a)
(After Exercise of License Option). Gilead will provide such notice at least thirty (30) days prior to any filing or payment due date, or any other due date that requires action, in connection with such Patent. In such event, Gilead will permit
Nurix, at its sole discretion and expense, to file or to continue Prosecution and Maintenance of such Patent. 

(b)    Following the exercise of the applicable License Option with respect to a Degrader Product, Nurix
will be responsible for the Prosecution and Maintenance of any Nurix Patent (other than a Degrader Product Patent) using outside counsel reasonably acceptable to Gilead. Such Nurix Patents will be Prosecuted and Maintained in Nurix’s name and
at Nurix’s expense. Nurix will notify Gilead of any decision not to file applications for, cease the Prosecution and Maintenance of or not continue to pay the expenses for the Prosecution and Maintenance of any such Nurix Patents described in
this Section 12.6.2(b) (After Exercise of License Option). Nurix will provide such notice at least thirty (30) days prior to any filing or payment due date, or any other due date that requires action, in connection with such Nurix Patent.
In such event, Nurix will permit Gilead, at its sole discretion and expense, to file or to continue Prosecution and Maintenance of such Nurix Patent. 

12.6.3    Cooperation. A Party that Prosecutes and Maintains any Patent in accordance with this Section 12.6
(Prosecution and Maintenance) (the “Prosecuting Party”) will keep the other Party (the “Non-Prosecuting Party”) reasonably informed of the status of such Patent and, prior to
making any filings or submissions to any Governmental Authority with respect to such Patent, will submit a copy thereof to the Non-Prosecuting Party for its review and comment and provide the Non-Prosecuting Party a reasonable period of time to comment on such filings and submissions (which comments will be considered by the Prosecuting Party in good faith). Notwithstanding the foregoing, if Nurix is the
Prosecuting Party under Section 12.6.1 (Before Exercise of License Option) and Gilead requests that any Nurix Patents be filed in any country outside of the territory in which Nurix ordinarily files, then Nurix will file in those countries and
Gilead will reimburse Nurix for those specific costs. In addition, the Non-Prosecuting Party will fully cooperate with the Prosecuting Party in connection with the Prosecution and Maintenance of such Patents
described in Section 12.6.1 (Before Exercise of License Option) and Section 12.6.2 (After Exercise of License Option), including by providing access to relevant persons and executing all documentation reasonably requested by the
Prosecuting Party. 
 12.7    Enforcement. 

12.7.1    Notification. Each Party will promptly notify the other Party of any infringement, misappropriation or
other violation by a Third Party of any (a) Nurix IP (solely with respect to this sub-clause (a), to the extent such infringement, misappropriation or other violation

  
 61 

 
is caused by the Research, Development, Manufacture or Commercialization of a product by or on behalf of such Third Party that is Directed To the same Collaboration Target To which a Licensed
Product is Directed), (b) Degrader Product Patent or (c) Joint IP, in each case ((a)-(c)) in the Territory of which it becomes aware, including any declaratory judgment, opposition or similar action alleging the invalidity, unenforceability or non-infringement with respect to any such Nurix Patent, Degrader Product Patent or Joint Patent (collectively, “Infringement”). 

12.7.2    Right to Enforce. 

(a)     Prior to the exercise of the applicable License Option with respect to a Degrader Product, neither
Party will have the right, without the prior written consent of the other Party (not to be unreasonably withheld, conditioned or delayed), to bring any legal action or take such other actions as it deems appropriate in connection with any
Infringement of any Nurix IP (as described in Section 12.7.1 (Notification)), Degrader Product Patent or Joint IP, in each case necessary or useful for the Development, Manufacture or Commercialization of such Degrader Product. If such consent
is provided to such Party, such Party will have the right (but not the obligation) to bring and control, at its cost and expense, any such legal action or take such other actions as it deems appropriate in connection with such Infringement. 

(b)    Following the exercise of the applicable License Option with respect to a Degrader Product, Gilead
will have the first right, but not the obligation, to bring and control any legal action or take such other actions as it deems appropriate in connection with any Infringement of any Nurix IP (as described in Section 12.7.1 (Notification)),
Degrader Product Patent or Joint IP, in each case necessary or useful for the Development, Manufacture or Commercialization of the respective Licensed Product, at its cost and expense. If (a) Gilead fails to bring or confirm to Nurix that it
will timely bring any such action with respect to any Nurix IP (as described in Section 12.7.1 (Notification)), Degrader Product Patent or Joint IP within ninety (90) days following the notice of alleged Infringement provided pursuant to
Section 12.7.1 (Notification), or (b) Gilead fails to bring any action with respect to any Nurix IP (as described in Section 12.7.1 (Notification)), Degrader Product Patent or Joint IP within fifteen (15) days before the time
limit, if any, set forth in Applicable Law for the filing of such actions, whichever comes first, Nurix will have the right (with Gilead’s prior written consent, not to be unreasonably withheld, conditioned or delayed) to bring and control any
such action at its own expense, and Gilead will have the right, at its own expense, to be represented in any such action by counsel of its own choice. 

(c)     A Party that elects to enforce under this Section 12.7.2 (Right to Enforce) (the
“Enforcing Party”) will keep the other Party (the “Non-Enforcing Party”) reasonably informed of the status and progress of such enforcement efforts, and reasonably consult
with the Non-Enforcing Party, including using reasonable efforts to take the Non-Enforcing Party’s comments into good faith consideration with respect to such
enforcement action, including the infringement or claim construction of any claim in any Nurix IP (as described in Section 12.7.1 (Notification)), Degrader Product Patent or Joint IP. The Non-Enforcing
Party will also provide reasonable assistance in connection with such enforcement actions, including by executing reasonably appropriate documents, cooperating in discovery and joining as a party to the action if required. 

  
 62 

 12.8    Defense. 

12.8.1    Notification. Each Party will promptly notify the other Party of any claim alleging that the Development,
Manufacture or Commercialization of the Licensed Products in the Territory infringes, misappropriates or otherwise violates any Patents, Know-How or other intellectual property rights of any Third Party
(“Third Party Infringement”). In any such instance, the Parties will as soon as practicable thereafter discuss in good faith the best response to such notice of Third Party Infringement. 

12.8.2    Right to Defend. Gilead will have the sole right, but not the obligation, to defend, and take other
actions (including to settle) with respect to, any such claim of Third Party Infringement, at Gilead’s sole discretion, cost and expense, and Nurix will have the right to be represented in any such action by counsel of its own choice at
Nurix’s sole cost and expense; provided that in no event will Gilead settle or otherwise compromise any Third Party Infringement by admitting that any Degrader Product Patent or Joint Patent is invalid or unenforceable, in each case without
first obtaining the prior written consent of Nurix, which consent will not be unreasonably withheld, conditioned or delayed. 

12.9    Recovery. 

12.9.1    Enforcement Actions. Any recovery (including any settlement) received as a result of any action under
Section 12.6 (Enforcement) will be allocated in the following order: (a) to reimburse the Enforcing Party for the costs and expenses (including attorneys’ and professional fees) that the Enforcing Party incurred in connection with
such action, to the extent not previously reimbursed; (b) to reimburse the Non-Enforcing Party, where it joins a legal action as provided under Section 12.7 (Enforcement), for the costs and expenses
(including attorneys’ and professional fees) that the Non-Enforcing Party incurred in connection with such action, to the extent not previously reimbursed; and (c) [*] of the remainder of the recovery
will be retained by the Enforcing Party, and [*] of the remainder of the recovery will be retained by the Non-Enforcing Party. 

12.9.2    Defense Actions. Any recovery (including any settlement) received as a result of any action under
Section 12.8 (Defense) will be allocated in the following order: (a) to reimburse Gilead for the costs and expenses (including attorneys’ and professional fees) that Gilead incurred in connection with such action, to the extent not
previously reimbursed; (b) to reimburse Nurix, where it joins a legal action as provided under Section 12.8 (Defense), for the costs and expenses (including attorneys’ and professional fees) that Nurix incurred in connection with such
action, to the extent not previously reimbursed; and (c) [*] of the remainder of the recovery will be retained by Gilead, and [*] of the recovery will be retained by Nurix. 

12.10    Trademarks. Gilead will have the right, but not the obligation, to brand the Licensed Products using
trademarks, trade dress and trade names it determines appropriate in its sole discretion for the Licensed Products, which may vary within the Territory (each, a “Licensed Product Mark”). Gilead will own all rights, title and
interests in and to the Licensed Product 

  
 63 

 
Marks, and all goodwill in the Licensed Product Marks will inure to the benefit of Gilead. Gilead will register and maintain the Licensed Product Marks to the extent it determines reasonably
necessary. Except as otherwise agreed in writing by both Parties, Gilead does not grant to Nurix, by implication, estoppel or otherwise, any license to any Licensed Product Mark. 

12.11    Patent Extensions. Nurix will reasonably cooperate, at Gilead’s reasonable expense, with Gilead upon
Gilead’s reasonable request in obtaining at Gilead’s expense patent term extension or supplemental protection certificates and the like with respect to any Degrader Product Patent or Joint Patent, in each country and region where it is
possible to do so. Gilead will make the election in accordance with the preceding sentence, and Nurix agrees to abide by such election. 

ARTICLE 13 

CONFIDENTIALITY 

13.1    Nondisclosure. Each Party agrees that a Party (the “Receiving Party”) which receives the
Confidential Information of the other Party (the “Disclosing Party”) pursuant to this Agreement will: (a) maintain in confidence such Confidential Information using not less than the efforts that such Receiving Party uses to
maintain in confidence its own proprietary information of similar kind and value, but in no event less than a reasonable degree of efforts; (b) not disclose such Confidential Information to any Third Party without first obtaining the prior
written consent of the Disclosing Party, except for disclosures expressly permitted pursuant to this Article 13 (Confidentiality); and (c) not use such Confidential Information for any purpose except those permitted under this Agreement,
including, in the case of Gilead, the exercise of the rights and licenses granted to Gilead hereunder. The obligations of confidentiality, non-disclosure and non-use
under this Section 13.1 (Nondisclosure) will be in full force and effect from the Effective Date until five (5) years following the Term. Except as otherwise requested in writing by the Disclosing Party, the Receiving Party will destroy
the Confidential Information of the Disclosing Party disclosed or transferred to it by the Disclosing Party pursuant to this Agreement, within sixty (60) days after the expiration or termination of this Agreement; provided, however, that a
Party may retain: (i) Confidential Information of the Disclosing Party to exercise rights and licenses which expressly survive such termination or expiration pursuant to this Agreement; (ii) one (1) copy of all other Confidential
Information in archives solely for the purpose of establishing the contents thereof or in accordance with Applicable Law and (iii) any backup media copies made in the ordinary course of business. In addition, Nurix will keep confidential, and
will cause its Affiliates and its and their employees, consultants, licensees, sublicensees, professional advisors and Affiliates to keep confidential, the Nurix IP and Joint IP, in each case specifically related to the Licensed Products on
confidentiality terms at least as protective as the confidentiality provisions of this Agreement without regard to Section 13.2 (Exceptions). 

13.2    Exceptions. 

13.2.1    General. Section 13.1 (Nondisclosure) will not apply with respect to any portion of the Confidential
Information of the Disclosing Party to the extent that such Confidential Information: 
 (a)     was
known to the Receiving Party or any of its Affiliates, as evidenced by written records, without any obligation to keep it confidential or any restriction on its use, prior to disclosure by the Disclosing Party; 

  
 64 

 (b)    is subsequently disclosed to the Receiving Party
or any of its Affiliates by a Third Party lawfully in possession thereof and without any obligation to keep it confidential or any restriction on its use; 

(c)     is published by a Third Party or otherwise becomes publicly available or enters the public domain,
either before or after it is disclosed to the Receiving Party, without any breach by the Receiving Party of its obligations hereunder; or 

(d)    is independently developed by or for the Receiving Party or any of its Affiliates, as evidenced by
written records, without reference to or reliance upon the Disclosing Party’s Confidential Information. 
 Any combination of features or disclosures
will not be deemed to fall within the foregoing exclusions merely because individual features are published or available to the general public or in the rightful possession of the Receiving Party unless the combination itself and principle of
operation are published or available to the general public or in the rightful possession of the Receiving Party. 

13.3    Authorized Disclosure. 

13.3.1    Disclosure. Notwithstanding Section 13.1 (Nondisclosure), the Receiving Party may disclose
Confidential Information belonging to the Disclosing Party in the following instances: 
 (a)     subject
to Section 13.5 (Securities Filings; Disclosure under Applicable Law), to comply with Applicable Law (including the rules and regulations of the U.S. Securities and Exchange Commission or any national securities exchange in any jurisdiction in
the Territory) (each, a “Securities Regulator”) or with judicial process (including prosecution or defense of litigation) if, in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such
compliance or for such judicial process (including prosecution or defense of litigation); 

(b)    disclosure to a Governmental Authority in order to obtain Patents, to obtain or maintain approval to
conduct Clinical Trials or to market the Licensed Products under this Agreement, in each case, in accordance with this Agreement; provided that reasonable steps are taken to ensure confidential treatment of such Confidential Information to the
extent available; 
 (c)     disclosure to (i) any of its officers, employees, consultants, agents
or Affiliates who need to know such Confidential Information to perform on behalf of such Party under this Agreement, (ii) in the case of Gilead, any actual or potential collaborators, licensees, Sublicensees or subcontractors in connection
with the Development, Manufacture and Commercialization of Licensed Products and (iii) in the case of either Party, such Party’s actual or potential acquirers or investors; provided that prior to any such

  
 65 

 
disclosure ((i)-(iii)), each such disclosee is bound by written obligations of confidentiality, non-disclosure and
non-use no less restrictive than the obligations set forth in this Article 13 (Confidentiality) to maintain the confidentiality thereof and not to use such Confidential Information except as expressly
permitted by this Agreement; provided, however, that, in each of the above situations in this Section 13.3.1(c) ((i)-(iii)) (Disclosure), the Receiving Party will remain responsible for any failure by any Person who receives Confidential
Information from such Receiving Party pursuant to this Section 13.3.1(c) (Disclosure) to treat such Confidential Information as required under this Article 13 (Confidentiality); and 

(d)    disclosure to its advisors (including attorneys and accountants) in connection with activities under
this Agreement; provided that prior to any such disclosure, each such disclosee is bound by written obligations of confidentiality, non-disclosure and non-use no less
restrictive than the obligations set forth in this Article 13 (Confidentiality) (provided, however, that in the case of legal advisors, no written agreement will be required), to maintain the confidentiality thereof and not to use such Confidential
Information except as expressly permitted by this Agreement; provided, however, that, in each of the above situations in this Section 13.3.1(d) (Disclosure), the Receiving Party will remain responsible for any failure by any Person who receives
Confidential Information from such Receiving Party pursuant to this Section 13.3.1(d) (Disclosure) to treat such Confidential Information as required under this Article 13 (Confidentiality). 

13.3.2    Terms of Disclosure. If and whenever any Confidential Information is disclosed in accordance with this
Section 13.3 (Authorized Disclosure), such disclosure will not cause any such information to cease to be Confidential Information, except to the extent that such disclosure results in a public disclosure of such information other than by breach
of this Agreement. 
 13.4    Terms of this Agreement. The Parties agree that this Agreement and the terms hereof
will be deemed to be Confidential Information of both Nurix and Gilead, and each Party agrees not to disclose this Agreement or any terms hereof without obtaining the prior written consent of the other Party; provided, that each Party may disclose
this Agreement or any terms hereof in accordance with the provisions of Section 13.3 (Authorized Disclosure), Section 13.5 (Securities Filings; Disclosure under Applicable Law), or Section 13.6.1 (Press Release; Nurix Obligations), as
applicable. 
 13.5    Securities Filings; Disclosure under Applicable Law. Each Party acknowledges and agrees
that the other Party may submit this Agreement to, or file this Agreement with, the Securities Regulators or to other Persons as may be required by Applicable Law, and if a Party submits this Agreement to, or files this Agreement with, any
Securities Regulator or other Person as may be required by Applicable Law, such Party agrees to consult with the other Party with respect to the preparation and submission of a confidential treatment request for this Agreement. Notwithstanding the
foregoing, if a Party is required by any Securities Regulator or other Person as may be required by Applicable Law to make a disclosure of the terms of this Agreement in a filing or other submission as required by such Securities Regulator or such
other Person, and such Party has: (a) provided copies of the disclosure to the other Party reasonably in advance under the circumstances of such filing or other disclosure; (b) promptly notified the other Party in writing of such
requirement and any respective timing constraints; and (c) given the other Party reasonable 

  
 66 

 
time under the circumstances from the date of provision of copies of such disclosure to comment upon and request confidential treatment for such disclosure, then such Party will have the right to
make such disclosure at the time and in the manner reasonably determined by its counsel to be required by the Securities Regulator or the other Person. Notwithstanding the foregoing, if a Party seeks to make a disclosure as required by a Securities
Regulator or other Person as may be required by Applicable Law as set forth in this Section 13.5 (Securities Filings; Disclosure under Applicable Law) and the other Party provides comments in accordance with this Section 13.5 (Securities
Filings; Disclosure under Applicable Law), the Party seeking to make such disclosure or its counsel, as the case may be, will use good faith efforts to incorporate such comments. 

13.6    Publicity. 

13.6.1    Press Release; Nurix Obligations. The Parties agree to issue a press release substantially similar to the
form of press release attached hereto as Exhibit C upon a mutually agreed-upon date after the Effective Date, but within ninety (90) days after execution of this Agreement. Subject to Section 13.3 (Authorized Disclosure), Section 13.5
(Securities Filings; Disclosure under Applicable Law) and this Section 13.6.1 (Nurix Obligations), Nurix will not, and will cause its Affiliates not to, issue any press release or other public statement disclosing this Agreement, the activities
hereunder or the transactions contemplated hereby, without first obtaining Gilead’s prior written consent; provided that Nurix will be authorized to make any disclosure, without first obtaining Gilead’s prior written consent, that is
required by Applicable Law (including the U.S. Securities Act of 1933 and the U.S. Securities Exchange Act of 1934), the rules of any Securities Regulator or by judicial process, subject to and in accordance with Section 13.3 (Authorized
Disclosure) and Section 13.5 (Securities Filings; Disclosure under Applicable Law), as applicable. The contents of any press release or other public statement that has been reviewed and approved by Gilead may be
re-released by Nurix without first obtaining Gilead’s prior written consent in accordance with this Section 13.6.1 (Press Release; Nurix Obligations). 

13.6.2    Gilead Rights. Gilead will have the right to issue any press release or other public statement disclosing
this Agreement, the activities under this Agreement or the transactions contemplated hereby without first obtaining the prior written consent of Nurix; provided that any such press release or other public statement does not include the Confidential
Information of Nurix. 
 13.7    Publications. During the Collaboration Term a Party will, and following the
expiration of the Collaboration Term Nurix will (each of the foregoing, during such applicable time, a “Publishing Party”), prior to publishing, publicly presenting or otherwise publicly disclosing any paper, publication, oral
presentation, abstract, poster, manuscript or other presentation relating to any activity or other matter under this Agreement (each, a “Publication”) provide the other Party (a “Reviewing Party”) an opportunity to
review such Publication to determine whether such Publication contains the Confidential Information of the Reviewing Party. The Publishing Party will deliver to the Reviewing Party a copy of any such proposed Publication or an outline of the
proposed oral disclosure at least sixty (60) days prior to submission for publication or presentation for review by the Reviewing Party. The Reviewing Party will have the right, in its sole discretion, to: (a) require the removal of its
Confidential Information from any such Publication by the Publishing Party or (b) request a reasonable delay in publication or presentation in order to protect patentable information. If the Reviewing Party requests such a

  
 67 

 
delay, the Publishing Party will delay submission or presentation for a period of ninety (90) days after its provision of the copy of the proposed publication or disclosure to enable patent
applications protecting the Reviewing Party’s rights in such information. 
 13.8    Use of Names. Except as
otherwise expressly set forth herein, neither Party (or any of its respective Affiliates) will use the name, trademark, trade name or logo of the other Party or any of its Affiliates, or its or their respective employees, in any publicity,
promotion, news release or other public disclosure relating to this Agreement or its subject matter, without first obtaining the prior written consent of the other Party; provided that such consent will not be required to the extent use thereof may
be required by Applicable Law, including the rules of any securities exchange or market on which a Party’s or its Affiliate’s securities are listed or traded. 

13.9    Clinical Trials Registry. For clarity, Gilead, its Affiliates and its designees will have the right to
publish registry information and summaries of data and results from any Clinical Trials conducted in connection with Licensed Products, on its Clinical Trials registry or on a government-sponsored database such as www.clinicaltrials.gov, without
first obtaining the prior consent of Nurix. The Parties will reasonably cooperate if required or reasonably requested by Gilead in order to facilitate any such publication by Gilead, any of its Affiliates or any of its designees. 

ARTICLE 14 

REPRESENTATIONS AND WARRANTIES; COVENANTS 

14.1    Representations and Warranties of Each Party. Each Party hereby represents and warrants to the other Party,
as of the Effective Date and each License Option Effective Date, that: 
 14.1.1    such Party is duly organized,
validly existing and in good standing under the Applicable Law of the jurisdiction of its formation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof; 

14.1.2    such Party has taken all necessary corporate action on its part to authorize the execution and delivery of this
Agreement and the performance of its obligations hereunder; 
 14.1.3    this Agreement has been duly executed and
delivered on behalf of such Party and constitutes a legal, valid and binding obligation, enforceable against it in accordance with its terms, except to the extent that enforcement of the rights and remedies created hereby is subject to:
(a) bankruptcy, insolvency, reorganization, moratorium and other similar laws of general application affecting the rights and remedies of creditors; or (b) laws governing specific performance, injunctive relief and other equitable
remedies; 
 14.1.4    the execution, delivery and performance of this Agreement by such Party does not breach or
conflict with any agreement or any provision thereof, or any instrument or understanding, oral or written, to which such Party (or any of its Affiliates) is a party or by which such Party (or any of its Affiliates) is bound, nor violate any
Applicable Law of any Governmental Authority having jurisdiction over such Party (or any of its Affiliates); 

14.1.5    no government authorization, consent, approval, license, exemption of or filing or registration with any court
or governmental department, commission, board, bureau, 

  
 68 

 
agency or instrumentality, domestic or foreign, under any Applicable Law currently in effect, is or will be necessary for, or in connection with, the transactions contemplated by this Agreement,
or for the performance by it of its obligations under this Agreement, except: (a) as may be required to conduct Clinical Trials or to seek or obtain Regulatory Approvals or applicable Regulatory Materials, or to Manufacture or Commercialize any
Licensed Product(s); or (b) as set forth in Section 3.3 (Antitrust Filings); and 
 14.1.6    it has obtained
all necessary authorizations, consents and approvals of any Third Party that is required to be obtained by it for, or in connection with, the transactions contemplated by this Agreement, or for the performance by it of its obligations under this
Agreement, except: (a) as may be required to conduct Clinical Trials or to seek or obtain Regulatory Approvals or applicable Regulatory Materials, or to Manufacture or Commercialize any Licensed Product(s); or (b) as set forth in
Section 3.3 (Antitrust Filings). 
 14.2    Representations and Warranties of Nurix. Nurix hereby represents
and warrants to Gilead (a) except as set forth on Schedule 14.2 (Exceptions to Representations and Warranties of Nurix), as of the Effective Date and (b) except as set forth in a disclosure letter delivered by Nurix to Gilead as set forth
in Section 3.3.2 (Effectiveness), which letter will only set forth specific facts and circumstances that have occurred on or after the Effective Date and will not limit or otherwise amend any representations or warranties contained in this
Section 14.2 (Representations and Warranties of Nurix) (“Disclosure Letter”), each License Option Effective Date, that: 

14.2.1    Schedule 1.147 (Nurix Patents) or, if provided to Gilead, the most recently provided Disclosure Letter sets
forth a complete and accurate list of all Nurix Patents (if any); 
 14.2.2    all issued Patents constituting Nurix
Patents (if any) have been Prosecuted and Maintained by or on behalf of Nurix in good faith, are in full force and effect and, to the Knowledge of Nurix, are valid and enforceable; 

14.2.3    Nurix has not received any written notice of a claim or written threat of a claim or litigation made by any
Person against Nurix or its Affiliates that alleges that any Nurix IP is invalid or unenforceable; 
 14.2.4    neither
Nurix nor any of its Affiliates is subject to any payment obligations to Third Parties as a result of the execution or performance of this Agreement, the performance of the Research activities hereunder or the Development, Manufacture or
Commercialization of the Licensed Products; 
 14.2.5    Nurix has the full right and authority to grant all of the
options, rights and licenses granted to Gilead (or purported to be granted to Gilead) hereunder, and neither Nurix nor its Affiliates have granted any option, right or license to any Third Party relating to any of the Nurix IP that would conflict
with or limit the scope of any of the options, rights or licenses granted to Gilead hereunder; 
 14.2.6    Nurix is the
sole and exclusive owner or exclusive licensee under an Existing Upstream License Agreement of the Nurix IP. All Affiliates of Nurix have exclusively licensed or assigned all of their rights, title and interests in and to the Nurix IP to Nurix.
Neither Nurix nor any of its Affiliates has granted any mortgage, pledge, claim, security interest, lien or other charge of any kind on or in the Nurix IP, and the Nurix IP is free and clear of any mortgage, pledge, claim, security interest, lien or
charge of any kind; 

  
 69 

 14.2.7    Nurix and its Affiliates have obtained from all individuals
who participated in any respect in the invention or authorship of any Nurix IP effective assignments of all ownership rights of such individuals in such Nurix IP, either pursuant to written agreement or by operation of law; and, to the Knowledge of
Nurix, no Person who claims to be an inventor of an Invention claimed in a Nurix Patent is not identified as an inventor of such Invention in the filed patent documents for such Nurix Patent; 

14.2.8    all of Nurix’s and its Affiliates’ employees, officers and consultants: (a) have executed
agreements or have existing obligations under Applicable Law requiring assignment to Nurix or its Affiliates of all Inventions made during the course of and as the result of their association with Nurix or its Affiliates, as applicable, and
obligating the individual to assign to Nurix or its Affiliate, as applicable, all Inventions made during the course of performance under this Agreement; (b) are not subject to any agreement with any other Third Party that requires such officer
or employee or consultant to assign any interest in any Nurix IP to such Third Party; and (c) have executed agreements or have existing obligations under Applicable Law obligating the individual to maintain as confidential Nurix’s
Confidential Information as well as confidential information of other parties (including of Gilead and its Affiliates) that such individual may receive in its performance under this Agreement, to the extent required to support Nurix’s
obligations under this Agreement; 
 14.2.9    neither Nurix nor its Affiliates have received any notice, written or
otherwise, of any claim that any Patent or Know-How (including any trade secret right) owned or controlled by a Third Party would be infringed, misappropriated or otherwise violated by the performance of the
Research activities hereunder or by the Development, Manufacture or Commercialization of the Licensed Products in accordance with this Agreement; 

14.2.10     to the Knowledge of Nurix, the performance of the Research activities hereunder and the Development,
Manufacture and Commercialization of the Licensed Products, in each case as contemplated to be conducted under this Agreement, will not infringe, misappropriate or otherwise violate any intellectual property or proprietary right that is owned or
controlled by any Third Party; 
 14.2.11     there are no claims, judgments, settlements, litigations, suits, actions,
disputes, arbitration, judicial, or legal, administrative or other proceedings, or governmental investigations pending or, to the Knowledge of Nurix, threatened against Nurix or its Affiliates which could reasonably be expected to adversely affect
or restrict the ability of Nurix to consummate or perform the transactions contemplated under this Agreement, or which would affect the Nurix IP, Nurix’s Control thereof or the Licensed Products; 

14.2.12     neither Nurix nor any of its Affiliates has made a claim against a Third Party alleging that a Third Party is
infringing or has infringed, is misappropriating or has misappropriated, or is violating or has violated, any Nurix IP, and, to the Knowledge of Nurix, no Nurix IP is being infringed, misappropriated or violated by any Third Party; 

  
 70 

 14.2.13     neither Nurix nor any of its Affiliates has employed, or
otherwise used in any capacity, the services of any Person suspended, proposed for debarment or debarred under United States law, including under 21 U.S.C. § 335a, or any foreign equivalent thereof, with respect to the performance of activities
hereunder; 
 14.2.14     all activities (including Research activities) conducted by or on behalf of Nurix or its
Affiliates hereunder has been and will be conducted in accordance with all Applicable Law (including, to the extent applicable, GCP, GLP and GMP), and in sufficient detail and in a good scientific manner appropriate for scientific, regulatory and
intellectual property protection purposes, and all such Research will be reasonably segregated from other Research activities not performed under this Agreement and be complete and accurate, and fully and accurately reflect all work done, data and
developments made, and results achieved in the performance of the Research Programs; 
 14.2.15     except as set forth
on Schedule 1.236 (Existing Upstream License Agreements) or, if provided to Gilead, the most recently provided Disclosure Letter, neither Nurix nor its Affiliates have entered into any agreement under which Nurix or its Affiliates: (a) has
obtained a license or sublicense of rights from a Third Party to any Nurix IP; or (b) has granted a license, sublicense, option or right to a Third Party that remains in effect to Develop, Manufacture or Commercialize any Licensed Product; 

14.2.16     Schedule 1.236 (Existing Upstream License Agreements) or, if provided to Gilead, the most recently provided
Disclosure Letter sets forth a complete and accurate list of the Existing Upstream License Agreements in effect (if any). Nurix has provided Gilead true, correct and complete copies of each such Existing Upstream License Agreement. Each such
Existing Upstream License Agreement is in full force and effect, and there has been no Default of or under (or notice of Default of or under) any such Existing Upstream License Agreement as a result of any action or omission or alleged act or
omission of Nurix or its Affiliates or, to the Knowledge of Nurix, the actions or omissions of any Third Party. Nurix has not waived any of its rights under any such Existing Upstream License Agreement to which it is party. Immediately following the
Effective Date, Nurix will continue to be permitted to exercise all of its rights under each such Existing Upstream License Agreement to which it is party pursuant to the terms thereof without the payment of any additional amounts of consideration
beyond ongoing fees, royalties or payments that Nurix would otherwise be required to pay in accordance with the terms of such Existing Upstream License Agreement had the transactions contemplated by this Agreement not occurred; 

14.2.17     other than the Existing Upstream License Agreements, Nurix (or its Affiliates, as applicable) has not entered
into any agreement relating to: (a) the Research activities contemplated hereunder, or (b) the Development, Manufacture or Commercialization of any Licensed Product; and 

14.2.18     no funding, facilities or personnel of any Governmental Authority or any public or private educational or
research institutions were used to develop or create any Nurix IP, and neither Nurix nor any of its Affiliates has entered into a government funding relationship that would result in rights to the Licensed Products residing in the U.S. Government,
the National Institutes of Health, the National Institute for Drug Abuse or other agency, and the options and 

  
 71 

 
licenses granted hereunder are not subject to overriding obligations to the U.S. Government as set forth in Public Law 96-517 (35 U.S.C. §§ 200-204), or any similar obligations under
the laws of any other country in the Territory. 
 14.3    Representations and Warranties of Gilead. Gilead
hereby represents and warrants to Nurix, as of the Effective Date, that: 
 14.3.1    there are no claims, judgments,
settlements, litigations, suits, actions, disputes, arbitration, judicial, or legal, administrative, or other proceedings or governmental investigations pending or, to the Knowledge of Gilead, threatened against Gilead which would reasonably be
expected to adversely affect or restrict the ability of Gilead to consummate or perform the transactions contemplated under this Agreement; 

14.3.2    Gilead has the full right and authority to grant all of the rights and licenses granted to Nurix (or purported
to be granted to Nurix) hereunder, and neither Gilead nor its Affiliates have granted any option, right or license to any Third Party relating to any of the Patents or Know-How that would conflict with or
limit the scope of any of the rights or licenses granted to Nurix hereunder, including under Section 12.1.1 (Research Licenses); and 

14.3.3    no Licensed Product would be an Encumbered Licensed Product if, on the Effective Date, it were Directed To any
of the Initial Collaboration Targets. 
 14.4    Covenants. 

14.4.1    Mutual Covenant. Each Party hereby covenants to the other Party that: (a) such Party and its
Affiliates will perform its activities pursuant to this Agreement in compliance (and will ensure compliance by any of its subcontractors) with all Applicable Law, including, to the extent applicable, GCP, GLP and GMP; and (b) will not employ,
or otherwise use in any capacity, the services of any Person suspended, proposed for debarment or debarred under United States law, including under 21 U.S.C. § 335a, or any foreign equivalent thereof, with respect to the performance of
activities hereunder. 
 14.4.2    Additional Nurix Covenants. Nurix hereby covenants to Gilead that: 

(a)     Neither Nurix nor its Affiliates will grant any option, right or license to any Third Party
relating to any of the intellectual property rights it Controls (including the Nurix IP), or otherwise with respect to any Licensed Product, which conflict with, or could otherwise adversely impact any of the options, rights or licenses granted to
Gilead hereunder. 
 (b)    Except as otherwise expressly agreed to by Gilead in writing, neither Nurix
nor its Affiliates will use (and neither will grant any Third Party the right to use) any Licensed Product for any purposes in the Territory. 

(c)     Except as otherwise expressly permitted under this Agreement, Nurix will not, and will cause its
Affiliates not to: (i) assign, transfer, convey, encumber (through a lien, charge, security interest, mortgage or similar encumbrance) or dispose of, or enter into any agreement with any Third Party to assign, transfer, convey, encumber

  
 72 

 
(through a lien, charge, security interest, mortgage or similar encumbrance) or dispose of, any assets related to the Nurix IP or any Licensed Product; (ii) license or grant to any Third
Party, or agree to license or grant to any Third Party, any rights to the Nurix IP or any Licensed Product; or (iii) disclose any Confidential Information relating to the Nurix IP or any Licensed Product to any Third Party; in each case
(i.e., with respect to clauses (i) through (iii)) except to the extent that such assignment, transfer, conveyance, encumbrance, disposition, license, grant or disclosure would not conflict with, be inconsistent with or adversely affect
in any respect any of the options, rights or licenses granted to Gilead hereunder. 
 (d)    Nurix will:
(i) maintain Control of all Nurix IP licensed or sublicensed to Gilead under each Existing Upstream License Agreement; and (ii) not terminate, breach or otherwise Default under any Existing Upstream License Agreement in a manner that would
permit the counterparty thereto to terminate such Existing Upstream License Agreement or otherwise diminish the scope or exclusivity of the licenses granted to Gilead under any Nurix IP. 

(e)     If Nurix receives notice of an alleged Default by Nurix or its Affiliates under any Existing
Upstream License Agreement, where termination of such Existing Upstream License Agreement or any diminishment of the scope or exclusivity of the licenses granted to Gilead under the Nurix IP is being or could be sought by the counterparty or result
from such Default, then Nurix will promptly, but in no event less than three (3) Business Days thereafter, provide written notice thereof to Gilead and hereby grants to Gilead the right (but not the obligation) to: (i) cure such alleged
breach; and (ii) offset any costs or expenses incurred in connection therewith against any payments due or that may become due under this Agreement. 

14.4.3    Additional Gilead Covenant. Gilead hereby covenants to Nurix that at the time Gilead provides Nurix with
Gilead Materials or Gilead Documentation, Gilead will Control such Gilead Materials or Gilead Documentation, as applicable. 

14.5    Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY
REPRESENTATIONS OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED (AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES NOT EXPRESSLY PROVIDED IN THIS AGREEMENT), INCLUDING WITH RESPECT TO ANY PATENTS OR KNOW-HOW, INCLUDING WARRANTIES OF VALIDITY OR ENFORCEABILITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR USE OR PURPOSE, PERFORMANCE AND NON-INFRINGEMENT OF ANY THIRD PARTY
PATENT OR OTHER INTELLECTUAL PROPERTY RIGHT. WITHOUT LIMITING THE FOREGOING, THE PARTIES AGREE THAT THE MILESTONE EVENTS, SALES MILESTONE EVENTS AND NET SALES LEVELS SET FORTH IN THIS AGREEMENT OR THAT HAVE OTHERWISE BEEN DISCUSSED BY THE PARTIES
ARE MERELY INTENDED TO DEFINE THE MILESTONE PAYMENTS, SALES MILESTONE PAYMENTS AND ROYALTY OBLIGATIONS IF SUCH MILESTONE EVENTS, SALES MILESTONE EVENTS OR NET SALES LEVELS ARE ACHIEVED. NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY, EITHER
EXPRESS OR IMPLIED, 

  
 73 

 
THAT IT WILL BE ABLE TO SUCCESSFULLY ADVANCE ANY DEGRADER PRODUCT OR DEVELOP, MANUFACTURE OR COMMERCIALIZE ANY LICENSED PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR SALES LEVEL OR PROFIT OF
SUCH LICENSED PRODUCT WILL BE ACHIEVED. 
 ARTICLE 15 

INDEMNIFICATION; INSURANCE 

15.1    Indemnification. 

15.1.1    Indemnification by Gilead. Gilead will indemnify, defend and hold harmless Nurix, its Affiliates
and its and their respective directors, officers, employees, agents, successors and assigns (each, a “Nurix Indemnitee”) from and against any and all Damages to the extent arising out of or relating to, directly or indirectly, any
Third Party Claim based upon: 
 (a)     the Research activities of Gilead or its Affiliates or
contractors prior to the applicable License Option Effective Date; 
 (b)    the Development, Manufacture
or Commercialization of Licensed Products in the Field in the Territory by Gilead, its Affiliates or its Sublicensees; 

(c)     the gross negligence or willful misconduct of Gilead or its Affiliates or its or their respective
directors, officers, employees or agents, in connection with Gilead’s performance of its obligations under this Agreement; or 

(d)    any breach by Gilead of any of its representations, warranties, covenants, agreements or obligations
under this Agreement; 
 provided, however, that, in each case ((a)-(d)), such indemnity will not apply to the extent Nurix has an indemnification
obligation pursuant to Section 15.1.2 (Indemnification by Nurix) for such Damages. 
 15.1.2    Indemnification
by Nurix. Nurix will indemnify, defend and hold harmless Gilead, its Affiliates and its and their respective directors, officers, employees, agents, successors, assigns and Sublicensees (each, a “Gilead Indemnitee”), from and
against any and all Damages to the extent arising out of or relating to, directly or indirectly, any Third Party Claim based upon: 

(a)     any Research or Manufacture activities of Nurix or its Affiliates, contractors or licensees prior
to the applicable License Option Effective Date; 
 (b)    the gross negligence or willful misconduct of
Nurix or its Affiliates or its or their respective directors, officers, employees or agents, in connection with Nurix’s performance of its obligations under this Agreement; or 

(c)     any breach by Nurix of any of its representations, warranties, covenants, agreements or obligations
under this Agreement; 

  
 74 

 provided, however, that, in each case ((a)-(c)), such indemnity will not apply to the extent Gilead has an
indemnification obligation pursuant to Section 15.1.1 (Indemnification by Gilead) for such Damages. 

15.2    Procedure. 

15.2.1    Notice. If a Nurix Indemnitee or Gilead Indemnitee is seeking indemnification under Section 10.4
(Assignment of Agreements), Section 15.1.1 (Indemnification by Gilead) or Section 15.1.2 (Indemnification by Nurix), as applicable (the “Indemnitee”), it will inform the other Party (the “Indemnitor”) of
the claim giving rise to the obligation to indemnify pursuant to Section 10.4 (Assignment of Agreements), Section 15.1.1 (Indemnification by Gilead) or Section 15.1.2 (Indemnification by Nurix), as applicable, as soon as reasonably
practicable after receiving notice of the claim (an “Indemnification Claim Notice”); provided that any delay or failure to provide such notice will not constitute a waiver or release of, or otherwise limit, the Indemnitee’s
rights to indemnification under Section 10.4 (Assignment of Agreements), Section 15.1.1 (Indemnification by Gilead) or Section 15.1.2 (Indemnification by Nurix), as applicable, except to the extent that such delay or failure
materially prejudices the Indemnitor’s ability to defend against the relevant claims. 
 15.2.2    Control of
Defense. The Indemnitor will have the right, upon written notice given to the Indemnitee within thirty (30) days after receipt of the Indemnification Claim Notice (and, where the Indemnitor is Nurix, subject to receipt of Gilead’s
prior written consent), to assume the defense of any such claim for which the Indemnitee is seeking indemnification pursuant to Section 10.4 (Assignment of Agreements), Section 15.1.1 (Indemnification by Gilead) or Section 15.1.2
(Indemnification by Nurix), as applicable. The Indemnitee will cooperate with the Indemnitor and the Indemnitor’s insurer as the Indemnitor may reasonably request, and at the Indemnitor’s cost and expense. The Indemnitee will have the
right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the Indemnitor. 

15.2.3    Settlements. The Indemnitor will not settle any claim without first obtaining the prior written consent
of the Indemnitee, not to be unreasonably withheld, conditioned or delayed; provided, however, that the Indemnitor will not be required to obtain such consent if the settlement: (a) involves only the payment of money and will not result in the
Indemnitee (or other Nurix Indemnitees or Gilead Indemnitees, as applicable) becoming subject to injunctive or other similar type of relief; (b) does not require an admission by the Indemnitee (or other Nurix Indemnitees or Gilead Indemnitees,
as applicable); and (c) does not adversely affect the rights or licenses granted to the Indemnitee (or its Affiliate) under this Agreement. The Indemnitee will not settle or compromise any such claim without first obtaining the prior written
consent of the Indemnitor. 
 15.2.4    Separate Defenses; Cooperation. If the Parties cannot agree as to the
application of Section 10.4 (Assignment of Agreements), Section 15.1.1 (Indemnification by Gilead) or Section 15.1.2 (Indemnification by Nurix), as applicable, to any claim, pending the resolution of the Dispute pursuant to
Section 17.6 (Choice of Law; Dispute Resolution; Jurisdiction), the Parties may conduct separate defenses of such claims, with each Party retaining the right to claim indemnification from the other Party in accordance with Section 10.4

  
 75 

 
(Assignment of Agreements), Section 15.1.1 (Indemnification by Gilead) or Section 15.1.2 (Indemnification by Nurix), as applicable, upon resolution of the underlying claim. In each
case, the Indemnitee will reasonably cooperate with the Indemnitor and will make available to the Indemnitor all pertinent information under the control of the Indemnitee, which information will be subject to Article 13 (Confidentiality). 

15.3    Insurance. 

15.3.1    Insurance Maintained by Each Party. During the Term, each Party will have and maintain in full force and
effect, at its own expense, insurance coverage (with a Third Party or solely with respect to Gilead through a program of self-insurance) to include: 

(a)     Commercial general liability insurance with limits of liability not less than [*] per occurrence
and [*] in the aggregate. General liability limit requirements may be satisfied by a combination of primary and umbrella or excess liability insurance coverage; 

(b)    Workers’ compensation insurance in compliance with Applicable Law (including the local law
requirements of the state or jurisdiction in which the work is to be performed). Employer’s liability insurance in amounts not less than [*] for each of: (i) bodily injury by accident (each accident); (ii) bodily injury by disease (policy
limit); and (iii) bodily injury by disease (each employee). Where permitted by Applicable Law, such policies will contain a waiver of the insurer’s subrogation rights against the other Party; and 

(c)     Automobile liability insurance for bodily injury, property damage and automobile contractual
liability covering all owned, hired and non-owned automobiles with a combined single limit of liability for each accident of not less than [*]. 

15.3.2    Additional Requirements. Each Party will name the other Party as an additional insured on the insurance
policies maintained pursuant to Section 15.3.1(a) (Insurance Maintained by Each Party) and Section 15.3.1(c) (Insurance Maintained by Each Party), as applicable, either by endorsement or blanket additional insured endorsement, and such
insuring Party will provide evidence of insurance maintained pursuant to this Section 15.3 (Insurance) on request of the other Party. Each Party will provide the other Party a notice of insurance policy cancellation in accordance with the
provisions of the applicable insurance policy maintained pursuant to this Section 15.3 (Insurance). Insurance policies maintained pursuant to this Section 15.3 (Insurance) should be occurrence type. If policies maintained pursuant to this
Section 15.3 (Insurance) are claims made, then insurance will be maintained for at least five (5) years following expiration or termination of this Agreement. All insurance maintained pursuant to this Section 15.3 (Insurance) will be
underwritten by companies with an AM best rating of at least A-VII. In addition, such insurance will not be construed to create a limit on either Party’s liability with respect to its indemnification
obligations under Section 10.4 (Assignment of Agreements), this Article 15 (Indemnification; Insurance) or otherwise. 

15.4    Limitation of Liability. NEITHER NURIX NOR GILEAD, NOR ANY OF THEIR RESPECTIVE AFFILIATES, WILL BE LIABLE
TO THE OTHER PARTY OR ITS 

  
 76 

 
AFFILIATES UNDER OR IN CONNECTION WITH THIS AGREEMENT FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING LOST PROFITS OR LOST REVENUES), WHETHER
LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT PRODUCT LIABILITY), INDEMNITY, CONTRIBUTION OR OTHERWISE, AND IRRESPECTIVE OF WHETHER THAT PARTY OR ANY REPRESENTATIVE OF THAT PARTY HAS BEEN ADVISED OF, OR OTHERWISE MIGHT
HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 15.4 (LIMITATION OF LIABILITY) IS INTENDED TO OR WILL LIMIT OR RESTRICT: (A) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY
PARTY UNDER SECTION 10.4 (ASSIGNMENT OF AGREEMENTS), SECTION 15.1.1 (INDEMNIFICATION BY GILEAD) OR SECTION 15.1.2 (INDEMNIFICATION BY NURIX), AS APPLICABLE, IN CONNECTION WITH ANY THIRD PARTY CLAIMS; (B) THE LIABILITY OF NURIX FOR BREACH OF ITS
EXCLUSIVITY OBLIGATIONS UNDER SECTION 2.9 (EXCLUSIVITY) OR (C) DAMAGES AVAILABLE FOR A PARTY’S GROSS NEGLIGENCE, INTENTIONAL MISCONDUCT OR FRAUD OR FOR BREACH OF ARTICLE 13 (CONFIDENTIALITY). 

ARTICLE 16 
 TERM AND
TERMINATION 
 16.1    Term; Expiration. 

16.1.1    Term. The term of this Agreement (the “Term”) will commence on the Effective Date and
(subject to earlier termination in accordance with Section 16.2 (Termination for Material Breach), Section 16.3 (Termination at Will) or Section 16.4 (Termination for Bankruptcy)) will expire, on a Licensed Product-by-Licensed Product and country-by-country basis, on the expiration of the Royalty Term
for such Licensed Product in such country; provided that (a) the Term with respect to any Profit-Share Product in the U.S. will expire upon expiration or termination of the applicable Profit-Share Term as defined in Exhibit B (Profit-Share
Exhibit), (b) if no License Option is exercised by the last day of the last-to-expire License Option Period, this Agreement will expire on the last day of the last-to-expire License Option Period and (c) if Gilead exercises one (1) or more License Options but no License Option Effective Date occurs on or before the last
applicable Outside Date, this Agreement will expire on the last applicable Outside Date. Upon the expiration of the Royalty Term or Profit-Share Term as defined in Exhibit B (Profit-Share Exhibit), as applicable, with respect to a Licensed Product
in a country, the license for such Licensed Product as set forth in Section 12.1.2 (License to Gilead for Licensed Products) will become fully paid-up, irrevocable, perpetual and royalty-free in such
country. Termination for Material Breach. 
 16.2.1    Material Breach. This Agreement may be
terminated in its entirety or in part for a Material Breach by the other Party upon written notice to the breaching Party if the breaching Party has not cured such Material Breach within [*] after the date of written notice to the breaching Party of
such breach (which notice will describe such Material Breach in reasonable detail and will state the non-breaching Party’s intention to terminate this Agreement, in its entirety or in part) or, if such
breach is not reasonably capable of being cured within such [*] period, then such [*] period will be extended for an additional [*] so long as the breaching Party continues to 

  
 77 

 
use Commercially Reasonable Efforts to cure such Material Breach during such extension period (such [*] period, as may be extended in accordance with this Section 16.2 (Termination for
Material Breach), the “Cure Period”). Notwithstanding the foregoing, in the event that any such Material Breach by Gilead is limited to one (1) or more (but not all) Research Programs, Licensed Products or countries, then Nurix
will have the right to terminate solely with respect to such Research Programs, Licensed Products or countries, as applicable. 

16.2.2    Disagreement as to Material Breach. Notwithstanding Section 16.2.1 (Material Breach), if the Parties
in good faith disagree as to whether there has been a Material Breach of this Agreement, then: (a) the Party that disputes whether there has been a Material Breach may contest the allegation by referring such matter, within [*] following its
receipt of notice of the alleged Material Breach, for resolution in accordance with Section 17.6 (Choice of Law; Dispute Resolution; Jurisdiction); (b) the relevant Cure Period with respect to such alleged Material Breach will be tolled from
the date on which the Party that disputes whether there has been a Material Breach notifies the other Party of such Dispute and through the resolution of such Dispute in accordance with the applicable provisions of this Agreement; and
(c) subject to Section 16.7 (Surviving Provisions), during the pendency of such Dispute, all of the terms and conditions of this Agreement will remain in effect and the Parties will continue to perform all of their respective obligations
hereunder. 
 16.3    Termination at Will. Gilead may terminate this Agreement at will, in its sole discretion,
in its entirety or on a Licensed Product-by-Licensed Product or country-by-country basis
at any time upon [*] prior written notice to Nurix. 
 16.4    Termination for Bankruptcy. 

16.4.1    Reject Events. If either Party makes a general assignment for the benefit of, or an arrangement or
composition generally with, its creditors, appoints or suffers appointment of an examiner or of a receiver or trustee over all or substantially all of its property, passes a resolution for its winding up, or files a petition under any bankruptcy or
insolvency act or law or has any such petition filed against it which is not dismissed, discharged, bonded or stayed within [*] after the filing thereof and seeks to reject this Agreement, (a “Rejection Event”), the other
Party may treat this Agreement as terminated by such rejection, effective immediately upon written notice to such Party. 

16.4.2    Section 365(n) Rights. For purposes of Section 365(n) of the U.S. Bankruptcy Code (the
“Code”) and any similar laws in any other country, all rights and licenses granted under or pursuant to any Section of this Agreement are rights to “intellectual property” (as defined in Section 101(35A) of the Code).
The Parties agree that the licensee of such rights under this Agreement will retain and may fully exercise all of its protections, rights and elections under the Code and any similar laws in any other country. Each Party hereby acknowledges that
copies of research data, laboratory samples, product samples and inventory, formulas, laboratory notes and notebooks, pre-clinical research data and results, tangible
Know-How and rights of reference, in each case that relate to such intellectual property, constitute “embodiments” of such intellectual property pursuant to Section 365(n) of the Code, and that
the licensee will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and the same, if not already in its possession, will be

  
 78 

 
promptly delivered to it upon its written request therefor and election under Bankruptcy Code Section 365(n)(1)(B) to retain the licenses granted by Nurix to Gilead hereunder in the event of
Nurix’s rejection of this Agreement, unless the licensor elects to continue to perform all of its obligations under this Agreement. The provisions of this Section 16.4.2 (Section 365(n) Rights) are without prejudice to any rights the non-subject Party may have arising under the Code, laws of other jurisdictions governing insolvency and bankruptcy or other Applicable Law. The Parties agree that they intend the following rights to extend to the
maximum extent permitted by law, including for purposes of the Code and any similar laws in any other country: (x) the right of access to any intellectual property (including all embodiments thereof) of the licensor, or any Third Party with
whom the licensor contracts to perform an obligation of such licensor under this Agreement which is necessary for the Development, Manufacture or Commercialization of a Licensed Product; (y) the right to contract directly with any Third Party
described in (x) to complete the contracted work and (z) the right to cure any breach of or default under any such agreement with a Third Party and set off the costs thereof against amounts payable to such licensor under this Agreement.

 16.5    Effects of Termination. 

16.5.1    Termination by Gilead at Will or by Nurix for Material Breach or Bankruptcy. Upon
termination of this Agreement with respect to a Terminated Licensed Product: (a) by Gilead, in accordance with Section 16.3 (Termination at Will); or (b) by Nurix, in accordance with Section 16.2 (Termination for Material Breach)
or Section 16.4 (Termination for Bankruptcy): 
 (a)     the license granted by Nurix to Gilead
pursuant to Section 12.1.2 (License to Gilead for Licensed Products) with respect to the Terminated Licensed Product will terminate and Gilead will not have any rights to use or exercise any rights under the Nurix IP with respect to such
Terminated Licensed Product; 
 (b)    Gilead will, commencing with the date such termination becomes
effective, have no further obligations under this Agreement to Develop, Manufacture or Commercialize such Terminated Licensed Product, including with respect to Section 4.2 (Development Diligence), Section 4.3 (Development Updates) and
Article 6 (Commercialization); and 
 (c)     upon written request from Nurix to Gilead provided within
[*] of the effective date of termination, the Parties will enter into good faith negotiations for up to [*] for a definitive agreement regarding the transition by Gilead to Nurix of assets and rights and the provision of assistance by each Party to
the other Party as reasonably necessary, subject to agreement of the Parties, to enable the continued Development, Manufacture and Commercialization of Licensed Products other than Combination Products (each, a “Licensed Product Transition
Agreement”); each Licensed Product Transition Agreement may address, among other things, the following matters: (a) the transfer or wind-down of Clinical Trials; (b) the continued Commercialization of Licensed Products for an
agreed transition period to avoid disruption to patients that may be caused by such termination; (c) supply of applicable Licensed Products or technology transfer to enable Nurix to Manufacture applicable Licensed Products; (d) the
transfer of applicable 

  
 79 

 
inventory; (e) the transfer of applicable Regulatory Materials; (f) the granting of necessary intellectual property licenses to Gilead Sole IP; (g) the treatment of Research
Results; (h) any Nurix rights to use Licensed Products containing any Gilead Materials; and (i) reasonable compensation to Gilead for providing such transition and assistance to Nurix. 

16.5.2    Termination by Gilead for Material Breach or Bankruptcy. Upon termination of this Agreement with respect
to a Terminated Licensed Product by Gilead in accordance with Section 16.2 (Termination for Material Breach) or Section 16.4 (Termination for Bankruptcy): 

(a)     Gilead will be released from its Development, Manufacturing and Commercialization obligations under
this Agreement with respect to the Terminated Licensed Product, including with respect to Section 4.2 (Development Diligence), Section 4.3 (Development Updates) and Article 6 (Commercialization); and 

(b)    Gilead’s rights and Nurix’s obligations pursuant to Section 12.5 (Ownership) will
survive. 
 16.6    Certain Additional Remedies of Gilead in Lieu of Termination. Subject to Section 16.2.2
(Disagreement as to Material Breach), if Nurix commits a Material Breach of Section 2.9 (Exclusivity), Section 14.2.5 (Representations and Warranties of Nurix) or Section 14.2.6 (Representations and Warranties of Nurix) and Gilead
would have the right to terminate this Agreement pursuant to Section 16.2 (Termination for Material Breach), then, in lieu of Gilead terminating this Agreement pursuant to Section 16.2 (Termination for Material Breach), and without
limiting any other rights or remedies of Gilead hereunder, Gilead may elect to have this Agreement continue in full force and effect by providing written notice thereof to Nurix; provided that if Gilead so elects to continue this Agreement, then
from and after such time as Gilead delivers such written notice to Nurix, any and all amounts thereafter payable by Gilead hereunder with respect to the Collaboration Targets, Research Programs, Target Binders, Degrader Compounds, Degrader Products
or Licensed Products in each case affected by such Material Breach (including Research Extension Fees, Selection Campaign Fees, Option Fees, Milestone Payments, Sales Milestone Payments, royalties or other payments described in Exhibit B
(Profit-Share Exhibit)) will, in each case, [*]. 
 16.7    Surviving Provisions. 

16.7.1    Accrued Rights; Remedies. The expiration or termination of this Agreement for any reason will be without
prejudice to any rights that will have accrued to the benefit of any Party prior to such expiration or termination, and any and all damages or remedies (whether at law or in equity) arising from any breach hereunder, each of which will survive
expiration or termination of this Agreement. Such expiration or termination will not relieve any Party from obligations which are expressly indicated to survive expiration or termination of this Agreement. Except as otherwise expressly set forth in
this Agreement, the termination provisions of this Article are in addition to any other relief and remedies available to either Party under this Agreement, at law or in equity. 

  
 80 

 16.7.2    Survival. Without limiting the provisions of
Section 16.7.1 (Accrued Rights and Remedies), the rights and obligations of the Parties set forth in the following Sections and Articles of this Agreement will survive the expiration or termination of this Agreement, in addition to those other
terms and conditions that are expressly stated to survive termination or expiration of this Agreement: Article 1 (Definitions) (to the extent the definitions are used in other surviving provisions), Section 2.6.2 (Property of Gilead),
Section 2.7.6 (Records Retention), Section 2.8 (Audits) (solely with respect to Licensed Products for which the license to Gilead has become fully paid-up, perpetual, irrevocable and royalty-free in
accordance with Section 11.8.2), Section 3.4 (Treatment of Compounds Incorporating Gilead Target Binders), Article 11 (Financial Terms) (solely to the extent that any payment accrued prior to expiration or termination of this Agreement),
Section 12.4 (No Implied Licenses), Section 12.5 (Ownership), Article 13 (Confidentiality), Section 15.1 (Indemnification), Section 15.2 (Procedure), Section 15.4 (Limitation of Liability), Section 16.1.1 (Term),
Section 16.4.2 (Section 365(n) Rights), Section 16.5 (Effects of Termination), Section 16.7 (Surviving Provisions) and Article 17 (Miscellaneous). 

ARTICLE 17 

MISCELLANEOUS 

17.1    Severability. If one (1) or more of the terms or provisions of this Agreement is held by a court of
competent jurisdiction to be void, invalid or unenforceable in any situation in any jurisdiction, such holding will not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the void,
invalid or unenforceable term or provision in any other situation or in any other jurisdiction, and the term or provision will be considered severed from this Agreement solely for such situation and solely in such jurisdiction, unless the void,
invalid or unenforceable term or provision is of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the void, invalid or unenforceable term or
provision. If the final judgment of such court declares that any term or provision hereof is void, invalid or unenforceable, the Parties agree to: (a) reduce the scope, duration, area or applicability of the term or provision or to delete
specific words or phrases to the minimum extent necessary to cause such term or provision as so reduced or amended to be enforceable; and (b) make a good faith effort to replace any void, invalid or unenforceable term or provision with a valid
and enforceable term or provision such that the objectives contemplated by the Parties when entering this Agreement may be realized. 

17.2    Notices. Any notice required or permitted to be given by this Agreement will be in writing and in English
and will be: (a) delivered by hand or by overnight courier with tracking capabilities; (b) mailed postage prepaid by first class, registered or certified mail; or (c) delivered by facsimile followed by delivery via either of the
methods set forth in Section 17.2(a) (Notices) or Section 17.2(b) (Notices), in each case, addressed as set forth below unless changed by notice so given: 

If to Gilead: 
 Gilead Sciences,
Inc. 
 333 Lakeside Drive 

Foster City, CA 94404 
 Attention:
Alliance Management 
 [*] 

  
 81 

 With copies to: 

Gilead Sciences, Inc. 
 333
Lakeside Drive 
 Foster City, CA 94404 

Attention: General Counsel 
 [*]

 If to Nurix: 
 Nurix
Therapeutics, Inc. 
 1700 Owens Street 

Suite 205 
 San Francisco, CA
94158 
 Attention: CEO 
 Any such notice will
be deemed given on the date received, except any notice received after 5:30 p.m. (in the time zone of the receiving Party) on a Business Day or received on a non-Business Day will be deemed to have been
received on the next Business Day. A Party may add, delete or change the person or address to which notices should be sent at any time upon written notice delivered to the other Parties in accordance with this Section 17.2 (Notices). 

17.3    Force Majeure. A Party will not be liable for delay or failure in the performance of any of its obligations
hereunder if such delay or failure is due to a cause beyond the reasonable control of such Party, including acts of God, fires, earthquakes, acts of war, terrorism, civil unrest, hurricane or other inclement weather; provided that the affected
Party: (a) promptly notifies the other Party; and (b) will use its Commercially Reasonable Efforts to avoid or remove such causes of non-performance and to mitigate the effect of such occurrence, and
will continue performance in accordance with the terms of this Agreement whenever such causes are removed. When such circumstances arise, the Parties will negotiate in good faith any modifications of the terms of this Agreement that may be necessary
or appropriate in order to arrive at an equitable solution. 
 17.4    Assignment; Change of Control. 

17.4.1    Assignment. Except as provided in this Section 17.4 (Assignment), this Agreement may not be assigned
or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the consent of the other Party; provided, however, that (and notwithstanding anything elsewhere in this Agreement to the
contrary) either Party may, without such consent, assign this Agreement and its rights and obligations hereunder in whole or in part: (a) to an Affiliate of such Party; (b) in connection with the transfer or sale of all or substantially
all of its assets or business related to the subject matter of this Agreement; or (c) pursuant to a merger or consolidation (or similar transaction) of the assigning Party. In addition, Gilead may, without the consent of Nurix, assign its
rights and obligations under this Agreement to a Third Party, where Gilead or its Affiliate divest rights to a Licensed Product. Any attempted assignment not in accordance with this Section 17.4

  
 82 

 
(Assignment) will be void. In the event that a permitted assignment of this Agreement by a Party increases the tax liability of the other Party or any of its Affiliates over the amount of any
Taxes that otherwise would have been payable in the absence of such assignment, the assigning Party will reimburse the other Party for the amount of such increased Tax liability. 

17.4.2    Change of Control. Whether or not this Agreement is assigned pursuant to Section 17.4.1
(Assignment), the Parties agree as follows: (a) the rights to information, materials, Patents, Know-How or other intellectual property rights: (i) controlled by a Third Party permitted assignee of a
Party or any of its Affiliates that were controlled by such assignee or any of its Affiliates (and not such Party) immediately prior to such assignment (other than as a result of a license or other grant of rights, covenant or assignment by such
Party or its Affiliates to, or for the benefit of, such Third Party); or (ii) controlled by any successor-in-interest of a Party as a result of a Change of Control
or any Person that becomes an Affiliate of a Party through any Change of Control of such Party, that were controlled by such successor or Person (and not such Party) immediately prior to such Change of Control (other than as a result of a license or
other grant of rights, covenant or assignment by such Party or its other Affiliates to, or for the benefit of, such Person), in each case ((i) and (ii)), shall be automatically excluded from the rights licensed or granted to the other Party under
this Agreement, provided that in each case ((i) and (ii)) such Third Party permitted assignee or successor-in-interest does not disclose or otherwise license or
sublicense (as applicable) such information, materials, Patents, Know-How or other intellectual property rights to such Party or any Persons that were Affiliates of such Party prior to such assignment or
Change of Control (as applicable). 
 17.5    Waivers and Modifications. The failure of any Party to insist on
the performance of any obligation hereunder will not be deemed to be a waiver of such obligation. Waiver of any breach of any provision hereof will not be deemed to be a waiver of any other breach of such provision or any other provision on such
occasion or any succeeding occasion. No waiver, modification, release or amendment of any obligation under or provision of this Agreement will be valid or effective unless in writing and signed by the Parties. 

17.6    Choice of Law; Dispute Resolution; Jurisdiction. 

17.6.1    Choice of Law. This Agreement and any Dispute arising from the performance or breach hereof will be
governed by and interpreted in accordance with the laws of the State of California, without giving effect to any choice of law rules. The provisions of the United Nations Convention on Contracts for the International Sale of Goods will not apply to
this Agreement or any subject matter hereof. 
 17.6.2    Dispute Escalation. Except as otherwise set forth in
this Agreement (including Section 9.5 (Committee Decisions) and Section 17.6.3 (Baseball Arbitration)), in the event of an unresolved matter, dispute or issue relating to the breach or alleged breach or interpretation of this Agreement
(“Dispute”), the Parties will refer the Dispute to the Executive Officers for discussion and resolution. If the Executive Officers are unable to resolve such Dispute within thirty (30) days of the Dispute being referred to them
by either Party in writing, then the Dispute will be resolved through litigation in accordance with Section 17.6.4 (Jurisdiction; Venue; Service of Process). 

  
 83 

 17.6.3    Baseball Arbitration. Any inability of the Parties to
agree upon (a) the terms of an agreement as set forth in Section 8.1.2 (Exercise of Profit-Share Options) or Section 8.2 (Co-Detail Option), including the U.S. Allocation Percentage as defined
in and described in Exhibit B (Profit-Share Exhibit) or (b) the royalties as described in Section 12.5 (Ownership) (each of sub-clauses (a) and (b), a “Short-Form Dispute”)
shall be finally determined by binding arbitration in accordance with this Section 17.6.3 (Baseball Arbitration) by a single arbitrator, which arbitrator shall (i) be neutral and independent of the Parties and all of their respective
Affiliates and (ii) have significant experience and expertise in the development of pharmaceutical or biologic products in oncology. Any such arbitration shall be administered by Judicial Arbitration and Mediation Services
(“JAMS”) and shall be seated in San Francisco, California in accordance with the applicable JAMS Streamlined Arbitration Rules, except as expressly set forth herein. If the Parties are unable to agree on an arbitrator within fifteen
(15) days of request by a Party for arbitration, the arbitrator shall be selected by JAMS. Each Party to the arbitration shall prepare a written proposal setting forth its position with respect to the Short-Form Dispute, including a proposed
form of agreement or terms (as applicable) as specified in sub-clauses (a) and (b) above. Without delaying the arbitration procedures, for a period not to exceed ten (10) days commencing no later
than fifteen (15) days after the arbitrator has been selected, the Parties shall exchange and discuss the Parties’ respective written proposals in good faith in an effort to resolve the matter. The arbitrator shall select one of the
requested proposals as her/his decision, and shall not have authority to render any substantive decision other than to so select the proposal of one of the Parties. If one Party does not submit to the arbitrator a written proposal setting forth its
position within the time period established by the arbitrator therefor, the arbitrator shall select the other Party’s proposal. The costs of such arbitration shall be shared equally by the Parties, and each Party shall bear its own costs and
expenses in connection with the arbitration. The Parties shall use good faith efforts to complete arbitration under this Section 17.6.3 (Baseball Arbitration) within sixty (60) days following the initiation of such arbitration. The
arbitrator shall establish reasonable additional procedures to facilitate and complete such arbitration within such sixty (60) day period. The existence of any arbitration and all submissions, correspondence and evidence relating to such
arbitration shall constitute the Confidential Information of each Party, and this provision shall survive the termination of any arbitration. 

17.6.4    Jurisdiction; Venue; Service of Process. Each Party irrevocably submits to the exclusive jurisdiction of
(a) the courts of the State of California located in San Francisco, CA, and (b) the United States District Court for the Northern District of California, for the purposes of any Dispute arising out of this Agreement. Each Party agrees to
commence any Action either in the United States District Court for the Northern District of California or if such Action may not be brought in such court for jurisdictional reasons, in the courts of the State of California located in San Francisco,
CA. Each Party further agrees that service of any process, summons, notice or document by the U.S. registered mail to such Party’s respective address set forth in Section 17.2 (Notices) will be effective service of process for any Action
in California with respect to any matters to which it has submitted to jurisdiction in this Section 17.6.4. (Jurisdiction; Venue; Service of Process). Each Party irrevocably and unconditionally waives any objection to the laying of venue of any
Action arising out of this Agreement in (i) the courts of the State of California located in San Francisco, CA and (ii) the United States District Court for the Northern District of California, and hereby and thereby further irrevocably
and unconditionally waives and agrees not to plead or claim in any such court that any such Action brought in any such court has been brought in an inconvenient forum. 

  
 84 

 17.6.5    Waiver of Jury Trial. THE PARTIES HEREBY WAIVE, AND
COVENANT THAT THEY WILL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE), ANY RIGHT TO TRIAL BY JURY IN ANY ACTION ARISING IN WHOLE OR IN PART UNDER OR IN CONNECTION WITH THIS AGREEMENT, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND
WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE. THE PARTIES AGREE THAT ANY OF THEM MAY FILE A COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY AND BARGAINED-FOR AGREEMENT
AMONG THE PARTIES IRREVOCABLY TO WAIVE ITS RIGHT TO TRIAL BY JURY IN ANY PROCEEDING WHATSOEVER BETWEEN THEM RELATING TO THIS AGREEMENT, AND THE PARTIES WILL INSTEAD BE TRIED IN A COURT OF COMPETENT JURISDICTION BY A JUDGE SITTING WITHOUT A JURY.

 17.6.6    Equitable Relief. Notwithstanding anything to the contrary, either Party may at any time seek to
obtain preliminary injunctive relief or other applicable provisional relief from a court of competent jurisdiction with respect to an issue arising under this Agreement if the rights of such Party would be prejudiced absent such relief. 

17.7    Relationship of the Parties. Nurix and Gilead are independent contractors under this Agreement. Nothing
contained herein is intended or is to be construed so as to constitute either Party as a partner, agent or joint venturer of the other Party. Neither Nurix nor Gilead, respectively, will have any express or implied right or authority to assume or
create any obligations on behalf of or in the name of Nurix and Gilead, respectively, or to bind Nurix and Gilead, respectively, to any contract, agreement or undertaking with any Third Party. 

17.8    Fees and Expenses. Except as otherwise specified in this Agreement, each Party will bear its own costs and
expenses incurred in connection with this Agreement and the transactions contemplated hereby. 
 17.9    Third Party
Beneficiaries. There are no express or implied Third Party beneficiaries hereunder. The provisions of this Agreement are for the exclusive benefit of the Parties, and no other Person will have any right or claim against any Party by reason of
these provisions or be entitled to enforce any of these provisions against any Party, except for the indemnification rights of the Nurix Indemnitees pursuant to Section 15.1.1 (Indemnification by Gilead) and Section 15.2 (Procedure) and
the Gilead Indemnitees pursuant to Section 10.4 (Assignment of Agreements), Section 15.1.2 (Indemnification by Nurix) and Section 15.2 (Procedure). 

17.10    Entire Agreement. This Agreement, together with the attached Exhibits and Schedules, contains the entire
agreement by the Parties with respect to the subject matter hereof and supersedes any prior express or implied agreements, understandings and representations, either oral or written, which may have related to the subject matter hereof in any way,
including any and all term sheets relating to the transactions contemplated by this Agreement and exchanged between the Parties prior to the Effective Date; provided that this Agreement will not supersede the terms and provisions of the Prior CDA
applicable to any period prior to the Effective Date. 
 17.11    Counterparts. This Agreement may be executed in
counterparts with the same effect as if both Parties had signed the same document. All such counterparts will be deemed an 

  
 85 

 
original, will be construed together and will constitute one and the same instrument. Any such counterpart, to the extent delivered by means of facsimile by .pdf, .tif, .gif, .jpeg or similar
attachment to electronic mail (any such delivery, an “Electronic Delivery”) will be treated in all manner and respects as an original executed counterpart and will be considered to have the same binding legal effect as if it were
the original signed version thereof delivered in person. No Party will raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of
Electronic Delivery as a defense to the formation of a contract, and each Party forever waives any such defense, except to the extent that such defense relates to lack of authenticity. 

17.12    Equitable Relief; Cumulative Remedies. Notwithstanding anything to the contrary herein, the Parties will
be entitled to seek equitable relief, including injunction and specific performance, as a remedy for any breach of this Agreement. Such remedies will not be deemed to be the exclusive remedies for a breach of this Agreement but will be in addition
to all other remedies available at law or in equity. The Parties further agree not to raise as a defense or objection to the request or granting of such relief that any breach of this Agreement is or would be compensable by an award of money
damages. No remedy referred to in this Agreement is intended to be exclusive, but each will be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under Applicable Law. 

17.13    Interpretation. 

17.13.1    Generally. This Agreement has been diligently reviewed by and negotiated by and between the Parties, and
in such negotiations each of the Parties has been represented by competent (in-house or external) counsel, and the final agreement contained herein, including the language whereby it has been expressed,
represents the joint efforts of the Parties and their counsel. Accordingly, in interpreting this Agreement or any provision hereof, no presumption will apply against any Party as being responsible for the wording or drafting of this Agreement or any
such provision, and ambiguities, if any, in this Agreement will not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. 

17.13.2    Definitions; Interpretation. 

(a)     The definitions of the terms herein will apply equally to the singular and plural forms of the
terms defined and, where a word or phrase is defined herein, each of its other grammatical forms will have a corresponding meaning. 

(b)    Whenever the context may require, any pronoun will include the corresponding masculine, feminine and
neuter forms. 
 (c)     The word “will” will be construed to have the same meaning and effect
as the word “shall.” 
 (d)    The words “including,” “includes,”
“include,” “for example,” and “e.g.,” and words of similar import, will be deemed to be followed by the words “without limitation.” 

  
 86 

 (e)     The word “or” will be interpreted to
mean “and/or,” unless the context requires otherwise. 
 (f)     The words “hereof,”
“herein” and “herewith,” and words of similar import, will, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of this Agreement. 

(g)    Unless the context requires otherwise or otherwise specifically provided: (i) all references
herein to Articles, Sections, Schedules or Exhibits will be construed to refer to Articles, Sections, Schedules and Exhibits of this Agreement; and (ii) reference in any Section to any sub-clauses are
references to such sub-clauses of such Section. 
 17.13.3    Subsequent
Events. Unless the context requires otherwise: (a) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time
amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein); (b) any reference to any Applicable Law herein will be construed as referring to such Applicable Law as from
time to time enacted, repealed or amended; and (c) subject to Section 17.4 (Assignment), any reference herein to any Person will be construed to include the Person’s successors and assigns. 

17.13.4    Headings. Headings, captions and the table of contents are for convenience only and will not be used in
the interpretation or construction of this Agreement. 
 17.13.5    Prior Drafts. No prior draft of this
Agreement will be used in the interpretation or construction of this Agreement. 
 17.13.6    Independent
Significance. Although the same or similar subject matter may be addressed in different provisions of this Agreement, the Parties intend that, except as reasonably apparent on the face of this Agreement or as expressly provided in this
Agreement, each such provision will be read separately, be given independent significance and not be construed as limiting any other provision of this Agreement (whether or not more general or more specific in scope, substance or content). 

17.14    Further Assurances. Each Party will execute, acknowledge and deliver such further instruments, and do all
such other ministerial, administrative or similar acts, as may be reasonably necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement. 

17.15    Extension to Affiliates. Except as expressly set forth otherwise in this Agreement, each Party will have
the right to extend the rights and obligations granted in this Agreement to one (1) or more of its Affiliates. All applicable terms and provisions of this Agreement, except this right to extend, will apply to any such Affiliate to which this
Agreement has been extended to the same extent as such terms and provisions apply to the Party extending such rights and obligations. The Party extending the rights and obligations granted hereunder will remain liable for any acts or omissions of
any of its Affiliates. 
 (Remainder of Page Intentionally Left Blank; Signature Page Follows) 

  
 87 

 IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this Agreement
to be executed by their respective duly authorized officers as of the Effective Date. 
  

									
	NURIX THERAPEUTICS, INC.	 		 	 GILEAD SCIENCES, INC. 

					
	By:	 	 /s/ Arthur T. Sands
	 	    	 	By:	 	 /s/ John McHutchison

	Name:	 	Arthur T. Sands	 		 	Name:	 	John McHutchison
	Title:	 	C.E.O.	 		 	Title:	 	CEO, Head of R&DEX-10.10

 Exhibit 10.10 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE
HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 COLLABORATION AND LICENSE AGREEMENT 

by and between 
 NURIX
THERAPEUTICS, INC. 
 and 

GENZYME CORPORATION 

dated as of December 19, 2019 
  

 TABLE OF CONTENTS 

ARTICLE 1 
 DEFINITIONS 

ARTICLE 2 
 RESEARCH 

 

							
			
	 2.1
	 	 Research Programs
	  	 	30	 
			
	 2.2
	 	 Collaboration Targets
	  	 	31	 
			
	 2.3
	 	 Reserved Targets
	  	 	32	 
			
	 2.4
	 	 Proposed Targets
	  	 	32	 
			
	 2.5
	 	 Gatekeeping
	  	 	33	 
			
	 2.6
	 	 Initial and Substitution Research Plans
	  	 	34	 
			
	 2.7
	 	 Research Activities
	  	 	34	 
			
	 2.8
	 	 Sanofi Provided Property
	  	 	35	 
			
	 2.9
	 	 Information Sharing; Records Retention
	  	 	36	 
			
	 2.10
	 	 Exclusivity
	  	 	37	 
			
	 2.11
	 	 DEL Library Blinding
	  	 	37	 
			
		 	 ARTICLE 3

GOVERNMENT APPROVALS
	  			
			
	 3.1
	 	 Efforts
	  	 	38	 
			
	 3.2
	 	 Filings
	  	 	38	 
			
	 3.3
	 	 Information Exchange
	  	 	39	 
			
		 	 ARTICLE 4

DEVELOPMENT
	  			
			
	 4.1
	 	 Responsibility
	  	 	40	 
			
	 4.2
	 	 Development Diligence
	  	 	40	 
			
	 4.3
	 	 Development Updates
	  	 	40	 
			
		 	 ARTICLE 5

REGULATORY
	  			
			
	 5.1
	 	 Regulatory Matters
	  	 	40	 
			
	 5.2
	 	 Regulatory Materials
	  	 	41	 
			
	 5.3
	 	 Right of Reference; Access to Data
	  	 	41	 
			
		 	 ARTICLE 6

COMMERCIALIZATION
	  			
			
	 6.1
	 	 Commercialization
	  	 	42	 

							
			
		 	 ARTICLE 7

MANUFACTURING
	  			
			
	 7.1
	 	 Manufacturing
	  	 	42	 
			
	 7.2
	 	 Transfer of Manufacturing Know-How
	  	 	42	 
			
		 	 ARTICLE 8

NURIX OPTIONS
	  			
			
	 8.1
	 	 Delivery of Profit/Loss Share Data Package to Nurix
	  	 	42	 
			
	 8.2
	 	 Option Exercise
	  	 	43	 
			
	 8.3
	 	 Additional Criteria for Option Exercise
	  	 	43	 
			
		 	 ARTICLE 9

GOVERNANCE
	  			
			
	 9.1
	 	 Alliance Manager
	  	 	44	 
			
	 9.2
	 	 Joint Research Committee
	  	 	44	 
			
	 9.3
	 	 Joint Patent Committee
	  	 	45	 
			
	 9.4
	 	 Decision Making
	  	 	46	 
			
	 9.5
	 	 Scope of Committee Authority
	  	 	46	 
			
	 9.6
	 	 Day-to-Day
Responsibilities
	  	 	46	 
			
		 	 ARTICLE 10

ASSISTANCE; TRANSITION
	  			
			
	 10.1
	 	 Assistance
	  	 	46	 
			
	 10.2
	 	 Know-How Transfer
	  	 	47	 
			
	 10.3
	 	 Licensed Products Inventory Transfer
	  	 	47	 
			
		 	 ARTICLE 11

FINANCIAL TERMS
	  			
			
	 11.1
	 	 Upfront Payment
	  	 	47	 
			
	 11.2
	 	 Additional Collaboration Target Payments
	  	 	48	 
			
	 11.3
	 	[*]	  	 	48	 
			
	 11.4
	 	 License Extension Fee
	  	 	48	 
			
	 11.5
	 	 Milestones
	  	 	48	 
			
	 11.6
	 	 Sales Milestones
	  	 	51	 
			
	 11.7
	 	 Royalties
	  	 	52	 
			
	 11.8
	 	 Effect of
Co-Development/Co-Promotion Option
	  	 	54	 
			
	 11.9
	 	 Royalty Payments and Reporting
	  	 	54	 
			
	 11.10
	 	 Additional Payment Terms
	  	 	54	 
			
	 11.11
	 	 Records; Audit Rights
	  	 	55	 

  
 3 

							
			
		 	 ARTICLE 12

LICENSES
	  			
			
	 12.1
	 	 License Grants
	  	 	56	 
			
	 12.2
	 	 Expiration; License Term Extension
	  	 	57	 
			
	 12.3
	 	 Subcontracting
	  	 	57	 
			
	 12.4
	 	 Sublicensing
	  	 	58	 
			
	 12.5
	 	 Residual Knowledge
	  	 	58	 
			
	 12.6
	 	 No Implied Licenses
	  	 	58	 
			
		 	 ARTICLE 13

INTELLECTUAL PROPERTY MATTERS
	  			
			
	 13.1
	 	 Ownership
	  	 	58	 
			
	 13.2
	 	 Prosecution and Maintenance
	  	 	59	 
			
	 13.3
	 	 Enforcement
	  	 	60	 
			
	 13.4
	 	 Defense
	  	 	61	 
			
	 13.5
	 	 Recovery
	  	 	61	 
			
	 13.6
	 	 Trademarks
	  	 	61	 
			
	 13.7
	 	 Patent Extensions
	  	 	62	 
			
	 13.8
	 	 Falsified Medicines
	  	 	62	 
			
		 	 ARTICLE 14

CONFIDENTIALITY
	  			
			
	 14.1
	 	 Nondisclosure
	  	 	62	 
			
	 14.2
	 	 Exceptions
	  	 	63	 
			
	 14.3
	 	 Authorized Disclosure
	  	 	63	 
			
	 14.4
	 	 Terms of this Agreement
	  	 	65	 
			
	 14.5
	 	 Securities Filings; Disclosure under Applicable Law
	  	 	65	 
			
	 14.6
	 	 Publicity
	  	 	66	 
			
	 14.7
	 	 Publications
	  	 	66	 
			
	 14.8
	 	 Use of Names
	  	 	67	 
			
	 14.9
	 	 Clinical Trials Registry
	  	 	67	 
			
		 	 ARTICLE 15

REPRESENTATIONS AND WARRANTIES; CLOSING CONDITIONS; COVENANTS
	  			
			
	 15.1
	 	 Representations and Warranties of Each Party
	  	 	67	 
			
	 15.2
	 	 Representations and Warranties of Nurix
	  	 	68	 
			
	 15.3
	 	 Representations and Warranties of Sanofi
	  	 	70	 
			
	 15.4
	 	 Closing Conditions
	  	 	70	 

  
 4 

							
			
	 15.5
	 	 Mutual Covenants
	  	 	71	 
			
	 15.6
	 	 FCPA Matters
	  	 	71	 
			
	 15.7
	 	 Disclaimer
	  	 	72	 
			
		 	 ARTICLE 16

INDEMNIFICATION; INSURANCE
	  			
			
	 16.1
	 	 Indemnification
	  	 	72	 
			
	 16.2
	 	 Procedure
	  	 	74	 
			
	 16.3
	 	 Insurance
	  	 	75	 
			
	 16.4
	 	 Limitation of Liability
	  	 	75	 
			
		 	 ARTICLE 17

TERM AND TERMINATION
	  			
			
	 17.1
	 	 Term; Expiration
	  	 	76	 
			
	 17.2
	 	 Termination for Material Breach
	  	 	76	 
			
	 17.3
	 	 Termination at Will
	  	 	77	 
			
	 17.4
	 	 Termination for Bankruptcy
	  	 	77	 
			
	 17.5
	 	 Termination by Sanofi for Safety
	  	 	78	 
			
	 17.6
	 	 Termination by Sanofi for a Change of Control of Nurix
	  	 	78	 
			
	 17.7
	 	 Effects of Expiration and Termination
	  	 	79	 
			
	 17.8
	 	 Surviving Provisions
	  	 	81	 
			
		 	 ARTICLE 18

MISCELLANEOUS
	  			
			
	 18.1
	 	 Severability
	  	 	82	 
			
	 18.2
	 	 Notices
	  	 	82	 
			
	 18.3
	 	 Force Majeure
	  	 	83	 
			
	 18.4
	 	 Assignment; Change of Control
	  	 	84	 
			
	 18.5
	 	 Waivers and Modifications
	  	 	84	 
			
	 18.6
	 	 Choice of Law; Dispute Resolution
	  	 	85	 
			
	 18.7
	 	 Relationship of the Parties
	  	 	87	 
			
	 18.8
	 	 Fees and Expenses
	  	 	87	 
			
	 18.9
	 	 Third Party Beneficiaries
	  	 	87	 
			
	 18.10
	 	 Entire Agreement
	  	 	87	 
			
	 18.11
	 	 Counterparts
	  	 	87	 
			
	 18.12
	 	 Equitable Relief; Cumulative Remedies
	  	 	87	 
			
	 18.13
	 	 Interpretation
	  	 	88	 
			
	 18.14
	 	 Further Assurances
	  	 	89	 

  
 5 

			
	 SCHEDULES
	  	
		
	 Schedule 1.62:
	  	 Development Candidate Data Package

	 Schedule 1.122:
	  	 Knowledge

	 Schedule 1.188:
	  	 Research Milestone Event Criteria

	 Schedule 2.2.1:
	  	 Initial Collaboration Targets

	 Schedule 2.3.1:
	  	 Reserved Targets

	 Schedule 10.2:
	  	 Technology Transfer Documentation

	 Schedule 15.2:
	  	 Exceptions to Representations and Warranties of Nurix

  
 6 

 COLLABORATION AND LICENSE AGREEMENT 

This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of December 19, 2019 (the
“Execution Date”) by and between Nurix Therapeutics, Inc., a Delaware corporation (“Nurix”) and Genzyme Corporation, a Massachusetts corporation (“Sanofi”). Nurix and Sanofi are each referred to
herein by name or as a “Party” or, collectively, as the “Parties.” 
 RECITALS 

WHEREAS, Nurix is a biotechnology company developing therapies that control ubiquitin E3 ligases (“E3 Ligases”), the
key enzymes responsible for protein breakdown in human cells, which have applications in the treatment of various diseases. 

WHEREAS, Sanofi is a pharmaceutical company with expertise in the development, manufacturing and commercialization of pharmaceutical
products. 
 WHEREAS, Nurix and Sanofi wish to enter into this collaboration for the discovery and development of chimeric targeting
molecules (“CTMs” as defined in more detail below) for the targeted degradation of defined protein targets (“Collaboration Targets” as defined in more detail below). 

WHEREAS, Sanofi will have an exclusive license for up to five (5) Research Programs (as defined below) and, following the
occurrence of a License Term Extension (as defined below), will perform further development, manufacturing and commercialization of such drug products, subject to the terms and conditions set forth herein. 

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements set forth below, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 Unless
specifically set forth to the contrary herein, the following terms will have the respective meanings set forth below. 
 1.1
“Accounting Standard” means, with respect to a Party or its Affiliate or Sublicensee, GAAP or IFRS, as such Party, Affiliate or Sublicensee uses for its financial reporting obligations, in each case consistently applied. 

1.2 “Acquired Party Family” means in the case of a Change of Control of a Party or its Affiliate, such Party or such
Affiliate existing immediately prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created). 

 1.3 “Acquiring Entity” means, in the case of a Change of Control of a Party
or its Affiliate, the successor in interest, resulting entity, assignee or purchaser, as applicable, of such Party or such Affiliate. 
 1.4
“Acquiring Entity Family” means in the case of a Change of Control of a Party or its Affiliate, the Acquiring Entity and its Affiliates existing immediately prior to the closing of the Change of Control transaction together with any
future Affiliates of such Party or such Affiliate (but excluding the Acquired Party Family). 
 1.5 “Action” means any
claim, action, suit, arbitration, inquiry, audit, proceeding or investigation by or before, or otherwise involving, any Governmental Authority. 

1.6 “Additional Active” is defined in Section 1.45 (Combination Product). 

1.7 “Additional Collaboration Target” is defined in Section 2.2.2 (Additional Collaboration Targets). 

1.8 “Additional Collaboration Target Notice” is defined in Section 2.2.2 (Additional Collaboration Targets). 

1.9 “Affiliate” means any Person which, directly or indirectly through one (1) or more intermediaries, controls, is
controlled by, or is under common control with, a Party for so long as such Person controls, is controlled by or is under common control with such Party. For purposes of this Section 1.9 (Affiliate) and Section 1.28 (Change of Control)
only, the term “control” (including, with correlative meanings, the terms “controlled by” and “under common control with”) as used with respect to a Person means: (a) direct or indirect ownership of fifty percent
(50%) or more of the voting securities or other voting interest of any Person (including attribution from related parties); or (b) the possession, directly or indirectly, of the power to direct, or cause the direction of, the management and
policies of such Person, whether through ownership of voting securities, by contract, as a general partner, as a manager or otherwise. 

1.10 “Agreement” is defined in the preamble set forth above. 

1.11 “Agreement Payment” means any payment made by a Payor to a Payee under this Agreement. 

1.12 “Alliance Manager” is defined in Section 9.1 (Alliance Manager). 

1.13 “Ancillary Agreement” means any Supply Agreement, Quality Agreement, Pharmacovigilance Agreement, Material Transfer
Agreement, Co-Development/Co-Commercialization Agreement, Profit/Loss Share Agreement, Co-Promotion Agreement or other agreement
entered into between the Parties (or their respective Affiliates) pursuant to this Agreement or the Correspondence. 
 1.14 “Annual
Net Sales” means, (a) in the case of a Sales Milestone Payment and with respect to all Licensed Product(s) Directed To the applicable Collaboration Target, [*], or (b) in the case of a royalty payment pursuant to Section 11.7
(Royalties) and with respect to one Licensed Product, [*]. 

  
 8 

 1.15 “Antitrust Clearance Date” is defined in Section 3.2 (Filings).

 1.16 “Antitrust Law” means any Applicable Law that is designed to prohibit, restrict or regulate actions having the
purpose or effect of monopolization, lessening of competition or restraint of trade, including the HSR Act, the Sherman Act, as amended, the Clayton Act, as amended, and the Federal Trade Commission Act, as amended. 

1.17 “Antitrust Remedy” is defined in Section 3.1 (Efforts). 

1.18 “Applicable Law” means all applicable laws, statutes, rules, regulations, treaties (including tax treaties), orders,
judgments or ordinances having the effect of law of any national, multinational, federal, state, provincial, county, city or other political subdivision, including, (a) to the extent applicable, GCP, GLP and GMP, (b) all applicable data
protection and privacy laws, rules and regulations, including, to the extent applicable, the United States Department of Health and Human Services privacy rules under the Health Insurance Portability and Accountability Act and the Health Information
Technology for Economic and Clinical Health Act and the EU Data Protection Directive (Council Directive 95/46/EC) and applicable laws implementing the EU Data Protection Directive and the General Data Protection Regulation (2016/679) and
(c) written governmental interpretations, the guidance related to, or the application of, any of the foregoing. 
 1.19
“Arbitrator” is defined in Section 18.6.3(a) (Binding Arbitration). 
 1.20 “Audited Party” is
defined in Section 11.11.2 (Audit Rights). 
 1.21 “Auditing Party” is defined in Section 11.11.2 (Audit Rights).

 1.22 “Auditor” is defined in Section 11.11.2 (Audit Rights). 

1.23 “Available Target” means each Target (other than a Reserved Target) that is not an Excluded Target as of the time of
such determination in accordance with Section 2.4 (Proposed Targets). 
 1.24 “Background IP” is defined in
Section 13.1 (Ownership). 
 1.25 “Business Day” means any day other than: (a) a Saturday or Sunday or any day on
which commercial banks in San Francisco, California, Cambridge, Massachusetts, Bridgewater, New Jersey, or Paris, France, are authorized or required by Applicable Law to remain closed; or (b) December 26 through December 31. 

1.26 “Calendar Quarter” means each of the three (3) month periods ending March 31, June 30, September 30
and December 31; provided that the first Calendar Quarter of the Term extends from the Effective Date to the end of the then-current Calendar Quarter, and the last Calendar Quarter extends from the first day of such Calendar Quarter until the
effective date of the termination or expiration of this Agreement. 
 1.27 “Calendar Year” means each period beginning on
January 1 and ending on December 31; provided that the first Calendar Year of the Term extends from the Effective Date to December 31 of the then-current Calendar Year, and the last Calendar Year extends from January 1 of such
Calendar Year until the effective date of the termination or expiration of this Agreement. 

  
 9 

 1.28 “Change of Control” means, with respect to a Party (an
“Acquired Person”), from and after the Execution Date: (a) a merger or consolidation in which (i) such Party is a constituent party, or (ii) an Affiliate of such Party that directly or indirectly controls such Party
is a constituent party, except in the case of either clause (i) or (ii) any such merger or consolidation involving such Party or such Affiliate in which the shares of capital stock of such entity outstanding immediately prior to such merger or
consolidation continue to represent, or are converted into or are exchanged for shares of capital stock which represent, immediately following such merger or consolidation, 50% or more by voting power of the capital stock of (A) the surviving
or resulting corporation or (B) a parent corporation of such surviving or resulting corporation, whether direct or indirect; (b) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of
related transactions, by such Party or an Affiliate of such Party of all or substantially all of the assets of such Party or such Affiliate taken as a whole and whether owned directly or indirectly through Affiliates (except where such sale, lease,
transfer, exclusive license or other disposition is to an Affiliate of such Party existing prior to such time); or (c) any “person” or “group”, as such terms are defined in Sections 13(d) and 14(d) of the U.S. Securities
Exchange Act of 1934, in a single transaction or series of related transactions, becomes the beneficial owner as defined under the U.S. Securities Exchange Act of 1934, directly or indirectly, whether by purchase or acquisition or agreement to act
in concert or otherwise, of 50% or more by voting power of the then-outstanding capital stock or other equity interests of such Party or a subsidiary of such Party. Notwithstanding the foregoing, the following shall not constitute a Change of
Control so long as they do not result in a Major Biopharmaceutical Company having more than 50% of the aggregate ordinary voting power in a Party or its Affiliate: (i) a sale of capital stock to underwriters in an underwritten public offering
of a Party’s capital stock solely for the purpose of financing, or (ii) the acquisition of securities of the Acquired Person by any Person or group of Persons that acquires the Acquired Person’s securities in a transaction or series
of related transactions the primary purpose of which is to obtain financing for the Acquired Person through the issuance of equity securities. 

1.29 “Clinical Proof-of-Concept” means the
establishment of clinical proof-of-concept by one or more Clinical Trials for a Licensed Product that is conducted as a pilot study by Sanofi to assess [*] for such
Licensed Product using the data set generated in the performance of such Clinical Trial(s), as determined by [*]. 
 1.30 “Clinical
Trial” means any clinical investigation conducted on human subjects, as that term is defined in FDA regulations at 21 C.F.R. § 312.3, or a similar clinical investigation conducted on human subjects, as defined under Applicable Law
outside the United States. Without limiting the foregoing, Clinical Trial includes any Phase 1 Clinical Trial, Phase 1/2 Clinical Trial, Phase 2 Clinical Trial, Phase 3 Clinical Trial or Pivotal Trial. 

1.31 “Closing Conditions” is defined in Section 15.4 (Closing Conditions). 

1.32 “Code” is defined in Section 17.4.1 (Termination Right). 

  
 10 

 1.33 “[*]” is defined in Section 8.1 (Delivery of Profit/Loss Share
Data Package to Nurix). 
 1.34
“Co-Development/Co-Commercialization Agreement” is defined in Section 8.2 (Option Exercise). 

1.35 “Co-Development/Co-Commercialization
Documentation” means, if Nurix exercises its Co-Development/Co-Promotion Option with respect to a Collaboration Target, the duly executed Co-Development/Co-Commercialization Agreement, Profit/Loss Share Agreement and Co-Promotion Agreement. 

1.36 “Co-Development/Co-Promotion Option” is
defined in Section 8.2 (Option Exercise). 
 1.37
“Co-Development/Co-Promotion Option Exercise Notice” is defined in Section 8.2 (Option Exercise). 

1.38 “Co-Promotion Agreement” is defined in Section 8.2 (Option Exercise). 

1.39 “Collaboration” means the activities of the Parties with respect to the Research, Development, Manufacture and
Commercialization of CTMs, Target Binders, Development Candidates or Licensed Products in the Field as and to the extent set forth in this Agreement and the Ancillary Agreements. 

1.40 “Collaboration License” is defined in Section 12.1.2 (Collaboration License to Sanofi for Licensed Products). 

1.41 “Collaboration Target” means any Initial Collaboration Target or Additional Collaboration Target, and any substitution
thereof made in accordance with Section 2.2.3 (Collaboration Target Substitution Right). For clarity, no Replaced Collaboration Target shall remain a Collaboration Target under this Agreement. 

1.42 “Collaboration Target Substitution Period” is defined in Section 2.2.3 (Collaboration Target Substitution Right).

 1.43 “Collaboration Target Substitution Right” is defined in Section 2.2.3 (Collaboration Target Substitution
Right). 
 1.44 “Collaboration Target Research Term” means, on a Collaboration Target-by-Collaboration Target basis, the period of time beginning (a) with respect to Initial Collaboration Targets, the Effective Date, and (b) with respect to Available Targets or Reserved
Targets that become Collaboration Targets in accordance with Section 2.2.2 (Additional Collaboration Targets) or Section 2.2.3 (Collaboration Target Substitution Right), the date that such Available Targets or Reserved Targets become
Collaboration Targets (as further described therein), and in each case (a) and (b) ending [*], provided that, notwithstanding the foregoing, each such period of time shall automatically expire upon the expiration of the Research Term unless
otherwise mutually agreed in writing by the Parties. 

  
 11 

 1.45 “Combination Product” means: (a) a Licensed Product that contains
one (1) of the compounds or products described in Section 1.127 (Licensed Product) and one (1) or more active pharmaceutical or biological ingredients (each, an “Additional Active”), sold as a fixed dose/unit, for
which no royalty would be due hereunder if such ingredients were sold separately; or (b) a Licensed Product that consists of one (1) of the compounds or products described in Section 1.127 (Licensed Product) and sold as separate
doses/units in a single package, or otherwise co-packaged or combined, with one (1) or more Additional Actives for which no royalty would be due hereunder if such item(s) were sold separately, and such
compounds or product described in Section 1.127 (Licensed Product) and Additional Active(s) are sold for a single price. 
 1.46
“[*]” is defined in Section 13.1(Ownership). 
 1.47 “Commercialization” means any and all activities
directed to the commercialization of a product, including marketing; detailing; promotion; market research; distributing; order processing; handling returns and recalls; booking sales; customer service; administering and commercially selling such
product; importing, exporting and transporting such product for commercial sale; and seeking Pricing Approval of a product (if applicable), whether before or after Regulatory Approval has been obtained, as well all regulatory compliance with respect
to the foregoing. For clarity, “Commercialization” does not include: (a) Manufacturing or (b) any Clinical Trials and other trials commenced after Regulatory Approval. When used as a verb, “Commercialize”
means to engage in Commercialization. 
 1.48 “Commercially Reasonable Efforts” means, (a) with respect to
Sanofi’s obligations under this Agreement or any Ancillary Agreement and a Licensed Product, [*] and (b) with respect to Nurix’s obligations under this Agreement or any Ancillary Agreement and a CTM, Target Binder, Development
Candidate or Licensed Product, [*]. 
 1.49 “Committee” means, as of the Effective Date, each of the JRC and JPC. If Nurix
exercises its Co-Development/Co-Promotion Option with respect to a Collaboration Target, “Committee” shall also include the JSC, JDC and JCC under, and as such
terms are defined in, the Co-Development/Co-Commercialization Agreement. 

1.50 “Competing Product” is defined in Section 2.10.2 (Exceptions for Change of Control). 

1.51 “Confidential Information” means, with respect to a Party, all confidential or proprietary information Controlled by
such Party, including chemical or biological materials, chemical structures, Commercialization plans, correspondence, customer lists, Research plans, Development plans, Know-How, regulatory filings,
strategies, or other information or data, in each case, that are disclosed or made available by or on behalf of such Party to the other Party pursuant to this Agreement or any Ancillary Agreement, regardless of whether any of the foregoing are
marked “confidential” or “proprietary” or communicated to the other Party by or on behalf of the disclosing Party in oral, written, visual, graphic or electronic form. 

1.52 “Contemplated Transactions” means the transactions contemplated by this Agreement and the Ancillary Agreements. 

  
 12 

 1.53 “Control,” “Controls” or
“Controlled” means, with respect to any particular item of Know-How, Patent or other intellectual property right or Regulatory Material, possession by the Party granting the applicable right,
license, sublicense, access, right to use or release to the other Party as provided herein of the power and authority (whether arising by sole, joint or other ownership interest, license, sublicense or other authorization, but in any case other than
by operation of the licenses granted to a Party in this Agreement or any Ancillary Agreement) to grant a license, sublicense, access, right to use or release (as applicable) to such Know-How, Patent or other
intellectual property or Regulatory Material of the scope granted to such other Party in this Agreement (a) without giving rise to any violation of the term of any written agreement with any Third Party existing at the time such right, license,
sublicense, access or release first comes into effect hereunder and (b) if any payment obligation to such Third Party that would not have existed but for a sublicense or other access or transfer to Sanofi hereunder, then such Know-How, Patent or other intellectual property right or Regulatory Material shall [*]. “Controlled” and “Controlling” have their correlative meanings. Notwithstanding anything to the contrary in
this Agreement, in the event of a Change of Control of a Party, then, whether or not this Agreement is assigned to the Acquiring Entity, any intellectual property rights owned or controlled by the Acquiring Entity Family shall not be deemed to be
Controlled by such Party after the effective date of such Change of Control transaction for purposes of this Agreement, except to the extent any such intellectual property rights are (a) developed, acquired or otherwise Controlled by the
Acquiring Entity Family pursuant to or in connection with a license or other agreement between the Acquiring Party or any of its Affiliates, on the one hand, and Nurix, on the other hand to the extent [*], (b) developed or acquired by the Acquiring
Entity Family following such Change of Control with the use of or access to the subject matter used or made available by the Acquired Party Family under this Agreement (including Nurix IP or Confidential Information), or (c) used by the
Acquiring Entity Family in the Development, Manufacture or Commercialization of [*] by or on behalf of the Acquiring Entity Family. 
 1.54
“Correspondence” means that certain letter between Sanofi and Nurix dated as of the Execution Date. 
 1.55
“Cover” means, with reference to a claim in a Patent or to a Valid Claim, as applicable, and a compound or product (including a composition of matter), that the Research, Development, Manufacture, Commercialization, making, using,
offering to sell, selling, importing or exporting of such compound or product would infringe such claim or Valid Claim in the country in which such activity occurs without a license thereto (or ownership thereof). 

1.56 “CTM” or “Chimeric Targeting Molecule” means, with respect to a Collaboration Target, any compound
that: (a) (i) is Directed To such Collaboration Target and consists of the following three moieties covalently bound together: (A) a Ligase Binder, (B) a Target Binder, and (C) a Linker, or (ii) both binds to an E3 Ligase
and is Directed To such Collaboration Target, and is derived from another compound consisting of those three moieties covalently bound together; and (b) is conceived of or reduced to practice prior to the expiration of the applicable
Collaboration Target Research Term. 
 1.57 “Cure Period” is defined in Section 17.2.1 (Material Breach). 

  
 13 

 1.58 “Damages” means all losses, costs, claims, damages, judgments,
liabilities and expenses (including reasonable attorneys’ fees and other reasonable out-of-pocket costs in connection therewith). 

1.59 “DEL” means the DNA-encoded libraries and related technology Controlled by Nurix
or its Affiliates and used to identify Ligase Binders or Target Binders, as may be modified from time to time during the Term. 
 1.60
“Development” means clinical drug development activities and other development activities with respect to a product, including Clinical Trials (and other trials commenced after Regulatory Approval), test method development and
stability testing; toxicology; formulation; process development; qualification; validation; quality assurance and quality control; statistical analysis and report writing; the preparation and submission of INDs and MAAs; medical and regulatory
affairs with respect to the foregoing and all other activities necessary or useful or otherwise requested or required by a Regulatory Authority or as a condition or in support of obtaining or maintaining a Regulatory Approval. For clarity,
“Development” does not include Research or Manufacturing. When used as a verb, “Develop” means to engage in Development. 

1.61 “Development Candidate” means any CTM or Standalone Target Binder nominated by Nurix for which Nurix has delivered a
Development Candidate Data Package in accordance with Section 2.9.2 (Development Candidate Data Package). 
 1.62 “Development
Candidate Data Package” means an information package relating to the CTMs (including [*]) and Target Binders (including [*]) in each case that are Directed To a Collaboration Target, containing such items set forth in Schedule 1.62
(Development Candidate Data Package), to the extent in existence and in the Control of Nurix or its Affiliates at the time that such information package is delivered to Sanofi in accordance with Section 2.9.2 (Development Candidate Data
Package), and including such other information that the JRC may agree upon depending on the stage of Development of such CTMs and Target Binders. 

1.63 “Development Milestone Event” is defined in Section 11.5.2 (Development Milestones). 

1.64 “Development Milestone Payment” is defined in Section 11.5.2 (Development Milestones). 

1.65 “Directed To” means, with regard to a particular Target, that the compound or product at issue [*] such Target or other
binding partner, and [*] causes pharmacologically relevant activity with respect to such Target. When required grammatically, the defined term “Directed To” may be separated and will have the same meaning set forth above; e.g., when
discussing Targets To which a compound or product is Directed. 
 1.66 “Disclosing Party” is defined in Section 14.1
(Nondisclosure). 
 1.67 “Dispute” is defined in Section 18.6.2 (Dispute Escalation). 

1.68 “DOJ” is defined in Section 3.2 (Filings). 

  
 14 

 1.69 “Dollars” or “$” means the legal tender of the United
States. 
 1.70 “E3 Ligases” is defined in the Recitals. 

1.71 “Effective Date” is defined in Section 3.2 (Filings). 

1.72 “Electronic Delivery” is defined in Section 18.11 (Counterparts). 

1.73 “EMA” is defined in Section 1.181 (Regulatory Authority). 

1.74 “Enforcing Party” is defined in Section 13.3.2(c) (Right to Enforce). 

1.75 “EU” means all countries that are officially recognized as member states of the European Union at any particular time;
except that, for purposes of this Agreement, the EU will be deemed to include France, Germany, Italy, Spain and the United Kingdom, irrespective of whether any such country leaves or as of the Effective Date has left the European Union. 

1.76 “EU Regulatory Approval” means Regulatory Approval of a Licensed Product by EMA, or the relevant Regulatory Authority in
at least three of the five Major European Market countries. 
 1.77 “Excluded Target” means any (a) Target (other than
a Reserved Target) that is an Exclusive Third Party Target or a Nurix Internal Target, as applicable, as of the time of such determination in accordance with Section 2.4 (Proposed Targets), or (b) Platform E3 Ligase. 

1.78 “Excluded Target List” is defined in Section 2.5.2 (Excluded Targets List). 

1.79 “Exclusive Third Party Target” means any Target for which Nurix has exclusivity obligations to a Third Party pursuant to
a definitive written agreement with such Third Party that has not been terminated or expired. 
 1.80 “Executive Officer”
means: (a) with respect to Nurix, the Chief Executive Officer of Nurix or his/her designee or successor with appropriate decision-making authority (as of the Effective Date such individual is Dr. Arthur Sands); and (b) with respect to
Sanofi, the [*] of Sanofi or his/her designee or successor with appropriate decision-making authority (as of the Effective Date such individual is [*]). 

1.81 “Existing Regulatory Materials” is defined in Section 5.2.1 (Existing Regulatory Materials). 

1.82 “Falsified Medicine” is defined in Section 13.8.1 (Falsified Medicines). 

1.83 “FCPA” means the United States Foreign Corrupt Practices Act (15 U.S.C. §
78dd-1, et seq.) as amended. 
 1.84 “FDA” is defined in Section 1.181
(Regulatory Authority). 

  
 15 

 1.85 “FFDCA” means the United States Federal Food, Drug, and Cosmetic Act,
21 U.S.C. 301, et. seq., as it may be amended from time to time, and the rules, regulations, guidance, guidelines, and requirements promulgated or issued thereunder. 

1.86 “Field” means any and all uses or purposes, including the treatment, prophylaxis, palliation, diagnosis or prevention of
any human or animal disease, disorder or condition. 
 1.87 “First Commercial Sale” means, on a Licensed Product-by-Licensed Product and country-by-country basis, the first sale of such Licensed
Product for monetary value in such country for use or consumption by the general public (following receipt of all Regulatory Approvals that are required in order to sell such Licensed Product in such country) and for which any of Sanofi or its
Affiliates or Sublicensees has invoiced sales of Licensed Products in the Territory; provided, however, that the following will not constitute a First Commercial Sale: (a) any sale to an Affiliate or Sublicensee, unless such Affiliate or
Sublicensee is the last Person in the distribution chain of the Licensed Product; (b) any use of such Licensed Product in Clinical Trials or non-clinical development activities with respect to such
Licensed Product by or on behalf of a Party; or (c) any disposal or transfer of such Licensed Product for a bona fide charitable purpose, compassionate use or samples. 

1.88 “Floor” is defined in Section 11.7.4(b) (Royalty Reduction Floor). 

1.89 “Foreground IP” is defined in Section 13.1 (Ownership). 

1.90 “Foreground Patent” means a Patent that is within Foreground IP. 

1.91 “FTC” is defined in Section 3.2 (Filings). 

1.92 “FTE” means a full time equivalent person year (consisting of [*] hours per year) of work as an employee or contractor
performing Research activities under a Research Plan hereunder as tracked by Nurix using its standard practice and methodologies. For clarity, indirect personnel (including support functions such as alliance management, managerial, financial, legal
or business development) will not constitute FTEs. Notwithstanding the foregoing, the time of a single individual will not account for more than one FTE for a given Calendar Year (or applicable pro-rata
portion of an FTE during any Calendar Quarter or other period of less than a Calendar Year). 
 1.93 “FTE Costs” means,
with respect to Nurix for any period, the applicable FTE Rate multiplied by the applicable number of FTEs of Nurix performing the applicable Research activity described hereunder during such period. 

1.94 “FTE Rate” means [*] per FTE basis, which rate shall be adjusted annually, with each annual adjustment effective as of
January 1 of each Calendar Year, with the first such annual adjustment to be made as of [*], to correspond with respect to Research activities under a Research Plan by or on behalf of Nurix, [*]. 

1.95 “GAAP” means the U.S. generally accepted accounting principles. 

1.96 “Gatekeeper” is defined in Section 2.5.1 (Appointment of Gatekeeper). 

  
 16 

 1.97 “GCP” means the applicable then-current ethical and scientific quality
standards for designing, conducting, recording and reporting Clinical Trials as are required by applicable Regulatory Authorities or Applicable Law in the relevant jurisdiction, including, in the United States, Good Clinical Practices established
through FDA guidances, and, outside the United States, Guidelines for Good Clinical Practice – ICH Harmonized Tripartite Guideline (ICH E6), to the extent such standards are not less stringent than United States GCP. 

1.98 “Generic Competition” means, with respect to a Licensed Product in a country in the Territory, the sale of [*] or more
Generic Product(s) of such Licensed Product in such country. 
 1.99 “Generic Product” means, with respect to a given
Licensed Product in a particular country in the Territory, a pharmaceutical product that (a) is approved for use in such country pursuant to a Regulatory Approval process governing approval of a generic product of such Licensed Product based on
the then-current standards for Regulatory Approval in such country, [*], and (b) is sold in the same country as such Licensed Product by any Third Party that (i) is not a Sublicensee (other than a Sublicensee that has been granted a
sublicense to any Product Patent by Sanofi solely in connection with any settlement) and (ii) did not purchase such pharmaceutical product in a chain of distribution that included any of Sanofi, its Affiliates or its or their Sublicensees. 

1.100 “GLP” means the applicable then-current good laboratory practice standards as are required by applicable Regulatory
Authorities or Applicable Law in the relevant jurisdiction, including, in the United States, those promulgated or endorsed by the FDA in U.S. 21 C.F.R. Part 58, or the equivalent thereof as promulgated or endorsed by the applicable Regulatory
Authorities outside of the United States, to the extent such standards are not less stringent than United States GLP. 
 1.101
“GMP” means all applicable then-current good manufacturing practice standards relating for fine chemicals, intermediates, bulk products or finished pharmaceutical or biological products, as are required by applicable Regulatory
Authorities or Applicable Law in the relevant jurisdiction, including, as applicable: (a) all applicable requirements detailed in the FDA’s current Good Manufacturing Practices regulations, U.S. 21 C.F.R. Parts 210 and 211; (b) all
applicable requirements detailed in the EMA’s “The Rules Governing Medicinal Products in the European Community, Volume IV, Good Manufacturing Practice for Medicinal Products” and (c) all Applicable Law promulgated by any
Governmental Authority having jurisdiction over the Manufacture of the applicable compound or pharmaceutical or biological product, as applicable. 

1.102 “Governmental Authority” means any: (a) federal, state, local, municipal, foreign, or other government;
(b) governmental or quasi-governmental authority of any nature (including any agency, board, body, branch, bureau, commission, council, department, entity, governmental division, instrumentality, office, officer, official, organization,
representative, subdivision, unit, and any court or other tribunal); (c) multinational governmental organization or body; or (d) entity or body exercising, or entitled to exercise, any executive, legislative, judicial, administrative,
regulatory, police, military or taxing authority or power of any nature (including any arbiter). 

  
 17 

 1.103 “HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of
1976 (15 U.S.C. § 18a) and the rules and regulations promulgated thereunder. 
 1.104 “HSR/Antitrust Filing” is
defined in Section 3.2 (Filings). 
 1.105 “IFRS” means the International Financial Reporting Standards. 

1.106 “IND” means an investigational new drug application (including any amendment or supplement thereto) submitted to the
FDA pursuant to U.S. 21 C.F.R. Part 312, including any amendments thereto. References herein to IND will include, to the extent applicable, any foreign counterpart of the foregoing filed with a Regulatory Authority outside the U.S. for the
investigation of a product in any other country or group of countries (such as a Clinical Trial Application in the EU) in conformance with the requirements of such Regulatory Authority. 

1.107 “Indemnification Claim Notice” is defined in Section 16.2.1 (Notice). 

1.108 “Indemnitee” is defined in Section 16.2.1 (Notice). 

1.109 “Indemnitor” is defined in Section 16.2.1 (Notice). 

1.110 “Indication” means a specific disease or medical condition in humans that is approved by a Regulatory Authority to be
included as a discrete claim (as opposed to a variant or subdivision or subset of a claim) in the labeling of a Licensed Product based on the results of a separate Pivotal Trial(s) sufficient to support Regulatory Approval of such claim;
provided, however, with respect to [*] Indications, a particular [*] Indication will be considered distinct from another [*] Indication only if it is has [*]. For clarity, the following shall be part of the same Indication: (a) [*];
(b) [*]; (c) [*]; (d) [*]; (e) [*] or (f) [*]. 
 1.111 “Infringement” is defined in Section 13.3.1 (Notification).

 1.112 “Initial Collaboration Target” is defined in Section 2.2.1 (Initial Collaboration Targets). 

1.113 “Initiation” means (a) with respect to a Phase 1 Clinical Trial (or the Phase 1 Clinical Trial portion of a Phase
1/2 Clinical Trial), the administration of the first dose of a Licensed Product to the first patient (or volunteer, as relevant) participating in such Clinical Trial or (b) with respect to any Clinical Trial other than as set forth in sub-clause (a), the administration of the first dose of a Licensed Product or placebo to the first patient (or volunteer, as relevant) participating in such Clinical Trial. 

1.114 “Invention” means any process, method, composition of matter, article of manufacture, discovery or finding that is
conceived or reduced to practice. 
 1.115 “In Vivo PD Milestone” means the Research Milestone Event titled
[*] as described in Schedule 1.188. 
 1.116 “[*]” is defined in Section 18.6.3 (Binding Arbitration). 

  
 18 

 1.117 “Joint Foreground IP” is defined in Section 13.1 (Ownership).

 1.118 “Joint Patent Committee” or “JPC” is defined in Section 9.3 (Joint Patent Committee). 

1.119 “JRC” is defined in Section 9.2.1 (JRC Membership). 

1.120 “JRC Chair” is defined Section 9.2.2 (JRC Chair). 

1.121 “Know-How” means algorithms, data, information, Inventions, improvements,
knowledge, methods (including methods of use or administration or dosing), practices, results, software, techniques, technology and trade secrets, including analytical and quality control data, analytical methods (including applicable reference
standards), assays, preclinical models, biomarkers, batch records, chemical structures and formulations, crystallization methods, X-ray diffraction data and analyses, compositions of matter, formulae,
synthesis route, manufacturing data, in-vitro and in-vivo pharmacological, toxicological and clinical test data and results, processes, reports, research data, research
tools, sequences, standard operating procedures and techniques, in each case, whether patentable or not, and, in each case, tangible manifestations thereof. 

1.122 “Knowledge” means, (a) with respect to Nurix, the actual knowledge of those persons listed for such Party on
Schedule 1.122 (Knowledge) after due inquiry, and (b) with respect to Sanofi, the actual knowledge of such Party, or what such Party should have known after due inquiry. 

1.123 “License Extension Fee” is defined in Section 11.4 (License Extension Fee). 

1.124 “License Extension Notice” is defined in Section 12.2 (Collaboration License to Sanofi for Licensed Products).

 1.125 “License Extension Fee Timeframe” means, for any Collaboration Target for which a Development Candidate Data
Package (a) has been delivered by Nurix in complete form and consistent with the requirements set forth in Schedule 1.62 (Development Candidate Data Package), the [*] period following such delivery, and (b) has not been delivered by Nurix,
the [*] period following receipt by Sanofi of the Nurix Key Data Report for such Collaboration Target. 
 1.126 “License Term
Extension” is defined in Section 12.2 (Collaboration License to Sanofi for Licensed Products). 
 1.127 “Licensed
Product” means any pharmaceutical preparation in final form containing (a) a CTM (including any Development Candidate) that has relevant pharmacological activity and is Directed To a Collaboration Target, or (b) a Selected Target
Binder that is Directed To a Collaboration Target and itself has relevant pharmacological activity (a “Standalone Target Binder”), in each case that was identified (except for Selected Target Binders provided by Sanofi), synthesized
and Researched by or on behalf of Nurix or its Affiliates prior to the expiration of the applicable Collaboration Target Research Term (whether alone or as part of a Combination Product, and in all presentations and formulations including manner of
delivery and dosage). 

  
 19 

 1.128 “Licensed Product Mark” is defined in Section 13.6 (Trademarks).

 1.129 “Ligase Binder” means any small molecule compound that binds with an E3 ubiquitin ligase. 

1.130 “Linker” means a moiety that covalently binds a Target Binder to a Ligase Binder. 

1.131 “MAA” means a Marketing Authorization Application or similar application, as applicable, and all amendments and
supplements thereto, submitted to the FDA, EMA or any equivalent filing in a country or regulatory jurisdiction other than the U.S. or EU with the applicable Regulatory Authority, to obtain marketing approval for a pharmaceutical or biological
product, in a country or in a group of countries. 
 1.132 “Major Biopharmaceutical Company” means (a) any entity that
itself or through its Affiliates develops or commercializes healthcare products for human consumption that has a fully diluted market capitalization of at least [*] as measured at the closing price on the last day of the preceding Calendar Quarter
during which the measurement is taken, or any Affiliate of such entity, or (b) any entity that itself or through its Affiliates has [*]. 

1.133 “Major European Market” means [*]. 

1.134 “Major Market” means at least one of [*]. 

1.135 “Manufacture” means all activities related to the manufacturing of a product or any component or ingredient thereof,
including the production, manufacture, having manufactured, processing, filling, finishing, packaging, labeling, shipping and holding of product or any intermediate thereof, including process development, process qualification and validation, scale-up, commercial manufacture and analytic development, product characterization, stability testing, quality assurance and quality control. 

1.136 “Material Adverse Event” means any event, occurrence, condition, change, circumstance, development, effect or state of
facts that has had or would reasonably be expected to have, individually or in the aggregate, a material adverse effect with respect to [*]; provided, however, that “Material Adverse Effect” shall not include the effect of any event,
occurrence, condition, change, circumstance, development, effect or state of facts arising out of or attributable to any of the following, either alone or in combination: [*] only to the extent such event, occurrence, condition, change,
circumstance, development, effect or state of facts does not have a disproportionate effect on a Party or its Affiliates as compared to other participants operating in the biopharmaceutical industry in the same markets in which such Party or its
Affiliates conduct their businesses. 
 1.137 “Material Transfer Agreement” is defined in Section 2.7.4 (Activities to
be Performed by Sanofi). 
 1.138 “Milestone Event” means any Research Milestone Event, Development Milestone Event or
Regulatory Milestone. 

  
 20 

 1.139 “Milestone Payment” means any Research Milestone Payment, Development
Milestone Payment or Regulatory Milestone Payment. 
 1.140 “NDA” means, with respect to a pharmaceutical product, a New
Drug Application submitted to the FDA in accordance with the FFDCA, and the rules and regulations promulgated thereunder, or any foreign counterpart to the foregoing filed with any Regulatory Authority outside of the United States in conformance
with the requirements of such Regulatory Authority. 
 1.141 “Net Sales” means, with respect to a Licensed Product for any
period, the gross amount billed or invoiced by Sanofi or any of its Affiliates or its or their Sublicensees for the sale of a Licensed Product to a Third Party commencing with the First Commercial Sale of such Licensed Product less the following
deductions determined in accordance with Accounting Standards from such gross amounts which are actually incurred, allowed, accrued or specifically allocated: 

[*] 
 Any of the deductions listed above that
involves a payment by Sanofi, its Affiliates or its or their Sublicensees shall be taken as a deduction in the Calendar Quarter in which the payment is accrued by such entity. For purposes of determining Net Sales, a Licensed Product shall be deemed
to be sold when [*]. Net Sales shall not include transfers or dispositions of such Licensed Product for pre-clinical or clinical purposes, compassionate use or as samples, in each case, without charge. Such
Party’s, its Affiliates’ or its or their Sublicensees’ transfer of any Licensed Product to an Affiliate or Sublicensee shall not result in any Net Sales unless the transferee is an end user. 

In the event that a Licensed Product is sold in any country in the form of a Combination Product, Net Sales of such Combination Product shall be adjusted by
multiplying actual Net Sales of such Combination Product in such country calculated pursuant to the foregoing definition of “Net Sales” by the fraction [*], then the adjustment to Net Sales shall be determined by [*]. In the event that a
dispute arises regarding the allocation mechanism under this paragraph, the dispute shall be resolved [*]. 
 In the case of pharmacy incentive programs,
hospital performance incentive programs, chargebacks, disease management programs, similar programs or discounts on portfolio product offerings, all [*]; provided that any such [*] shall be done in accordance with Applicable Law, including
any price reporting laws, rules and regulations. 
 Subject to the above, Net Sales shall be calculated in accordance with the standard internal policies
and procedures of Sanofi, its Affiliates or its or their Sublicensees, which must be in accordance with applicable Accounting Standards. 

1.142 “Non-Enforcing Party” is defined in Section 13.3.2(c) (Right to Enforce).

 1.143 “Non-Product Patent” is defined in Section 13.2.2 (Reverted Products,
Terminated Licensed Products; Non-Product Patents; No License Extension). 
 1.144 “Non-Prosecuting Party” is defined in Section 13.2.4 (Cooperation via JPC). 

  
 21 

 1.145 “Notice of Dispute” is defined in Section 18.6.2 (Dispute
Escalation). 
 1.146 “Nurix” is defined in the preamble to this Agreement. 

1.147 “Nurix Indemnitee” is defined in Section 16.1.1 (Indemnification by Sanofi). 

1.148 “Nurix Internal Target” means (a) the Target BTK, and (b) any Target (other than a Collaboration
Target, Substituted Collaboration Target, Replaced Collaboration Target (solely for the period of time described in Section 2.10.1(b) (Target Exclusivity)), or Reserved Target) that is subject to a bona fide internal Nurix research program and
is not conducted for a Third Party, where Nurix is conducting active drug discovery activities (including activities related to compound structure discovery, drug discovery screening, compound chemistry, structure-activity relationships and
manufacturing) with respect to a compound or product that is Directed To such Target, provided that [*] 
 1.149 “Nurix
IP” means the Nurix Patents and the Nurix Know-How, but excluding any Joint Foreground IP (including any [*]). 

1.150 “Nurix Key Data Report” means, with respect to any Collaboration Target for which a Development Candidate has
not been nominated by Nurix during the Research Term for such Collaboration Target’s Research Program, an information package relating to the CTMs (including [*]) and Target Binders (including [*]) in each case Directed To such Collaboration
Target, containing such items set forth in Schedule 1.62 (Development Candidate Data Package) to the extent such items have been generated by or on behalf of Nurix as of the date such information package is required to be delivered to Sanofi
hereunder. 
 1.151 “Nurix Know-How” means any and all Know-How Controlled by Nurix or any of its Affiliates as of the Execution Date or thereafter during the Term which is necessary or useful for the Research, Development, Manufacture or Commercialization of one or
more CTMs, Target Binders, Development Candidates, or Licensed Products in the Field in the Territory. 
 1.152 “Nurix
Patent” means any Patent Controlled by Nurix or any of its Affiliates as of the Execution Date or thereafter during the Term that is used or believed necessary for the Research, Development, Manufacture or Commercialization of one or more
CTMs, Target Binders Development Candidates, or Licensed Products in the Field in the Territory. 
 1.153 “Outside Date”
means that date that is [*] after the date upon which an HSR/Antitrust Filing has been submitted by each Party to a Governmental Authority in relation to the Agreement. 

1.154 “Party” is defined in the preamble to this Agreement. 

1.155 “Patent” means: (a) any patent or patent application in any country or supranational jurisdiction worldwide,
including any provisional patent application; (b) any application claiming priority to any such patent or patent application or any substitution, divisional, continuation,
continuation-in-part, reissue, renewal, registration, confirmation or the like of any such patent or patent application, or (c) any extension or restoration by any
existing or future extension or restoration mechanism, including revalidation, reissue, re-examination or extension, including any supplementary protection certificate of any of the foregoing. 

  
 22 

 1.156 “Payee” means a Party receiving a payment under this Agreement. 

1.157 “Payor” means a Party owing or making a payment under this Agreement. 

1.158 “Person” means any individual, partnership, joint venture, limited liability company, corporation, firm, trust,
association, unincorporated organization, Governmental Authority or any other entity not specifically listed herein. 
 1.159 “Phase
1 Clinical Trial” means a Clinical Trial which provides for the first introduction into humans of a product, conducted in normal volunteers or patients to get information on product safety, tolerability, immunogenicity, pharmacological
activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the foreign equivalent thereof). 
 1.160
“Phase 1/2 Clinical Trial” means a Clinical Trial that combines both a Phase 1 Clinical Trial and a Phase 2 Clinical Trial into a single protocol, where the Phase 1 Clinical Trial portion is performed first to (a) establish
initial safety, tolerability, pharmacokinetic and pharmacodynamic information for the Licensed Product as a monotherapy or in combination with another agent or (b) determine the maximum tolerable dose of such Licensed Product in subjects, and
the Phase 2 Clinical Trial portion is performed second to further evaluate safety and/or efficacy of such Licensed Product as a monotherapy or in combination with another agent in subjects treated with a selected dose. 

1.161 “Phase 2 Clinical Trial” means a single randomized, placebo or active controlled Clinical Trial, the principal purposes
of which are the evaluation of the efficacy of such product for a particular Indication in the target patient population and a determination of the common side-effects and risks associated with the product in
the dosage range to be prescribed and to obtain sufficient information about the efficacy for such pharmaceutical or biological product in the disease or condition being studied to permit the design and dose of such product in a Pivotal Trial, and
otherwise consistent with 21 C.F.R. §312.21(b) or its foreign equivalents. “Phase 2 Clinical Trial” will exclude in all cases any combined Phase 1 Clinical Trial/Phase 2 Clinical Trial. 

1.162 “Phase 3 Clinical Trial” means a controlled Clinical Trial of the efficacy and safety of a product, which is
prospectively designed to demonstrate statistically whether such product is effective and safe for use in a particular Indication in a manner sufficient to file for an MAA, and otherwise consistent with the requirements of US 21 C.F.R. §
312.21(c) or its foreign equivalents. 
 1.163 “Pivotal Trial” means a single randomized, controlled (e.g., compared
against SOC (standard of care), e.g., against a checkpoint inhibitor alone) Clinical Trial of a Licensed Product that: (a) (i) satisfies the requirements of 21 C.F.R. 312.21(c) or corresponding foreign regulations or (ii) is
intended to provide sufficient efficacy data to support the filing of a MAA for such Licensed Product without the need for additional Clinical Trials; and (b) which, at the time of Initiation of such Clinical Trial, is expected to be the basis
for EU Regulatory Approval or Regulatory Approval by the FDA of such Licensed Product based on discussions with the relevant Regulatory Authority. For clarity, a Pivotal Trial shall include Phase 3 Clinical Trials. 

  
 23 

 1.164 “Platform E3 Ligase” means any E3 Ligase that is used at any time in
the performance of any Research Plan. 
 1.165 “PMDA” is defined in Section 1.181 (Regulatory Authority). 

1.166 “Post-Termination Royalty Term” means, with respect to a particular country and a particular Reverted Product or
Terminated Licensed Product that is the subject of the royalty obligations under Sections 17.7.2 (Reversion) or 17.7.3(c) (Termination by Sanofi at Will or for a Change of Control of Nurix, or by Nurix for material breach or Bankruptcy), the period
of time commencing upon the [*] of such Reverted Product or Terminated Licensed Product in such country and ending upon the latest of (a) the date on which there is no Valid Claim (as such term is applied mutatis mutandis to the
Foreground IP licensed by Sanofi to Nurix under Section 17.7.3(c)) that would be infringed by [*] of such Reverted Product or Terminated Licensed Product in such country, (b) the expiration of any Regulatory Exclusivity granted with
respect to such Reverted Product or Terminated Licensed Product in such country, and (c) [*] of such Reverted Product or Terminated Licensed Product in such country. 

1.167 “Pricing Approval” means any approval, agreement, determination or decision establishing prices that can be charged to
consumers for a pharmaceutical or biological product or that will be reimbursed by Governmental Authorities for a pharmaceutical or biological product, in each case, in a country where Governmental Authorities approve or determine pricing for
pharmaceutical or biological products for reimbursement or otherwise. 
 1.168 “Prior CDA” means that certain Amended and
Restated Confidentiality Agreement, [*], by and between Nurix, Inc. and Sanofi. 
 1.169 “Product Patent” means a Patent
within Foreground IP that includes at least one (1) claim that Covers the composition of matter, formulation, method of use, or method of manufacturing in each case for a Standalone Target Binder or an entire CTM that is Directed To a
Collaboration Target. For clarity, a Patent that has a claim that Covers the [*], is not a Product Patent even if [*], unless such Patent also has a claim that Covers the [*]. 

1.170 “Profit/Loss Share Agreement” is defined in Section 8.2 (Option Exercise). 

1.171 “Profit/Loss Share Data Package” is defined in Section 8.1 (Delivery of Profit/Loss Share Data Package to
Nurix). 
 1.172 “Profit/Loss Share Product” means a Licensed Product for a Collaboration Target for which Nurix exercises
its Co-Development/Co-Promotion Option and the Parties have entered into the
Co-Development/Co-Commercialization Documentation, but only for so long as the applicable Profit/Loss Share Term for such Licensed Product remains in effect. 

1.173 “Profit/Loss Share Term” means, if Nurix exercises its
Co-Development/Co-Promotion Option with respect to a Collaboration Target, on a Profit/Loss Share
Product-by-Profit/Loss Share Product basis, the period of time [*]. 

  
 24 

 1.174 “Prosecuting Party” is defined in Section 13.2.4 (Cooperation
via JPC). 
 1.175 “Prosecution and Maintenance” or “Prosecute and Maintain” means, with regard to a
Patent, the preparation, filing, prosecution and maintenance of such Patent, as well as re-examinations, reissues and appeals with respect to such Patent, together with the initiation or defense of
interferences, oppositions, inter partes review, derivations, re-examinations, post-grant proceedings and other similar proceedings (or other defense proceedings with respect to such Patent, but excluding the
defense of challenges to such Patent as a counterclaim in an infringement proceeding) with respect to the particular Patent, and any appeals therefrom, and actions to obtain patent term extensions and supplementary protection certificates with
respect to such Patent and the like. For clarification, “Prosecution and Maintenance” or “Prosecute and Maintain” will not include any other enforcement actions taken with respect to a Patent. 

1.176 “Public Official or Entity” means (a) any officer, employee (including physician, hospital administrator, or other
healthcare professional), agent, representative, department, agency, de facto official, representative, corporate entity, instrumentality or subdivision of any government, military or public international organization, including any ministry or
department of health or any state-owned or affiliated company or hospital, (b) any candidate for political office, any political party or any official of any political party, or (c) any other person acting in an official capacity for or on
behalf of any of the foregoing. 
 1.177 “Publication” is defined in Section 14.7 (Publications) 

1.178 “Publishing Party” is defined in Section 14.7 (Publications). 

1.179 “Receiving Party” is defined in Section 14.1 (Nondisclosure). 

1.180 “Regulatory Approval” means all approvals, licenses and authorizations of the applicable Regulatory Authority necessary
for the marketing and sale of a pharmaceutical or biological product for a particular Indication in a country or region (including separate Pricing Approvals, as necessary to maximize the Commercial potential of the applicable Licensed Product), and
including the approvals by the applicable Regulatory Authority of any expansion or modification of the label for such Indication. 
 1.181
“Regulatory Authority” means any national or supranational Governmental Authority, including the U.S. Food and Drug Administration (and any successor entity thereto) (the “FDA”) in the U.S., the European Medicines
Agency (and any successor entity thereto) (the “EMA”) in the EU or any health regulatory authority in any country or region that is a counterpart to the foregoing agencies, or the Pharmaceutical and Medical Device Agency in
Japan (“PMDA”) in each case, that holds responsibility for development and commercialization of, and the granting of Regulatory Approval for, a pharmaceutical or biological product in such country or region. 

1.182 “Regulatory Exclusivity” means, with respect to a Licensed Product, any rights or protections which are recognized,
afforded or granted by the FDA or any other Regulatory Authority in any country or region of the Territory, in association with the Regulatory Approval of the Licensed Product, providing the Licensed Product[*] a period of marketing exclusivity,
during which a Regulatory Authority recognizing, affording or granting such marketing exclusivity will refrain from either reviewing or approving a MAA or similar regulatory submission, submitted by a Third Party seeking to market a Generic Product
of such Licensed Product, [*]. 

  
 25 

 1.183 “Regulatory Materials” means the regulatory registrations,
applications, authorizations and approvals (including approvals of MAAs, supplements and amendments, pre- and post-approvals, Pricing Approvals and labeling approvals), Regulatory Approvals and other
submissions made to or with any Regulatory Authority, including drug master files, for Research, Development (including the conduct of Clinical Trials), Manufacture or Commercialization of a pharmaceutical or biological product in a regulatory
jurisdiction, together with all related correspondence to or from any Regulatory Authority and all documents referenced in the complete regulatory chronology for each NDA, MAA, IND and foreign equivalents of any of the foregoing. 

1.184 “Regulatory Milestone Event” is defined in Section 11.5.3 (Regulatory Milestones). 

1.185 “Regulatory Milestone Payment” is defined in Section 11.5.3 (Regulatory Milestones). 

1.186 “Replaced Collaboration Target” is defined in Section 2.2.3 (Collaboration Target Substitution Right). 

1.187 “Research” means any pre-clinical research activities (including Target
validation, drug discovery, identification or synthesis) with respect to a Collaboration Target, Replaced Collaboration Target, Substituted Collaboration Target, Target Binder, CTM or Licensed Product. When used as a verb,
“Research” means to engage in Research. 
 1.188 “Research Milestone Event” means each of the four
(4) events set forth in the table in Section 11.5.1 (as further described in Schedule 1.188). 
 1.189 “Research Milestone
Payment” is defined in Section 11.5.1 (Research Milestones). 
 1.190 “Research Plan” means, on a
Collaboration Target-by-Collaboration Target basis, the plan governing the Research activities under a Research Program, as such plan may be created and amended from
time to time in accordance with this Agreement. 
 1.191 “Research Program” means, on a Collaboration Target-by-Collaboration Target basis, all Research activities undertaken under the Research Plan for such Collaboration Target to identify compounds that are Target Binders
and CTMs, in each case that are Directed To such Collaboration Target. 
 1.192 “Research Results” means any Research data,
relevant compound structures (including CTM, Ligase Binder, Linker and Target Binder structures), material, results or other information related to or otherwise arising under or out of a Research Program, including the contents of any Development
Candidate Data Package or Nurix Key Data Report. 

  
 26 

 1.193 “Research Term” means the period of time beginning on the Effective
Date and ending [*] in accordance with Section 2.1.2 (Collaboration Target Research Term Extension). 
 1.194 “Reserved
Target” is defined in Section 2.3 (Reserved Targets). 
 1.195 “[*]” is defined in Section ([*]). 

1.196 “Reserved Target Substitution Right” is defined in Section 2.3.3 (Reserved Target Substitution Right). 

1.197 “Residual Knowledge” means intangible Know-How relating to the Collaboration
(or otherwise to this Agreement or any Ancillary Agreement) retained in the unaided memories of any employees or contractors of a Party or any of its Affiliates or Sublicensees. 

1.198 “Reverted Product” means all CTMs, Target Binders, Standalone Target Binders and Development Candidates (and backups
thereto) that are Directed To a Reverted Target, but in each case excluding any [*] and any CTMs comprising a [*]. 
 1.199
“Reverted Target” means any Collaboration Target for which a License Term Extension has not occurred prior to the expiration of the License Extension Fee Timeframe for such Collaboration Target. 

1.200 “Reviewing Party” is defined in Section 14.7 (Publications). 

1.201 “ROW” means all of the countries in the Territory other than the United States. 

1.202 “Royalty-Bearing Product” means any Licensed Product other than a Profit/Loss Share Product. 

1.203 “Royalty Term” means, on a Licensed
Product-by-Licensed Product and country-by-country basis, the period of time that
commences upon the First Commercial Sale of such Licensed Product in such country and ends upon the later of: (a) the date on which use or sale of such Licensed Product is no longer Covered by a Valid Claim in such country; or
(b) expiration of Regulatory Exclusivity for such Licensed Product in such country; or (c) 10 years after First Commercial Sale in such country. 

1.204 “Royalty Territory” means: (a) the Territory, with respect to Royalty-Bearing Products; and (b) the ROW, with
respect to Profit/Loss Share Products. 
 1.205 “Rules” is defined in Section 18.6.3 (Binding Arbitration). 

1.206 “Sales Milestone Event” is defined in Section 11.6.1 (Sales Milestones). 

1.207 “Sales Milestone Payment” is defined in Section 11.6.1 (Sales Milestones). 

1.208 “Sanofi” is defined in the preamble to this Agreement. 

1.209 “Sanofi Desired Targets” is defined in Section 2.5.3 (Gatekeeper Responsibilities). 

  
 27 

 1.210 “Sanofi Documentation” is defined in Section 2.8.1 (Provision of
Sanofi Materials). 
 1.211 “Sanofi Indemnitee” is defined in Section 16.1.2 (Indemnification by Nurix). 

1.212 “Sanofi M1 Criteria” means, with respect to a CTM, the criteria that serve as a basis for Sanofi’s
determination in accordance with its standard internal policies and formal governance procedures to further commit resources to potentially achieve [*] for such CTM, which criteria include, as applicable, [*]. 

1.213 “Sanofi Materials” means any [*] materials, [*] developed outside of this Agreement and Controlled by Sanofi or its
Affiliates provided by Sanofi in accordance with Section 2.8.1 (Provision of Sanofi Materials) for use in a Research Program. 
 1.214
“Sanofi Provided Property” means, on a Collaboration Target-by-Collaboration Target basis, the Sanofi Materials and the Sanofi Documentation related to
such Collaboration Target provided by Sanofi to Nurix in accordance with Section 2.8.1 (Provision of Sanofi Materials). 
 1.215
“[*]” is defined in Section 1.225 (Target Binder). 
 1.216 “Securities Regulator” is defined in
Section 14.3.1(a) (Disclosure). 
 1.217 “Segregate” means, with respect to a Competing Product, to segregate the
Research, Development, Manufacture and Commercialization strategy, decisions and activities relating to such Competing Product from the Research, Development, Manufacture or Commercialization strategy, decisions and activities with respect to the
Licensed Products or any products Directed To a Target that is subject to Section 2.10.1 (Target Exclusivity) under this Agreement, including ensuring that: (a) no personnel involved in overseeing, directing or performing the Research,
Development, Manufacture or Commercialization, as applicable, of such Competing Product have access to non-public plans or non-public information or data relating to the
Research, Development, Manufacture or Commercialization of Licensed Products or products Directed To any Target that is subject to Section 2.10.1 (Target Exclusivity) or any other relevant Confidential Information of either Party; and
(b) no personnel involved in overseeing, directing or performing the Research, Development, Manufacture or Commercialization of Licensed Products or products Directed To any Target that is subject to Section 2.10.1 (Target Exclusivity)
have access to non-public plans or information relating to the Research, Development, Manufacture or Commercialization of such Competing Product; provided that, in either case ((a) or (b)), personnel at the
level of (or comparable to) vice-president and above may review and evaluate plans and information regarding the Research, Development, Manufacture or Commercialization of such Competing Product solely in connection with monitoring the progress of
products, including portfolio decision-making among product opportunities. 
 1.218 “Selected Target Binder” means, with
respect to a particular Collaboration Target, a Target Binder Directed To such Collaboration Target approved by the JRC (or otherwise in accordance with Section 9.4 (Decision Making)) to be a “Selected Target Binder.” 

1.219 “Standalone Target Binder” is defined in Section 1.127 (Licensed Product). 

  
 28 

 1.220 “Subcommittee” is defined in Section 9.2.1 (JRC Membership).

 1.221 “Sublicensee” means, with respect to Sanofi, a Third Party to whom Sanofi has granted a sublicense or license in
accordance with Section 12.4 (Sublicensing), either directly or indirectly, in each case of the rights licensed to Sanofi by Nurix pursuant to this Agreement, to Develop, Manufacture or Commercialize a Licensed Product in the Field in the
Territory, but excluding: (a) any Third Party acting as a distributor and (b) Nurix and any of its Affiliates. 
 1.222
“Substituted Collaboration Target” is defined in Section 2.2.3 (Collaboration Target Substitution Right). 
 1.223
“Substituted Reserved Target” is defined in Section 2.3.3 (Reserved Target Substitution Right). 
 1.224
“Target” means (a) a specific protein that is (i) identified by a GenBank protein accession number or by its amino acid sequence and (ii) coded by a genetic locus or (b) any
non-synonymous mutation, splice variation, or any post-translational modification of such protein described in sub-clause (a) of this Section 1.224 (Target).

 1.225 “Target Binder” means, with respect to a Collaboration Target, any compound that is: (a) discovered or
derived from a DEL screen for such Collaboration Target (without any corresponding deoxyribonucleic acid tag), (b) based upon a compound that has been publicly disclosed, or (c) [*] (sub-clause (c), a
“[*]”), in each case that is Directed To such Collaboration Target. 
 1.226 “Target Binder Selection
Milestone” is defined in sub-section (a) in the table in Section 11.5.1 (Research Milestones). 

1.227 “Target Confirmation Notice” is defined in Section 2.5.3 (Gatekeeper Responsibilities). 

1.228 “Target Exclusivity Period” is defined in Section 2.10.1 (Target Exclusivity). 

1.229 “Taxes” is defined in Section 11.10.5(a) (Generally). 

1.230 “Term” is defined in Section 17.1 (Term; Expiration). 

1.231 “Terminated Target” means: (a) in the case of the termination of this Agreement with respect to a Collaboration
Target by Nurix pursuant to Section 17.2 (Termination for Material Breach) or by Sanofi pursuant to Section 17.3 (Termination at Will), the Collaboration Target subject to such termination; or (b) in the case of termination of this
Agreement in its entirety by Nurix pursuant to Section 17.2 (Termination for Material Breach), or by Sanofi pursuant to Section 17.3 (Termination at Will) or Section 17.6(A) (Termination by Sanofi for a Change of Control of Nurix),
all Collaboration Targets in all countries in the Territory. 

  
 29 

 1.232 “Terminated Licensed Product” means: (a) in the case of the
termination of this Agreement with respect to a Collaboration Target by Nurix pursuant to Section 17.2 (Termination for Material Breach) or by Sanofi pursuant to Section 17.3 (Termination at Will), all Licensed Products Directed To such
Collaboration Target; (b) in the case of the termination of this Agreement with respect to one or more Licensed Products by Nurix pursuant to Section 17.2 (Termination for Material Breach) or by Sanofi pursuant to Section 17.3
(Termination at Will), all such Licensed Products; and (c) in the case of termination of this Agreement in its entirety by Nurix pursuant to Section 17.2 (Termination for Material Breach), or by Sanofi pursuant to Section 17.3
(Termination at Will) or Section 17.6(A) (Termination by Sanofi for a Change of Control of Nurix), all Licensed Products in all countries in the Territory. 

1.233 “Territory” means worldwide. 

1.234 “Third Party” means any Person other than Nurix or Sanofi that is not an Affiliate of Nurix or of Sanofi. 

1.235 “Third Party Claim” means any and all suits, claims, actions, proceedings or demands brought by a Third Party. 

1.236 “Third Party Infringement” is defined in Section 13.4.1 (Notification). 

1.237 “Transferred Inventory” is defined in Section 10.3 (Licensed Products Inventory Transfer). 

1.238 “United States” or “U.S.” means the United States of America and all of its territories and
possessions. 
 1.239 “Valid Claim” means any [*] in an issued and unexpired Patent within the Foreground IP that is owned
[*], and in each case that is [*], which issued Patent has not been held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, and which has not been admitted to be invalid or
unenforceable through abandonment, reissue, disclaimer or otherwise. 
 1.240 “VAT” means value added tax. 

1.241 “Wire Instructions” is defined in Section 11.1 (Upfront Payment). 

ARTICLE 2 
 RESEARCH

 2.1 Research Programs. 

2.1.1 General. Subject to the terms and conditions herein, during each applicable Collaboration Target Research Term, on a
Collaboration Target-by-Collaboration Target basis, (a) the Parties will conduct the Research activities allocated to such Party in the applicable Research Plan, or
as otherwise agreed upon by Parties in writing in advance, and (b) without limiting the foregoing, Nurix will use Commercially Reasonable Efforts to identify Target Binders and CTMs that are Directed To such Collaboration Target in order to
identify Development Candidates. Each Research Program will be subject to the oversight of the JRC. As between the Parties, each Party will bear its own costs and expenses incurred by or on behalf of it or its respective Affiliates in the
performance of such Party’s respective Research activities under this Agreement (other than as set forth below in Section 2.1.2 (Collaboration Target Research Term Extension). Sanofi shall not, without its prior written consent, be
assigned any activities under any Research Program or Research Plan. 

  
 30 

 2.1.2 Collaboration Target Research Term Extension. Sanofi shall have the right to
extend the Collaboration Target Research Term of any Collaboration Target that would, but for the maximum [*] Research Term and assuming a full [*] duration thereof, expire after the [*] of the Effective Date in accordance with this
Section 2.1.2 (Collaboration Target Research Term Extension). Sanofi may extend such Collaboration Target Research Term (i) by delivery of written notice at least [*] days prior to the [*] anniversary of the Effective Date, and
(ii) for a period of time expiring upon the earlier of either (x) the remainder of the applicable [*] Collaboration Target Research Term, or (y) the [*] of the Effective Date. In such case and on a Calendar Quarterly basis [*], in
each case (a) that are [*] by Nurix after the [*] of the Effective Date and before the end of the applicable extended Collaboration Target Research Term, (b) required in order for Nurix to perform its Research activities under the
applicable Research Plan(s), and (c) [*] by Nurix pursuant to a Research [*] that has been [*]. Following the end of each applicable Calendar Quarter, [*]. 

2.2 Collaboration Targets. 

2.2.1 Initial Collaboration Targets. The three (3) Targets listed in Schedule 2.2.1 are each Collaboration Targets on the
Effective Date (each, an “Initial Collaboration Target”). 
 2.2.2 Additional Collaboration Targets. For a period of
[*] after the Effective Date and subject to Section 2.4 (Proposed Targets), Sanofi shall have the right to select up to two (2) Available Targets or Reserved Targets as Collaboration Targets (each an “Additional Collaboration
Target”) by delivery of written notice to Nurix (“Additional Collaboration Target Notice”). 
 2.2.3
Collaboration Target Substitution Right. On a Collaboration Target-by-Collaboration Target basis, during the period of time beginning on the first day of the
Collaboration Target Research Term for such Collaboration Target and [*] (such time period the “Collaboration Target Substitution Period”), Sanofi shall have the right, for any reason and at no cost to Sanofi, to substitute such
Collaboration Target (a) for a Reserved Target upon delivery of written notice to Nurix’s Alliance Manager prior to the expiration of the applicable Collaboration Target Substitution Period, or (b) subject to Section 2.4
(Proposed Targets), for an Available Target (collectively, the “Collaboration Target Substitution Right”) (each such Collaboration Target that is replaced by a Reserved Target or Available Target thereafter a “Replaced
Collaboration Target” and each such new Collaboration Target that is substituted for the Replaced Collaboration Target, a “Substituted Collaboration Target”), provided, however, that (x) there will in no event be more
than five (5) Collaboration Targets in total under this Agreement at any time during the Research Term, (y) at any given time during the Research Term, there will be no more than five (5) Research Programs with Collaboration Targets
then ongoing, and (z) Sanofi shall only have the right to exercise its Collaboration Target Substitution Right [*] per Collaboration Target for [*], after which Sanofi shall no longer have the right to exercise its Collaboration Target
Substitution Right. 

  
 31 

 2.3 Reserved Targets. Subject to Section 2.4 (Proposed Targets), Sanofi shall
have the right to designate up to [*] Available Targets that will be subject to the exclusivity obligations set forth in Section 2.10 (Exclusivity) during the Research Term (each, a “Reserved Target”) in accordance with this
Section 2.3 (Reserved Targets). 
 2.3.1 As of Effective Date. [*] Sanofi shall have the right to reserve [*] Available
Targets as Reserved Targets for the period of time beginning on the Effective Date and ending on the [*] of the Effective Date. The [*] Reserved Targets in existence as of the Effective Date are set forth in Schedule 2.3.1. 

2.3.2 Additional Reserved Targets; Subsequent Years. Subject to this Section 2.3 (Reserved Targets) and Section 2.4 (Proposed
Targets) and during the Research Term, Sanofi shall have the right at any time to designate additional Available Targets as Reserved Targets (including (a) during the period of time beginning on the Effective Date and ending on the [*] of the
Effective Date, Reserved Targets in excess of the initial [*] described in Section 2.3.1 above, and (b) following the [*] of the Effective Date, any and all Reserved Targets whether or not initially nominated under Section 2.3.1, in
each case up to the maximum number described in this Section 2.3) for a [*] period commencing on such date of delivery of written notice to Nurix in accordance with Section 2.4 (Proposed Targets), provided that [*]. Prior to the expiration
of any such [*] period, Sanofi shall provide written notice to Nurix if Sanofi desires to extend such Reserved Target for subsequent [*] period(s) during the Research Term, provided that [*]. 

2.3.3 Reserved Target Substitution Right. Subject to Section 2.4 (Proposed Targets) and during the Research Term, Sanofi shall
have the right to substitute any or all Reserved Targets (“Reserved Target Substitution Right”) with Available Targets (such substituted Reserved Target thereafter, a “Substituted Reserved Target”), provided,
however, that Sanofi shall only have the right to exercise its Reserved Target Substitution Right [*] per Calendar Year, provided, further, that each such exercise may be with respect to one (1) or more (including all) Reserved Targets then in
existence. 
 2.4 Proposed Targets. 

2.4.1 In the event that Sanofi wishes to (a) select a Target as an Additional Collaboration Target in accordance with Section 2.2.2
(Additional Collaboration Targets), (b) exercise its Collaboration Target Substitution Right under Section 2.2.3 (Collaboration Target Substitution Right) for a Collaboration Target, (c) select a Target as a Reserved Target under
Section 2.3.2 (Additional Reserved Targets; Subsequent Years), or (d) exercise its Reserved Target Substitution Right under Section 2.3.3 (Reserved Target Substitution Right) for a Reserved Target, then in each case Sanofi shall have
the right to first undertake the Gatekeeper process described in 2.5 (Gatekeeper), provided that for any desired exercise by Sanofi of the rights described in (a)-(d) above, Sanofi shall provide email notice to [*] (each such notice a
“Proposed Available Target Notice”) of the identity of such Target (each a “Proposed Target”) and which of the Sanofi rights described in (a)-(d) above Sanofi is exercising. If such Proposed Target is already a
Reserved Target at the time of delivery of such Proposed Available Target Notice to [*], then Sanofi will be deemed to have exercised its applicable right described in (a) or (b) with respect to such Target upon delivery of such written notice.
If such Proposed Target is not a Reserved Target and is an Excluded Target at the time of delivery of such Proposed Available Target Notice to [*], 

  
 32 

 
then Sanofi shall not have the right to exercise its applicable right described in (a)-(d) with respect to such Proposed Target. If such Target is an Available Target at the time of delivery of
such Proposed Available Target Notice to [*], then Sanofi will be deemed to have exercised its applicable right described in (a)-(d) with respect to such Available Target upon delivery of such Proposed Available Target Notice. [*] 

2.4.2 During the Research Term, at the request of Sanofi, upon at least [*] prior written notice from Sanofi to Nurix, [*] other than for
proposed Collaboration Targets under Section 2.2.2 (Additional Collaboration Targets) or Section 2.2.3 (Collaboration Target Substitution Right) (which, for the avoidance of doubt, shall have no limit), and at the expense of Sanofi, Nurix
will permit an independent law firm selected by Sanofi and reasonably acceptable to Nurix to inspect, during regular business hours, the relevant records of Nurix required to determine whether a Proposed Target was an Available Target or an Excluded
Target as of the time in question. Prior to its inspection, the law firm will enter into a confidentiality agreement with both Parties having obligations of confidentiality and non-use no less restrictive than
those set forth in ARTICLE 14 (Confidentiality) and limiting the disclosure and use of such information by such law firm to authorized representatives of the Parties and the purposes germane to such determination. The law firm will report to
Sanofi only whether the status of a particular Proposed Target as an Available Target or an Excluded Target as of the particular time was accurate and will report no other information to Sanofi. Sanofi will treat the results of such review of
Nurix’s records as Confidential Information of Nurix subject to the terms of ARTICLE 14 (Confidentiality). 
 2.4.3 In the event
such audit leads to the discovery that Sanofi was incorrectly notified that a particular Proposed Target was an Excluded Target and such Proposed Target: 

(a) remains an Available Target at the time of such discovery, then Sanofi shall have the right to [*]; 

(b) is a Nurix Internal Target at the time of such discovery, then Sanofi shall have the right to [*]; or 

(c) is an Exclusive Third Party Target at the time of such discovery, then Sanofi shall have the right, [*], by delivery of
written notice to Nurix within [*] of such discovery, to [*]. 
 2.5 Gatekeeping. 

2.5.1 Appointment of Gatekeeper. During the Research Term of this Agreement, the Parties shall cooperate to qualify and select, and
Nurix shall engage, an independent Third Party gatekeeper reasonably acceptable to both Parties (the “Gatekeeper”). If required to do so by the Gatekeeper in order to engage the Gatekeeper, each Party shall execute a written
agreement indemnifying and holding the Gatekeeper harmless from liabilities arising from the performance of the Gatekeeper’s responsibilities in connection with this Agreement on terms reasonably acceptable to such Party. As of the Effective
Date, the Parties have engaged [*] under that particular Confidential Target Availability Determination Agreement dated [*] to serve as Gatekeeper. 

  
 33 

 2.5.2 Excluded Targets List. Within [*] after the Effective Date (if not already
provided as of the Effective Date), Nurix shall provide the Gatekeeper with a complete and accurate written list of all Targets that are Excluded Targets as of the date such list is submitted to the Gatekeeper (such list the “Excluded Target
List”). The Excluded Target List shall include the common name and [*] of each such Excluded Target listed therein. Thereafter, Nurix shall notify the Gatekeeper in writing of updates to the Excluded Target List promptly after (a) a
Target becomes an Excluded Target, and (b) a Target is no longer an Excluded Target, in each case by written notification to the Gatekeeper on an ongoing basis throughout the Research Term. Nurix shall also provide the Gatekeeper with an
updated Excluded Target List within [*] of receiving notice by the Gatekeeper of the delivery of any Target Confirmation Notice by Sanofi. 

2.5.3 Gatekeeper Responsibilities. The Gatekeeper shall maintain a complete and accurate Excluded Target List, including updating the
Excluded Target List upon receipt of notice by Nurix under Section 2.5.2 (Excluded Targets List). At any time during the Research Term, Sanofi shall have the right to notify the Gatekeeper in writing of Targets that Sanofi desires to have
reviewed as Available Targets against the most recent version of the Excluded Target List (such Targets “Sanofi Desired Targets” and such notice “Target Confirmation Notice”). Promptly (but no later than [*]
Business Days) after receiving a Target Confirmation Notice, the Gatekeeper shall review and compare the Sanofi Desired Targets listed in the Target Confirmation Notice and the Excluded Targets List then in effect (including updated Excluded Targets
Lists provided by Nurix under Section 2.5.2 (Excluded Targets List )) to identify which Sanofi Desired Targets are Excluded Targets (if any) or Available Targets (if any) and shall notify Sanofi in writing of such review no later than [*]
Business Days after delivery of the applicable Target Confirmation Notice. The Gatekeeper shall not disclose to Nurix, any Nurix Affiliate or any Person other than Sanofi of the identity of, or any other information with respect to, the Sanofi
Desired Targets. 
 2.6 Initial and Substitution Research Plans. The initial Research Plan for each of the Initial Collaboration
Targets is attached to the Correspondence as a sequentially numbered part of Exhibit A.1 (e.g., Exhibit A.1-(i), Exhibit A.1-(ii)). Within [*] days following receipt by
Nurix’s Alliance Manager of an Additional Collaboration Target Notice or Sanofi’s exercise of its Collaboration Target Substitution Right, as applicable, the JRC will discuss, prepare and approve a Research Plan for the Collaboration
Target described in such Additional Collaboration Target Notice or that is the subject of Sanofi’s exercise of its Collaboration Target Substitution Right, as applicable. Each Research Plan (including new Research Plans for Additional
Collaboration Targets and Substituted Collaboration Targets and any amendments to Research Plans) will be substantially consistent with the Initial Research Plans unless otherwise mutually agreed by the Parties. From time to time (at least on an
annual basis), the JRC will discuss, prepare and approve amendments, as appropriate, to each then-current Research Plan. Each amended Research Plan will become effective and supersede the previous Research Plan as of the date of approval by the JRC.

 2.7 Research Activities. 

2.7.1 Research Term. The Research activities hereunder will commence, on a Research Program-by-Research Program basis, on the first date of the Collaboration Target Research Term for such Research Program and shall end upon the expiration of the Research Term. 

  
 34 

 2.7.2 Activities and Data Sharing for Collaboration Targets. Nurix will use
Commercially Reasonable Efforts to identify Target Binders, CTMs and Development Candidates (as applicable) in each case Directed To the respective Collaboration Target. Nurix will disclose all results generated to date for such Collaboration Target
to the JRC. The JRC will (a) review such results, and (b) determine whether any Target Binder or CTM (as applicable) should be advanced as a Development Candidate. 

2.7.3 Activities for Reserved Targets. Upon the establishment or selection of a Reserved Target in accordance with Section 2.3
(Reserved Targets), Nurix shall [*] with respect to such Reserved Target exclusively under this Agreement to enable such Reserved Target to be selected by Sanofi as an Additional Collaboration Target in accordance with Section 2.2.2 (Additional
Collaboration Targets) or a Substituted Collaboration Target in accordance with Section 2.2.3 (Collaboration Target Substitution Right). 

2.7.4 Activities to be Performed by Sanofi. The Parties agree that Sanofi shall have the right to perform certain
research activities under the Agreement, including [*]. If Sanofi performs any such [*] research activities, then Nurix shall transfer upon request by Sanofi and at no cost to Sanofi, adequate amounts of biological and CTM materials for such
purposes. Prior to Nurix transferring any such materials to Sanofi, the Parties shall enter into a material transfer agreement in substantially the form set forth on Exhibit F to the Correspondence (a “Material Transfer Agreement”).

 2.7.5 [*] Target Binders in Research Plan. Whenever Nurix proposes to use a [*] Target Binder in the performance of Research
activities, Nurix shall notify Sanofi’s Alliance Manager in writing prior to any such use and Sanofi shall have the right to veto such use. Sanofi shall notify the Alliance Manager of Nurix in writing of such veto within ten (10) Business
Days after receipt of Nurix’ written notice, in which case Nurix shall not use such Target Binder in the performance of such Research activities. 

2.8 Sanofi Provided Property. 

2.8.1 Provision of Sanofi Materials. Sanofi will provide Nurix with (a) the Sanofi Materials (including any [*]) set forth in the
applicable Research Plan (provided that no Research Plan will require Sanofi to provide Sanofi Materials without Sanofi’s prior written consent), and (b) any other data or written materials and information that relate to such Sanofi
Materials set forth in the applicable Research Plan (“Sanofi Documentation”) (provided that no Research Plan will require Sanofi to provide any such data, written materials or information without Sanofi’s prior written
consent). Prior to Sanofi transferring any such materials to Nurix, the Parties shall enter into a Material Transfer Agreement. Nurix will have a period of thirty (30) days after Nurix’s receipt thereof, or such longer period of time as
may be determined by the JRC, during which Nurix may [*], in each case, subject to the terms of the Material Transfer Agreement, for the purpose of [*]. Nurix may develop or generate any materials or assays that are necessary to perform any Research
activities set forth under a Research Plan for a Collaboration Target if the Parties agree in writing that the Sanofi Provided Property with respect to a Collaboration Target are not available or are insufficient for use in the performance of such
Research activities. 

  
 35 

 2.9 Information Sharing; Records Retention. 

2.9.1 Information Sharing. During the applicable Collaboration Target Research Term at each meeting of the JRC or as otherwise agreed
by the Parties, the JRC shall review written reports or presentations regarding each Party’s activities (as applicable) with respect to the Research of respective CTMs, Target Binders, Development Candidates and Licensed Products. Each report
or presentation under this Section 2.9.1 (Information Sharing) will cover such activities since the previous JRC meeting, including a summary of results, information, chemical structures and data with respect to such Target Binders, CTMs,
Development Candidates and Licensed Products. Upon request by the JRC or by the other Party, a Party will provide the JRC with such other information and such additional access to records with respect to Target Binders, CTMs, Development Candidates
and Licensed Products as the JRC or such other Party may reasonably request for the conduct or evaluation of the respective Research Programs, including the underlying information used to create such summaries, such as data listings, data sets and
programs used for the analyses collected by a Party in the course of conducting its activities with respect to the respective Target Binders, CTMs, Development Candidates and Licensed Products. 

2.9.2 Development Candidate Data Package. For each Collaboration Target for which Nurix has nominated a Development Candidate within
the Collaboration Target Research Term, Nurix will provide Sanofi with a Development Candidate Data Package promptly after such nomination. Following such receipt by Sanofi, Sanofi will promptly notify Nurix if Sanofi in good faith believes such
Development Candidate Data Package is incomplete or otherwise inconsistent with the requirements of Schedule 1.62. If Sanofi so notifies Nurix that such Development Candidate Data Package is incomplete or inconsistent, then Nurix shall [*] For
purposes of determining License Extension Fee Timeframes, the date of [*] shall be used. 
 2.9.3 Nurix Key Data Report. With
respect to each Collaboration Target for which a Development Candidate will not be nominated by Nurix within the applicable Collaboration Target Research Term, within [*] prior to the expiration of such Collaboration Target Research Term, Nurix will
provide Sanofi with the Nurix Key Data Report for such Collaboration Target. For clarity, Nurix shall have no obligation to provide a Nurix Key Data Report for any Replaced Collaboration Target. 

2.9.4 Additional Information. At any time during the License Extension Fee Timeframe for a Collaboration Target following Sanofi’s
receipt of a Development Candidate Data Package or Nurix Key Data Report for such Target, Sanofi may provide Nurix with written notice requesting (a) additional information with respect to such Collaboration Target and the Licensed Products,
Development Candidates, CTMs and Target Binders in each case Directed To such Collaboration Target, or (b) a discussion with Nurix representative(s) who have the relevant knowledge and information regarding such Target, Development Candidates,
Licensed Products, Target Binders and CTMs (each, an “Information Request Notice”). Nurix will provide such information or hold such discussion as promptly as practicable, provided that notwithstanding anything to the contrary in
this Agreement, Nurix’s obligations under this Section 2.9.4 (Additional Information) with respect to any Collaboration Target shall expire upon the expiration of the applicable License Extension Fee Timeframe for such Collaboration
Target. 
 2.9.5 Records Retention. On a Research
Program-by-Research Program basis, each Party will retain, and cause its Affiliates and its and their permitted subcontractors to retain, all records, accounts, notes,
reports, data and laboratory notebooks with respect to the Research activities performed under such Research Program until the [*] anniversary of the expiration of the Research Term for such Research Program or such longer period as may be required
by Applicable Law. 

  
 36 

 2.10 Exclusivity. 

2.10.1 Target Exclusivity. Nurix will not conduct, and will cause its Affiliates to not conduct, by itself or themselves, or in
collaboration with or on behalf of any Third Party, any Research, Development, Manufacture or Commercialization activities with respect to (a) any Collaboration Target for the period of time [*] applicable to such Collaboration Target,
including such activities with respect to any compound Directed To such Collaboration Target alone or together with any other Target(s), (b) any Replaced Collaboration Target, any Collaboration Target terminated by Sanofi pursuant to ARTICLE 17
(Term and Termination), or any other Collaboration Target for which a License Term Extension does not occur within the License Extension Fee Timeframe, for a period of [*] after the date Sanofi has exercised its Collaboration Target Substitution
Right with respect to any such Replaced Collaboration Target, the effective date of any such termination by Sanofi, or the last day of the License Extension Fee Timeframe (in each case as applicable), including such activities with respect to any
compound Directed To such Target alone or together with any other Target(s), and (c) any Reserved Target during the Research Term, including such activities with respect to any compound Directed To such Target alone or together with any other
Target(s), (each such time period a “Target Exclusivity Period”), in each case (a), (b) and (c) other than such Research activities expressly contemplated herein. 

2.10.2 Exceptions for Change of Control. Notwithstanding anything in Section 2.10.1 (Target Exclusivity) to the contrary, if Nurix
undergoes a Change of Control, and if Sanofi does not exercise its right to terminate the Collaboration activities pursuant to Section 17.6(B) (Termination by Sanofi for a Change of Control of Nurix), and on the date of the closing of such
Change of Control, the Acquiring Entities are Researching, Developing, Manufacturing or Commercializing a product that is [*] (such product a “Competing Product”), then Nurix will not be in breach of Section 2.10.1 (Target
Exclusivity) as a result of such Change of Control or the continuation of such activities by such Acquiring Entities thereafter; provided that such Acquiring Entities: (a) provide written notice to Sanofi no later than [*] days following the
closing of such Change of Control which identifies such Competing Product, and (b) Segregate such Competing Product. 
 2.10.3
Research Results. All Research Results generated by or on behalf of Nurix under this Agreement or any Ancillary Agreement will be deemed the Confidential Information of both Parties, provided, however, that upon the expiration of the Target
Exclusivity Period for a Target, all Research Results related to such Target that are generated by Nurix in the performance of the Collaboration will be deemed the Confidential Information of Nurix, to the extent such Research Results do not include
any data, results or other information pertaining to any CTM comprising a [*], any [*] or other Sanofi Materials. 
 2.11 DEL Library
Blinding. With respect to any Collaboration Target, promptly following the identification of any Target Binder discovered or developed under a Research Program that is Directed To such Collaboration Target, Nurix will promptly mark and identify
all such Target Binders from its DELs by electronic means so as to prevent such Target Binders from 

  
 37 

 
being identified as hits against any other Target-screening effort performed by or on behalf of Nurix using DELs. In addition, Nurix will exclude all Target Binders having the same synthetic
feature (“Related Binders”) from being identified as hits against any other non-Collaboration Target-screening effort, wherein a synthetic feature is comprised of two chemical building blocks
and is responsible for a significant Target-screen signal. Upon selection of such Target Binders for a Collaboration Target as a Selected Target Binder, Nurix may unmark and restore Target Binder Hits that are not Selected Target Binders, as well as
the Related Binders of the not Selected Target Binders, provided that such Selected Target Binders and Related Binders will remain marked as described in this Section 2.11 (DEL Library Blinding) for the remainder of the applicable Target
Exclusivity Period for such Collaboration Target. 
 ARTICLE 3 

GOVERNMENT APPROVALS 
 3.1
Efforts. Each of Nurix and Sanofi will use its commercially reasonable good faith efforts to remove promptly any and all impediments to consummation of the Contemplated Transactions, including obtaining government antitrust clearance,
cooperating in good faith with any Governmental Authority investigation, promptly producing any documents and information and providing witness testimony if requested by a Governmental Authority. Notwithstanding anything to the contrary in this
Agreement, this Section 3.1 (Efforts) and the term “commercially reasonable good faith efforts” do not require that either Party (i) offer, negotiate, commit to or effect, by consent decree, hold separate order, trust or
otherwise, the sale, divestiture, license or other disposition of any capital stock, assets, rights, products or businesses of Nurix or Sanofi or its Affiliates, (ii) agree to any restrictions on the businesses of Nurix or Sanofi or its
Affiliates, or (iii) pay any amount or take any other action to prevent, effect the dissolution of, vacate, or lift any decree, order, judgment, injunction, temporary restraining order, or other order in any suit or proceeding that would
otherwise have the effect of preventing or delaying the transaction contemplated by this Agreement (collectively, an “Antitrust Remedy”). 

3.2 Filings. As soon as reasonably practicable following the Execution Date (but no later than [*] Business Days following the
Execution Date unless otherwise agreed to in writing by the Parties), each of Nurix and Sanofi will prepare and submit to the United States Federal Trade Commission (the “FTC”), the Antitrust Division of the United States Department
of Justice (the “DOJ”) any HSR/Antitrust Filing required of it under the HSR Act, along with a request for “early termination” of the applicable HSR waiting period, and, as soon as practicable, file with the
appropriate Governmental Authority any other HSR/Antitrust Filing required of it under any other Antitrust Law as determined in the reasonable opinion of either Party with respect to the Contemplated Transactions. The Parties shall cooperate with
one another to the extent necessary in the preparation of any such HSR/Antitrust Filing. Each Party shall be responsible for its own external legal and internal costs and expenses associated with any HSR/Antitrust Filing; provided, however, that
[*]. In the event that the Parties make an HSR/Antitrust Filing under this Section 3.2 (Filings), this Agreement shall terminate (i) at the election of either Party, immediately upon notice to the other Party, in the event that the FTC,
DOJ or other Governmental Authority (x) obtains a preliminary injunction or final order under Antitrust Law enjoining the Contemplated Transactions, or (y) issues an Antitrust Remedy as a condition of approval, or (ii) at the election
of either Party, immediately upon notice to the other Party, upon the occurrence of the Outside Date. Notwithstanding anything to the contrary contained herein, except for the terms and 

  
 38 

 
conditions of this ARTICLE 3 (Government Approvals), none of the terms and conditions contained in this Agreement shall be effective until the “Effective Date,” which is agreed
and understood to mean, subject to the Closing Conditions having been fulfilled or waived in accordance with Section 15.4 (Closing Conditions), the later of (A) if a determination is made pursuant to this Section 3.2 (Filings) that an
HSR/Antitrust Filing is not required to be made under any Antitrust Law for this Agreement, the date of such determination, or (B) if a determination is made pursuant to this Section 3.2 (Filings) that an HSR/Antitrust Filing is required
to be made under any Antitrust Law for this Agreement, the Antitrust Clearance Date. As used herein: (1) “Antitrust Clearance Date” means the earliest date on which the Parties have actual knowledge that all applicable waiting
periods under the HSR Act and any comparable waiting periods as required under any other Antitrust Law, in each case with respect to the Contemplated Transactions have expired or have been terminated; and (2) “HSR/Antitrust Filing”
means (x) a filing by Nurix and a filing by Sanofi with the FTC and the DOJ of a Notification and Report Form for Certain Mergers and Acquisitions (as that term is defined in the HSR Act), together with all required documentary attachments
thereto or (y) any comparable filing by Nurix or Sanofi required under any other Antitrust Law, in each case ((x) and (y)) with respect to the Contemplated Transactions. 

3.3 Information Exchange. Each of Nurix and Sanofi will, in connection with any HSR/Antitrust Filing, (i) reasonably cooperate
with each other in connection with any communication, filing or submission and in connection with any investigation or other inquiry, including any proceeding initiated by a private party; (ii) keep the other Party and/or its counsel informed
of any communication received by such Party from, or given by such Party to, the FTC, the DOJ or any other U.S. or other Governmental Authority and of any communication received or given in connection with any proceeding by a private party, in each
case regarding the transaction contemplated by this Agreement; (iii) consult with each other in advance of any meeting or conference with the FTC, the DOJ or any other Governmental Authority or, in connection with any proceeding by a private
party, with any other Person, and to the extent permitted by the FTC, the DOJ or such other Governmental Authority or other Person, give the Parties and/or their counsel the opportunity to attend and participate in such meetings and conferences; and
(iv) to the extent practicable, permit the other Party and/or its counsel to review in advance any submission, filing or communication (and documents submitted therewith) intended to be given by it to the FTC, the DOJ or any other Governmental
Authority; provided, that materials may be redacted to remove references concerning the valuation of the business of the disclosing Party or other sensitive information in the judgment of such disclosing Party. Nurix and Sanofi, as each deems
advisable and necessary, may reasonably designate any competitively sensitive material to be provided to the other under this ARTICLE 3 (Government Approvals) as “Antitrust Counsel Only Material.” Such materials and the information
contained therein shall be given only to the outside antitrust counsel of the recipient and will not be disclosed by such outside counsel to employees, officers or directors of the recipient unless express permission is obtained in advance from the
source of the materials (Nurix or Sanofi, as the case may be) or its legal counsel. 

  
 39 

 ARTICLE 4 

DEVELOPMENT 
 4.1
Responsibility. Subject to the terms and conditions of this Agreement and the Co-Development/Co-Commercialization Documentation (if executed), Sanofi will have
the sole and exclusive right to Develop (and will solely and exclusively control, at its discretion, the Development of), itself or with or through its Affiliates, Sublicensees or other Third Parties, the respective Development Candidates, backups
thereto and Licensed Products in the Field in the Territory. Subject to the Co-Development/Co-Commercialization Documentation (if executed), all such Development will be
at Sanofi’s sole cost and expense. 
 4.2 Development Diligence. Subject to the terms and conditions of this Agreement, Sanofi
itself or with or through its Affiliates or Sublicensees or other Third Parties will use Commercially Reasonable Efforts to obtain Regulatory Approval of at least one (1) Licensed Product in one (1) Indication in one (1) of the Major
Markets. 
 4.3 Development Updates. With respect to any Licensed Product, until the date on which Sanofi has submitted an MAA to the
applicable Regulatory Authority for at least one (1) Licensed Product Directed To such Collaboration Target in the United States, Sanofi will submit to Nurix, one (1) time per Calendar Year, a written report summarizing Sanofi’s
material Development activities with respect to the Licensed Products Directed To such Collaboration Target pursuant to this Agreement since Sanofi’s delivery of the prior report. 

ARTICLE 5 
 REGULATORY

 5.1 Regulatory Matters. 

5.1.1 Responsibility. Subject to the terms and conditions of this Agreement, Sanofi will have the sole and exclusive right (and will
solely and exclusively control, at its discretion), itself or with or through its Affiliates, Sublicensees or other Third Parties, to: (a) prepare and submit to applicable Regulatory Authorities all Regulatory Materials, including marketing
applications (e.g., NDAs, MAAs and JNDAs) and Clinical Trial applications (e.g., INDs, CTAs and CTNs), for the respective Development Candidates, backups thereto and Licensed Products and (b) obtain and maintain all Regulatory Approvals for the
respective Licensed Products. 
 5.1.2 Communications with Regulatory Authorities. For clarity and without limiting
Section 5.1.1 (Responsibility), Sanofi will have the sole and exclusive right to correspond or communicate with Regulatory Authorities regarding the respective Development Candidates, backups thereto and Licensed Products. Unless required by
Applicable Law, Nurix, its Affiliates and its permitted subcontractors will not correspond or communicate with Regulatory Authorities regarding any respective Development Candidate, backup thereto or Licensed Product without first obtaining
Sanofi’s prior written consent. If Nurix, its Affiliates or its permitted subcontractors receive any correspondence or other communication from a Regulatory Authority regarding the foregoing, Nurix will provide Sanofi with access to or copies
of all such material written or electronic correspondence promptly after its receipt. 
 5.1.3 Nurix Support. Nurix will
support Sanofi as may be reasonably requested by Sanofi from time to time in connection with Sanofi’s preparation, submission to Regulatory Authorities and maintenance of Regulatory Materials for the respective Development Candidates, backups
thereto [*] and Licensed Products, including, upon Sanofi’s reasonable request, attending 

  
 40 

 
meetings with Regulatory Authorities regarding any respective Licensed Product. Nurix will bear all costs of the first [*] hours of such support per Collaboration Target under this Agreement;
thereafter, Sanofi will reimburse Nurix for all reasonable costs actually incurred in connection with its support at the rate [*]. Such assistance shall be tracked by Nurix using its standard practice and methodologies and upon reasonable request
from Sanofi Nurix shall provide Sanofi with a written summary sufficient for Sanofi to verify the hours of assistance or costs incurred, as applicable. 

5.2 Regulatory Materials. 

5.2.1 Existing Regulatory Materials. Except to the extent notified otherwise in writing by Sanofi, on a Licensed Product-by-Licensed Product basis, Nurix will assign and transfer (and hereby does assign and transfer), or cause to be assigned and transferred to the extent not owned by
Nurix, to Sanofi (or its designee) within [*] days after the Effective Date any and all Regulatory Materials for the applicable Development Candidates, backups thereto [*] and Licensed Products Controlled by or on behalf of Nurix, its Affiliates or
contractors (the “Existing Regulatory Materials”), including by providing true, accurate and complete hard and electronic copies thereof to Sanofi. From and after such assignment and transfer, Sanofi (or its designee) will have the
sole right, in its sole discretion, to file, maintain and hold title to all such Existing Regulatory Materials. 
 5.2.2 New Regulatory
Materials. All Regulatory Materials generated or arising from or in connection with activities under this Agreement or any Ancillary Agreement with respect to Development Candidates, backups thereto or Licensed Products after the Effective Date
for such Licensed Product will be owned by and held in the name of Sanofi or its designee, and, except for Existing Regulatory Materials (which are addressed in Section 5.2.1 (Existing Regulatory Materials)), any such Regulatory Materials
issued in the name of Nurix, its Affiliates or contractors will, promptly be assigned by Nurix to Sanofi or its designee to the extent permitted by Applicable Law or, in the event assignment is not permitted under Applicable Law, held in trust for,
or for the sole benefit of, Sanofi or its designee. 
 5.3 Right of Reference; Access to Data. In the event of failure to transfer
and assign any Regulatory Materials to Sanofi or its designee, as required by Section 5.2.1 (Existing Regulatory Materials) or Section 5.2.2 (New Regulatory Materials), Sanofi and its designees will have, and Nurix (on behalf of itself and
its Affiliates) hereby grants to Sanofi and its designees, access (as described in Section 5.2.1 (Existing Regulatory Materials) or Section 5.2.2 (New Regulatory Materials)) and a right of reference (without any further action required on
the part of Nurix, its Affiliates or contractors, whose authorization to file this consent with any Regulatory Authority is hereby granted) to all Existing Regulatory Materials and Regulatory Materials described in Section 5.2.2 (New Regulatory
Materials) and all data contained or referenced therein for Sanofi and its designees to exercise its rights and perform its obligations under this Agreement with respect to the applicable Development Candidates, backups thereto and Licensed
Products. In all cases, Sanofi and its designees will have access to all data contained or referenced in all such Regulatory Materials Section 5.2.1 (Existing Regulatory Materials) or Section 5.2.2 (New Regulatory Materials), and Nurix
will ensure that Sanofi and its designees are afforded such access by fulfilling its obligations thereunder. 

  
 41 

 ARTICLE 6 

COMMERCIALIZATION 
 6.1
Commercialization. Subject to the terms and conditions of this Agreement and the Co-Development/Co-Commercialization Documentation (if executed), Sanofi will have
the sole and exclusive right to Commercialize (and will solely and exclusively control, at its discretion, the Commercialization of), itself or with or through its Affiliates, Sublicensees or other Third Parties, the applicable Licensed Products in
the Field in the Territory. Subject to the Co-Development/Co-Commercialization Documentation (if executed), all such Commercialization will be at Sanofi’s sole cost
and expense. 
 ARTICLE 7 

MANUFACTURING 
 7.1
Manufacturing. Subject to the terms and conditions of this Agreement, (a) Nurix, at its sole cost and expense, will Manufacture, itself or through Third Parties, Research supplies (other than GLP tox supplies) for the Parties’ use
of the respective CTMs, Target Binders and Development Candidates in the Field in the Territory under the Collaboration, provided that Sanofi will have the right to provide CMC inputs about the CMC developability of CTMs and Target Binders prior to
nomination of any Development Candidate, provided, further, that Research supplies for Sanofi shall be limited to those specified in any Research Plan for Sanofi activities or otherwise as permitted under Section 2.7.4 (Activities to be
Performed by Sanofi), and (b) Sanofi will have the sole and exclusive right to Manufacture (and will solely and exclusively control, at its discretion, the Manufacture of), itself or with or through its Affiliates, Sublicensees or other Third
Parties, the GLP tox supplies, and supplies to support Development or Commercial activities for the respective Development Candidates, backups thereto and Licensed Products in the Field in the Territory. Subject to the
Co-Development/Co-Commercialization Agreement and Profit/Loss Share Agreement (if executed), all such Manufacturing described in clause (b) will be at Sanofi’s
sole cost and expense. 
 7.2 Transfer of Manufacturing Know-How. After receipt by Nurix of
the License Extension Fee with respect to a Collaboration Target, or sooner as may be expressly set forth in a Research Plan or determined by the JRC, Nurix shall provide Sanofi with a copy of all clinical manufacturing controls data and transfer
all analytical and manufacturing Know-How and materials (including analytical reference standards) that are Controlled by Nurix or any of its Affiliates and that are necessary or useful for Sanofi to be able
to Manufacture and further scale-up the Manufacturing process of Development Candidates and other CTMs and Target Binders [*] that are Directed To such Collaboration Target. 

ARTICLE 8 
 NURIX OPTIONS

 8.1 Delivery of Profit/Loss Share Data Package to Nurix. Within [*] after the Clinical
Proof-of-Concept for a Licensed Product, Sanofi will deliver to Nurix a top-line data package from the Clinical Trial performed
to establish such Clinical Proof-of-Concept as described in more detail below (such package, a “Profit/Loss Share Data Package”). Sanofi will deliver
such Profit/Loss Share Data Package for each Licensed Product to achieve Clinical Proof-of-Concept for so long 

  
 42 

 
as there is a Co-Development/Co-Promotion Option available hereunder to Nurix with respect to the Collaboration
Target associated with such Licensed Product. Each Profit/Loss Share Data Package shall include: (a) a top-line data summary with [*], and a summary of [*], (b) material data generated with respect to [*]
for such Licensed Product, (c) the applicable [*] report for such Licensed Product, (d) [*] correspondence to and from any Regulatory Authority regarding such Licensed Product, and (e) [*] (collectively, the “[*]”). For
clarity, the information contained in each Profit/Loss Share Data Package will be deemed the Confidential Information of Sanofi. 
 8.2
Option Exercise. Beginning on Sanofi’s delivery of a Profit/Loss Share Data Package and ending [*] after delivery of such Profit/Loss Share Data Package (the “Option Exercise Timeframe”), Nurix will have the option, with
respect to the Collaboration Target associated with such Licensed Product, exercisable by written notice provided to Sanofi (such option, a
“Co-Development/Co-Promotion Option,” and such notice, a
“Co-Development/Co-Promotion Option Exercise Notice”), to enter into a
Co-Development/Co-Commercialization Agreement that includes the terms attached as Exhibit B to the Correspondence (the “Co-Development/Co-Commercialization Agreement”), a Profit/Loss Share Agreement that includes the terms attached as Exhibit C to the Correspondence (the “Profit/Loss Share
Agreement”), and a Co-Promotion Agreement that includes the terms attached as Exhibit D to the Correspondence (the “Co-Promotion Agreement”),
in each case with Sanofi and with respect to all Licensed Products associated with such Collaboration Target. Each of the Co-Development/Co-Commercialization Agreement,
Profit/Loss Share Agreement and Co-Promotion Agreement will contain the terms and conditions set forth in the respective Exhibits referenced above as well as other terms and conditions as are reasonable and
customary for the applicable subject matter of the respective agreements, and the Parties will execute such agreements within [*] following Nurix’s delivery to Sanofi of the
Co-Development/Co-Promotion Option Exercise Notice. Nurix may only exercise a
Co-Development/Co-Promotion Option on up to two (2) Collaboration Targets, [*]. If (i) Nurix does not provide the above exercise notice in compliance with the
requirements of this Section 8.2 (Option Exercise) with respect to a Collaboration Target, or (ii) Nurix provides written notice to Sanofi that it does not intend to exercise its Co-Development/Co-Promotion Option with respect to a Collaboration Target, then Nurix shall be deemed to have waived such right to exercise a
Co-Development/Co-Promotion Option with respect to such Collaboration Target. 

8.3 Additional Criteria for Option Exercise. Nurix shall not be permitted to exercise any Co-Development/Co-Promotion Option unless and until during the Option Exercise Timeframe the following criteria are demonstrated by Nurix: 

8.3.1 With respect to the first Co-Development/Co-Promotion
Option, Nurix has as of such time [*] in cash or [*] (in each case net of debt); 
 8.3.2 With respect to the second Co-Development/Co-Promotion Option, Nurix has as of such time [*] in cash or [*] (in each case net of debt); and 

8.3.3 Nurix’s plans to hire an adequate sales force at least [*] before Commercial launch of the first Licensed Product associated with
the applicable Collaboration Target, subject to the terms of the Co-Promotion Agreement that allow for Nurix to [*]. 

  
 43 

 ARTICLE 9 

GOVERNANCE 
 9.1
Alliance Manager. Within [*] Business Days following the Effective Date, each Party will appoint an individual to act as the alliance manager for such Party (each, an “Alliance Manager”). Each Alliance Manager will thereafter
be permitted to attend meetings of each Committee and any Subcommittee as a nonvoting observer. The Alliance Managers will be the primary point of contact for the Parties regarding the activities under the Collaboration and will help facilitate all
such activities hereunder. At any given time, the Alliance Managers will be responsible for keeping a then-current list of with respect to each Research Program (a) Target Binders, CTMs and Licensed Products that are being Researched under such
Research Program, (b) Research Milestone Events that have been achieved and (c) Collaboration Targets, Reserved Targets and Substituted Collaboration Targets under such Research Program. The Alliance Managers will also keep the JRC
reasonably informed of any changes to the items identified in the immediately previous sentence. 
 9.2 Joint Research Committee.

 9.2.1 JRC Membership. Promptly, and in any event within [*] days following the Effective Date, the Parties will establish a joint
research committee (the “JRC”) to oversee and coordinate the activities of the Parties under this Agreement with respect to the Research Programs. The JRC will be comprised of three (3) employee representatives of Sanofi and
three (3) employee representatives of Nurix (or such other equal number of representatives as the JRC may determine), and the Alliance Managers will also attend JRC meetings in a non-voting capacity.
Subject to the foregoing, each Party will appoint its respective representatives to the JRC from time to time, and may change its representatives, in its sole discretion, effective upon notice to the other Party designating such change.
Representatives from each Party will have appropriate technical credentials, experience and knowledge pertaining to and ongoing familiarity with the Research activities hereunder. The JRC may from time to time establish one (1) or more
subcommittees (each, a “Subcommittee”), to perform certain duties and exercise certain powers of the JRC as expressly set forth in this Agreement as delegated by the JRC to such Subcommittee. The JRC and each Subcommittee (other
than the JPC) will be promptly disbanded following the end of the last-to-expire Collaboration Target Research Term. 

9.2.2 JRC Chair. One (1) of the members of the JRC appointed by Nurix will be designated solely by Nurix the JRC chairperson (the
“JRC Chair”). The JRC Chair will be responsible for calling meetings of the JRC, circulating agenda and performing administrative tasks required to assure efficient operation of the JRC. The JRC Chair or his/her designee will send
meeting minutes to all members of the JRC promptly after a meeting for review. Each member will have [*] Business Days from receipt in which to comment on and to approve or provide comments to the minutes (such approval not to be unreasonably
withheld, conditioned or delayed). If a member, within such time period, does not notify the JRC Chair that he/she does not approve of the minutes, the minutes will be deemed to have been approved by such member. 

9.2.3 JRC Meetings. The JRC will meet by mutual written agreement of the Parties no less frequently than once every [*] months. The
location for meetings will alternate between Nurix and Sanofi facilities (or such other location as is determined by the JRC). Alternatively, the JRC may meet by means of teleconference, videoconference or other similar means. Each Party may also
call for special meetings to discuss particular matters requested by such Party upon [*] Business Days’ prior written notice to the other Party. 

  
 44 

 9.2.4 Other Members; Expenses. As appropriate, additional employees or consultants of
each Party may from time to time attend the JRC meetings as nonvoting observers; provided that any such consultant will agree in writing to comply with the confidentiality obligations substantially similar to those under this Agreement; and provided
further that no Third Party personnel may attend unless otherwise agreed by both Parties and such Third Party is bound by confidentiality and non-use obligations consistent with the terms of this Agreement.
Each Party will bear its own expenses related to the attendance of the JRC meetings by its representatives. 
 9.2.5 JRC Functions.
The purpose of the JRC will be to oversee and coordinate the conduct of the Research Programs. The JRC’s specific responsibilities are as follows: 

(a) Overseeing and coordinating the activities of each Party (including those of any of its Affiliates and Third Parties acting
under its authority) under each Research Program, including the performance of Research activities as set forth in the applicable Research Plan; 

(b) Preparing and approving Research Plans and amendments to Research Plans; 

(c) Identifying Target Binders or CTMs for further Research under the Research Plans; 

(d) Identifying and advancing CTMs or Standalone Target Binders as Development Candidates; 

(e) Receiving and reviewing Research Results; 

(f) Reviewing progress reports with respect to the performance of Research activities under each Research Plan, and requesting
such additional information as set forth in Section 2.9.4 (Additional Information); and 
 (g) Fulfilling such other
responsibilities as may be allocated to the JRC under this Agreement or by mutual written agreement of the Parties. 
 9.3 Joint Patent
Committee. Promptly after the first Joint Steering Committee meeting, the Parties will form a Joint Patent Committee (the “Joint Patent Committee” or “JPC”). The Joint Patent Committee shall be comprised of an
equal number of representatives from each Party. The Joint Patent Committee will be responsible for the coordination of the Parties’ efforts in accordance with the provisions set forth in ARTICLE 13. 

  
 45 

 9.4 Decision Making. 

9.4.1 JRC Decisions. Each Party will have one vote at the JRC. The JRC will endeavor to make decisions by consensus. In the absence of
consensus, any dispute will be escalated to the Executive Officers, and if the Executive Officers are unable to resolve such dispute within [*] Business Days after such matter has been referred to them then (a) for matters relating to [*],
Nurix shall have final decision-making ability, and (b) for all other matters [*], Sanofi shall have final decision-making ability. For clarity, Nurix shall not use its final decision-making ability to (i) [*]; (ii) [*] or (iii) [*].

9.4.2 JPC Decisions. In the event of a dispute within the Joint Patent Committee, such dispute shall be submitted to [*] for
resolution; provided, however, that [*]. 
 9.5 Scope of Committee Authority. For clarity and notwithstanding the creation of the JRC
or any Subcommittee, each Party will retain the rights, powers and discretion granted to it hereunder, and none of the JRC or any Subcommittee will be delegated or vested with such rights, powers or discretion unless such delegation or vesting is
expressly provided herein, or the Parties expressly so agree in writing. None of the JRC, any Subcommittee or a Party via exercise of its final decision-making authority will have the power to (a) resolve any Dispute regarding the existence or
amount of any payment owed under this Agreement or any Ancillary Agreement, (b) amend, waive or modify any term of this Agreement or any Ancillary Agreement, (c) determine whether or not a Party has met its diligence or other obligations
under this Agreement or any Ancillary Agreement or (d) determine whether any Milestone Event or Sales Milestone Event has been achieved or any payment obligation hereunder or under any Ancillary Agreement has been triggered, and no decision of
the JRC or any Subcommittee will be in contravention of any terms and conditions of this Agreement or any Ancillary Agreement. It is understood and agreed that issues to be formally decided by the JRC are limited to those specific issues that are
expressly provided in Section 9.2.5 (JRC Functions) of this Agreement and the Disputes which relate to subjects other than those expressly set forth in Section 9.2.5 (JRC Functions) will be handled according to Section 18.6 (Choice of
Law; Dispute Resolution). Once a Committee is disbanded, such Committee will have no further obligations under this Agreement and, thereafter, each Party will designate a contact person for the exchange of information under this Agreement or such
exchange of information will be made through the Alliance Managers. In the event a Committee is disbanded, any decisions that are designated under this Agreement as being subject to the review or approval of such Committee will be made by the
Parties directly, subject to the other terms and conditions of this Agreement. 
 9.6 Day-to-Day Responsibilities. Each Party will be responsible for day-to-day implementation and operations of the activities
for which it has or is otherwise assigned responsibility under this Agreement; provided that such implementation is not inconsistent with the express terms of this Agreement or the decisions of the JRC within the scope of its authority specified
herein. 
 ARTICLE 10 

ASSISTANCE; TRANSITION 

10.1 Assistance. Subject to the costs provisions of Section 10.2 (Know-How Transfer),
Nurix will, and will cause its Affiliates to, cooperate with Sanofi and its designees and provide assistance to Sanofi and its designees to transition to Sanofi and its designees the Research, Development, Manufacture and Commercialization of each
applicable Development Candidate [*] or Licensed Product after the occurrence of a License Term Extension for a Collaboration Target, 

  
 46 

 
as and to the extent reasonably requested by Sanofi, including by: (a) providing Sanofi and its designees assistance with respect to Research, Development, regulatory and Manufacturing
transition matters related to such Development Candidates, such backups and Licensed Products; and (b) providing Sanofi and its designees with reasonable access by teleconference or in-person (as
requested by Sanofi) to Nurix personnel (and personnel of its Affiliates and Third Party contractors) involved in Research, Development, regulatory or Manufacturing matters related to such Development Candidates, such backups and Licensed Products
to assist with the transition and answer questions related to such Development Candidates, such backups and Licensed Products. 
 10.2 Know-How Transfer. Without limiting the provisions of Section 10.1 (Assistance), as soon as reasonably practicable following the occurrence of the applicable License Term Extension, and thereafter during
the Term as may be reasonably requested by Sanofi from time to time, Nurix will during such initial period disclose to Sanofi and its designees in English, including by providing hard and electronic copies thereof: (a) all data, information,
regulatory filings, assets, DNA, protein sequences, constructs, synthesis routes and cell lines, and materials included therein and any other physical embodiments thereof, in each case relating to such Licensed Products or the Research Program or
Development Candidates, [*] backup CTMs or Target Binders for such Licensed Products and (b) copies of the documents set forth on Schedule 10.2 (Technology Transfer Documentation), as applicable. Nurix will bear all costs of the first [*] of
such assistance per Collaboration Target under this Agreement (including under Section 10.1 (Assistance)); thereafter, Sanofi will reimburse Nurix for all reasonable costs actually incurred in connection with its assistance at the rate of [*].
Such assistance shall be tracked by Nurix using its standard practice and methodologies and upon reasonable request from Sanofi Nurix shall provide Sanofi with a written summary sufficient for Sanofi to verify the hours of assistance or costs
incurred, as applicable. 
 10.3 Licensed Products Inventory Transfer. Without limiting the provisions of Section 10.1
(Assistance), upon Sanofi’s written request and at no cost to Sanofi, Nurix will promptly following the occurrence of the applicable License Term Extension assign and transfer to Sanofi or its designee and deliver to Sanofi or its designee, at
a location to be specified by Sanofi, any or all (as and to the extent requested by Sanofi) inventory of such Licensed Products, Development Candidates, Target Binders and CTMs held at such time by or on behalf of Nurix or its Affiliates (the
“Transferred Inventory”), along with all applicable Manufacturing, GMP and shelf-life information reasonably in Nurix’s possession. 

ARTICLE 11 
 FINANCIAL
TERMS 
 11.1 Upfront Payment. No later than [*] Business Days after the Effective Date, Sanofi will pay to Nurix a one (1)-time
payment of fifty-five million dollars ($55,000,000) in immediately available funds by wire transfer, in accordance with wire instructions to be provided in writing by Nurix to Sanofi no later than [*] Business Days following the Effective Date
(“Wire Instructions”). 

  
 47 

 11.2 Additional Collaboration Target Payments. No later than [*] Business Days after
the selection of an Additional Collaboration Target in accordance with Section 2.2.2 (Additional Collaboration Targets), Sanofi shall pay Nurix [*] for each such Additional Collaboration Target in immediately available funds by wire transfer,
in accordance with Wire Instructions (for clarity, not to exceed [*]). 
 11.3 [*] Fee. For each [*], Sanofi shall pay Nurix [*]
within [*] Business Days after the [*] (each such payment a “[*] Fee”). 
 11.4 License Extension Fee. On a
Collaboration Target-by-Collaboration Target basis, in the event that Sanofi exercises a License Term Extension with respect to a Collaboration Target, Sanofi will pay
to Nurix a [*] in immediately available funds by wire transfer, in accordance with the Wire Instructions, no later than [*] Business Days following delivery of the applicable License Extension Notice for such Collaboration Target in accordance with
Section 12.2 (Expiration; License Term Extension) (each, a “License Extension Fee”). 
 11.5 Milestones. 

11.5.1 Research Milestones. Subject to the terms and conditions herein (including this Section 11.5.1 (Research Milestones),
Section 11.7.4 (Offset for Third Party Payments; Floor), and Section 11.10 (Additional Payment Terms), and on a Collaboration Target-by-Collaboration Target
basis, Sanofi will pay the applicable amount set forth in the table below in this Section 11.5.1 (Research Milestones) (each a “Research Milestone Payment”) associated with each Research Milestone Event described in the table
below (in each case as further described in Schedule 1.188) with respect to the first (and only the first) Standalone Target Binder or CTM (as the case may be) to achieve such Research Milestone Event under this Agreement for such Collaboration
Target, as may be adjusted in accordance herewith: 
  

			
	 Research Milestone Event
	  	 Research Milestone
Payment

	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 TOTAL NOT TO EXCEED PER COLLABORATION TARGET:
	  	[*]

 Each Research Milestone Payment will be payable up to a maximum of one (1) time per Collaboration Target
as set forth in the table above, regardless of the number of Standalone Target Binders or CTMs, as applicable, that achieve the applicable Research Milestone Event for such Collaboration Target. 

  
 48 

 11.5.2 Development Milestones. Subject to the terms and conditions herein (including
this Section 11.5.2 (Development Milestones), Section 11.7.4 (Offset for Third Party Payments; Floor) and Section 11.10 (Additional Payment Terms), and in the
Co-Development/Co-Commercialization Documentation (if executed), and on a Collaboration
Target-by-Collaboration Target basis, Sanofi will pay the applicable amount set forth in the table below in this Section 11.5.2 (Development Milestones) associated
with each milestone event described below (each event described in (a)-(e) in the table below, a “Development Milestone Event,” and each respective payment, a “Development Milestone Payment”) under this Agreement
for a Licensed Product that is Directed To such Collaboration Target, as may be adjusted in accordance herewith: 
  

			
	 Development Milestone Event
	  	 Development Milestone
Payment

	 (a) [*]
	  	[*]
	 (b) [*]
	  	[*]
	 (c) [*]
	  	[*]
	 (d) [*]
	  	[*]
	 (e) [*]
	  	[*]
	 TOTAL NOT TO EXCEED PER COLLABORATION TARGET:
	  	[*]

 Each Development Milestone Payment will be payable up to a maximum of one (1) time per Collaboration
Target as set forth in the table above, upon achievement of the applicable Development Milestone Event for such Collaboration Target, regardless of the number of times the applicable Development Milestone Event is achieved with respect to such
Collaboration Target. For clarity, (x) if for a particular Collaboration Target, the [*], then Sanofi would pay the Development Milestone Payment due under (b) above and milestone (a) in the table above would thereafter not be payable
for such Collaboration Target and (y) if for a particular Collaboration Target, the [*], then Sanofi would pay the Development Milestone Payment due under (c) above and milestone (b) in the table above would thereafter not be payable
for such Collaboration Target. 
 For purposes of determining whether an Indication is distinct from another Indication under this
Section 11.5.2 (Development Milestones) or Section 11.5.3 (Regulatory Milestones), in addition to the factors set forth in Section 1.110 (Definition of Indication), an Indication (“New Indication”) is distinct from an
existing Indication (“Existing Indication”) if the Licensed Product [*]. 
 11.5.3 Regulatory Milestones. Subject to
the terms and conditions herein (including this Section 11.5.3 (Regulatory Milestones), Section 11.7.4 (Offset for Third Party Payments; Floor) and Section 11.10 (Additional Payment Terms), and in the Co-Development/Co-Commercialization Documentation (if executed), and on a Collaboration Target-by-Collaboration Target basis,
Sanofi will pay the applicable amount set forth in the table below in this Section 11.5.3 (Regulatory Milestones) associated with each milestone event described below (each event 

  
 49 

 
described in (a)-(i) in the table below, a “Regulatory Milestone Event,” and each respective payment, a “Regulatory Milestone Payment”) under this Agreement for
a Licensed Product that is Directed To such Collaboration Target, as may be adjusted in accordance herewith: 
  

			
	 Regulatory Milestone Event
	  	 Regulatory Milestone
Payment

	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 [*]
	  	[*]
	 TOTAL NOT TO EXCEED PER COLLABORATION TARGET:
	  	[*]

 Each Regulatory Milestone Payment will be payable up to a maximum of one (1) time per Collaboration
Target as set forth in the table above upon achievement of the applicable Regulatory Milestone Event for such Collaboration Target, regardless of the number of times the applicable Regulatory Milestone Event is achieved with respect to such
Collaboration Target. For clarity, no Regulatory Milestone Payment will be due hereunder for any subsequent or repeated achievement of any such same Regulatory Milestone Event (as the case may be) for a Collaboration Target. 

11.5.4 Invoice and Payment of Milestone Payments. 

(a) In the event that Sanofi, its Affiliates or its Sublicensees under this Agreement achieves a Milestone Event, it will
notify Nurix thereof within [*] days of such achievement. Following Nurix’s receipt of notice from Sanofi that Sanofi has achieved a Milestone Event, Nurix will invoice Sanofi for the applicable Milestone Payment, and Sanofi will pay such
Milestone Payment within [*] days after receipt of such invoice. 
 (b) In the event that Nurix or its Affiliates achieves a
Milestone Event, it will notify Sanofi thereof within [*] days of such achievement and invoice Sanofi for the applicable Milestone Payment, and Sanofi, subject to any good faith dispute as to whether such Milestone Event has been achieved, will pay
such Milestone Payment within [*] days after receipt of such invoice. 

  
 50 

 11.6 Sales Milestones. 

11.6.1 Sales Milestones. Subject to the terms and conditions herein (including this Section 11.6 (Sales Milestones),
Section 11.7.4 (Offset for Third Party Payments; Floor), Section 11.10 (Additional Payment Terms) and Section 11.11 (Records; Audit Rights), and in the
Co-Development/Co-Commercialization Documentation (if executed), and on a Collaboration
Target-by-Collaboration Target basis, Sanofi will notify Nurix within [*] days after the end of the Calendar Quarter during which a given milestone event described below
in this Section 11.6.1 (Sales Milestones) (each, a “Sales Milestone Event”) was first achieved by Sanofi under this Agreement, and Sanofi will thereafter pay the applicable one-time
sales-based amounts set forth below associated with the applicable Sales Milestone Event for Annual Net Sales of all Licensed Products that are Directed to such Collaboration Target in accordance with Section 11.6.2 (Invoice and Payment of
Sales Milestone Payments) (each, a “Sales Milestone Payment”), as may be adjusted in accordance herewith: 
  

			
	 Sales Milestone Event
	  	 Sales Milestone Payment

	 (a)   Annual Net Sales for such Collaboration Target in the Royalty Territory
in a Calendar Year exceed $[*]
	  	[*]
	 (b)   Annual Net Sales for such Collaboration Target in the Royalty Territory
in a Calendar Year exceed $[*]
	  	[*]
	 (c)   Annual Net Sales for such Collaboration Target in the Royalty Territory
in a Calendar Year exceed $[*]
	  	[*]
	 (d)   Annual Net Sales for such Collaboration Target in the Royalty Territory
in a Calendar Year exceed $[*]
	  	[*]
	 TOTAL NOT TO EXCEED PER COLLABORATION TARGET:
	  	[*]

 Each Sales Milestone Event will be payable up to a maximum of one (1) time per Collaboration Target as
set forth in the table above, upon achievement of the applicable Sales Milestone Event for such Collaboration Target, regardless of the number of times the applicable Sales Milestone Event is achieved with respect to such Collaboration Target. For
clarity, no Sales Milestone Payment will be due hereunder for any subsequent or repeated achievement of any such same Sales Milestone Event. Further, Net Sales for a given Licensed Product in a given country for which the Royalty Term has expired
will not be included in the Annual Net Sales for purposes of the Sales Milestone Events or Sales Milestone Payments. 
 11.6.2 Invoice
and Payment of Sales Milestone Payments. Sanofi will notify Nurix if the aggregate Annual Net Sales of any applicable Licensed Product first achieved a Sales Milestone Event during a Calendar Quarter in the royalty report for such Calendar
Quarter as described in Section 11.9 (Royalty Payments and Reporting), and Sanofi will pay to Nurix such Sales Milestone Payment concurrent with the delivery of such report. 

  
 51 

 11.7 Royalties. 

11.7.1 Royalty Rates. Subject to the terms and conditions herein (including this Section 11.7 (Royalties), Section 11.7.4
(Offset for Third Party Payments; Floor), Section 11.10 (Additional Payment Terms) and Section 11.11 (Records; Audit Rights), Sanofi will pay Nurix royalties on Annual Net Sales in the Royalty Territory, on a Licensed Product-by-Licensed Product basis, during the applicable Royalty Term, equal to the following portions of Annual Net Sales of the applicable Licensed Product multiplied by the
applicable royalty rate set forth below for such portion of Annual Net Sales in the Royalty Territory during the applicable Royalty Term for each such Licensed Product, as may be adjusted in accordance herewith. For clarity, the royalties (and
royalty tiers) will be calculated separately on a Licensed Product-by-Licensed Product basis. 
  

			
	 Annual Net Sales in the Royalty Territory for a given Licensed
Product in a given Calendar Year
	  	 Royalty Rate

	 (a)   Portion of Annual Net Sales in the Royalty Territory of a given
Licensed Product in a given Calendar Year up to and including $[*]
	  	[*]
	 (b)   Portion of Annual Net Sales in the Royalty Territory of a given
Licensed Product in a given Calendar Year above $[*] up to and including $[*]
	  	[*]
	 (c)   Portion of Annual Net Sales in the Royalty Territory of a given
Licensed Product in a given Calendar Year above $[*] up to and including $[*]
	  	[*]
	 (d)   Portion of Annual Net Sales in the Royalty Territory of a given
Licensed Product in a given Calendar Year above $[*] up to and including $[*]
	  	[*]
	 (e)   Portion of Annual Net Sales in the Royalty Territory of a given
Licensed Product in a given Calendar Year above $[*]
	  	[*]

 11.7.2 Royalty Term. Sanofi’s royalty obligations to Nurix under Section 11.7.1 (Royalty
Rates) will apply, on a Licensed Product-by-Licensed Product and country-by-country
basis, only during the applicable Royalty Term for such Licensed Product in such country. Following the expiration of the applicable Royalty Term for a given Licensed Product in a given country: (a) no further royalties will be payable with
respect to sales of such Licensed Product in such country; and (b) the license granted to Sanofi under this Agreement with respect to such Licensed Product in such country will become fully paid-up,
perpetual, irrevocable and royalty-free in accordance with Section 17.1 (Term; Expiration). 

11.7.3 Royalty Reductions. 

(a) On a Licensed Product-by-Licensed Product
and country-by-country basis, if such Licensed Product is no longer Covered by a Valid Claim in such country, then the royalties payable with respect to such Licensed
Product pursuant to Section 11.7.1 (Royalty Rates) in such country will be reduced by [*] during such period. 

  
 52 

 (b) On a Licensed Product-by-Licensed Product and country-by-country basis, if in a Calendar Quarter following the first Calendar Quarter in which
Generic Competition first occurs in such country (such first Calendar Quarter the “Launch Quarter”) the Annual Net Sales of such Licensed Product decline by the percentage described in (a)-(d) in the table below relative to the
average Net Sales occurring during the [*] Calendar Quarters immediately preceding the Launch Quarter, then, thereafter, the royalties payable with respect to Annual Net Sales of such Licensed Product pursuant to Section 11.7.1 (Royalty Rates)
in such country will be [*]. 
  

			
	 Decline in Annual Net Sales
	  	 Royalty Reduction

	 (a)   Portion of Annual Net Sales in the Royalty Territory of a given
Licensed Product in a given Calendar Year decreases between [*]
	  	[*]
	 (b)   Portion of Annual Net Sales in the Royalty Territory of a given
Licensed Product in a given Calendar Year decreases greater than [*] but less than [*]
	  	[*]
	 (c)   Portion of Annual Net Sales in the Royalty Territory of a given
Licensed Product in a given Calendar Year decreases greater than [*] but less than [*]
	  	[*]
	 (d)   Portion of Annual Net Sales in the Royalty Territory of a given
Licensed Product in a given Calendar Year decreases greater than [*]
	  	[*]

 11.7.4 Offset for Third Party Payments; Floor. 

(a) Offset for Third Party Payments. If Sanofi, any of its Affiliates or any of its Sublicensees obtains a right or
license under any Patent, Know-How or other intellectual property right of a Third Party after the Effective Date in connection with the Development, Manufacturing or Commercialization of the Licensed Products
by or on behalf of Sanofi, its Affiliates or its Sublicensees that results in any payment(s) to such Third Party as a result of such right or license by Sanofi, its Affiliates or its Sublicensees, as applicable, then Sanofi may deduct from any and
all payments under this Agreement or any Ancillary Agreement (to the extent not prohibited thereunder) that would otherwise have been due to Nurix in a particular Calendar Quarter an amount equal to [*] of the amount of any such payments (including
payments for obtaining such right or license, royalties, milestones, amounts paid in settlement and any other amounts) paid by Sanofi or any of its Affiliates or Sublicensees to such Third Party for such right or license or the exercise thereof
during such Calendar Quarter. 
 (b) Royalty Reduction Floor. Notwithstanding Section 11.7.4(a) (Offset for Third
Party Payments), in no event will royalties payable to Nurix in accordance with Section 11.7 (Royalties) in any country in any Calendar Quarter for any Licensed Product be reduced pursuant to Section 11.7.3(a) (Royalty Reductions –
Valid Claim) and Section 11.7.4(a) (Offset for Third Party Payments), to less than [*] of the amount that would otherwise be payable to Nurix in accordance with the provisions of Section 11.7 (Royalties) in such country in such Calendar
Quarter for such Licensed Product (the “Floor”). [*] 

  
 53 

 11.8 Effect of
Co-Development/Co-Promotion Option. If Nurix exercises its
Co-Development/Co-Promotion Option with respect to a Collaboration Target, then (a) subject to the terms applicable to Nurix opting out of its Co-Development/Co-Promotion Option described in the applicable
Co-Development/Co-Commercialization Documentation, all of the Regulatory Milestone Payments, Development Milestone Payments and Sales Milestone Payments for such
Collaboration Target, other than the Regulatory Milestone Payments for Regulatory Approvals by the EMA or the PMDA, that have not been paid as of the date of such exercise will be reduced by [*], and (b) Sanofi’s obligation to pay
royalties under Section 11.7 (Royalties) with respect to Licensed Products that are Directed to such Collaboration Target would be limited to Net Sales arising from countries outside of the United States. 

11.9 Royalty Payments and Reporting. Sanofi will calculate all amounts payable to Nurix pursuant to this Section 11.7 (Royalties)
at the end of each Calendar Quarter. Sanofi will pay to Nurix the royalty amounts due, less any applicable withholding tax that is required by Applicable Law in accordance with Section 11.10.5 (Taxes; Withholding), with respect to a given
Calendar Quarter within [*] days after the end of such Calendar Quarter. Commencing as of the First Commercial Sale for a Licensed Product Sanofi will, with respect to each Calendar Quarter (or portion thereof), provide a written report showing
(a) aggregate Net Sales of such Licensed Product that are royalty bearing and the royalties due thereon for such Calendar Quarter, (b) the withholding taxes, if any, required by law to be deducted in respect of such royalties, and
(c) the exchange rates used in determining the royalty amount expressed in Euro (each, a “Royalty Report”), within [*] days after the end of such Calendar Quarter. Sanofi shall provide such Royalty Reports for so long as
any Royalty Term remains in effect for a given Licensed Product. 
 11.10 Additional Payment Terms. 

11.10.1 Currency. All payments hereunder will be made in Dollars by wire transfer to a bank account designated in writing by the Payee.
Conversion of sales recorded in local currencies to Dollars will be performed in a manner consistent with the Accounting Standard and the Payor’s normal practices used to prepare its audited financial statements. 

11.10.2 Other Amounts Payable. With respect to any amounts owed under this Agreement by a Party to the other Party for which no other
invoicing and payment procedure is specified in this Agreement, the Party owing such payment obligation will provide to the other Party an invoice, together with reasonable supporting documentation, for such amounts owed and such other Party will
pay any undisputed amounts within [*] days after receipt of the invoice, and will pay any disputed amounts owed by such other Party within [*] days of final resolution of the Dispute. 

11.10.3 Invoices. Notwithstanding any term to the contrary of this Agreement, Nurix shall deliver an invoice to Sanofi’s Alliance
Manager for all payments owed by Sanofi to Nurix under this Agreement. Except where a different timeframe is expressly provided in another section of this Agreement, Sanofi will make all payments owed to Nurix within [*] days after the date on which
Sanofi receives an undisputed invoice for such owed amount. 

  
 54 

 11.10.4 General Right to Reconcile Payments. Sanofi will have the right to
offset any amount owed by Nurix to Sanofi under or in connection with this Agreement or any Ancillary Agreement which obligation is not being contested by Nurix in good faith, including in connection with any breach or indemnification obligation by
Nurix, against any payments owed by Sanofi to Nurix under this Agreement or any Ancillary Agreement. Such offsets will be in addition to any other rights or remedies available under this Agreement and Applicable Law. 

11.10.5 Taxes; Withholding. 

(a) Generally. Each Party will be liable for all taxes legally assessable against it arising from any payment received
under this Agreement, including income, applicable sales or use, goods and services, value added and consumption or other similar fees or taxes (“Taxes”). 

(b) Tax Withholding. If Applicable Law requires the withholding of Taxes, the Payor will subtract the amount thereof
from the Agreement Payments and remit such withheld amount to the relevant Governmental Authority in a timely manner. For the avoidance of doubt, the Payor’s remittance of such withheld Taxes, together with payment to the Payee of the remaining
Agreement Payments, will constitute the Payor’s full satisfaction of Agreement Payments under this Agreement. The Payor will promptly (as available) submit to the Payee appropriate proof of payment of the withheld Taxes as well as the official
receipts within a reasonable period of time. The Parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate such withholding of Taxes under Applicable Law, including under the benefit of any present or future
treaty against double taxation. 
 11.11 Records; Audit Rights. 

11.11.1 Records. Each Party will keep, and will cause its Affiliates and as applicable Sublicensees, to keep complete, true and
accurate books and records in accordance with its Accounting Standard in relation to this Agreement and Net Sales, royalties, Milestone Payments, Sales Milestone Payments and any other payments required hereunder, as applicable. Each Party will keep
such books and records for at least [*] years following the Calendar Year to which they pertain or for such longer period of time as required under any Applicable Law. 

11.11.2 Audit Rights. Subject to the other terms of this Section 11.11.2 (Audit Rights), during the Term, at the request of a
Party (the “Auditing Party”), which will not be made more frequently than [*] per Calendar Year, upon at least [*] days’ prior written notice from the Auditing Party, and at the expense of the Auditing Party, the other Party
(the “Audited Party”) will permit an independent, nationally-recognized certified public accountant selected by the Auditing Party and reasonably acceptable to the Audited Party (the “Auditor”) to inspect, during
regular business hours, the relevant records required to be maintained by the Audited Party under Section 11.11.1 (Records); provided that such audit right will not apply to records beyond [*] years from the end of the Calendar Year to which
they pertain and that records for a particular 

  
 55 

 
period may only be audited once. Prior to its inspection, the Auditor will enter into a confidentiality agreement with both Parties having obligations of confidentiality and non-use no less restrictive than those set forth in ARTICLE 14 (Confidentiality) and limiting the disclosure and use of such information by such accountant to authorized representatives of the Parties and the
purposes germane to Section 11.11.1 (Records). The Auditor will report to the Auditing Party only whether the particular amount being audited was accurate and, if not, the amount of any discrepancy and a reasonable summary of the reason for
such discrepancy, and the Auditor will not report any other information to the Auditing Party. The Auditing Party will treat the results of the Auditor’s review of the Audited Party’s records as Confidential Information of the Audited
Party subject to the terms of ARTICLE 14 (Confidentiality). In the event such audit leads to the discovery of a discrepancy to the Auditing Party’s detriment, the Audited Party will, within [*] days after receipt of such report from the
Auditor, pay any undisputed amount of the discrepancy. The Auditing Party will pay the full cost of the audit unless the underpayment of amounts due to the Auditing Party is greater than [*] of the amount due for the entire period being examined and
such underpayment also exceeds [*], in which case the Audited Party will pay the reasonable cost charged by the Auditor for such review. Any undisputed overpayments by the Audited Party revealed by an examination will be paid by the Auditing Party
within [*] days of the Auditing Party’s receipt of the applicable report. Sanofi will use Commercially Reasonable Efforts to include substantially similar rights as set forth in this Section 11.11.2 (Audit Rights) in any sublicense
agreement with its Sublicensee; provided, however, that such sublicense agreement may provide that such audit be conducted by Sanofi, its Affiliate or an independent auditor designated by Sanofi instead of by an independent auditor designated by
Nurix. 
 11.11.3 Records Final. Upon the expiration of [*] years following the end of a given Calendar Year, subject and without
prejudice to the determination of any review commenced prior to such third anniversary pursuant to Section 11.11.2 (Audit Rights), the calculation of any amounts payable by a Party to the other Party with respect to such Calendar Year will not
be subject to the audit provisions of this Section 11.11 (Records; Audit Rights). 
 ARTICLE 12 

LICENSES 
 12.1 License
Grants. 
 12.1.1 Research License to Nurix. Subject to the terms and conditions of this Agreement, and on a Collaboration
Target-by-Collaboration Target basis, during the Collaboration Target Research Term for such Collaboration Target, Sanofi hereby grants to Nurix a non-exclusive, worldwide, transferrable (pursuant to Section 18.4 (Assignment; Change of Control)) and sublicensable (solely to Nurix’s permitted subcontractors in accordance with Section 12.3
(Subcontracting) and Section 12.4 (Sublicensing)) license, under (a) the Background IP Controlled by Sanofi and Sanofi’s interest in the Foreground IP and (b) the rights exclusively licensed to Sanofi pursuant to
Section 12.1.2 (Collaboration License to Sanofi for Licensed Products) below, in each case (a) and (b) solely to the extent necessary for Nurix to perform the Research activities assigned to Nurix under the applicable Research Plan for the
applicable Collaboration Target Research Term and in accordance with such Research Plan. 

  
 56 

 12.1.2 Collaboration License to Sanofi for Licensed Products. Subject to the terms
and conditions of this Agreement (including Section 12.2 (Expiration; License Term Extension)), on a Collaboration Target-by-Collaboration Target basis, Nurix
hereby grants to Sanofi an exclusive (even as to Nurix and its Affiliates, except as set forth in the Co-Development/Co-Commercialization Agreement and Co-Promotion Agreement (if executed)), transferrable (pursuant to Section 18.4 (Assignment; Change of Control)) and sublicensable (through multiple tiers in accordance with Section 12.4 (Sublicensing))
license, under the Nurix IP and Nurix’s interest in the Joint Foreground IP, to Research, Develop, Manufacture and Commercialize CTMs, Standalone Target Binders, Development Candidates and Licensed Products in each case that are Directed To
such Collaboration Target in the Field in the Territory (each such license for a Collaboration Target a “Collaboration License”). Notwithstanding the foregoing, prior to the occurrence of a License Term Extension for a Collaboration
Target, Sanofi shall only practice the Collaboration License to perform Research to the extent [*]. For clarity, the foregoing exclusive Collaboration License does not preclude Nurix from using or practicing (or licensing others to use and practice)
the Nurix IP and Nurix’s interest in the Joint Foreground IP with chimeric targeting molecules that are not Directed To either Collaboration Targets or other Targets that are subject to Section 2.10.1 (Target Exclusivity), subject to the
other terms and conditions of the Agreement, including confidentiality and exclusivity obligations; provided, however, Nurix shall not use or practice, or license others to use or practice, any Sanofi Materials (including any [*]) or any
Confidential Information of Sanofi unless and until permitted to do so under Section 17.7.2 (Reversion) or Section 17.7.3(c) (Termination by Sanofi at Will or for a Change of Control of Nurix, or by Nurix for material breach or
Bankruptcy), as applicable. 
 12.2 Expiration; License Term Extension. Each Collaboration License for a Collaboration Target shall
expire upon the expiration of the License Extension Fee Timeframe for such Collaboration Target unless Sanofi delivers a written notice of its intent to pay the License Extension Fee to Nurix for such Collaboration Target (“License Extension
Notice”) within the License Extension Fee Timeframe and thereafter pays to Nurix the License Extension Fee for such Collaboration Target in accordance with Section 11.4 (License Extension Fee), in which case the Collaboration License
shall remain in force and effect during the Term and thereafter to the extent set forth in this Agreement (each such extension a “License Term Extension”). If Sanofi fails to make the License Extension Fee for a Collaboration Target
in accordance with Section 11.4 (License Extension Fee) prior to the expiration of the License Extension Fee Timeframe for such Collaboration License, then the Collaboration License for such Collaboration Target shall automatically expire upon
the expiration of such License Extension Fee Timeframe, and, for clarity, all CTMs (other than those comprising [*]), Development Candidates (other than those comprising [*]), Target Binders (other than [*]) and Standalone Target Binders (other than
[*]) that are Directed To such Collaboration Target shall thereafter be Reverted Products and such Collaboration Target thereafter a Reverted Target and Nurix shall have the right to exercise the license described in Section 17.7.2 (Reversion)
with respect to such Reverted Products and Reverted Targets. 
 12.3 Subcontracting. Each Party may subcontract the performance of
tasks and other obligations hereunder to its Affiliates or Third Parties (provided that prior to Nurix subcontracting such performance to Third Parties, it will obtain the prior written consent of Sanofi, not to be unreasonably withheld, conditioned
or delayed), which subcontract may include a sublicense of rights necessary for the performance of the subcontract as reasonably required, provided that any such Third Party will not be deemed to be a Sublicensee as a result of such sublicense. 

  
 57 

 12.4 Sublicensing. If a Party is permitted to grant a sublicense under the rights
licensed to such Party under Section 12.1 (License Grants), then the following terms shall apply to each sublicense: (a) any such permitted sublicense shall be consistent with and subject to the terms and conditions of this Agreement; and
(b) such Party will continue to be responsible for full performance of its obligations under this Agreement and will be responsible for all actions of such sublicensed Affiliate or Third Party, as applicable, as if such Affiliate or Third
Party, as applicable, were such Party hereunder. 
 12.5 Residual Knowledge. Notwithstanding anything to the contrary in this
Agreement, nothing shall restrict any Party from using Residual Knowledge for any purpose. 
 12.6 No Implied Licenses. Each Party
retains all rights under Patents, Know-How or other intellectual property rights Controlled by such Party which are not expressly granted to the other Party pursuant to this Agreement. Except as otherwise
expressly provided in this Agreement, under no circumstances will a Party or any of its Affiliates, as a result of this Agreement, obtain any ownership interest, license or other right in or to any Patents,
Know-How or other intellectual property rights of the other Party, including tangible or intangible items owned, controlled or developed by the other Party, or provided by the other Party to the receiving
Party at any time, in each case, pursuant to this Agreement. For clarity, Nurix shall have the right to exercise or license the Nurix IP in any manner, subject to the other terms and conditions of this Agreement, including the Collaboration Licenses
granted under Section 12.1.2 (Collaboration License to Sanofi for Licensed Products) and the exclusivity provisions described in Section 2.10 (Exclusivity). 

ARTICLE 13 
 INTELLECTUAL
PROPERTY MATTERS 
 13.1 Ownership. 

13.1.1 General. As between the Parties, each Party will retain ownership of all Patents,
Know-How and other intellectual property rights that are Controlled by such Party prior to the Execution Date or are otherwise developed by such Party outside of this Agreement (with respect to such Party, its
“Background IP”). As between the Parties, all Inventions made or created in the course of conducting activities under this Agreement (together with all intellectual property rights therein, including all Patents)
(“Foreground IP”) that are made or created (a) solely by a Party’s or any of its Affiliates’ employees, independent contractors or consultants will be [*], and (b) jointly by each Party’s (or any of its
Affiliates’) employees, independent contractors or consultants will be [*] (“Joint Foreground IP”). Foreground IP shall also include any Patents filed by or on behalf of Nurix during the Term that claim or otherwise reasonably
could Cover [*]. For clarity, [*]. All determinations of inventorship under this Agreement will be made in accordance with [*]. 

  
 58 

 13.1.2 Invention Assignments. Each Party shall cause all employees and contractors
who perform activities for such Party or its Affiliate under this Agreement to be under an obligation to assign their rights in any Inventions, Know-How and works of authorship resulting therefrom to such
Party or its Affiliate. At the request of the Party controlling the relevant Prosecution and Maintenance, enforcement or defense activities with respect to a Patent under this Agreement in accordance with this ARTICLE 13 (Intellectual Property), the
other Party shall require its employees and contractors who are inventors on any such Patent to cooperate and provide assistance to its employer or its Affiliate in relevant intellectual property-related matters, including by executing all
appropriate documents, cooperating in discovery and, if legally required to continue any such enforcement activities, joining as a party to any action or providing a power of attorney solely for such purpose. 

13.2 Prosecution and Maintenance. 

13.2.1 Product Patents. 

(a) Before License Term Extension. Prior to the occurrence of a License Term Extension with respect to a Collaboration
Target, [*] will be responsible for the Prosecution and Maintenance of Product Patents, including [*], at [*] cost and expense. Product Patents invented [*] will be Prosecuted and Maintained in [*] and Product Patents that are [*] will be Prosecuted
and Maintained in [*], provided that [*]. 
 (b) After License Term Extension. Following the occurrence of a
License Term Extension with respect to a Collaboration Target, Sanofi will be responsible for the Prosecution and Maintenance of the Product Patents that Cover [*]. Product Patents that are [*] will be Prosecuted and Maintained in [*], and Product
Patents that are [*] will be Prosecuted and Maintained in [*]. The JPC shall have the right to review and comment on all applicable Prosecution and Maintenance that is performed with respect to each Product Patent after the occurrence of a License
Term Extension with respect to such Product Patent. [*]. 
 13.2.2 Reverted Products, Terminated Licensed Products; Non-Product Patents; No License Extension. Nurix shall have the right in its sole discretion to Prosecute and Maintain (a) all Foreground Patents that are [*]
(“Non-Product Patents”), and (b) Product Patents that Cover a Reverted Product or a Terminated Licensed Product that do not also Cover a Licensed Product, in each case, at Nurix’s
expense, in each case (a) and (b) to the extent not Covering any [*]. 
 13.2.3 Patent Listings. Sanofi shall have the sole
right to make all patent listings of Product Patents or other Patent-related submissions with Regulatory Authorities for the Licensed Products. Nurix shall cooperate with Sanofi’s reasonable requests in connection therewith, including meeting
any submission deadlines, to the extent required or permitted by Applicable Law. 
 13.2.4 Cooperation via JPC. A Party that
Prosecutes and Maintains any Patent in accordance with this Section 13.2 (Prosecution and Maintenance) (the “Prosecuting Party”) will keep the other Party (the “Non-Prosecuting
Party”) reasonably informed of the status of such Patent via the JPC. The Non-Prosecuting Party will fully cooperate with the Prosecuting Party in connection with the Prosecution and Maintenance of
such Patents described in Section 13.2.1 (Before License Term Extension) and Section 13.2.1(b) (After License Term Extension), including 

  
 59 

 
as set forth in Section 13.1.2 (Invention Assignments) above. With respect to Non-Product Patents, Sanofi will have an opportunity to comment through
the JPC on the Prosecution and Maintenance of such Non-Product Patent solely to the extent [*]. Each Party through the JPC will promptly notify the other Party of any opposition by a Third Party or similar
adverse proceeding by a Third Party with respect to a Product Patent or, to the extent described in the foregoing sentence, a Non-Product Patent, of which it becomes aware. 

13.3 Enforcement. 

13.3.1 Notification. Each Party will promptly notify the other Party of any infringement, misappropriation or other violation by a
Third Party of any Product Patent in the Territory of which it becomes aware, including any declaratory judgment or similar action alleging invalidity, unenforceability or non-infringement with respect to any
such Product Patent (collectively, “Infringement”). 
 13.3.2 Right to Enforce. 

(a) Prior to the occurrence of a License Term Extension with respect to a Licensed Product, [*]. 

(b) Following the occurrence of a License Term Extension with respect to a Licensed Product, Sanofi will have the first right,
but not the obligation, to bring and control any legal action (including settlements thereof) or take such other actions as it deems appropriate in connection with any Infringement of any Product Patent at its cost and expense. If (a) Sanofi
fails to bring or confirm to Nurix that it will timely bring any such action with respect to any such Product Patent within [*] days following the notice of alleged Infringement provided pursuant to Section 13.3.1 (Notification), or
(b) Sanofi fails to bring any action with respect to any Product Patent within [*] days before the time limit, if any, set forth in Applicable Law for the filing of such actions, whichever comes first, Nurix will have the right (with
Sanofi’s prior written consent, not to be unreasonably withheld, conditioned or delayed) to bring and control any such action at its own expense, and Sanofi will have the right, at its own expense, to be represented in any such action by
counsel of its own choice. 
 (c) A Party that elects to enforce under this Section 13.3.2 (Right to Enforce) (the
“Enforcing Party”) will keep the other Party (the “Non-Enforcing Party”) reasonably informed of the status and progress of such enforcement efforts, and reasonably consult
with the Non-Enforcing Party, including using reasonable efforts to take the Non-Enforcing Party’s comments into good faith consideration with respect to such
enforcement action, including the infringement or claim construction of any claim in any Product Patent. The Non-Enforcing Party will also provide reasonable assistance in connection with such enforcement
actions, including by executing reasonably appropriate documents, cooperating in discovery and joining as a party to the action if required. The Enforcing Party will in no event settle or otherwise compromise any legal action by [*], in each case
without first obtaining the prior written consent of the Non-Enforcing Party, which consent will not be unreasonably withheld, conditioned, or delayed. 

  
 60 

 13.4 Defense. 

13.4.1 Notification. Each Party will promptly notify the other Party of any claim alleging that the Development, Manufacture or
Commercialization of the Licensed Products in the Territory infringes, misappropriates or otherwise violates any Patents, Know-How or other intellectual property rights of any Third Party (“Third Party
Infringement”). In any such instance, the Parties will as soon as practicable thereafter discuss in good faith the best response to such notice of Third Party Infringement. 

13.4.2 Right to Defend. Sanofi will have the sole right, but not the obligation, to defend, and take other actions (including to
settle), with respect to any such claim of Third Party Infringement, at Sanofi’s sole discretion, cost and expense, and Nurix will have the right to be represented in any such action by counsel of its own choice at Nurix’s sole cost and
expense; provided that in no event will Sanofi settle or otherwise compromise any Third Party Infringement by admitting that any Product Patent is invalid or unenforceable, in each case without first obtaining the prior written consent of Nurix,
which consent will not be unreasonably withheld, conditioned or delayed. 
 13.5 Recovery. 

13.5.1 Enforcement Actions. Any recovery (including any settlement) received as a result of any action under Section 13.3
(Enforcement) will be allocated in the following order: (a) to reimburse the Enforcing Party for the costs and expenses (including attorneys’ and professional fees) that the Enforcing Party incurred in connection with such action, to the
extent not previously reimbursed; (b) to reimburse the Non-Enforcing Party, where it joins a legal action as provided under Section 13.3 (Enforcement), for the costs and expenses (including
attorneys’ and professional fees) that the Non-Enforcing Party incurred in connection with such action, to the extent not previously reimbursed; and (c) any recoveries in excess of such costs and
expenses shall be [*]. 
 13.5.2 Defense Actions. Any recovery (including any settlement) received as a result of any action under
Section 13.4 (Defense) will be allocated in the following order: (a) to reimburse Sanofi for the costs and expenses (including attorneys’ and professional fees) that Sanofi incurred in connection with such action, to the extent not
previously reimbursed; (b) to reimburse Nurix, where it joins a legal action as provided under Section 13.4 (Defense), for the costs and expenses (including attorneys’ and professional fees) that Nurix incurred in connection with such
action, to the extent not previously reimbursed; and (c) any recoveries in excess of such costs and expenses shall be [*]. 
 13.6
Trademarks. Sanofi will have the sole and exclusive right, but not the obligation, to brand and promote the Licensed Products using trademarks, designs, copyrights, domain names, trade dress and trade names it determines appropriate in its
sole discretion for the Licensed Products, which may vary within the Territory (each, a “Licensed Product Mark”). Sanofi will own all rights, title and interests in and to the Licensed Product Marks, and all goodwill in the Licensed
Product Marks will inure to the benefit of Sanofi. Sanofi shall have the sole and exclusive right and responsibility to register, maintain, defend and enforce the Licensed Product Marks to the extent it determines reasonably necessary. Except as
otherwise agreed in writing by both 

  
 61 

 
Parties, Sanofi does not grant to Nurix, by implication, estoppel or otherwise, any license to any Licensed Product Mark. For the avoidance of doubt, trademarks, designs, trade dress and trade
names evaluated for use as Licensed Products but not actually used in the Commercialization of a Licensed Product shall not be a Licensed Product Mark and will remain property of Sanofi after termination or expiration of this Agreement. In any
event, any trademarks, service marks, names or logos that include any corporate name or logo of the Parties or their Affiliates shall not be a Licensed Product Mark and will remain the property of each respective Party. 

13.7 Patent Extensions. Nurix will reasonably cooperate, at Sanofi’s reasonable expense, with Sanofi upon Sanofi’s reasonable
request in obtaining at Sanofi’s expense patent term extension or supplemental protection certificates and the like with respect to any Product Patent, in each country and region where it is possible to do so. Sanofi will make the election in
accordance with the preceding sentence, and Nurix agrees to abide by any election made by Sanofi. 
 13.8 Falsified Medicines.
Without limiting either Party’s rights or obligations under the terms of Section 13.3 (Enforcement): 
 13.8.1 Each Party shall
promptly notify the other Party in writing if it becomes aware of any Third Party’s manufacturing, sale, offer for sale, distribution or contribution to the manufacturing, shipment or commercialization of a medical product purporting to be a
Licensed Product which deliberately or fraudulently misrepresents its identity, composition or source (“Falsified Medicine”); and 

13.8.2 Sanofi shall have the sole and exclusive right, but not the obligation, to lead any detection program, investigation or collaboration
with any Governmental Authority and the sole and exclusive right, but not the obligation, to file or threaten to file a claim or lawsuit to enforce any rights against any Third Party manufacturing, selling, offering for sale or distributing
Falsified Medicines or contributing to any of these actions. If requested by Sanofi, Nurix will reasonably cooperate with Sanofi with respect to any suspected Falsified Medicines to provide complementary information related to the applicable
Licensed Product when necessary or requested by any Governmental Authority. 
 ARTICLE 14 

CONFIDENTIALITY 
 14.1
Nondisclosure. Each Party agrees that a Party (the “Receiving Party”) which receives the Confidential Information of the other Party (the “Disclosing Party”) pursuant to this Agreement or any Ancillary
Agreement will: (a) maintain in confidence such Confidential Information using not less than the efforts that such Receiving Party uses to maintain in confidence its own proprietary information of similar kind and value, but in no event less
than a reasonable degree of efforts; (b) not disclose such Confidential Information to any Third Party without first obtaining the prior written consent of the Disclosing Party, except for disclosures expressly permitted pursuant to this
ARTICLE 14 (Confidentiality); and (c) not use such Confidential Information for any purpose except those expressly permitted under this Agreement, including, in the case of Sanofi, the exercise of the rights and licenses granted to Sanofi
hereunder. The obligations of confidentiality, non-disclosure and non-use under this Section 14.1 (Nondisclosure) will be in full force and effect from the
Effective Date until [*] years following the Term. Except 

  
 62 

 
as otherwise requested in writing by the Disclosing Party, the Receiving Party will destroy the Confidential Information of the Disclosing Party, promptly (but in any case within [*] calendar
days after the expiration or termination of this Agreement); provided, however, that a Party may retain: (i) Confidential Information of the Disclosing Party to exercise rights and licenses which expressly survive such termination or expiration
pursuant to this Agreement; (ii) access to all other Confidential Information in archives solely for the purpose of establishing the contents thereof or in accordance with Applicable Law and (iii) any backup media copies made in the
ordinary course of business. In addition, subject to Section 2.10.3 (Research Results), Nurix will keep confidential, and will cause its Affiliates and its and their employees, consultants, licensees, sublicensees, professional advisors and
Affiliates to keep confidential, the Nurix IP and Joint Foreground IP, in each case to the extent related to the CTMs, Target Binders, or Licensed Products, on confidentiality terms at least as protective as the confidentiality provisions of this
Agreement without regard to Section 14.2 (Exceptions). 
 14.2 Exceptions. 

14.2.1 General. Section 14.1 (Nondisclosure) will not apply with respect to any portion of the Confidential Information of the
Disclosing Party to the extent that such Confidential Information: 
 (a) was known to the Receiving Party or any of its
Affiliates, as evidenced by written records, without any obligation to the Disclosing Party to keep it confidential or to restrict its use, prior to disclosure by the Disclosing Party; 

(b) is subsequently disclosed to the Receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof
and without any obligation to the Disclosing Party to keep it confidential or to restrict its use; 
 (c) is published by a
Third Party or otherwise becomes publicly available or enters the public domain, either before or after it is disclosed to the Receiving Party, without any breach by the Receiving Party of its obligations hereunder; or 

(d) is independently developed by or for the Receiving Party or any of its Affiliates, as evidenced by written records, without
reference to or reliance upon the Disclosing Party’s Confidential Information. 
 Any combination of features or disclosures will not be deemed to fall
within the foregoing exclusions merely because individual features are published or available to the general public or in the rightful possession of the Receiving Party unless the combination itself and principle of operation are published or
available to the general public or in the rightful possession of the Receiving Party. 
 14.3 Authorized Disclosure. 

14.3.1 Disclosure. Notwithstanding Section 14.1 (Nondisclosure), the Receiving Party may disclose Confidential Information
belonging to the Disclosing Party in the following instances: 
 (a) as permitted by and in accordance with Section 14.5
(Securities Filings; Disclosure under Applicable Law), to the U.S. Securities and Exchange Commission or any national securities exchange in any jurisdiction in the Territory) (each, a “Securities Regulator”); 

  
 63 

 (b) in response to a valid order of a court of competent jurisdiction or
other Governmental Authority or Regulatory Authority or, if in the reasonable opinion of the Receiving Party’s legal counsel, such disclosure is otherwise required by Applicable Law (other than to a Securities Regulator); provided that to the
extent legally permissible the Receiving Party will first give written notice to the Disclosing Party and give the Disclosing Party a reasonable opportunity to quash such order or to obtain a protective order or confidential treatment requiring that
the Confidential Information and documents that are the subject of such order or requirement be held in confidence by such court or agency or, if disclosed, be used only for the purposes for which the order was issued and redacted in accordance with
the Disclosing Party’s instruction; provided further that the Confidential Information disclosed in response to such court or governmental order or Applicable Law will be limited to that information which is legally required to be disclosed in
response to such court or governmental order or Applicable Law; 
 (c) by either Party, solely to the extent reasonably
necessary to exercise its rights to Prosecute and Maintain any Patents for which it has a right under ARTICLE 13; provided that such Party will provide the other Party with at least [*] days’ prior written notice of any such disclosure and take
reasonable and lawful actions to avoid or minimize the degree of disclosure; 
 (d) by either Party, to a Regulatory
Authority, as reasonably required or useful in connection with any filing, submission or communication with respect to any Licensed Product, Reverted Product or Terminated Product; provided that reasonable measures will be taken by such Party to
obtain confidential treatment of such information, to the extent such protection is available; 
 (e) disclosure (i) to
any of its officers, employees, consultants, agents or Affiliates who need to know such Confidential Information to perform on behalf of such Party under this Agreement or any Ancillary Agreement, (ii) in the case of Sanofi, to any actual or
potential collaborators, partners, licensees, Sublicensees or subcontractors in connection with the Development, Manufacture and Commercialization of Licensed Products or otherwise to the extent necessary or reasonably useful for Sanofi to exercise
its rights or perform its obligations hereunder or under any Ancillary Agreement, (iii) in the case of either Party, to such Party’s actual or bona fide potential acquirers or investors on a strictly need to know basis for the sole purpose
of evaluating or carrying out a bona fide investment in or acquisition of such Party (provided that [*]); and (iv) in the case of Nurix, [*]; provided further that prior to any such disclosure ((i)-(iv)), each such disclosee is bound by written
obligations of confidentiality, non-disclosure and non-use no less restrictive than the obligations set forth in this ARTICLE 14 (Confidentiality) to maintain the
confidentiality thereof and not to use such Confidential Information except as expressly permitted by this Agreement; provided, however, that, in each of the above situations in this Section 14.3.1(e) ((i)-(iii)) (Disclosure), the Receiving
Party will remain responsible for any failure by any Person who receives Confidential Information from such Receiving Party pursuant to this Section 14.3.1(e) (Disclosure) to treat such Confidential Information as required under this
ARTICLE 14 (Confidentiality); and 

  
 64 

 (f) disclosure to its advisors (including attorneys and accountants) in
connection with activities under this Agreement or any Ancillary Agreement; provided that prior to any such disclosure, each such disclosee is bound by written obligations of confidentiality, non-disclosure
and non-use no less restrictive than the obligations set forth in this ARTICLE 14 (Confidentiality) (provided, however, that in the case of legal advisors, no written agreement will be required), to
maintain the confidentiality thereof and not to use such Confidential Information except as expressly permitted by this Agreement; provided, however, that, in each of the above situations in this Section 14.3.1 (Disclosure), the Receiving Party
will remain responsible for any failure by any Person who receives Confidential Information from such Receiving Party pursuant to this Section 14.3.1 (Disclosure) to treat such Confidential Information as required under this ARTICLE 14
(Confidentiality). 
 14.3.2 Terms of Disclosure. If and whenever any Confidential Information is disclosed in accordance with this
Section 14.3 (Authorized Disclosure), such disclosure will not cause any such information to cease to be Confidential Information, except to the extent that such disclosure results in a public disclosure of such information other than by breach
of this Agreement. 
 14.4 Terms of this Agreement. The Parties agree that this Agreement and the Ancillary Agreements and the terms
hereof and thereof will be deemed to be Confidential Information of both Nurix and Sanofi, and each Party agrees not to disclose this Agreement or any Ancillary Agreement or any terms hereof or thereof without obtaining the prior written consent of
the other Party; provided, that each Party may disclose this Agreement or any Ancillary Agreement or any terms hereof or thereof in accordance with the provisions of Section 14.3 (Authorized Disclosure), Section 14.5 (Securities Filings;
Disclosure under Applicable Law), or Section 14.6.1 (Press Release; Nurix Obligations), as applicable. 
 14.5 Securities Filings;
Disclosure under Applicable Law. Each Party acknowledges and agrees that the other Party may submit this Agreement to, or file this Agreement with, the Securities Regulators or to other Persons as may be required by Applicable Law, and if a
Party submits this Agreement to, or files this Agreement with, any Securities Regulator or other Person as may be required by Applicable Law, such Party agrees to consult with the other Party with respect to the preparation and submission of a
confidential treatment request for this Agreement and shall incorporate comments from the other Party to the extent legally permissible. Notwithstanding the foregoing, if a Party is required by any Securities Regulator or other Person as may be
required by Applicable Law to make a disclosure of the terms of this Agreement in any other filing or submission as required by such Securities Regulator or such other Person, and such Party has: (a) provided copies of the disclosure to the
other Party reasonably in advance under the circumstances of such filing or other disclosure; (b) promptly notified the other Party in writing of such requirement and any respective timing constraints; and (c) given the other Party
reasonable time under the circumstances from the date of provision of copies of such disclosure to comment upon and request confidential treatment for such disclosure, then such Party will have the right to

  
 65 

 
make such disclosure at the time and in the manner reasonably determined by its counsel to be required by the Securities Regulator or the other Person. Notwithstanding the foregoing, if a Party
seeks to make a disclosure as required by a Securities Regulator or other Person as may be required by Applicable Law as set forth in this Section 14.5 (Securities Filings; Disclosure under Applicable Law) and the other Party provides comments
in accordance with this Section 14.5 (Securities Filings; Disclosure under Applicable Law), the Party seeking to make such disclosure or its counsel, as the case may be, will use good faith efforts to incorporate such comments. 

14.6 Publicity. 
 14.6.1
Press Release; Nurix Obligations. Sanofi agrees that Nurix may issue an individual press release substantially similar to the form of press release set forth in Exhibit E to the Correspondence upon a mutually agreed-upon date
after the Effective Date, but within [*] days thereafter. Nurix shall also have the right disclose via press release Sanofi’s selection of Additional Collaboration Targets (in form reasonably acceptable to Sanofi), provided that Nurix does not
disclose the identity of such Additional Collaboration Targets. Nurix will not make any other press release or other public statement disclosing this Agreement or any Ancillary Agreement, or the activities hereunder or thereunder, or the
Contemplated Transactions, without Sanofi’s prior written consent. The contents of any press release or other public statement that has been reviewed and approved by Sanofi may be re-released by Nurix in
exactly the same language as previously approved by Sanofi without first obtaining Sanofi’s prior written consent in accordance with this Section 14.6.1 (Press Release; Nurix Obligations). 

14.6.2 Sanofi Rights. Sanofi will have the right to issue any press release or other public statement disclosing this Agreement, the
activities under this Agreement or the Contemplated Transactions without first obtaining the prior written consent of Nurix; provided that any such press release or other public statement does not include the Confidential Information of Nurix. 

14.7 Publications. During each Collaboration Target Research Term neither Party will publish, publicly present or otherwise publicly
disclose any paper, publication, oral presentation, abstract, poster, manuscript or other presentation relating to any activity or other matter under this Agreement or any Ancillary Agreement (each, a “Publication”) relating to the
applicable Collaboration Target, without the other Party’s prior written consent. Following the Collaboration Target Research Term for a Collaboration Target, Sanofi shall be responsible for and control all Publications relating to the
applicable Collaboration Target for which Sanofi has paid the License Extension Fee, and Nurix shall have the right to make and disclose any such Publication with the prior written consent of Sanofi. To the extent a Party has a right pursuant to
this Section 14.7 to make a Publication, then the publishing Party (the “Publishing Party”) shall provide the other Party (a “Reviewing Party”) an opportunity to review such Publication to determine whether
such Publication contains the Confidential Information of the Reviewing Party. The Publishing Party will deliver to the Reviewing Party a copy of any such proposed Publication or an outline of the proposed oral disclosure, together with any slides
or other materials to be provided in connection with such oral disclosure (if any), at least [*] days prior to submission for publication or presentation for review by the Reviewing Party. The Reviewing Party will have the right, in its sole
discretion, to: (a) require the removal of its Confidential Information from any such Publication by the Publishing Party or (b) request a reasonable delay in publication or presentation in order to protect patentable information. If the
Reviewing Party requests such a delay, the Publishing Party will delay submission or presentation for a period of [*] days after its provision of the copy of the proposed publication or disclosure to enable patent applications protecting the
Reviewing Party’s rights in such information. 

  
 66 

 14.8 Use of Names. Except as otherwise expressly set forth herein, neither Party (or
any of its respective Affiliates) will use any corporate name, trademark, trade name or logo of the other Party or any of its Affiliates, or its or their respective employees, in any publicity, promotion, news release or other public disclosure
relating to this Agreement or any Ancillary Agreement or its or their subject matter, without first obtaining the prior written consent of the other Party; provided that such consent will not be required (a) to the extent use thereof may be
required by Applicable Law, including the rules of any securities exchange or market on which a Party’s or its Affiliate’s securities are listed or traded, and (b) for Nurix’s use of Sanofi’s name and company logo, in
accordance with written specifications and standards to be provided by Sanofi to Nurix, solely to [*]. If Sanofi at any time determines that the use of Sanofi’s name and company logo for such purpose does not comply with such specifications and
standards provided by Sanofi and so notifies Nurix, then Nurix shall cease using Sanofi’s name and company logo in such unapproved manner as soon as reasonably possible. Each Party shall retain all rights, title and interests in and to all such
corporate names, trademarks, trade names and logos of such Party and its Affiliates. 
 14.9 Clinical Trials Registry. For clarity,
Sanofi, its Affiliates and its designees will have the right to publish registry information and summaries of data and results from any Clinical Trials conducted in connection with Licensed Products, on its Clinical Trials registry or on a
government-sponsored database such as www.clinicaltrials.gov, without first obtaining the prior consent of Nurix. The Parties will reasonably cooperate if required or reasonably requested by Sanofi in order to facilitate any such publication by
Sanofi, any of its Affiliates or any of its designees. 
 ARTICLE 15 

REPRESENTATIONS AND WARRANTIES; CLOSING CONDITIONS; COVENANTS 

15.1 Representations and Warranties of Each Party. Each Party hereby represents and warrants to the other Party, as of the Execution
Date and Effective Date, that: 
 15.1.1 such Party is duly organized, validly existing and in good standing under the Applicable Law of the
jurisdiction of its formation and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as contemplated in this Agreement, including the
full right to grant the licenses and sublicenses granted by it hereunder; 
 15.1.2 such Party has the corporate power and authority and the
legal right to enter into this Agreement and perform its obligations hereunder, and has taken all necessary corporate action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; 

  
 67 

 15.1.3 this Agreement has been duly executed and delivered on behalf of such Party and
constitutes a legal, valid and binding obligation, enforceable against it in accordance with its terms, except to the extent that enforcement of the rights and remedies created hereby is subject to: (a) bankruptcy, insolvency, reorganization,
moratorium and other similar laws of general application affecting the rights and remedies of creditors; or (b) laws governing specific performance, injunctive relief and other equitable remedies; 

15.1.4 the execution, delivery and performance of this Agreement by such Party does not breach, violate, or conflict with any agreement or any
provision thereof (including any confidentiality or non-competition obligation, any exclusivity obligation, or any provisions with respect to the ownership, prosecution and enforcement of intellectual property
rights), or any instrument or understanding, oral or written, to which such Party (or any of its Affiliates) is a party or by which such Party (or any of its Affiliates) is bound, nor violate any Applicable Law of any Governmental Authority having
jurisdiction over such Party (or any of its Affiliates); 
 15.1.5 no government authorization, consent, approval, license, exemption of or
filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any Applicable Law currently in effect, is or will be necessary for, or in connection with, the
Contemplated Transactions, or for the performance by it of its obligations under this Agreement, except as may be required to conduct Clinical Trials or to seek or obtain Regulatory Approvals or applicable Regulatory Materials, or to Manufacture or
Commercialize any Licensed Product(s); or (b) as set forth in ARTICLE 3 (Government Approvals); 
 15.1.6 it has obtained all necessary
authorizations, consents and approvals of any Third Party that is required to be obtained by it for, or in connection with, the Contemplated Transactions, or for the performance by it of its obligations under this Agreement and the Ancillary
Agreements, except: (a) as may be required to conduct Clinical Trials or to seek or obtain Regulatory Approvals or applicable Regulatory Materials, or to Manufacture or Commercialize any Licensed Product(s); or (b) as set forth in ARTICLE
3 (Government Approvals); and 
 15.1.7 (a) Neither it nor any of its Affiliates has been debarred or is subject to debarment pursuant to
Section 306 of the FFDCA or analogous provisions of Applicable Law outside the United States or listed on any excluded list, and (b) neither it nor any of its Affiliates has, to its Knowledge, used in any capacity, in connection with the
activities to be performed under this Agreement, any individual or entity that has been debarred pursuant to Section 306 of the FFDCA or analogous provisions of Applicable Law outside the United States, or that is the subject of a conviction
described in such Section or analogous provisions of Applicable Law outside the United States, or listed on any excluded list. 
 15.2
Representations and Warranties of Nurix. 
 15.2.1 Nurix hereby represents and warrants to Sanofi except as set forth on
Schedule 15.2 (Exceptions to Representations and Warranties of Nurix), as of the Execution Date and Effective Date that: 

(a) Nurix has never had and does not as of such date have any Affiliates; 

  
 68 

 (b) Nurix has the full right and authority to grant all of the rights and
licenses granted to Sanofi hereunder, and neither Nurix nor its Affiliates have granted any right or license, or committed to grant any right or license, to any Third Party relating to any of the Nurix IP that would conflict with or limit the scope
of any of the options, rights or licenses granted to Sanofi hereunder; 
 (c) there are no issued Nurix Patents and Schedule
15.2 sets forth a complete and accurate list of all pending applications included in the Nurix Patents; 
 (d) Nurix is the
sole and exclusive owner of the Background IP that is Controlled by Nurix, free and clear of all liens and encumbrances, and no such Background IP is licensed to Nurix from another Person; 

(e) Nurix has not misappropriated any trade secret or other Know How of a Third Party in connection with developing the Nurix
IP; 
 (f) the pending applications included in the Nurix Patents are being prosecuted in accordance with Applicable Law, and
Nurix has presented all relevant references, documents and information of which it and the inventors are aware to the relevant patent examiners and patent offices that are required to be so submitted under Applicable Law; 

(g) Nurix and its Affiliates have obtained from all individuals who participated in any respect in the invention or authorship
of any Nurix IP effective written assignments of all ownership rights of such individuals in such Nurix IP; and, to the Knowledge of Nurix, no Person who claims to be an inventor of an Invention claimed in a Nurix Patent is not identified as an
inventor of such Invention in the filed patent documents for such Nurix Patent; 
 (h) neither Nurix nor any of its
Affiliates has employed, or otherwise used in any capacity, the services of any Person suspended, proposed for debarment or debarred under United States law, including under 21 U.S.C. § 335a, or any foreign equivalent thereof, with respect to
the performance of activities hereunder; 
 (i) the inventions claimed or covered by the Nurix IP (i) were not
conceived, discovered, developed or otherwise made in connection with any research activities funded, in whole or in part, by the federal government of the United States or any agency thereof; (ii) are not a “subject invention” as
that term is described in 35 U.S.C. §201(e); (iii) are not otherwise subject to the provisions of the Patent and Trademark Law Amendments Act of 1980, as amended, codified at 35 U.S.C.
§§200-212, as amended, or any regulations promulgated pursuant thereto, including in 37 C.F.R. Part 401; and (iv) are not the subject of any licenses, options or other rights of any Governmental
Authority, within or outside the United States; and 
 (j) Nurix has included in the electronic dataroom for this Agreement
information requested by Sanofi in its possession that is material to the Research, Development, Manufacture or Commercialization of Target Binders, CTMs or Licensed Products under this Agreement, and, to the Knowledge of Nurix, such information
does not contain any untrue statement(s) of fact, or omit to state any fact(s), in either case that are collectively material to the Research, Development, Manufacture or Commercialization of Target Binders, CTMs or Licensed Products. 

  
 69 

 15.2.2 Nurix hereby represents and warrants to Sanofi except as set forth on Schedule 15.2
(Exceptions to Representations and Warranties of Nurix), as of the Execution Date that: 
 (a) Nurix has not received any
written notice of a claim or written threat of a claim or litigation made by any Person against Nurix or its Affiliates that alleges that any Nurix IP is invalid or unenforceable; 

(b) To the Knowledge of Nurix, there are no activities by Third Parties within the Territory that would constitute
misappropriation of Nurix Know-How; 
 (c) To the Knowledge of Nurix, the use of the Know-How included within the Background IP that is Controlled by Nurix to conduct Research activities does not infringe the claims of any issued patent of any Third Party; 

(d) neither Nurix nor its Affiliates have received any notice, written or otherwise, of any claim that any Patent or Know-How (including any trade secret right) owned or controlled by a Third Party would be infringed, misappropriated or otherwise violated by the performance of the Research activities hereunder or by the
Development, Manufacture or Commercialization of the Licensed Products in accordance with this Agreement; and 
 (e) there
are no claims, judgments, settlements, litigations, suits, actions, disputes, arbitration, judicial, or legal, administrative or other proceedings, or governmental investigations pending or, to the Knowledge of Nurix, threatened against Nurix or its
Affiliates which could reasonably be expected to adversely affect or restrict the ability of Nurix to consummate or perform the Contemplated Transactions, or which would affect the Nurix IP, Nurix’s Control thereof or the Licensed Products.

 15.3 Representations and Warranties of Sanofi. Sanofi hereby represents and warrants to Nurix, as of the Execution Date and
Effective Date, that: 
 15.3.1 there are no claims, judgments, settlements, litigations, suits, actions, disputes, arbitration, judicial, or
legal, administrative, or other proceedings or governmental investigations pending or, to the Knowledge of Sanofi, threatened against Sanofi which would reasonably be expected to adversely affect or restrict the ability of Sanofi to consummate or
perform the Contemplated Transactions. 

  
 70 

 15.4 Closing Conditions. The obligations of each Party to consummate the Contemplated
Transactions is subject to the fulfillment, or, to the extent permitted by Applicable Law, waiver by such Party, of each of the following conditions (collectively, the “Closing Conditions”): 

15.4.1 The representations and warranties of the other Party contained in this Agreement (i) that are not qualified by materiality,
material adverse effect, substantial compliance or similar materiality qualifier will be true and correct in all material respects both when made and at the closing with the same force and effect as if made on the Effective Date and (ii) that
are qualified by materiality, material adverse effect, substantial compliance or similar materiality qualifier will be true and correct in all respects both when made and at the closing with the same force and effect as if made on the Effective
Date, except, in each of (i) and (ii) as would not reasonably be expected, individually or in the aggregate, to have a material impact on the transaction contemplated by this Agreement;

15.4.2 All actions by (including any authorization, consent or approval), in respect of (including notice to), or filings with, any
Governmental Authority or other Person that are required to be obtained pursuant to Section 3.2 (Filings) to consummate the Contemplated Transactions (including any HSR/Antitrust Filing) will have been obtained or made, in a manner reasonably
satisfactory in form and substance to such Party, and no such authorization, consent or approval will have been revoked; 
 15.4.3 No
Material Adverse Event shall have occurred or arisen since the Execution Date; 
 15.4.4 As of the Effective Date, [*]; and 

15.4.5 As of the Effective Date, [*]. 

15.5 Mutual Covenants. Each Party hereby covenants to the other Party that during the Term: (a) such Party and its Affiliates will
perform its activities pursuant to this Agreement and each Ancillary Agreement in compliance (and will ensure compliance by any of its subcontractors) with all Applicable Law, including, to the extent applicable, FCPA, GCP, GLP and GMP and in
accordance with good scientific, clinical and manufacturing practices and applicable industry ethical codes; (b) will not employ, or otherwise use in any capacity, the services of any Person suspended, proposed for debarment or debarred under
United States law, including under 21 U.S.C. § 335a, or any foreign equivalent thereof, with respect to the performance of activities hereunder; (c) such Party will not enter into any agreement, contract, commitment or other arrangement
that could reasonably be expected to conflict with the rights granted to the other Party hereunder or under any Ancillary Agreement or otherwise prevent the other Party from exercising the rights granted to it hereunder or under any Ancillary
Agreement; (d) such Party will not misappropriate any trade secret of a Third Party in connection with the performance of its activities hereunder or under any Ancillary Agreement; and (e) such Party will maintain all permits, licenses,
registrations and other forms of authorizations and approvals from any Governmental Authority, necessary or required to be obtained or maintained by such Party in order for such Party to execute and deliver this Agreement or any Ancillary Agreement
and to perform its obligations hereunder and thereunder in a manner which complies with all Applicable Law. 
 15.6 FCPA Matters.
Each Party hereby covenants to the other Party that during the Term: 
 15.6.1 It is familiar with the provisions and restrictions contained
in the OECD Convention and FCPA and it has adopted and maintains an FCPA policy; and 

  
 71 

 15.6.2 Its and its Affiliates’ employees will not, and it will use reasonable efforts
to cause its contracts to not, in connection with the performance of their respective obligations under this Agreement, directly or indirectly through Third Parties, pay, promise or offer to pay, or authorize the payment of, any money or give any
promise or offer to give, or authorize the giving of anything of value to a Public Official or Entity or other Person for purpose of improperly obtaining or retaining business for or with, or directing business to, any Person, including either Party
(it being understood that such Party, and to its Knowledge, its and its Affiliates’ employees and contractors, has not directly or indirectly promised, offered or provided any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift
or hospitality or other illegal or unethical benefit to a Public Official or Entity or any other person in connection with the performance of such Party’s obligations under this Agreement, and will not, directly or indirectly, engage in any of
the foregoing). 
 15.7 Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT OR ANY ANCILLARY AGREEMENT, NEITHER
PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED (AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES NOT EXPRESSLY PROVIDED IN THIS AGREEMENT OR ANY ANCILLARY
AGREEMENT), INCLUDING WITH RESPECT TO ANY PATENTS OR KNOW-HOW, INCLUDING WARRANTIES OF VALIDITY OR ENFORCEABILITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR USE OR PURPOSE, PERFORMANCE AND NON-INFRINGEMENT OF ANY THIRD PARTY PATENT OR OTHER INTELLECTUAL PROPERTY RIGHT. WITHOUT LIMITING THE FOREGOING, THE PARTIES AGREE THAT THE MILESTONE EVENTS, SALES MILESTONE EVENTS AND NET SALES LEVELS SET FORTH IN
THIS AGREEMENT OR THAT HAVE OTHERWISE BEEN DISCUSSED BY THE PARTIES ARE MERELY INTENDED TO DEFINE THE MILESTONE PAYMENTS, SALES MILESTONE PAYMENTS AND ROYALTY OBLIGATIONS IF SUCH MILESTONE EVENTS, SALES MILESTONE EVENTS OR NET SALES LEVELS ARE
ACHIEVED. NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY ADVANCE ANY LICENSED PRODUCT OR DEVELOP, ACHIEVE REGULATORY APPROVAL FOR, MANUFACTURE OR COMMERCIALIZE ANY LICENSED PRODUCT
OR, IF COMMERCIALIZED, THAT ANY PARTICULAR SALES LEVEL OR PROFIT OF SUCH LICENSED PRODUCT WILL BE ACHIEVED. 
 ARTICLE 16 

INDEMNIFICATION; INSURANCE 

16.1 Indemnification. 

16.1.1 Indemnification by Sanofi. Sanofi will indemnify, defend and hold harmless Nurix, its Affiliates and its and their respective
directors, officers, employees, agents, successors and assigns (each, a “Nurix Indemnitee”) from and against any and all Damages to the extent arising out of or relating to, directly or indirectly, any Third Party Claim based
upon: 
 (a) (i) any Research activities conducted by Sanofi or its Affiliates or contractors and (ii) any Research
activities conducted by Nurix or its Affiliates or contractors using any materials (including any [*]) provided by Sanofi under a Material Transfer Agreement executed by the Parties, to the extent such Research activities are permitted in accordance
with such Material Transfer Agreement; 

  
 72 

 (b) the Development, Manufacture or Commercialization of Licensed Products
in the Field in the Territory by Sanofi, its Affiliates or its Sublicensees, including pursuant to the Co-Development/Co-Commercialization Documentation (if executed and
to the extent indemnification for such activities is not covered under the Co-Development/Co-Commercialization Documentation); 

(c) the gross negligence, recklessness or willful misconduct of Sanofi or its Affiliates or its or their respective directors,
officers, employees or agents, in connection with Sanofi’s performance of its obligations under this Agreement or any Ancillary Agreement; or 

(d) any breach by Sanofi of any of its representations, warranties, covenants, agreements or obligations under this Agreement
or any Ancillary Agreement; 
 provided, however, that, in each case ((a)-(d)), such indemnity will not apply to the extent Nurix has an indemnification
obligation pursuant to Section 16.1.2 (Indemnification by Nurix) for such Damages. 
 16.1.2 Indemnification by Nurix.
Nurix will indemnify, defend and hold harmless Sanofi, its Affiliates and its and their respective directors, officers, employees, agents, successors, assigns and Sublicensees (each, a “Sanofi Indemnitee”), from and against any and
all Damages to the extent arising out of or relating to, directly or indirectly, any Third Party Claim based upon: 
 (a) any
Research or Manufacture activities conducted by Nurix or its Affiliates, contractors or licensees hereunder, other than any Research activities conducted by Nurix or its Affiliates or contractors using any materials (including any [*]) provided by
Sanofi under a Material Transfer Agreement executed by the Parties, to the extent such Research activities are permitted in accordance with such Material Transfer Agreement; 

(b) any Development, Manufacture or Commercialization activities conducted by Nurix or its Affiliates, contractors or licensees
pursuant to the Co-Development/Co-Commercialization Documentation (if executed and to the extent indemnification for such activities is not covered under the Co-Development/Co-Commercialization Documentation); 

(c) the gross negligence, recklessness or willful misconduct of Nurix or its Affiliates or its or their respective directors,
officers, employees or agents, in connection with Nurix’s performance of its obligations under this Agreement or any Ancillary Agreement; or 

(d) any breach by Nurix of any of its representations, warranties, covenants, agreements or obligations under this Agreement or
any Ancillary Agreement; 
 provided, however, that, in each case ((a)-(c)), such indemnity will not apply to the extent Sanofi has an indemnification
obligation pursuant to Section 16.1.1 (Indemnification by Sanofi) for such Damages. 

  
 73 

 16.2 Procedure. 

16.2.1 Notice. If a Nurix Indemnitee or Sanofi Indemnitee is seeking indemnification under Section 16.1.1 (Indemnification by
Sanofi) or Section 16.1.2 (Indemnification by Nurix), as applicable (the “Indemnitee”), it will inform the other Party (the “Indemnitor”) of the claim giving rise to the obligation to indemnify pursuant to
Section 16.1.1 (Indemnification by Sanofi) or Section 16.1.2 (Indemnification by Nurix), as applicable, as soon as reasonably practicable after receiving notice of the claim (an “Indemnification Claim Notice”); provided
that any delay or failure to provide such notice will not constitute a waiver or release of, or otherwise limit, the Indemnitee’s rights to indemnification under Section 16.1.1 (Indemnification by Sanofi) or Section 16.1.2
(Indemnification by Nurix), as applicable, except to the extent that such delay or failure materially prejudices the Indemnitor’s ability to defend against the relevant claims. 

16.2.2 Control of Defense. The Indemnitor will have the right, upon written notice given to the Indemnitee within [*] days after
receipt of the Indemnification Claim Notice (and, where the Indemnitor is Nurix, subject to receipt of Sanofi’s prior written consent), to assume the defense of any such claim for which the Indemnitee is seeking indemnification pursuant to
Section 16.1.1 (Indemnification by Sanofi) or Section 16.1.2 (Indemnification by Nurix), as applicable. The Indemnitee will cooperate with the Indemnitor and the Indemnitor’s insurer as the Indemnitor may reasonably request, and at
the Indemnitor’s cost and expense. The Indemnitee will have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the Indemnitor. 

16.2.3 Settlements; No Presumption of Liability. The Indemnitor will not settle any claim without first obtaining the prior written
consent of the Indemnitee, not to be unreasonably withheld, conditioned or delayed. The assumption of the defense of a claim by the Indemnitor will not be construed as an acknowledgment that the Indemnitor is liable to indemnify the Indemnitee in
respect of the claim, nor will it constitute a waiver by the Indemnitor of any defenses it may assert against the Indemnitee’s claim for indemnification. In the event that it is ultimately determined that the Indemnitor is not obligated to
indemnify, defend or hold harmless the Indemnitee from and against the claim, the Indemnitee will reimburse the Indemnitor for any and all costs and expenses (including attorneys’ fees and costs of suit) and any Damages incurred by the
Indemnitor in its defense of the claim. 
 16.2.4 Separate Defenses; Cooperation. If the Parties cannot agree as to the application
of Section 16.1.1 (Indemnification by Sanofi) or Section 16.1.2 (Indemnification by Nurix), as applicable, to any claim, pending the resolution of the Dispute pursuant to Section 18.6 (Choice of Law; Dispute Resolution), the Parties
may conduct separate defenses of such claims, with each Party retaining the right to claim indemnification from the other Party in accordance with Section 16.1.1 (Indemnification by Sanofi) or Section 16.1.2 (Indemnification by Nurix), as
applicable, upon resolution of the underlying claim. In each case, the Indemnitee will reasonably cooperate with the Indemnitor and will make available to the Indemnitor all pertinent information under the control of the Indemnitee, which
information will be subject to ARTICLE 14 (Confidentiality). 

  
 74 

 16.3 Insurance. 

16.3.1 Insurance Maintained by Each Party. During the Term and for a period of [*] thereafter, each Party will have and maintain in
full force and effect, at its own expense, insurance coverage (with a Third Party insurance company with a current AM Best rating of A- or equivalent or higher, or solely with respect to Sanofi through a
program of self-insurance) to include: 
 (a) Commercial general liability insurance (including product liability coverage
and completed operations liability coverage and covering bodily injury and property damage) with limits of liability not less than [*]; 

(b) Statutory workers’ compensation insurance in compliance with Applicable Law (including the local law requirements of
the state or jurisdiction in which the work is to be performed); 
 (c) Employer’s liability insurance with limits of
liability not less than [*]; and 
 (d) Umbrella/excess liability insurance providing additional limits above the commercial
general liability insurance policy with limits of liability not less than [*]. 
 For the avoidance of doubt, none of the coverage under this section shall
serve to limit or expand the Parties’ indemnification obligations or other liability under this Agreement. As of the Effective Date and upon each anniversary thereof, each Party shall furnish one or more certificates, from its brokers
evidencing that the coverage required by this Section 16.3 is in full force and effect in compliance with the provisions of this Section 16.3. Each such certificate shall state the relevant policy number(s), date(s) of expiration and
required limits of coverage. In addition, Nurix shall provide Sanofi with written notice at least [*] days prior to the cancellation or non-renewal of, or material changes to, such insurance coverage. 

16.4 Limitation of Liability. NEITHER NURIX NOR SANOFI, NOR ANY OF THEIR RESPECTIVE AFFILIATES, WILL BE LIABLE TO THE OTHER PARTY OR
ITS AFFILIATES UNDER OR IN CONNECTION WITH THIS AGREEMENT OR ANY ANCILLARY AGREEMENT FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING LOST PROFITS OR LOST REVENUES), WHETHER LIABILITY IS ASSERTED IN
CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT PRODUCT LIABILITY), INDEMNITY, CONTRIBUTION OR OTHERWISE, AND IRRESPECTIVE OF WHETHER THAT PARTY OR ANY REPRESENTATIVE OF THAT PARTY HAS BEEN ADVISED OF, OR OTHERWISE MIGHT HAVE ANTICIPATED THE
POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 16.4 (LIMITATION OF LIABILITY) IS INTENDED TO OR WILL LIMIT OR RESTRICT: (A) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION

  
 75 

 
16.1.1 (INDEMNIFICATION BY SANOFI) OR SECTION 16.1.2 (INDEMNIFICATION BY NURIX), AS APPLICABLE, IN CONNECTION WITH ANY THIRD PARTY CLAIMS; (B) THE LIABILITY OF NURIX FOR BREACH OF ITS
EXCLUSIVITY OBLIGATIONS UNDER SECTION 2.10 (EXCLUSIVITY); (C) DAMAGES AVAILABLE FOR A PARTY’S GROSS NEGLIGENCE, RECKLESSNESS, INTENTIONAL MISCONDUCT OR FRAUD; OR (D) LIABILITY OF EITHER PARTY FOR BREACH OF ARTICLE 14
(CONFIDENTIALITY). 
 ARTICLE 17 

TERM AND TERMINATION 
 17.1
Term; Expiration. The term of this Agreement (the “Term”) will commence on the Effective Date and (subject to earlier termination in accordance with Section 17.2 (Termination for Material Breach), Section 17.3
(Termination at Will), Section 17.4 (Termination for Bankruptcy), Section 17.5 (Termination by Sanofi for Safety) or Section 17.6 (Termination by Sanofi for a Change of Control of Nurix)) will expire, on a Licensed Product-by-Licensed Product and country-by-country basis, on the expiration of the Royalty Term
for such Licensed Product in such country; provided that (a) if Nurix exercises its Co-Development/Co-Promotion Option with respect to a Collaboration Target, the
term with respect to each Profit/Loss Share Product for such Collaboration Target in the U.S. shall be the Profit/Loss Share Term for such Profit/Loss Share Product, (b) if no License Term Extension for any Collaboration Target has occurred by
the last day of the last-to-expire License Extension Fee Timeframe, this Agreement will expire on the last day of the last-to-expire License Extension Fee Timeframe, and (c) if the Effective Date does not occur prior to the Outside Date and either Party terminates this Agreement in accordance with Section 3.2
(Filings). Upon the expiration of the Royalty Term or Profit/Loss Share Term, as applicable, with respect to a Licensed Product or Profit/Loss Share Product, as applicable, in a country, the Collaboration License for such Licensed Product or
Profit/Loss Share Product as set forth in Section 12.1.2 (Collaboration License to Sanofi for Licensed Products) will become fully paid-up, irrevocable, perpetual and royalty-free in such country. 

17.2 Termination for Material Breach. 

17.2.1 Material Breach. This Agreement may be terminated in its entirety or in part on a Collaboration
Target-by-Collaboration Target or Licensed Product-by-Licensed Product basis for a
material breach by the other Party upon written notice to the breaching Party if the breaching Party has not cured such material breach within [*] after the date of written notice to the breaching Party of such breach (which notice will describe
such material breach in reasonable detail and will state the non-breaching Party’s intention to terminate this Agreement, in its entirety or in part) (such [*] period the “Cure Period”).

 17.2.2 Disagreement as to Material Breach. Notwithstanding Section 17.2.1 (Material Breach), if the Parties in good faith
disagree as to whether there has been a material breach of this Agreement, then: (a) the Party that disputes whether there has been a material breach may contest the allegation by referring such matter, within [*] following its receipt of
notice of the alleged material breach, for resolution in accordance with Section 18.6 (Choice of Law; Dispute Resolution); (b) the relevant Cure Period with respect to such alleged material breach will be tolled from the date on which the Party
that disputes whether there has been a material breach notifies the other Party of such Dispute and through the resolution of such Dispute in accordance with the applicable provisions of this Agreement; and (c) subject to Section 17.8
(Surviving Provisions), during the pendency of such Dispute, all of the terms and conditions of this Agreement will remain in effect and the Parties will continue to perform all of their respective obligations hereunder. 

  
 76 

 17.3 Termination at Will. Sanofi may terminate this Agreement at will, in its sole
discretion, in its entirety or in part on a Collaboration Target-by-Collaboration Target basis or Licensed Product-by-Licensed Product basis, (a) prior to the expiration of the License Extension Fee Timeframe for such Collaboration Target or Licensed Product, upon delivery of [*] prior written notice to
Nurix, and (b) after the expiration of the License Extension Fee Timeframe for such Collaboration Target or Licensed Product, upon delivery of [*] prior written notice to Nurix. If a Milestone Event or Sales Milestone Event is achieved during
the notice periods specified above, Sanofi shall have no obligation to make the associated Milestone Payment or Sales Milestone Payment to Nurix. 

17.4 Termination for Bankruptcy. 

17.4.1 Termination Right. In the event that either Party (a) files for protection under the United States Bankruptcy Code (the
“Code”) or any similar bankruptcy or insolvency law foreign or domestic, (b) makes an assignment for the benefit of, or an arrangement or composition generally with, its creditors, (c) appoints an examiner or of a receiver
or trustee over all or substantially all of its property or suffers the appointment of such party that is not discharged within [*] days after such filing or appointment, (d) proposes a written agreement of composition or extension of its
debts, (e) proposes or is a party to any dissolution, liquidation or winding up, (f) has a petition filed against it under the Code or any similar bankruptcy or insolvency law that is not discharged or dismissed within [*] of the filing
thereof, or (g) admits in writing its inability generally to meet its obligations as they fall due in the ordinary course, then the other Party may terminate this Agreement in its entirety effective immediately upon writing notice to such
Party. 
 17.4.2 Section 365(n) Rights. For purposes of Section 365(n) of the Code and any similar law, foreign or domestic, all
rights and licenses granted under or pursuant to any Section of this Agreement are rights to “intellectual property” (as defined in Section 101(35A) of the Code). The Parties agree that the licensee of such rights under this Agreement
will retain and may fully exercise all of its protections, rights and elections under the Code and any similar laws in any other country. Each Party hereby acknowledges that copies of research data, laboratory samples, product samples and inventory,
formulas, laboratory notes and notebooks, pre-clinical research data and results, tangible Know-How and rights of reference, in each case that relate to such
intellectual property, constitute “embodiments” of such intellectual property pursuant to Section 365(n) of the Code, and that the licensee will be entitled to a complete duplicate of (or complete access to, as appropriate) any such
intellectual property and all embodiments of such intellectual property, and the same, if not already in its possession, will be promptly delivered to it upon its written request therefor and election under Bankruptcy Code Section 365(n)(1)(B)
to retain the licenses granted hereunder. The provisions of this Section 17.4.2 (Section 365(n) Rights) are without prejudice to any rights the non-subject Party may have arising under the Code, laws of
other jurisdictions governing insolvency and bankruptcy or other Applicable Law. The Parties agree that they intend the following rights to extend to the maximum extent permitted by law, including for purposes of the Code and any similar laws in any
other country: (x) the right of access to any intellectual property (including all embodiments thereof) of the licensor, or any Third Party 

  
 77 

 
with whom the licensor contracts to perform an obligation of such licensor under this Agreement which is necessary for the Development, Manufacture or Commercialization of a Licensed Product;
(y) the right to contract directly with any Third Party described in (x) to complete the contracted work and (z) the right to cure any breach of or default under any such agreement with a Third Party and set off the costs thereof
against amounts payable to such licensor under this Agreement. 
 17.5 Termination by Sanofi for Safety. Sanofi will have the right
to terminate this Agreement in its entirety or in part on a Collaboration Target-by-Collaboration Target or Licensed Product-by-Licensed Product basis, upon [*] prior written notice to Nurix, due to safety concerns raised by a Regulatory Authority, an Institutional Review Board for a Clinical Trial or by Sanofi’s
internal regulatory decision makers acting in accordance with Sanofi’s standard internal policies, where such Person recommends cessation of Development or Commercialization of the applicable Licensed Product(s) (and a summary of such concerns
will be stated in the notice of termination). 
 17.6 Termination by Sanofi for a Change of Control of Nurix. Nurix will
notify Sanofi in writing as soon as possible after Nurix announces publicly any information regarding any proposed Change of Control of Nurix (or if the Change of Control will not be publicly announced, then no later than one Business Day after the
closing of the Change of Control transaction). Sanofi will have the option to either (A) terminate this Agreement in its entirety upon written notice to Nurix provided to Nurix within [*] of the effective date of such Change of Control; or
(B) in the case of a Change of Control involving an Acquiring Entity of Nurix that is a Major Biopharmaceutical Company, then, on a Collaboration
Target-by-Collaboration Target basis: 
 17.6.1 Sanofi shall
have the right to terminate Nurix’s participation in all Development, Manufacturing and Commercialization activities under this Agreement or any Ancillary Agreement (but, for the avoidance of doubt, not this Agreement in its entirety and not
Research activities) as further set forth below in Section 17.7.5 (Effect of Termination by Sanofi of Nurix Participation in Research, Development, Manufacturing or Commercialization Activities for Change of Control of Nurix) by delivery of
written notice to Nurix within [*] of the effective date of such Change of Control; or 
 17.6.2 Sanofi shall have the right to terminate
Nurix’s participation in all Research, Development, Manufacturing and Commercialization activities under this Agreement or any Ancillary Agreement (but, for the avoidance of doubt, not this Agreement in its entirety) as further set forth below
in Section 17.7.5 (Effect of Termination by Sanofi of Nurix Participation in Research, Development, Manufacturing or Commercialization Activities for Change of Control of Nurix) only if [*] by delivery of written notice to Nurix within [*] of
the effective date of such Change of Control. In such case (i) Nurix shall deliver a Nurix Key Data Report to Sanofi for such Collaboration Target within [*] of such termination of Nurix’ participation, and (ii) all subsequent
payments to Nurix under Sections 11.4 (License Extension Fee), 11.5 (Milestones), 11.6 (Sales Milestones) and 11.7 (Royalties) shall be [*] with respect to such Collaboration Target. 

  
 78 

 17.7 Effects of Expiration and Termination. 

17.7.1 General. Upon any expiration or termination of this Agreement with respect to any particular Collaboration Target or Licensed
Product, all rights and obligations of the Parties under this Agreement with respect to such Collaboration Target or Licensed Product (including any licenses granted by a Party hereunder except as necessary for the other Party to perform its
surviving obligations (including as described in Section 17.7.2 (Reversion)) shall cease except as otherwise set forth in this Section 17.7 or elsewhere in this Agreement, but, for clarity, such termination or expiration shall not affect
the Parties’ rights and obligations under this Agreement with respect to the other Collaboration Targets or Licensed Products then in effect. 

17.7.2 Reversion. Sanofi hereby grants to Nurix [*] license, under [*] to Develop, Manufacture and Commercialize all Reverted Products
in the Field in each applicable country in the Territory, subject to Nurix’s obligations under Section 2.10.1 (Target Exclusivity). Nurix will only exercise its rights under the foregoing license with respect to Reverted Products in
existence as of the expiration date of the applicable Collaboration License. For clarity, Sanofi shall retain right to use all such intellectual property rights, Patents or Know-How owned or Controlled by
Sanofi for any purpose other than with respect to a Reverted Product. Nurix shall have the right to terminate all or any portion of the rights granted to it under this 17.7.2 (Reversion), upon written notice to Sanofi. Subject to the previous
sentence, Nurix shall pay to Sanofi royalties on Annual Net Sales (as such term is applied mutatis mutandis to Nurix and its Affiliates and sublicensees) of Reverted Products to the extent Covered by [*], on a Reverted Product-by-Reverted Product basis, until the expiration of the applicable Post-Termination Royalty Term at [*]. 

17.7.3 Termination by Sanofi at Will or for a Change of Control of Nurix, or by Nurix for material breach or
Bankruptcy. Upon termination of this Agreement with respect to a Terminated Target or Terminated Licensed Product or in its entirety (as applicable): (i) by Sanofi, in accordance with Section 17.3 (Termination at Will) or
Section 17.6(A) (Termination by Sanofi for Change of Control of Nurix); or (ii) by Nurix, in accordance with Section 17.2 (Termination for Material Breach) or Section 17.4 (Termination for Bankruptcy): 

(a) the Collaboration License granted by Nurix to Sanofi pursuant to Section 12.1.2 (License to Sanofi for Licensed
Products) with respect to the applicable Terminated Licensed Product and/or Terminated Target will terminate and Sanofi will not have any rights to use or exercise any rights under the Nurix IP with respect to such Terminated Licensed Product or
Terminated Target, as applicable; 
 (b) Sanofi will, commencing with the date such termination becomes effective, have no
further obligations under this Agreement except as expressly set forth in this Section 17.7.3; 
 (c) Sanofi hereby
grants to Nurix [*] license, under [*] to Develop, Manufacture and Commercialize all Terminated Licensed Products in the Field in each applicable country in the Territory, subject to Nurix’s obligations under Section 2.10.1 (Target
Exclusivity). Nurix will only exercise its rights under the foregoing license with respect to Terminated Licensed Products in existence as of the effective date of such termination. For clarity, Sanofi shall retain right to use all such
intellectual property rights, Patents or Know-How owned or Controlled by Sanofi for any purpose other than with respect to a Terminated Licensed Product. Nurix shall have the right to terminate all or any
portion of the rights granted to it under this subsection (c), upon written notice to Sanofi. Subject to the previous sentence Nurix shall pay to Sanofi royalties on Annual Net 

  
 79 

 
Sales (as such term is applied mutatis mutandis to Nurix and its Affiliates and sublicensees) of Terminated Licensed Products to the extent Covered by [*], on a Terminated Licensed Product-by-Terminated Licensed Product basis, until the expiration of the applicable Post-Termination Royalty Term at the following rates: (i) if such termination has
taken effect prior to [*] then [*], (ii) if such termination has taken effect after [*], then [*], (iii) if such termination has taken effect after [*], then [*], and (iv) if such termination has taken effect after [*], then [*]; 

(d) Sanofi shall, to the extent Sanofi has the right to do so and Controlled by Sanofi and subject to the confidentiality
provisions of this Agreement, transfer to Nurix all Regulatory Filings and Regulatory Approvals, all final (or drafts, if final reports are not available) nonclinical and clinical study reports and clinical study protocols, Trademarks, Know-How, and a copy of all clinical study data generated under this Agreement, including materials and information, in Sanofi’s possession and Control related to each Licensed Product in the Territory;
provided, however, that Sanofi will (X) be entitled, to redact or withhold such information or materials to the extent that (i) they relate to products or programs of Sanofi other than the Licensed Products and are proprietary or sensitive
based on Sanofi’s reasonable belief and assessment thereof, and (ii) Sanofi grants Nurix a right of reference to Regulatory Filings and Regulatory Approvals Controlled by Sanofi that contain such redacted or withheld information or
materials, and (Y) not be required to provide or transfer ownership, as applicable, to Nurix of any (I) raw data or assays (in vivo or in vitro), (II) methods, protocols, or information that would enable Nurix to reverse engineer any
Sanofi methods or protocols, or (III) any information and documentation with respect to device technology or other active ingredients (in the case of a Combination Product), which may in all cases ((I) to (III)) be redacted or withheld, as
applicable; 
 (e) Sanofi shall assign all clinical trial agreements that are assignable to Nurix by Sanofi, [*]; 

(f) Sanofi shall assign and hereby assigns to Nurix all of Sanofi’s right, title and interest in, to and under the
Licensed Product Marks, provided that such Licensed Product Marks do not contain the business entity names of Sanofi or its Affiliates or variations thereof; 

(g) Nurix shall, upon transfer, have the right to disclose such Regulatory Filings, Regulatory Approvals and clinical study
data to (a) Governmental Authorities to the extent required or desirable to secure government Regulatory Approval for the Development, Manufacture or sale of Licensed Product(s); (b) Third Parties acting on behalf of Nurix, its Affiliates,
licensees or sublicensees for the Development, Manufacture, or sale of Licensed Product(s), or (c) Third Parties to the extent reasonably necessary to market Licensed Product(s); and 

(h) upon written request from Nurix to Sanofi provided within [*] days of the effective date of termination, the Parties will
enter into good faith negotiations for up to [*] for a definitive transition services agreement regarding the following matters: (i) the transfer (at [*] sole cost and expense) or wind-down (at [*] cost and expense if [*]) of

  
 80 

 
Clinical Trials; (ii) the continued Commercialization of Licensed Products for an agreed transition period, (including, [*]); (iii) at Nurix’s sole cost and expense, technology transfer
to enable Nurix to [*]; (iv) at Nurix’s sole cost and expense, the transfer of applicable inventory; (v) at Nurix’s sole cost and expense, the transfer of applicable Regulatory Materials; (vi) the treatment of Research Results;
and (vii) any other transition or assistance mutually agreed upon by the Parties and compensation to Sanofi for providing any such transition or assistance to Nurix (collectively, each, a “Licensed Product Transition
Agreement”). 
 17.7.4 Termination by Sanofi for Material Breach or Bankruptcy. Upon termination of this Agreement with
respect to a Terminated Target or Terminated Licensed Product or in its entirety (as applicable) by Sanofi in accordance with Section 17.2 (Termination for Material Breach) or Section 17.4 (Termination for Bankruptcy): 

(a) At Sanofi’s option following written notice provided to Nurix, the Collaboration License(s) granted to Sanofi under
Section 12.1.2 (Collaboration License to Sanofi for Licensed Products) with respect to such Terminated Licensed Products(s) and/or Terminated Target(s) shall continue in full force and effect and, if Sanofi provides such written notice to
Nurix, as Sanofi’s sole and exclusive remedy, Sanofi will be released from all of its obligations under the Agreement, including its payment obligations under ARTICLE 11 (Financial Terms), except that Sanofi shall be required to pay royalties
to Nurix for such Terminated Licensed Product(s) on the terms set forth in Section 11.7 (Royalties) but the rates set forth in Section 11.7.1 (General) shall be [*]. 

17.7.5 Effect of Termination by Sanofi of Nurix Participation in Research, Development, Manufacturing or
Commercialization Activities for Change of Control of Nurix. Upon termination of any Research, Development, Manufacturing or Commercialization activities of Nurix by Sanofi pursuant to Section 17.6(B)(ii) (Termination by Sanofi for
Change of Control of Nurix) in the case of an Acquiror of Nurix that is a Major Biopharmaceutical Company, Nurix, at Nurix’s sole cost and expense, will (1) provide Sanofi with copies of [*], (2) provide Sanofi with all deliverables from
[*], and related materials and inventory in Nurix’s possession or Control, and (3) otherwise provide Sanofi reasonable assistance in transitioning Nurix’s activities under the Agreement or any Ancillary Agreement from Nurix to Sanofi
or Sanofi’s designee. Furthermore, in such case, all Committees shall disband as of the effective date of such termination. 
 17.8
Surviving Provisions. 
 17.8.1 Accrued Rights; Remedies. The expiration or termination of this Agreement for any reason will
be without prejudice to any rights that will have accrued to the benefit of any Party prior to such expiration or termination, and any and all damages or remedies (whether at law or in equity) arising from any breach hereunder, each of which will
survive expiration or termination of this Agreement. Such expiration or termination will not relieve any Party from obligations that are expressly indicated to survive expiration or termination of this Agreement. Except as otherwise expressly set
forth in this Agreement, the termination provisions of this Article are in addition to any other relief and remedies available to either Party under this Agreement, at law or in equity. 

  
 81 

 17.8.2 Survival. Without limiting the provisions of Section 17.8.1 (Accrued
Rights; Remedies), the rights and obligations of the Parties set forth in the following Sections and Articles of this Agreement will survive the expiration or termination of this Agreement, in addition to those other terms and conditions that are
expressly stated to survive termination or expiration of this Agreement: ARTICLE 1 (Definitions) (to the extent the definitions are used in other surviving provisions), Section 2.9.5 (Records Retention), ARTICLE 11 (Financial Terms)
(solely to the extent that any payment accrued prior to expiration or termination of this Agreement (other than a Milestone Payment or Sales Milestone Payment for which no payment is due as expressly provided in Section 17.3 (Termination at
Will)), Section 12.6 (No Implied Licenses), Section 13.1 (Ownership), ARTICLE 14 (Confidentiality), Section 16.1 (Indemnification), Section 16.2 (Procedure), Section 16.3 (Insurance) (for the time period expressly set
forth therein), Section 16.4 (Limitation of Liability), Section 17.1 (Term; Expiration), Section 17.4.2 (Section 365(n) Rights), Section 17.5 (Effects of Termination), Section 17.8.2 (Survival) and ARTICLE 18
(Miscellaneous). 
 ARTICLE 18 

MISCELLANEOUS 
 18.1
Severability. If one (1) or more of the terms or provisions of this Agreement is held by a court of competent jurisdiction to be void, invalid or unenforceable in any situation in any jurisdiction, such holding will not affect the
validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the void, invalid or unenforceable term or provision in any other situation or in any other jurisdiction, and the term or provision will be
considered severed from this Agreement solely for such situation and solely in such jurisdiction, unless the void, invalid or unenforceable term or provision is of such essential importance to this Agreement that it is to be reasonably assumed that
the Parties would not have entered into this Agreement without the void, invalid or unenforceable term or provision. If the final judgment of such court declares that any term or provision hereof is void, invalid or unenforceable, the Parties agree
to: (a) reduce the scope, duration, area or applicability of the term or provision or to delete specific words or phrases to the minimum extent necessary to cause such term or provision as so reduced or amended to be enforceable; and
(b) make a good faith effort to replace any void, invalid or unenforceable term or provision with a valid and enforceable term or provision such that the objectives contemplated by the Parties when entering this Agreement may be realized. 

18.2 Notices. Any notice required or permitted to be given by this Agreement will be in writing and in English and will be:
(a) delivered by hand or by overnight courier with tracking capabilities; (b) mailed postage prepaid by first class, registered or certified mail; or (c) delivered by facsimile followed by delivery via either of the methods set forth
in Section 18.2(a) (Notices) or Section 18.2(b) (Notices), in each case, addressed as set forth below unless changed by notice so given: 

If to Sanofi: 

Sanofi – Global Business Development & Licensing 

50 Binney Street 

Cambridge, MA 02142 

[*] 

  
 82 

 With copies to: 

Sanofi – Legal Global Functions 

50 Binney Street 

Cambridge, MA 02142 

[*] 

-and- 

Sanofi – Global Alliance Management 

[*] 
 If to
Nurix: 
 Nurix Therapeutics, Inc. 

1700 Owens Street 

Suite 205 

San Francisco, CA 94158 

Attention: Legal Department 

With copies to: 

Sidley Austin LLP 

555 California Street, Suite 2000 

San Francisco, California 94104 

Attention: [*] 
 Any such notice
will be deemed given on the date received, except any notice received after 5:30 p.m. (in the time zone of the receiving Party) on a Business Day or received on a non-Business Day will be deemed to have
been received on the next Business Day. A Party may add, delete or change the person or address to which notices should be sent at any time upon written notice delivered to the other Parties in accordance with this Section 18.2 (Notices). 

18.3 Force Majeure. A Party will not be liable for delay or failure in the performance of any of its obligations hereunder if such
delay or failure is due to a cause beyond the reasonable control of such Party, including acts of God, fires, earthquakes, acts of war, terrorism, civil unrest, hurricane or other inclement weather, embargoes, shortages, epidemics, quarantines,
strikes, lockouts or other labor disturbances (whether involving the workforce of the non-performing Party or of any other Person), or acts, omissions or delays in acting by any Governmental Authority (except
to the extent such omission or delay results from the breach by the non-performing Party or any of its Affiliates of its or their Research, Development, Manufacturing or Commercialization obligations or any
other term or condition of this Agreement); provided that: (a) the affected Party promptly notifies the other Party (but no later than [*] calendar days after such occurrence and stating the nature of the event, its anticipated duration and any
action being taken to avoid or minimize the effect); (b) the affected Party will use its Commercially Reasonable Efforts to avoid 

  
 83 

 
or remove such causes of non-performance and to mitigate the effect of such occurrence, and will continue performance in accordance with the terms of this
Agreement whenever such causes are removed and (c) the suspension of performance by the affected Party will be of no greater scope and no longer duration than is necessary under the circumstances. When such circumstances arise, the Parties will
negotiate in good faith any modifications of the terms of this Agreement that may be necessary or appropriate in order to arrive at an equitable solution; provided, however, in the event that the force majeure continues for more than [*] days, the
Party not affected by such force majeure will have the right, at its sole election and expense, and without limitation to any other right or remedy available to such Party, to assume and complete some or all of the activities that the non-performing Party is not performing as a result of such force majeure. 
 18.4 Assignment; Change of
Control. 
 18.4.1 Assignment. Except as provided in this Section 18.4 (Assignment; Change of Control), this Agreement may
not be assigned or transferred, whether by operation of law or otherwise, nor may any right or obligation hereunder be assigned or transferred, by either Party without the prior written consent of the other Party; provided, however, that (and
notwithstanding anything elsewhere in this Agreement to the contrary) either Party may, without such consent, assign this Agreement and its rights and obligations hereunder in whole or in part: (a) to its successor in interest in the transfer
or sale of all or substantially all of its assets or business related to the subject matter of this Agreement; or (b) to its successor in interest in a merger or consolidation (or similar transaction) of the assigning Party. In addition, Sanofi
will have the right, without the consent of Nurix, (a) to perform any or all of its obligations and exercise any or all of its rights under this Agreement through any of its Affiliates or Sublicensees, and (b) assign any or all of its
rights and delegate any or all of its obligations hereunder to any of its Affiliates or its or their Sublicensees or to any successor in interest (whether by merger, acquisition, asset purchase or otherwise) to all or substantially all of the
business to which this Agreement (or the applicable Licensed Product(s)) relates; provided that Sanofi will provide written notice to Nurix within [*] calendar days after such assignment or delegation. Any successor of Sanofi or any assignee
of all of Sanofi’s rights under this Agreement that has also assumed all of Sanofi’s obligations hereunder in writing will, upon any such succession or assignment and assumption, be deemed to be a party to this Agreement as though named
herein in substitution for Sanofi, whereupon Sanofi will cease to be a party to this Agreement and will cease to have any rights or obligations under the Agreement; provided, however, in the case of an assignment by Sanofi to its Affiliate, Sanofi
will be jointly and severally liable with such Affiliate assignee under this Agreement. Any attempted assignment not in accordance with this Section 18.4 (Assignment; Change of Control) will be void. In the event that a permitted assignment of
this Agreement by a Party increases the tax liability of the other Party or any of its Affiliates over the amount of any Taxes that otherwise would have been payable in the absence of such assignment, the assigning Party will reimburse the other
Party for the amount of such increased Tax liability. 
 18.5 Waivers and Modifications. The failure of any Party to insist on the
performance of any obligation hereunder will not be deemed to be a waiver of such obligation. Waiver of any breach of any provision hereof will not be deemed to be a waiver of any other breach of such provision or any other provision on such
occasion or any succeeding occasion. No waiver, modification, release or amendment of any obligation under or provision of this Agreement will be valid or effective unless in writing and signed by the Parties. 

  
 84 

 18.6 Choice of Law; Dispute Resolution. 

18.6.1 Choice of Law. This Agreement and any Dispute arising from the performance or breach hereof will be governed by and interpreted
in accordance with the laws of the State of New York, without giving effect to any choice of law rules. The provisions of the United Nations Convention on Contracts for the International Sale of Goods will not apply to this Agreement or any subject
matter hereof. 
 18.6.2 Dispute Escalation. In the event of an unresolved matter, dispute or issue relating to this Agreement
(“Dispute”), the Alliance Manager of the Party claiming that such Dispute exists will give notice in writing (a “Notice of Dispute”) to the other Party of the nature of the Dispute. Within [*] Business Days
following receipt of a Notice of Dispute, the Executive Officers will meet (including via teleconference) at a mutually agreed upon time and location for discussion and resolution. 

18.6.3 Binding Arbitration. Any dispute unresolved under Section 18.6.2 (Dispute Escalation) will be settled by binding
arbitration administered by [*] (or any successor entity thereto) and in accordance with the [*] then in effect and the [*] contained therein, as modified in this paragraph (the “Rules”), except to the extent such Rules are
inconsistent with this Section 18.6.3 in which case, this Section 18.6.3 will control (including with regard to any limitations of liability or forms of relief). Pursuant to this section: 

(a) Upon receipt of a Notice of Dispute by a Party, the applicable dispute will be resolved by final and binding arbitration
before an arbitrator mutually agreed by the Parties; provided, however, that if the Parties cannot agree within [*] days of the date such Notice of Dispute is received, then the arbitrator shall be chosen in accordance with [*] (the
“Arbitrator”). The Arbitrator shall not be from academia, and the Arbitrator shall be a qualified attorney in private practice or a retired judge with experience in complex commercial disputes, and professionally fluent in English.
The Arbitrator will have not less than [*] years of experience in the biotechnology or pharmaceutical industry and subject matter expertise with respect to the matter subject to arbitration. Any Arbitrator chosen hereunder will have educational
training and industry experience sufficient to demonstrate a reasonable level of scientific, financial, medical and industry knowledge relevant to the particular dispute. 

(b) The Rules will be modified to [*] as in effect on the Effective Date, and the timelines will be modified to provide that
(i) [*], (ii) [*], and (iii) [*]. 
 (c) The Arbitrator will, within [*] days after the conclusion of the hearing, issue a
written award and statement of decision describing the material facts and the grounds for the conclusions on which the award is based, including the calculation of any damages awarded. The Arbitrator will be authorized to award compensatory damages,
but will not be authorized to reform, modify or materially change this Agreement. The proceedings and decisions of the Arbitrator will be confidential, final and binding on the Parties, and judgment upon the award of the Arbitrator may be entered in
any court having jurisdiction thereof. 

  
 85 

 (d) Each Party will bear its own costs and expenses (including legal fees
and expenses) relating to the arbitration proceeding, except that the fees of the Arbitrator and other related costs of the arbitration will be shared equally by the Parties, unless the Arbitrator determines that a Party has incurred unreasonable
expenses due to vexatious or bad faith positions taken by the other Party, in which event the Arbitrator may make an award of all or any portion of such expenses (including legal fees and expenses) so incurred. 

(e) The Arbitrator will be required to render the decision in writing that is no more than [*] pages. The Arbitrator shall
comply with, and the award will be limited by, any express provisions of this Agreement relating to damages or the limitation thereof. The Arbitrator will not have the power to award punitive damages under this Agreement regardless of whether any
such damages are contained in a proposal, and such award is expressly prohibited. 
 (f) Unless the Parties otherwise agree
in writing, during the period of time that any arbitration proceeding is pending under this Agreement, (i) the Parties will continue to comply with all those terms and provisions of this Agreement that are not the subject of the pending
arbitration proceeding; (ii) in the event the arbitration proceeding concerns a potential material breach under Section 17.2 (Termination for Material Breach), the cure period shall be stayed until the conclusion of the proceedings under
this Section 18.6.3; and (iii) in the event that the subject of the dispute relates to the exercise by a Party of a termination right hereunder, including in the case of a material breach of this Agreement, the effectiveness of such
termination will be stayed until the conclusion of the proceedings under this Section 18.6.3. All arbitration proceedings and decisions of the Arbitrator under this Section 18.6.3 will be deemed Confidential Information of both Parties
under ARTICLE 14 (Confidentiality). 
 (g) The arbitration proceedings will take place in [*], in the English language. 

(h) Nothing in this Section 18.6.3 will preclude either Party from seeking equitable relief or interim or provisional
relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the interests of
such Party or to preserve the status quo pending the arbitration proceeding. 
 (i) In the event of a dispute regarding any
payments owing under this Agreement, all undisputed amounts will be paid promptly when due and the balance, if any, promptly after resolution of the dispute. 

18.6.4 Equitable Relief. Notwithstanding anything to the contrary, either Party may at any time seek to obtain preliminary injunctive
relief or other applicable provisional relief from a court of competent jurisdiction with respect to an issue arising under this Agreement if the rights of such Party would be prejudiced absent such relief. 

  
 86 

 18.7 Relationship of the Parties. Nurix and Sanofi are independent contractors under
this Agreement. Nothing contained herein is intended or is to be construed so as to constitute either Party as a partner, agent or joint venturer of the other Party. Neither Nurix nor Sanofi, respectively, will have any express or implied right or
authority to assume or create any obligations on behalf of or in the name of Nurix and Sanofi, respectively, or to bind Nurix and Sanofi, respectively, to any contract, agreement or undertaking with any Third Party. 

18.8 Fees and Expenses. Except as otherwise specified in this Agreement, each Party will bear its own costs and expenses incurred in
connection with this Agreement and the transactions contemplated hereby. 
 18.9 Third Party Beneficiaries. There are no express or
implied Third Party beneficiaries hereunder. The provisions of this Agreement are for the exclusive benefit of the Parties, and no other Person will have any right or claim against any Party by reason of these provisions or be entitled to enforce
any of these provisions against any Party, except for the indemnification rights of the Nurix Indemnitees pursuant to Section 16.1.1 (Indemnification by Sanofi) and Section 16.2 (Procedure) and the Sanofi Indemnitees pursuant to
Section 16.1.2 (Indemnification by Nurix) and Section 16.2 (Procedure). 
 18.10 Entire Agreement. This Agreement, together
with the Schedules and Correspondence, contains the entire agreement by the Parties with respect to the subject matter hereof and supersedes any prior express or implied agreements, understandings and representations, either oral or written, which
may have related to the subject matter hereof in any way, including any and all term sheets relating to the Contemplated Transactions and exchanged between the Parties prior to the Effective Date; provided that this Agreement will not supersede the
terms and provisions of the Prior CDA applicable to any period prior to the Effective Date. 
 18.11 Counterparts. This Agreement may
be executed in counterparts with the same effect as if both Parties had signed the same document. All such counterparts will be deemed an original, will be construed together and will constitute one and the same instrument. Any such counterpart, to
the extent delivered by means of facsimile by .pdf, .tif, .gif, .jpeg or similar attachment to electronic mail (any such delivery, an “Electronic Delivery”) will be treated in all manner and respects as an original executed
counterpart and will be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. No Party will raise the use of Electronic Delivery to deliver a signature or the fact that any signature
or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and each Party forever waives any such defense, except to the extent that such defense relates to lack of
authenticity. 
 18.12 Equitable Relief; Cumulative Remedies. Notwithstanding anything to the contrary herein, the Parties will be
entitled to seek equitable relief, including injunction and specific performance, as a remedy for any breach of this Agreement. Such remedies will not be deemed to be the exclusive remedies for a breach of this Agreement but will be in addition to
all other remedies available at law or in equity. The Parties further agree not to raise as a defense or objection to the request or granting of such relief that any breach of this Agreement is or would be compensable by an award of money damages.
No remedy referred to in this Agreement is intended to be exclusive, but each will be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under Applicable Law. 

  
 87 

 18.13 Interpretation. 

18.13.1 Generally. This Agreement has been diligently reviewed by and negotiated by and between the Parties, and in such negotiations
each of the Parties has been represented by competent (in-house or external) counsel, and the final agreement contained herein, including the language whereby it has been expressed, represents the joint
efforts of the Parties and their counsel. Accordingly, in interpreting this Agreement or any provision hereof, no presumption will apply against any Party as being responsible for the wording or drafting of this Agreement or any such provision, and
ambiguities, if any, in this Agreement will not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. 

18.13.2 Definitions; Interpretation. 

(a) The definitions of the terms herein will apply equally to the singular and plural forms of the terms defined and, where a
word or phrase is defined herein, each of its other grammatical forms will have a corresponding meaning. 
 (b) Whenever the
context may require, any pronoun will include the corresponding masculine, feminine and neuter forms. 
 (c) The word
“will” will be construed to have the same meaning and effect as the word “shall.” 
 (d) The
“U.S.” and “United States” will be construed to have the same meaning and mean the United States of America and its territories and possessions. 

(e) The words “including,” “includes,” “include,” “for example,” and “e.g.,”
and words of similar import, will be deemed to be followed by the words “without limitation.” 
 (f) The word
“or” will be interpreted to mean “and/or,” unless the context requires otherwise. 
 (g) The words
“hereof,” “herein” and “herewith,” and words of similar import, will, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of this Agreement. 

(h) Unless the context requires otherwise or otherwise specifically provided: (i) all references herein to Articles,
Sections or Schedules will be construed to refer to Articles, Sections or Schedules of this Agreement; (ii) all references herein to Exhibits will be construed to refer to Exhibits of the Correspondence and (iii) reference in any Section
to any sub-clauses are references to such sub-clauses of such Section. 

  
 88 

 (i) Whenever this Agreement refers to a number of days, unless otherwise
specified (including references to Business Days), such number refers to calendar days. 
 (j) Unless otherwise specified,
deadlines within which any payment is to be made or act is to be done within or following a specified time period after a date will be calculated by excluding the day, Business Day, month or year of such date, as applicable, and including the day,
Business Day, month or year of the date on which the period ends. 
 (k) Whenever any payment is to be made or action to be
taken under this Agreement is required to be made or taken on a day other than a Business Day, such payment will be made or action taken on the next Business Day following such day to make such payment or do such act. 

18.13.3 Subsequent Events. Unless the context requires otherwise: (a) any definition of or reference to any agreement, instrument
or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications
set forth herein); (b) any reference to any Applicable Law herein will be construed as referring to such Applicable Law as from time to time enacted, repealed or amended; and (c) subject to Section 18.3 (Assignment; Change of Control), any
reference herein to any Person will be construed to include the Person’s successors and assigns. 
 18.13.4 Headings. Headings,
captions and the table of contents are for convenience only and will not be used in the interpretation or construction of this Agreement. 

18.13.5 Prior Drafts. No prior draft of this Agreement will be used in the interpretation or construction of this Agreement. 

18.13.6 Independent Significance. Although the same or similar subject matter may be addressed in different provisions of this
Agreement, the Parties intend that, except as reasonably apparent on the face of this Agreement or as expressly provided in this Agreement, each such provision will be read separately, be given independent significance and not be construed as
limiting any other provision of this Agreement (whether or not more general or more specific in scope, substance or content). 
 18.14
Further Assurances. Each Party will execute, acknowledge and deliver such further instruments, and do all such other ministerial, administrative or similar acts, as may be reasonably necessary or appropriate in order to carry out the
expressly stated purposes and the clear intent of this Agreement. 
 (Remainder of Page Intentionally Left Blank; Signature Page Follows)

  
 89 

 IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this Agreement
to be executed by their respective duly authorized officers as of the Execution Date. 
  

									
	NURIX THERAPEUTICS, INC.	 		 	GENZYME CORPORATION
					
	By:	 	/s/ Arthur T. Sands	 		 	By:	 	/s/ William Sibold
	Name:	 	Arthur T. Sands	 		 	Name:	 	William Sibold
	Title:	 	Chief Executive Officer	 		 	Title:	 	President and CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]